freq-10k_20201231.htm

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001564590-21-016117.txt : 20210329 0001564590-21-016117.hdr.sgml : 20210329 20210329160606 ACCESSION NUMBER: 0001564590-21-016117 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 108 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210329 DATE AS OF CHANGE: 20210329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Frequency Therapeutics, Inc. CENTRAL INDEX KEY: 0001703647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472324450 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39062 FILM NUMBER: 21781751 BUSINESS ADDRESS: STREET 1: 19 PRESIDENTIAL WAY, SUITE 203 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-315-4600 MAIL ADDRESS: STREET 1: 19 PRESIDENTIAL WAY, SUITE 203 CITY: WOBURN STATE: MA ZIP: 01801 10-K 1 freq-10k_20201231.htm 10-K freq-10k_20201231.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

Commission File Number 001-39062

FREQUENCY THERAPEUTICS, INC.

(Exact name of Registrant as specified in its Charter)

Delaware	47-2324450
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

19 Presidential Way, 2nd Floor Woburn, MA	01801
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (866) 389-1970

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

FREQ

The Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☒ NO ☐

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ NO ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐NO ☒

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

The aggregate market value of common stock held by non-affiliates of the registrant based on the closing price of the registrant’s common stock as reported on the Nasdaq Global Select Market on June 30, 2020, was $625.8 million.

The number of shares of Registrant’s Common Stock outstanding as of March 19, 2021 was 34,177,771.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Proxy Statement for the registrant’s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.

Table of Contents

		Page

	Forward-Looking Statements	1
	Risk Factors Summary	3
PART I
Item 1.	Business	4
Item 1A.	Risk Factors	39
Item 1B.	Unresolved Staff Comments	82
Item 2.	Properties	82
Item 3.	Legal Proceedings	82
Item 4.	Mine Safety Disclosures	82

PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	86
Item 6.	Selected Financial Data	87
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	89
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	106
Item 8.	Financial Statements and Supplementary Data	106
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	106
Item 9A.	Controls and Procedures	106
Item 9B.	Other Information	107

PART III
Item 10.	Directors, Executive Officers and Corporate Governance	108
Item 11.	Executive Compensation	108
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	108
Item 13.	Certain Relationships and Related Transactions, and Director Independence	108
Item 14.	Principal Accounting Fees and Services	108

PART IV
Item 15.	Exhibits, Financial Statement Schedules	109
Item 16	Form 10-K Summary	111

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, clinical development plans and expectations, prospective products, product approvals, research and development costs, timing and likelihood of success, and plans and objectives of management for future operations and results, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the risks, uncertainties and assumptions described under the sections in this Annual Report titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These forward-looking statements are subject to numerous risks, including, without limitation, the following:

•

the initiation, timing, progress and results of our preclinical and clinical trials and research and development of programs, including our ongoing Phase 1b and Phase 2a clinical trials and any planned additional Phase 2 clinical trials or Phase 3 clinical trials for FX-322 and our program to develop a product candidate for the treatment of multiple sclerosis, or MS;

•

the impact of the novel coronavirus, COVID-19, on our ongoing and planned clinical trials, our research and development activities and our business and financial markets;

•

our ability to continue to develop our progenitor cell activation, or PCA, platform and identify additional product candidates;

•

our ability to successfully complete clinical trials of any product candidate and obtain regulatory approval for it;

•

the timing or likelihood of regulatory filings and approvals, including our planned filing of an investigational new drug application for our MS product candidate;

•

the commercialization, marketing and manufacture of any product candidate, if approved;

•

the pricing and reimbursement of any product candidate, if approved;

•

the rate and degree of market acceptance and clinical utility of any products for which we receive regulatory approval;

•

the implementation of our strategic plans for our business, product candidates, and technology;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, PCA platform, and technology;

•

estimates of our expenses, future revenues, capital requirements, and our needs for additional financing;

•

our ability to maintain and establish collaborations, including our License and Collaboration Agreement with Astellas Pharma Inc.;

•

our financial performance and the sufficiency of our financial resources; and

•

developments relating to our competitors and our industry, including the impact of government regulation.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.

You should read this Annual Report and the documents that we reference in this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify that all of our forward-looking statements by these cautionary statements.

RISK FACTORS SUMMARY

Our business is subject to numerous risks and uncertainties, including those described in Part I Item 1A. “Risk Factors” in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:

•

We are heavily dependent on the success of FX-322, our lead product candidate, which is still under clinical development. If FX-322 does not receive regulatory approval or is not successfully commercialized, our business will be materially adversely harmed;

•

We utilize our PCA platform to develop product candidates that are designed to activate progenitor cells, which is a new approach to therapeutic intervention and, as a result, successful development, approval, and commercialization of our product candidates, including FX-322, is uncertain;

•

Clinical trials are expensive, time consuming, and difficult to design and implement, and involve an uncertain outcome. The results of preclinical studies and early clinical trials are not always predictive of future results. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval;

•

The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for FX-322 or any other product candidates, our business will be substantially harmed;

•

We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business;

•

If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business;

•

We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of FX-322 and additional product candidates;

•

We face significant competition from biotechnology, pharmaceutical, and medical device companies and our operating results will suffer if we fail to compete effectively;

•

If we are unable to establish sales and marketing capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidate we develop, if approved; and

•

The COVID-19 pandemic has caused and could continue to cause disruptions to our business, including our preclinical studies, clinical trials and operations and could adversely impact our financial condition and results of operations.

PART I

Item 1. Business.

Overview

We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases and a global leader in the science and development of medicines for inner-ear cellular regeneration and hearing restoration. Our initial focus is on advancing our lead product candidate, FX-322, through clinical studies with the goal of developing and commercializing a medicine to help millions of patients with the most common form of hearing loss and build upon the potential of regenerative therapeutics for hearing. We believe we are a leading company using mitotic regeneration for cochlear sensory hair cell regeneration and that FX-322 has the potential to meaningfully improve overall hearing function and enhance quality of life.

Our proprietary approach, called Progenitor Cell Activation, or PCA, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. These progenitor cells, which are closely related to stem cells, are already resident in the targeted location in the body and programmed to develop and differentiate into specific cell types within an organ, which we believe provide us the opportunity to pursue multiple proposed indications and develop potential treatments for an array of degenerative diseases throughout the body. To that end, in addition to our lead program in hearing, we are working to rapidly advance discovery efforts focused on using our PCA approach to potentially remyelinate nerves in patients with multiple sclerosis, or MS and are advancing this program in collaboration with The Scripps Research Institute, or Scripps, and Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge), or Cambridge.

Our hearing program is for a condition called sensorineural hearing loss, or SNHL, which is the most prevalent type of hearing loss, typically caused by permanent loss of sensory hair cells in the cochlea within the ear. Cochlear sensory hair cells can be lost by noise exposure, as a result of aging, certain viral infections or exposure to ototoxic drugs. FX-322 aims to treat the underlying cause of SNHL by regenerating hair cells through the activation of progenitor cells already present in the cochlea. In July 2019, we entered into a license and collaboration agreement, or the Astellas Agreement, with Astellas Pharma Inc., or Astellas, under which we granted them rights to develop and commercialize FX-322 outside of the United States. In September 2019, at the annual meeting of the American Academy of Otolaryngology, the principal investigator from our Phase 1/2 clinical trial evaluating FX-322 in 23 patients with stable SNHL shared preclinical and clinical data that showed that FX-322 was well-tolerated with no serious adverse effects and that we observed statistically significant and clinically meaningful improvement in key measures of hearing loss, including word recognition, or WR, and clarity of sound. Specifically, thirty-three percent (33%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear. The study results were accepted for publication in the peer-reviewed journal Otology and Neurotology and were published in February 2021. They were also presented at the 2021 Association for Research in Otolaryngology 44^th Annual Mid-Winter Meeting in February 2021.

In May 2020, we announced top-line data from an exploratory clinical study in Germany that we believe demonstrated that FX-322 effectively reached the cochlea at levels predicted, based on computer models, to be therapeutically active. Results from the exploratory study showed measurable concentrations of FX-322 in every sample analyzed and that anatomical factors did not prevent FX-322 from reaching the cochlea. The study results were based on analyzing samples of cochlear fluid, known as perilymph, taken intraoperatively from patients undergoing cochlear implant surgery. A total of seven patients received a single intratympanic injection of FX-322, enabling researchers to directly measure the level of FX-322 in perilymph, which is not otherwise feasible in inner-ear studies because accessing the cochlea involves an invasive surgical procedure. Study patients were followed for approximately 30 days after the procedure and no serious treatment related adverse events were observed. The results of this study were included in the article accepted for publication in Otology and Neurotology and published in February 2021.

In June 2020, we shared preliminary findings from a longer-term, follow-up study of certain patients that had been treated with FX-322 in the randomized portion of the Phase 1/2 clinical trial, where we observed improvements in certain key measures of hearing loss. WR tests were performed for five patients at timepoints between 12- and 21-months following FX-322 administration. Four of the patients that were observed to have statistically significant WR scores during the Phase 1/2 clinical trial were observed to have maintained the hearing benefit, three of which remained at statistically significant levels. An additional patient who did not achieve a statistically significant improvement in WR during the Phase 1/2 clinical trial was also retested and it was observed that the WR score had returned to baseline. The results of this study were presented at the American Academy of Otolaryngology – Head & Neck Surgery meeting in September 2020.

In March 2021, we announced new data from a Phase 1b clinical trial of FX-322 designed to evaluate the impact of injection conditions on tolerability. The data showed hearing improvement from a single injection of FX-322. In the multi-center, randomized study, subjects with mild to severe SNHL (n=33) were injected in one ear with FX-322 with the untreated ear as the control. Hearing function was tested over the course of 90 days following dosing. Thirty-two (n=32) subjects completed the 90 day clinical assessment period and, at day 90 following dosing, thirty-four percent (34%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear (p <0.05). This included a subset of subjects that more than doubled their WR scores. The single dose had a favorable safety profile and was well tolerated.

We commenced a Phase 1b clinical trial of FX-322 for age-related hearing loss in October 2020. The clinical trial is a double-blind, placebo-controlled, randomized multicenter safety study of up to 30 individuals aged 66-85 with mild to moderately severe age-related hearing loss. The primary objectives of the Phase 1b study are to assess the local and systemic safety of a single dose of FX-322 and evaluate hearing responses in an older adult cohort. Study participants will be randomized 4:1 to receive either FX-322 or placebo in one ear. Validated measures of hearing including WR, WIN, and pure tone audiometry will be used. Safety, otologic and audiologic assessments will be conducted at day 30 and 90 following administration of FX-322 or placebo. We expect to share results from this clinical trial in the second quarter of 2021.

We commenced a Phase 1b clinical trial of FX-322 in patients aged 18-65 with severe SNHL in November 2020. Severe SNHL is defined as a pure tone average deficit between 71-90 dB. Many patients with this clinical profile typically would be candidates for cochlear implants. This clinical trial employs a similar design to the age-related Phase 1b clinical trial that is currently underway. We expect to share results from this clinical trial in the third quarter of 2021.

To date, no drug therapies have been approved by the FDA or, to our knowledge, by other regulatory bodies, for the treatment of SNHL. Existing devices such as hearing aids amplify sounds but do not replace hair cells, which have roles in clarifying sound and improving speech intelligibility, particularly in noisy environments. Hearing aids also cannot repair the underlying pathology of hearing loss. While hearing loss is often thought to be caused by aging, the condition is strongly correlated with living in an industrialized society. According to the World Health Organization, or WHO, 1.5 billion people, 20% of the world’s population, suffer from some degree of hearing loss worldwide, and, according to the National Institutes of Health, or NIH, more than 90% of people with hearing loss have SNHL. Based on our estimates, we believe that 41 million people in the United States alone have SNHL. The WHO also estimates that 1.1 billion children and adults ages 12 to 35 years old are at risk for hearing loss from recreational noise exposure.

Under the Astellas Agreement, Astellas is responsible for the development and commercialization of FX-322 outside of the United States. As consideration for the licensed rights under the Astellas Agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments of up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively, and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments plus tiered royalties on any future product sales ranging from low- to mid-teen percentages.

Our MS program focuses on activating oligodendrocyte progenitor cells in the central nervous system to repair the myelin sheath that protects nerves and may have the potential to reverse damage done by the disease. We established an internal research program using PCA to drive remyelination as a potential therapy for MS and have identified compounds that display promising preliminary preclinical results in an in vivo model of remyelination. Our research efforts are focused on optimizing these compounds and identifying a lead therapeutic candidate to advance into clinical trials. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this approach at Cambridge University.

Impact of COVID-19

Our offices are located in states that are currently operating under a phased re-opening plan in response to the COVID-19 pandemic. As of the date of the filing of this Annual Report, the majority of our employees continue to work from home, while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. While we have resumed experiments at our Farmington site, we have transitioned certain key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We are also have taken steps consistent with the FDA’s updated industry guidance for conducting clinical trials.

The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, while no significant disruptions have occurred, the COVID-19 pandemic may cause such disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue.

Our product pipeline

The following table summarizes our PCA therapeutic candidate pipeline and discovery research programs:

Our team and history

Our company was founded in 2014 with the goal of creating medicines based on breakthrough research focused on activating the body’s regenerative potential. In their groundbreaking research, Professors Robert S. Langer at the Massachusetts Institute of Technology and Jeffrey Karp at Harvard Medical School, decoded the natural signals between cells that make the intestine one of the most regenerative organs in the body through the continuous activation of progenitor cells. Recognizing that similar progenitor cells were present but inactive in other organs, they discovered how to adapt these natural signals using small molecules to temporarily activate progenitor cells in other organs, including the cochlea, and create a localized healing response. Using these insights, we are developing FX-322 for the treatment of SNHL, and, in a

Phase 1/2 trial of FX-322 in stable hearing loss patients, we have observed statistically significant improvement in WR, a key measure of hearing function. Further, we have identified several additional potential indications for our PCA platform and expanded our team to incorporate domain expertise to pursue our goal of becoming a fully integrated biotechnology company.

Our leadership team includes experienced biotech executives David L. Lucchino, our Chief Executive Officer and co-founder, Christopher R. Loose, our Chief Scientific Officer and co-founder, Peter P. Pfreundschuh, our Chief Financial Officer, Carl P. LeBel, our Chief Development Officer, Dana C. Hilt, our Chief Medical Officer, Quentin McCubbin, our Chief Manufacturing Officer, Michael D. Bookman, our General Counsel, and Wendy S. Arnold, our Chief People Officer. We have also assembled a world-class team of leaders in regenerative biology, otology, drug development, and drug delivery. Our Clinical Advisory Board is comprised of leaders in hearing science and technology who shape how the community thinks about hearing function and restoration. Our Regenerative Medicine Advisory Board members are at the forefront of scientific discovery on the activation of progenitor cells and their potential application to therapeutic interventions in diseases of multiple tissues and organs.

Our strategy

We intend to create and commercialize therapeutics to potentially transform the lives of patients by repairing or reversing damage done to cells, tissue, and organs. To do so, we are implementing the following strategies:

•

Advance development of a single dose regimen of FX-322 for the treatment of SNHL. We believe our lead product candidate has the potential to improve hearing function for the millions of patients affected by SNHL who currently have no therapeutic options. We now have two independent, single-dose studies in patients with mild to severe SNHL that showed a hearing signal with FX-322 and with statistically significant improvements in speech intelligibility. The interim results from our Phase 2a study demonstrated that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Therefore, we plan to advance further development of FX-322 as a single dose regimen.

•

Establish our position as a global leader in the field of hearing function. We plan to continue to grow our discovery organization and add experts in the field of otology to drive the optimization of our PCA approach for the treatment of hearing loss. We also plan to expand our presence in the field of hearing restoration and to work closely with the broader community of advocates, physicians, and payors to bring new treatments to patients globally.

•

Expand the opportunities of our PCA platform beyond hearing. We believe our PCA platform has the potential to address a wide range of clinical applications. We will continue to invest in research and development to enhance our PCA platform with the goal of delivering new therapeutics in additional indications, such as diseases of the muscle, gastrointestinal tract, skin, and bone. We identified MS as a disease where PCA has the potential to produce a restorative effect by stimulation of oligodendrocyte precursor cells (OPCs) to myelinate axons. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge, on approaches to promote remyelination of nerve fibers. We established an internal research program using PCA to drive remyelination as a potential therapy for MS and have identified compounds that display promising preliminary preclinical results in an in vivo model of remyelination. Our research efforts are focused on optimizing these compounds and identifying a lead therapeutic candidate to advance into clinical trials. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this approach at Cambridge University.

•

Continue to build strategic collaborative relationships. Given the broad potential opportunity of our PCA platform, we believe entering into strategic research, development, and commercial collaborations in select therapeutic areas may provide an attractive avenue to facilitate the capital-efficient development of our PCA platform and product pipeline. We believe these strategic collaborations could potentially provide significant funding to advance our product candidates while allowing us to benefit from the development and therapeutic area expertise of our collaborators. We may collaborate with large pharmaceutical companies, biotechnology companies, and academic institutions to maximize the potential of our PCA platform to create new therapies for patients.

Our approach: Progenitor cell activation within the body

We are pioneering a new class of small molecule therapeutics designed to activate progenitor cells already present within the body to create healthy functional tissues and organs. We developed our PCA platform to identify combinations of small molecules that selectively activate progenitor cells to regenerate tissues. Our initial therapeutic focus is SNHL. We believe that our preclinical and clinical studies in SNHL have validated the potential of our PCA platform to provide a new approach to regenerative medicine. Other potential applications of our PCA platform include, but are not limited to, diseases of the muscle, gastrointestinal tract, skin, and bone.

The graphic below illustrates the application of our PCA platform to activate progenitor cells and create healthy functioning target cells. Our small molecules are designed to activate key genes in a progenitor cell, which enable the cell to go through asymmetric division, leaving behind a copy of the progenitor cell as well as creating a functional cell, such as a hair cell. This asymmetric division process is a common mechanism used during the natural development and repair of tissues.

Relationship between stem cells and progenitor cells

All cells in the human body arise from a single unspecialized, or undifferentiated, cell type called a pluripotent stem cell. Two of the key characteristics of pluripotent stem cells are their ability to renew themselves through cell division and the ability to differentiate into any cell type. Progenitor cells have similar self-renewal properties as pluripotent stem cells. However, progenitor cells are programmed to develop and differentiate into specific cell types within an organ. This process can be visualized using Waddington’s epigenetic landscape, which depicts a pluripotent stem cell as a ball rolling down a hill as development progresses (see graphic below). As the ball commits to specific valleys, the cell becomes more specialized and increasingly commits to a tissue-specific fate, such as a progenitor cell. The progenitor cells are programmed to create specific cell types, and, in some cases, allow mature tissue and organs to repair and renew. However, researchers have discovered that many organs throughout the human body that do not spontaneously regenerate do contain inactive progenitor cells that, if stimulated, are potentially available to drive regeneration.

Over the course of several decades, multiple attempts have been made to harness the regenerative potential of stem cells. More recently, the 2012 Nobel Prize in Physiology or Medicine was awarded to Dr. Shinya Yamanaka for discovering how to create induced pluripotent stem cells by adding four genetic factors to a fully differentiated cell, as illustrated by the solid black arrow in the graphic below. However, the Yamanaka factors cannot be applied in vivo, and it has proven challenging to manufacture pluripotent or other human stem cells outside of the body and to control their differentiation to

produce a particular cell type. Further, delivering and properly integrating these cells back into the body adds substantial complexity. Using another approach, some investigators have tried to force progenitor cells within the body to directly convert into other cell types through a process called trans-differentiation, as illustrated by the dotted black arrow in the graphic below. However, trans-differentiation may deplete progenitor cells, which reduces the target cell population for future treatments.

We believe that our PCA approach bypasses the challenges presented by stem cell therapies by utilizing small molecule therapeutics to temporarily reactivate progenitor cells that are already located at the tissue target site within the body and are pre-programmed to make specific cell types. Our combinations of small molecules are designed to induce a progenitor cell to temporarily enter an active state, where it then divides asymmetrically, replacing itself (blue arrows) and regenerating a desired cell type (orange arrow). Asymmetric division occurs when organs naturally regenerate, so progenitor cells are thought to be maintained for future use.

Key attributes of our PCA platform

Our discoveries in regenerative medicine allow us to activate the innate and under-utilized capabilities of progenitor cells. We believe our PCA platform represents a transformative step in the evolution of regenerative medicine by providing the following key attributes:

•

Activates progenitor cells in the right location. We overcome the major challenge of delivering and integrating cells into the proper location within tissue. Our small molecule therapeutic candidates activate the body’s own progenitor cells at the desired location in targeted tissues.

•

Enables ease of manufacturing. We eliminate the need to remove and grow live cells ex vivo, which can be costly and complex to manufacture, difficult to control quality, and may pose potential safety risks. In contrast, our small molecule therapeutic candidates will be produced using standard manufacturing methods.

•

Avoids permanent genetic changes. Instead of altering genes, our small molecules are designed to temporarily activate the innate genes that play a central role in the development of organs and tissues. This small molecule approach could create a disease-modifying or restorative effect without changing the body’s genetic code. In addition, we believe we avoid the risk of acquiring immune reactivity to our therapeutics, which is commonly associated with genetically modifying cells.

Our therapeutic discovery process

We utilize a proprietary process to identify small molecule combinations for activating progenitor cells.

•

Discovery in the right context. Traditional drug screening uses immortalized cell lines that are convenient for use in a laboratory but may not reflect the complex biology of tissue-specific cell types in the body. In our

discovery process, we develop primary progenitor cell assays that are designed to maintain these cells in their natural state in order to increase the likelihood of successful drug discovery and translation into an effective tissue-specific therapeutic.

•

Decoding and controlling activation pathways for progenitor cells. We use our accumulated insights into progenitor cell signaling and aging to identify biological pathways that may activate a specific progenitor cell. We then select and apply combinations of small molecules from our proprietary toolbox of compounds to modulate the chosen biological pathways and achieve PCA.

By assessing our small molecule combinations in a highly relevant context, we and our collaborators have applied this discovery process to identify compounds that activate progenitor cells in numerous tissues.

Our hearing program

We first applied our PCA platform to create FX-322, our lead product candidate designed to restore hearing function in patients with SNHL. We completed a Phase 1/2 clinical trial in 23 patients with stable SNHL in which we observed a statistically significant improvement in WR, a key measure of hearing function, and FX-322 was observed to be well-tolerated. Specifically, thirty-three percent (33%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear. In May 2020, we shared clinical data that showed delivery of FX-322 to the cochlea at levels predicted to reach the therapeutically active range of the treatment. In September 2020, at the American Academy of Otolaryngology annual meeting, we presented data showing sustained improvements in speech intelligibility and audibility measures in patients up to 21 months after receiving an initial dose of FX-322 in our Phase 1/2 study. The Phase 1/2 and cochlear delivery study results were accepted for publication in the peer-reviewed journal Otology and Neurotology and were published in February 2021. We believe that FX-322 has the potential to meaningfully improve overall hearing function and significantly enhance quality of life for patients with hearing loss.

In October 2019, we commenced dosing in a Phase 2a clinical trial of FX-322 and the FDA granted FX-322 Fast Track designation. The goals of the trial are to further establish the hearing signal observed in the Phase 1/2 clinical trial, evaluate the impact of multiple doses and provide insights on endpoints and patient population for further studies. In March 2021, we announced topline, day-90 interim data from the Phase 2a clinical trial. The results showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. In the four-arm Phase 2a study, 95 subjects aged 18-65 are being evaluated for hearing improvement using WR, Words-In-Noise, or WIN, pure tone audiometry and additional exploratory measures. All subjects were administered a total of four weekly intratympanic injections comprised of zero, one, two, or four doses of FX-322 with the balance of injections comprised of placebo doses. While our interim data showed that WR scores increased across all groups, repeated weekly injections appeared to dampen the hearing benefit observed compared to other single injection-studies. The Phase 2a interim results also showed an unexpected apparent level of hearing benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards, potentially suggesting bias due to trial design. Given these challenges observed in the Phase 2a study design, the interim results showed no discernible hearing benefit of FX-322 over placebo.

In May 2020, we announced top-line data from an exploratory clinical study in Germany that we believe demonstrated that FX-322 effectively reached the cochlea at levels predicted, based on computer models, to be therapeutically active. Top-line results from the exploratory study showed measurable concentrations of FX-322 in every sample analyzed and that anatomical factors did not prevent FX-322 from reaching the cochlea. The study results were based on analyzing samples of cochlear fluid, known as perilymph, taken intraoperatively from patients undergoing cochlear implant surgery. A total of seven patients received a single intratympanic injection of FX-322, enabling researchers to directly measure the level of FX-322 in perilymph, which is not otherwise feasible in inner-ear studies because accessing the cochlea involves an invasive surgical procedure. Study patients were followed for approximately 30 days after the procedure and no serious treatment related adverse events were observed. The study results were accepted for publication in the peer-reviewed journal Otology and Neurotology and were published in February 2021.

As shown in the graph below, we now have two independent, single-dose studies in patients with mild to severe SNHL that showed a hearing signal with FX-322 and with statistically significant improvements in speech intelligibility.

Impact and prevalence of hearing loss

According to the WHO, 1.5 billion people suffer from some degree of hearing loss worldwide, and, according to the NIH, more than 90% of people with hearing loss have SNHL. Based on our estimates, we believe that approximately 41 million people in the United States alone have SNHL. The WHO also estimates that 1.1 billion children and adults ages 12 to 35 years old are at risk for hearing loss from recreational noise exposure. In middle- and high-income countries, the WHO estimates that nearly 50% of people aged 12 to 35 listen to personal audio devices at unsafe sound levels. Moreover, damage from noise exposure in early childhood can render the ears more susceptible to the effects of aging. Noise exposure is difficult to avoid in modern society. Noise at restaurants, for example, routinely climbs into the high 70-decibel, or dB, range, equivalent to a canister vacuum cleaner, and sometimes to the mid-80 dB, as loud as a nearby diesel truck.

U.S. prevalence of SNHL, ranging from mild to moderate to severe, is shown in the graph below, which is from data from the National Center for Health Statistics (NCHS). Each SNHL patient population is being studied in the current FX-322 clinical program.

After a patient first complains of hearing loss, which is most often to their primary care physician, patients with SNHL are managed by audiologists and otolaryngologists, who are trained as ear, nose, and throat specialists, or ENTs. In the United States, there are about 13,000 audiologists and about 12,500 ENTs. Developing a therapeutic to potentially modify an underlying cause of SNHL may provide a critically important treatment option for this group of health-care providers and their patients.

There are also further direct and indirect impacts on individuals suffering from SNHL. Hearing loss profoundly affects an individual’s ability to participate in the social interactions of daily life, which can lead to feelings of loneliness, isolation, and frustration. Untreated hearing loss is associated with a 50% increase in dementia and a 40% increase in depression. Adults with hearing loss also have higher unemployment rates than non-hearing-impaired adults, and a relationship between hearing loss and diminished employment and advancement opportunities has been reported. According to a 2020 study in the medical journal The Lancet, hearing loss is the largest modifiable risk factor for developing dementia.

Biology and measurement of hearing

As shown in the figure below, we hear sounds when sound waves enter the inner ear and generate movement of the fluid in the cochlea, a portion of the inner ear that looks like a snail shell. This fluid movement causes hair cells within the cochlea to bend and in turn generate electrical signals that are transmitted to the brain via the auditory nerve. The cochlea is arranged so that hair cells at the base detect high frequencies and hair cells at the apex detect low frequencies.

Humans are born with about 15,000 hair cells in the cochlea of each ear. Hair cells are commonly lost due to noise exposure in work settings, travel or leisure activities, or as a result of aging, certain viral infections or exposure to ototoxic drugs. Lost hair cells do not spontaneously regenerate. Over time, hearing loss can accumulate with greater prevalence at high frequencies. The left panel of the figure below shows a picture of the inside of a healthy cochlea, with one row of inner hair cells, or IHCs, and three rows of outer hair cells, or OHCs. OHCs amplify or dampen sound volume and tune the cochlea to detect specific frequencies. IHCs convert sound waves into nerve impulses that are sent to the auditory nerve. Functional hair cells allow the auditory system to focus on a sound and filter it appropriately throughout the cochlea. The right panel in the below image, adapted from Ryan AF PNAS 2000, shows a cochlea after noise damage, with both IHCs and OHCs missing.

Healthy and Noise-Damaged Cochlea

The two primary components for hearing testing are intelligibility, or the ability to understand spoken words, and the audibility or loudness of sound. While amplifying devices such as hearing aids can make sounds louder, they have limited ability to improve intelligibility, particularly in noisy environments. Intelligibility is particularly important to understand speech in social settings such as in meetings or at restaurants, where filtering sound is critical for communication.

Intelligibility is typically measured by playing a list of words that are repeated back by the person being tested and scoring based on the number of words that the person gets correct. The two validated testing methods of speech intelligibility that are most widely used by audiologists are: word recognition, or WR, where patients are asked to identify monosyllabic words delivered at a loud, but conversational volume level, and words-in-noise, or WIN, where patients are asked to identify monosyllabic words in the presence of background, multi-talker noise.

Audibility is determined by measuring hearing function at different levels of loudness and pitch or frequency. Patients are most often tested using pure tone audiometry, in which a tone is played at a particular frequency and patients are asked to indicate whether they can hear the tone at varying levels of loudness. Loudness is recorded in dB HL. Frequency is recorded in Hertz, or Hz, and is generally measured in the range of 250 to 8000 Hz. According to the WHO, normal hearing is defined as the ability to hear sounds at a loudness value of less than 26 dB HL, which is the average of loudness values measured at a range of low, middle, and high frequencies, such as 500, 1000, 2000, and 4000 Hz. The larger the loudness value needed for a patient to hear sounds the greater the decline in hearing function, or more severe hearing loss. The graphic below depicts the severity of hearing loss across a range of frequencies based on the American Speech-Language-Hearing Association scale.

Limitations of current treatment options

Current treatment options for hearing loss have significant limitations and none are disease modifying. The only available treatments for hearing loss are hearing aids, or in extreme cases, cochlear implants. No drug therapies have been approved by the FDA or, to our knowledge, by other regulatory bodies, for the treatment of SNHL.

Hearing aids

Hearing aids help many patients cope with mild-to-moderate hearing loss and are used or have been tried by more than 10 million patients in the United States. Only one in four patients with hearing loss has ever used hearing aids, and approximately half of patients who seek medical assistance for their hearing loss do not get hearing aids. Limitations of hearing aids include:

•

Poor sound quality. Hearing aids amplify sounds, allowing patients to perceive sounds that would otherwise be too soft for them to hear, but do not address the loss of hair cells, which determine sound quality and intelligibility, particularly in noisy environments.

•

Challenges in social settings. The wide range of frequencies and sharp tuning provided by hair cells enables the auditory system to accurately recognize and distinguish different sounds, allowing the brain to focus on a single sound source. Hearing aids on the other hand typically amplify all sounds and do not enable this important

sound-processing capability. As a result, interactions in social settings, which require distinguishing one speaker among many sound sources, are significantly impaired.

•

Difficulties with background noise. Patients with hearing loss may become more sensitive to background noise, and many patients with hearing aids turn them off in noisy environments.

•

Stigma associated with wearing a visible device. Some patients refuse to wear hearing aids, or do not wear them regularly, as they do not want to be stigmatized or identified as having a physical handicap.

•

Need for maintenance. Hearing aids must be replaced, on average, every four to six years, need regular battery replacement, and can require repair due to damage during use. Medicare and most private insurance plans do not pay for hearing aids, and most patients must pay for these devices out of pocket.

Cochlear Implants

Patients with severe or profound hearing loss who have not been helped by hearing aids may be candidates for a cochlear implant. Of the roughly one million people in the United States who qualify, only about 100,000 patients have cochlear implants. Cochlear implants comprise an external microphone, sound processor and transmitter system, which receive sounds from the environment, and an implanted receiver and electrode system that directly stimulates the auditory nerve. Cochlear implants do not mimic natural hearing, and patients with cochlear implants need to learn to interpret the low-resolution electric signal produced by the device as sound. Cochlear implants also require an invasive, costly surgical procedure.

Our lead product candidate: FX-322

Using our PCA platform, we are developing our lead product candidate, FX-322, for the treatment of SNHL. FX-322 is designed to treat the underlying cause of SNHL by regenerating hair cells through activation of progenitor cells already present in the cochlea. We believe that FX-322 has the potential to meaningfully improve overall hearing function and significantly enhance quality of life for patients with hearing loss.

Mechanism of Action

By studying the most regenerative organ in the body, the intestine, we discovered that signaling for proliferation and differentiation among stem cells could be replicated with small molecules. Specifically, activating the Wnt pathway, which is fundamental for cell growth, using a glycogen synthase kinase 3, or GSK3, inhibitor and inhibiting histone deacetylase, or HDAC, caused intestinal stem cells expressing the protein Lgr5 to proliferate. The inner ear contains progenitor cells with the Lgr5 protein that do not regenerate on their own. On the hypothesis that these progenitor cells lacked the signals required for regeneration, we applied a GSK3 inhibitor and HDAC inhibitor to these cells and found that they proliferated and regenerated lost hair cells. Based on this discovery, we created FX-322, which is a proprietary combination of an FDA-approved HDAC inhibitor, sodium valproate, and a new chemical entity that inhibits GSK3.

Administration

FX-322 is our proprietary thermoreversible polymer formulation that is administered through the eardrum, or intratympanically, into the middle ear in a procedure that takes approximately 10 to 15 minutes. The intratympanic administration procedure is generally well-tolerated and is routinely performed by ENTs as an office-based procedure. FX-322, which is liquid at room temperature, gels at body temperature inside the middle ear, allowing the active ingredients to diffuse into the inner ear and reach the cochlea. Similar thermoreversible polymer formulations have been used in FDA-approved products for other indications in the ear.

The image below shows delivery of FX-322 via intratympanic injection.

Preclinical studies

Prior to commencing clinical trials, we tested FX-322 in multiple preclinical studies, including in human cells ex vivo and functional hearing tests in mice in vivo. In in vitro testing of isolated human inner ear progenitor cells with the compounds comprising FX-322, we observed the formation of new progenitor cells and their subsequent conversion into hair cells. We also observed translation across species in our in vitro studies of the inner ear progenitor cells from rhesus macaques in which a similar expansion of cell numbers were observed as in the in vitro studies of human cells.

We also conducted ex vivo testing in intact cochlea isolated from mice. To cause hair cell loss, we exposed the cochlea for 16 hours to an aminoglycoside antibiotic that is toxic to hair cells. We then treated the cochlea for 72 hours with the compounds comprising the active agents in FX-322. Aminoglycoside treatment (left panel in the figure below) killed more than 80% of the hair cells in the cochlea (shown in green). By contrast, cochlea treated with the compounds in FX-322 (shown in the right panel) regenerated hair cells to a near native level, as shown graphically in the right panel.

Restoration of Hair Cells in Mouse Cochlea

We also tested FX-322 in a mouse model of severe noise-induced hearing loss. Following noise exposure, 47 mice were treated with FX-322 and 37 were treated with placebo. Hearing function was measured using auditory brainstem response, or ABR, in which the signal generated by the auditory nerve upon sensing sound is detected by electrodes on the scalp. We performed ABR testing after 24 hours, and measured hearing recovery after 30 days. The figure below shows the percentage of mice treated with FX-322 (shown in orange) or with placebo (shown in blue) that achieved a hearing recovery of at least 10 dB at 20000 Hz, a mid-range frequency for mice. The improvement observed in the placebo-treated mice was due to recovery of temporary effects not related to hair cell death, which is typical following acute hearing loss.

Hearing Recovery in Mice Treated with FX-322

We have also conducted pharmacokinetic tests in multiple species in which we observed that FX-322 administration achieved therapeutic levels of the active pharmaceutical ingredients in the cochlea.

Clinical results

Phase 1/2 clinical trial

We conducted a Phase 1/2 clinical trial of FX-322 in which we enrolled 23 adult patients aged 33 to 64 with an established diagnosis of mild to moderately severe stable SNHL, defined as the average pure tone value of 26 to 70 dB at the 500, 1000, 2000 and 4000 Hz frequencies, who had no change of 10 db or more at any frequency for more than six months. Fourteen patients had mild SNHL and nine patients had moderate to moderately severe SNHL. Of the nine moderate to moderately severe patients, six were randomized to FX-322 and three to placebo. In this trial, 15 patients were treated with a single injection of FX-322 and eight patients received placebo. Each patient had a documented medical history consistent with either noise-induced hearing loss, or NIHL, typically from noise exposure at work, or sudden SNHL, or SSNHL, which is characterized as a loss of 30 dB at three adjacent frequencies occurring over a 72-hour period. All patients had stable SNHL, meaning their hearing function at study entry was not significantly different based on a documented audiogram from at least six months prior to the study. Hearing function, specifically speech intelligibility, was assessed using WR and WIN. Hearing loudness was also measured using pure tone audiometry. Patients were randomized to a single injection of FX-322 or placebo administered at one of two different dose volumes (0.05 mL and 0.2 mL) to assess the safety of FX-322 administration and systemic exposure to FX-322. Follow-up visits occurred at 15, 30, 60, and 90 days after injection.

The objectives of the trial were to assess:

•

the systemic safety of FX-322;

•

the plasma pharmacokinetic profile to determine the systemic exposure to FX-322; and

•

the effect of FX-322 on measures of ear health and hearing function.

FX-322 was observed to be well-tolerated in this trial. No serious adverse events were observed, and all treatment-related adverse events were mild, procedure-related, and generally resolved within minutes after dosing. We also observed limited concentrations of the FX-322 components in systemic circulation.

In addition to the prospective analysis, we conducted a prospective statistical analysis where we tested whether the Day 90 WR value for each patient fell outside of the 95% confidence interval compared to their baseline WR value. A confidence interval, or CI, is a range of values in which, statistically, there is a specified level of confidence where the result lies. In this patient-by-patient analysis, we observed statistically significant and clinically meaningful increases in WR in four of 15 patients treated with FX-322 at Day 90, who were among the six FX-322 patients that had moderate to moderately severe SNHL (as shown in the figure below).We also observed improvements for the two remaining FX-322 patients in the study that had moderate to moderately severe SNHL in the range of 30-50% from their baseline score, but these improvements were not statistically significant.

In June 2020, we shared preliminary findings from a follow-up study we conducted that assessed durability of the WR improvements beyond 90 days at a single follow-up visit from 407 to 639 days post-FX-322 administration in five of the subjects that showed a response in the Phase 1/2 trial (the 6^th patient was unable to participate in the follow-up study). The mean percentage of words correct in the treated ear was 38.4% at baseline, 69.6% at day 90, and 54.8% at follow-up. Three of five subjects showed statistically significant improvements in WR at the follow-up visit compared to baseline (see following figure). We believe that the results suggest that a single dose of FX-322 can result in durable improvements in speech intelligibility and support further investigation of the efficacy of FX-322.

There was no apparent association between WR improvements and whether the patients had stable NIHL, or stable SSNHL, and similar results were obtained with both dose volumes. This is consistent with published work showing drug delivery to the cochlea depends more on the concentration of the drug than the volume of injection. There were no clinically meaningful WR improvements observed in the placebo group.

We also performed a post hoc analysis on WR and WIN data for the Phase 1/2 study. The analysis showed a statistically significant improvement in WR by all FX-322-treated patients versus all placebo patients (p=0.010). A p value is the probability that the difference between two data sets was due to chance. The smaller the p value, the more likely the differences are not due to chance alone. In general, if the p value is less than or equal to 0.05, the outcome is statistically significant. The data in the figures below are presented as adjusted mean relative percent change from baseline. FX-322 treated patients saw improvements in WR as early as 15 days after treatment that were sustained over 90 days.

As shown in the figure below for WIN, the adjusted mean relative percent change from baseline was assessed at 15, 30, 60, and 90 days after injection, and a trend in improvement was seen in FX-322-treated patients versus placebo. Also, there were non-statistically significant trends in improved WIN scores at Day 90 in the four FX-322, treated patients that had statistically significant and clinically meaningful improvements in WR in the prospective statistical analysis.

The same WR data was published in Otology and Neurotology in February 2021, as shown in the figure below. In compliance with the publication’s policy, the data was presented with standard error, resulting in a slightly different adjusted mean and p value. Despite the change, the results were consistent with the figure above.

As shown in the figure below, published in Otology and Neurotology in February 2021, speech recognition in a noisy background also improved over time for FX-322-treated patients versus placebo patients. Performance was quantified as the signal-to-noise ratio, or SNR, consistent with 50% correct WR, with lower SNR values indicating better speech perception in background noise. Analyses showed a significant improvement in average SNR from baseline to Day 90 in FX-322-treated patients versus placebo patients.

We also assessed audiometric changes from 250 Hz to 8000 Hz for all patients. Since drug enters closest to the high frequency region, the greatest drug exposure is expected to occur in the high frequency region. While no statistical differences were observed at any frequency when comparing pooled treatment groups, four of the moderate to moderately severe FX-322 patients showed a 10 dB threshold improvement at 8000 Hz at Day 90.

Phase 2a clinical trial

Based on our analysis of the data from our Phase 1/2 clinical trial, we initiated a randomized, double-blind, placebo-controlled, single- and repeat-dose Phase 2a clinical trial of FX-322 in the fourth quarter of 2019. In September 2020, we completed enrollment of 95 patients across 16 sites in the Phase 2a clinical trial. As in the Phase 1/2 clinical trial, patients were required to have a documented medical history consistent with either stable NIHL or stable SSNHL, meaning that a patient’s hearing deficit has remained consistent over a defined period of time based on a patient’s audiograms. All subjects in the clinical trial have meaningful WR deficits including patients who are considered to have “mild” hearing loss.

To explore how a single dose compares to multiple doses of FX-322, we randomized patients to one of four groups, each of which received four injections, once per week at weekly intervals starting at the initial visit. Group 1 received one injection of FX-322 and three injections of placebo. Group two received two injections of FX-322 and two injections of placebo. Group three received four injections of FX-322. Group four received four injections of placebo. Patients have follow-up visits two weeks after dosing and then monthly for seven months. The efficacy endpoints of this trial are WR, WIN, and pure tone audiometry in the range of 250 to 8000 Hz. The exploratory efficacy endpoints are the TFI, the HHIA, and pure tone audiometry in the range of 9000 to 16000 Hz. The selection of the efficacy endpoints in this study builds on the learnings from the Phase 1/2 trial, and we believe will add to our knowledge on the potential ways in which FX-322 may improve hearing function.

In March 2021, we announced topline, day-90 interim data from the Phase 2a clinical trial. The results showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. In the four-arm Phase 2a study, 95 subjects aged 18-65 were evaluated for hearing improvement using WR, WIN, pure tone audiometry and additional exploratory measures. All subjects were administered a total of four weekly intratympanic injections comprised of zero, one, two, or four doses of FX-322 with the balance of injections comprised of placebo doses. While WR scores increased across all groups, the interim data showed that repeated weekly injections appeared to dampen the hearing benefit observed compared to other single injection-studies. The Phase 2a interim results also showed an unexpected apparent level of hearing

benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards, potentially suggesting bias due to trial design. Given these challenges observed in the Phase 2a study design, there was no discernible hearing benefit of FX-322 over placebo. We plan to report an analysis of the end of Phase 2a data (210 days) late in the second quarter of 2021.

Phase 1b clinical studies

In March 2021, we announced new data from a Phase 1b clinical trial of FX-322 designed to evaluate the impact of injection conditions on tolerability. The results showed hearing improvement from a single injection of FX-322. In the multi-center, randomized study, subjects with mild to severe SNHL (n=33) were injected in one ear with FX-322 with the untreated ear as the control. Hearing function was tested over the course of 90 days following dosing. Thirty-two (n=32) subjects completed the 90 day clinical assessment period and, at day 90 following dosing, thirty-four percent (34%) of these subjects achieved a ten percent (10%) or greater absolute improvement in WR scores in the treated ear, which was clinically meaningful and statistically significant compared to the untreated ear (p <0.05). This included a subset of subjects that more than doubled their WR scores. The single dose had a favorable safety profile and was well tolerated.

Other Clinical Studies

In May 2020, we announced top-line data from an exploratory clinical study in Germany that we believe demonstrated that FX-322 effectively reached the cochlea at levels predicted, based on computer models, to be therapeutically active. Top-line results from the exploratory study showed measurable concentrations of FX-322 in every sample analyzed and that anatomical factors did not prevent FX-322 from reaching the cochlea. The study results were based on analyzing samples of cochlear fluid, known as perilymph, taken intraoperatively from patients undergoing cochlear implant surgery. A total of seven patients received a single intratympanic injection of FX-322, enabling researchers to directly measure the level of FX-322 in perilymph, which is not otherwise feasible in inner-ear studies because accessing the cochlea involves an invasive surgical procedure. Study patients were followed for approximately 30 days after the procedure and no serious treatment related adverse events were observed. The study results were included in the article accepted for publication in the journal Otology and Neurotology and were published in February 2021.

Our multiple sclerosis (MS) program

We have initiated a discovery and preclinical program in MS after identifying MS as a degenerative disease that has the potential to be treated with small molecules that activate oligodendrocyte progenitor cells, or OPCs, leading to remyelination. In 2017, we initiated a relationship with Scripps, where researchers had discovered that anti-muscarinic and other classes of pharmacologic agents activate OPCs in the brain. We are pursuing this and other approaches to stimulating myelination of axons in MS. Oligodendrocytes are responsible for making myelin, which accelerates the conduction of information through the brain and provides metabolic support for axons. We believe that stimulating progenitor cells in the central nervous system to grow oligodendrocytes and remyelinate axons could potentially reverse the damage caused by the immune system in MS. The presently approved therapies for MS suppress demyelination but do not repair the damage to myelin.

The potential for anti-muscarinic drugs to treat the symptoms of MS was supported by an independently-run, double-blinded Phase 2 cross-over study entitled Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD), conducted at the University of California, San Francisco. In the ReBUILD study, 50 adult, relapsing-remitting MS patients with optic neuropathy were randomized to either clemastine, which has anti-muscarinic and anti-histaminic activity, or placebo, both in combination with standard of care. The primary endpoint of the study was visual evoked potential latency, or VEP, a test commonly used for optic neuritis and other demyelinating events, such as MS. Patients

treated with clemastine showed an improvement in VEPs indicating remyelination of optic nerve axons. The results of this study were published in the medical journal The Lancet and showed a statistically significant improvement in VEP in patients treated using a single agent, clemastine. Other agents which have been reported to show remyelinating activity in MS patients include a Histamine receptor 3 (H3) inverse agonist and Bexarotene (an RXR antagonist). In all of the above studies the remyelinating effects were reported based on measures of nerve function (electrophysiology) or imaging (MRI imaging). These methods are considered to be measures or biomarkers of the degree of remyelination, supporting the idea that remyelination may be possible in MS patients.

We have been applying our expertise in finding synergistic combinations of small molecules for activating progenitor cells to the treatment of MS. We believe that combinations of the agents may be more active than single agents such as clemastine. The increased remyelination activity may lead to a clinical benefit in patients with MS. We have licensed the worldwide rights to the related Scripps patent estate and are continuing to advance this discovery both on our own and through a sponsored research arrangement with Scripps. Through this work we have discovered combinations that enhance both in vitro and in vivo remyelination over single agents, and have obtained a worldwide, exclusive license from Cambridge for one such combination. We established an internal research program using PCA to drive remyelination as a potential therapy for MS and have identified compounds that display promising preliminary preclinical results in an in vivo model of remyelination. Our research efforts are focused on optimizing these compounds and identifying a lead therapeutic candidate to advance into clinical trials. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this approach at Cambridge University.

In 2020 we established an internal research and discovery effort to identify novel compounds that activate OPCs and induce remyelination in animal models of MS. The goal of the program is to identify product candidates that are novel and that show significantly more remyelination activity than existing remyelination agents.

Overview of multiple sclerosis

According to the National Multiple Sclerosis Society, nearly one million people in the United States are living with MS. The symptoms of MS include numbness or tingling, weakness, dizziness and vertigo, spasticity, vision problems, sexual problems, bladder or bowel problems, pain, cognitive changes, emotional changes, and depression. Most MS is initially relapsing-remitting MS in which patients experience periods of new or relapsing symptoms followed by recovery and periods of remission. Early in the disease course, the patients are able to remyelinate the demyelinated nerves at least in part. As the disease progresses the ability of the body to remyelinate axons significantly decreases. This leads to progressive and irreversible neurological deficits.

The FDA has approved a number of disease-modifying therapies for MS that reduce the immune system attack on myelin, which may reduce the number of relapses, delay progression of disability, and limit new disease activity. However, none of these products repair the central nervous system or lead to remyelination of the nerve fibers, and there is no cure for MS. There are no FDA approved remyelinating therapies for MS. Our program aims to induce OPCs to become functional myelinating oligodendrocytes leading to myelin repair.

Leveraging our PCA platform for future applications

In addition to our hearing and MS programs, we believe our PCA platform has the potential to address a wide range of clinical applications. In directing our internal research, research collaborations, and in-licensing efforts, we intend to target areas of high unmet medical need for which the underlying disease process involves loss or degeneration of key cells that could be reversed using PCA. We believe the PCA platform could further be applied to diseases of the muscle, gastrointestinal tract, skin, and bone. We intend to continue to identify areas with high unmet need where our PCA platform and novel approach to regenerative medicine could lead to potentially disease-modifying therapeutics that create healthy functional tissues and improve patients’ lives.

Manufacturing

Our product candidates consist of small chemical compounds to stimulate cell and tissue regeneration in vivo. As a result, we can rely on the well-established and available manufacturing and drug-delivery technologies developed over decades by the pharmaceutical industry. We source our active pharmaceutical ingredients from contract manufacturers with a track record of FDA-compliant manufacturing. After rigorous internal and external quality control testing, we release these materials to additional contract manufacturers for formulation and packaging into final drug product for use in clinical testing. We expect to use a similar hybrid of internal and contract resources for commercialization of our products, at least until our operations reach a scale sufficient to justify investment in internal manufacturing capacity.

Commercialization

We intend to directly market and commercialize our lead product candidate, FX-322 for the treatment of SNHL, if approved in the United States, by developing our own sales and marketing force, targeting ENTs and audiologists. Under the Astellas Agreement, Astellas has the right to market and commercialize FX-322 for the treatment of SNHL, and any other products containing both a GSK-3 inhibitor and an HDAC inhibitor if approved, outside of the United States. For any other product candidates that are not part of the Astellas Agreement and that may be approved, we intend to establish marketing and commercialization strategies for each as we approach potential approval and expect to be able to leverage our then-existing sales and marketing force.

Intellectual property

We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in our field.

Our future commercial success depends, in part, on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business; defend and enforce our intellectual property rights, in particular our patent rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing products identical or similar to ours may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.

The patent positions of biotechnology and pharmaceutical companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our product candidates and methods of manufacturing the same. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our products will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented, or invalidated by third parties. See “Risk factors—Risks related to our intellectual property” for a more comprehensive description of risks related to our intellectual property.

In an effort to secure our intellectual property positions we generally file patent applications directed to our programs. As of March 19, 2021, we owned, licensed, or have an option to license 38 patent families. These patent families include 6 pending Patent Cooperation Treaty (PCT) applications, 22 U.S. patents, 35 ex-U.S. patents, 83 pending ex-U.S. patent applications, and 27 pending U.S. utility applications.

The intellectual property portfolio for our lead programs as of February 28, 2021, are summarized below. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications referred to below.

Hearing loss

The patent portfolio for our Hearing Loss program is based upon our owned and in-licensed patent families that include patents and patent applications directed generally to compositions of matter, pharmaceutical compositions, and methods of using the same to treat hearing loss; and specifically directed to compositions of matter of our lead product FX-322, pharmaceutical compositions of FX-322 and methods of using the same to treat hearing loss. The in-licensed patents and patent applications are subject to license agreements with Massachusetts Institute of Technology and Massachusetts Eye and Ear Infirmary described herein. As of March 19, 2021, we have rights to, through ownership and in-licensing, 31 patent families, including 17 U.S. patents, 32 ex-U.S. patents, 21 pending U.S. utility patent applications, 65 pending ex-U.S. patent applications, and 5 pending PCT applications relate to treating hearing loss, both generally and related to FX-322. While we believe that the specific and generic claims contained in our issued U.S. patents provide protection for the composition of matter and the method of using FX-322 to treat hearing loss and/or diseases associated with the absence or lack of certain tissue cells, third parties may nevertheless challenge such claims in our patents. If any such claims are invalidated or rendered unenforceable for any reason, we will lose valuable intellectual property rights, and our ability to prevent others from competing with us would be impaired. Any U.S. or ex-U.S. patents that may issue from pending applications that we control,

if any, for our hearing program, including our lead product FX-322, are projected to have a statutory expiration date in between 2035 and 2040, excluding any additional term for patent term adjustments or patent term extensions, if applicable.

Multiple sclerosis program

We plan to use a similar intellectual property strategy when building protection with respect to other programs. Within our MS program, we advise on a portfolio of intellectual property directed to the treatment of MS, through ownership and exclusive in-licensing from Scripps and Cambridge Enterprise. As of March 19, 2021, no development candidate has been designated, but the intellectual property portfolio for our MS research program currently includes 4 patent families including 3 U.S. patents, 3 ex-U.S. patents, 4 pending U.S. utility patent applications, and 11 ex-U.S. patent applications. While we believe that the specific and generic claims, contained in our U.S. and ex-U.S. patents provide protection for the claimed pharmaceutical compositions and methods of use third parties may nevertheless challenge such claims. If any such claims are invalidated or rendered unenforceable for any reason, we will lose valuable intellectual property rights, and our ability to prevent others from competing with us would be impaired. Any U.S. or ex-U.S. patents that may issue from pending applications that we control, if any, for our MS are projected to have a statutory expiration date between 2032 and 2039, excluding any additional term for patent term adjustments or patent term extensions. The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application.

In the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering the use of products from our intellectual property may be entitled to patent term extensions. If our use of drug candidates or the drug candidate itself receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or drug candidate. We also intend to seek patent term extensions in any jurisdictions where available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and, even if granted, the length of such extensions.

In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any collaborators, scientific advisors, employees and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information.

Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March 16, 2013, in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office, or USPTO, to determine priority of inventions. See “Risk factors—Risks related to our intellectual property” for a more comprehensive description of risks related to our intellectual property.

License and collaboration agreements

Astellas Pharma Inc.

products, including our product candidate FX-322, outside of the United States. We also granted Astellas a right of first negotiation and a right of last refusal if we enter into any negotiation or agreement of any kind (other than an acquisition of all of our stock or assets) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas licensed products in the United States.

We and Astellas have agreed to jointly develop the Astellas licensed products, including potentially carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in SNHL and in age-related hearing loss, in each case, in one major Asian country and one major European country. We have agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in the United States. Astellas has the sole right to commercialize the Astellas licensed products outside of the United States, and we have the sole right to commercialize the Astellas licensed products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas licensed products in a major Asian country and a major European country following receipt of regulatory approval in such countries.

As consideration for the licensed rights under the Astellas agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively, and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages.

The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas licensed product in such country or (ii) a set number of years from the first commercial sale of such Astellas licensed product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days’ written notice. Each party has the right to terminate the Astellas Agreement due to the other party’s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt.

Massachusetts Institute of Technology

In December 2016, we entered into an Exclusive Patent License Agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, or the MIT licensed products, and to develop and perform processes, or the MIT licensed processes, which incorporate the licensed technology for the treatment of disease, including, but not limited to, the prevention and remediation of hearing loss. We also have the right to grant sublicenses under the MIT License. MIT and Brigham and Women’s Hospital retain the right on behalf of themselves and all other nonprofit research institutions to practice the licensed patent rights for nonclinical research, teaching, and educational purposes.

We are required to use diligent efforts to develop and commercialize the MIT licensed products or processes and to make such products or processes reasonably available to the public. We are also subject to certain development obligations with regards to a first MIT licensed product. We have satisfied certain obligations related to preclinical and clinical studies and the filing of an IND for a first MIT licensed product with our development activities related to FX-322. Our future development obligations are: (i) to commence a Phase III clinical trial for such product within five years of the IND filing for such product, (ii) to file a New Drug Application, or NDA, or equivalent with the FDA or comparable European regulatory agency for such product within nine years of the IND filing for such product, and (iii) to make a first commercial sale of such product within 11 years of the IND filing for such product. We also have certain development obligations with regards to a second MIT licensed product. If we fail to meet our development obligations, other than those relating to a second MIT licensed product, MIT may terminate the MIT License. In the event that we have failed to fulfill our development timeline obligation with respect to a second MIT licensed product and fail to cure such breach within 90 days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. We do not have the right to control prosecution of the in-licensed patent applications, and our rights to enforce the in-licensed patents are subject to certain limitations.

Upon entering the MIT License, we paid a $50 thousand license fee payment and issued to MIT shares of our common stock equal to 5% of our then-outstanding capital stock. We are required to pay certain annual license maintenance fees ranging from $30 thousand to $0.1 million per year prior to first commercial sale of a MIT licensed product and an annual

license maintenance fee of $0.2 million every year afterwards, which may be credited to running royalties during the same calendar year, if any. We are also required to make potential milestone payments in an aggregate amount of up to $2.9 million on each MIT licensed product or process. In addition, we agreed to pay a low single-digit royalty on the MIT licensed products and processes and a 20% royalty on sub-license revenues. In 2019, we paid MIT $16.0 million dollars representing the royalty on the upfront payment received from Astellas.

The MIT License will remain in effect until the expiration or abandonment of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon three months’ prior written notice. MIT has the right to terminate immediately if we cease to carry on any business related to the MIT License. MIT may also terminate the MIT License for our material breach if such breach remains uncured for 90 days (or 30 days in the case of nonpayment). MIT may also terminate the MIT License if we or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed, or if our sub-licensee commences such actions and we do not terminate such sub-license within 30 days after MIT’s demand. MIT has the right to increase all payments due by us, instead of terminating the MIT License in the case of a patent challenge.

In May 2019, the MIT License was amended to update the diligence milestones for a second MIT licensed product.

Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary)

In February 2019, we entered into an Non-Exclusive Patent License Agreement, or the MEE License, with the Massachusetts Eye and Ear, or MEE, under which we received a non-exclusive, non-sub-licensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes that incorporate the licensed technology for the treatment or prevention of hearing loss, or the MEE licensed products.We are obligated to use diligent efforts to develop and commercialize the MEE licensed products. We met one of our milestone timeline obligations by dosing a first patient in a Phase II trial by December 31, 2020. We are still subject to a milestone timeline obligation to dose a first patient in a Phase III trial by December 31, 2024. We do not control the filing, prosecution, enforcement, and defense of any licensed patent rights.

Upon entering the MEE License, we made a $20 thousand license fee payment. We are obligated to pay certain annual license maintenance fees between $5 thousand and $7.5 thousand per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. We are also obligated to pay a minimum annual royalty payment of $15 thousand per each MEE patent family case number included in the licensed MEE patent rights after first commercial sale of an MEE licensed product. We are also obligated to make milestone payments up to $350 thousand on each product or process that incorporates the licensed patent rights. In addition, we have agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights.

The MEE License remains in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. We have the right to terminate the MEE License at will by 30 business days’ advance written notice to MEE. MEE has the right to terminate the MEE License (i) if we fail to make any payment due within 30 business days after MEE notifies us of such failure, (ii) if we fail to maintain required insurance, (iii) upon 45 business days’ written notice if we become insolvent, or (iv) for any other default by us that is not cured within 60 business days of receipt of written notice. MEE also has the right to terminate if we or our affiliates challenge the validity of the licensed patent rights.

The Scripps Research Institute (California Institute for Biomedical Research)

We have agreed to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR licensed product. We are also subject to certain milestone timeline obligations, which may be extended in certain circumstances as set forth in the CALIBR License to: (i) submit an IND (or equivalent) for a CALIBR licensed product by the 30th month after the effective date of the CALIBR License, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR licensed product by the fourth anniversary of the effective date of the CALIBR License, and (iii) initiate a Phase III clinical trial (or

equivalent) for a CALIBR licensed product by the sixth anniversary of the effective date of the CALIBR License. We do not have the right to control prosecution of the in-licensed patent applications, and our rights to enforce the in-licensed patents are subject to certain limitations.

Upon entering the CALIBR license, we made a $1.0 million license fee payment, and are required to make milestone payments in an aggregate amount of up to $26.0 million for each category of CALIBR licensed products. Category 1 is any CALIBR licensed products containing a compound that modulates any muscarinic receptor, and Category 2 is any CALIBR licensed products not included in Category 1 that could differentiate oligodendrocyte precursor cells from in vitro studies and/or are active in animal models relevant to MS. We are also required to pay a mid-single-digit royalty on CALIBR licensed products and a royalty on sub-license revenues ranging from a low-teen percentage to 50%.

The CALIBR License continues in effect until expiration of all our obligations to pay royalties. Royalties are payable by us on a country-by-country and licensed-product-by-licensed product basis upon the later of (i) the expiration or abandonment of all valid claims of the licensed patent rights in such country and (ii) 10 years from the first commercial sale of each CALIBR licensed product in such country. We may terminate the CALIBR License at will upon 30 days’ prior written notice. We may also elect to terminate our license to one or more licensed patents in any or all jurisdictions by giving 90 days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License for our material breach if such breach remains uncured for 30 days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if we fail to use diligent efforts to develop and commercially exploit CALIBR licensed products.

The Scripps Research Institute

As consideration for the Scripps option agreement, we are required to make funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement.

In September 2020, we extended the term of the Scripps option agreement through the end of December 2021. As consideration for this extension, we are required to make additional funding payments of $0.6 million to Scripps through December 2021. We have the right to terminate by giving 90 days’ advance written notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt.

Cambridge Enterprise Limited

In December 2019, we entered into an Exclusive Patent License Agreement, or the Cambridge License, with Cambridge, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the Cambridge licensed products, which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant sublicenses under the Cambridge License. Cambridge reserves the right to use for itself (as well as for the inventors and the funder) and the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.

We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge licensed product. Upon entering into the Cambridge License, we made a $50.0 thousand license fee payment. We are obligated to pay an annual license fee of $50.0 thousand. We are also obligated to make milestone payments up to $10.5 million on each Cambridge licensed product. In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.

The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon 90 days’ prior written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge licensed product or we or our affiliates or sub-licensees commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.

Competition

As a clinical-stage biotechnology company, we face competition from a wide array of companies in the pharmaceutical, biotechnology, and medical device industries. These include both small companies and large companies with much greater financial and technical resources and far longer operating histories than our own. We also compete with the intellectual property, technology, and product development efforts of academic, governmental, and private research institutions.

Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

The key competitive factors affecting the success of any product candidates that we develop, if approved, are likely to be their efficacy, safety, convenience, price, and the availability of reimbursement from government and other third-party payors. Our commercial opportunity for any of our product candidates could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may commercialize products more quickly than we are able to.

We are aware of the following treatment options in the areas that we are initially targeting:

Hearing loss

There are dozens of hearing aid brands, although approximately 80% of these devices are manufactured by four leading companies. There are three manufacturers of cochlear implants that market in the United States. We are also aware of multiple companies developing therapeutics to treat various forms of hearing loss. There are two companies with potential therapies to regenerate hair cells currently in clinical trials. Novartis conducted a Phase 1/2 trial with intracochlear delivery of an adenovirus-based gene therapy in subjects with severe to profound hearing loss, the data from which has not been shared to date, and Audion Therapeutics is conducting a Phase 2 study of its notch inhibitor, LY3056480, and Pipeline Therapeutics is conducting a Phase 1/2 study of its gamma secretase inhibitor. In 2020 Otonomy, Inc. disclosed top level data from a Phase 1/2 study of OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor, in subjects with a condition described as speech-in-noise impairment. In addition, Sensorion, a clinical stage company is conducting a Phase 2 study to treat sudden SNHL. There are also multiple programs in early-stage or preclinical development by pharmaceutical and biotechnology companies. In addition, there are several companies with programs to regrow neurons in the cochlea to treat hearing loss, and companies developing otoprotective therapies, which are intended to reduce damage to hair cells.

Multiple sclerosis

There are multiple therapeutic options for treating the symptoms of MS, as well as the underlying disease. However, all approved therapies are directed at blocking demyelination, and, to our knowledge, there are no approved therapies which promote remyelination. We are aware of numerous efforts to identify drugs or biologics that can stimulate oligodendrocyte regeneration and myelin repair in the central nervous system. These include Acorda Therapeutics which has conducted two Phase 1 trials of its monoclonal antibody rHIgM22 in MS patients. Convelo Therapeutics is developing potential remyelinating compounds that inhibit enzymes in the brain involved in the production of cholesterol for which they planned

to begin clinical trials in 2019, while Pipeline Therapeutics is developing a selective M1 receptor antagonist to treat multiple sclerosis and other demyelinating disorders. This is an active research area with a number of entities researching compounds, antibodies, and protein which may enhance remyelination.

Government regulation

The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing. These agencies and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of our product candidates.

U.S. drug development process

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA’s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.

The process required by the FDA before a drug may be marketed in the United States generally involves the following:

•

completion of preclinical laboratory tests and formulation studies, as well as animal safety studies, in compliance with the FDA’s good laboratory practice, or GLP, regulations, as appropriate;

•

submission to the FDA of an IND which must become effective before human clinical trials may begin;

•

approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;

•

performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication;

•

submission to the FDA of an NDA;

•

endorsement by an FDA advisory committee, if applicable;

•

satisfactory completion of an FDA inspection of the clinical site(s), and related services involved in the conduct of the clinical studies to assess compliance with good clinical practices, or GCP;

•

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice, or cGMP, requirements, and to assure that the facilities, methods, and controls are adequate to preserve the drug’s identity, strength, quality, and purity;

•

FDA review and approval of the NDA prior to commercial marketing or sale of the drug in the United States; and

•

compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, or to conduct a post-approval study or studies.

Preclinical studies

Preclinical studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the submission including to one or more proposed clinical trials and places the clinical trial on a partial or full clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical

holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or noncompliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.

Clinical trials

Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific time frames to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website.

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

•

Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and, if possible, to gain an early indication of its effectiveness.

•

Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage.

•

Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.

The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unreasonable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.

Concurrent with clinical trials, companies usually complete additional animal studies, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate, and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. There are also requirements governing the registration of, reporting of ongoing clinical trials and completed trial results to public registries.

Marketing approval

Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product’s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of “filing” of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a “filing” decision. Specifically, the FDA conducts a preliminary review of all NDAs within the first 60 days after submission,

before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the submitted information supports that the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product’s continued safety, quality, and purity.

The FDA also may require submission of a REMS plan to ensure that for certain medications with serious safety concerns the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.

The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.

After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter, or CRL. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application for approval. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.

Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.

The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver, or the indication sought is for an orphan condition. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current, or fails to submit a request for approval of a pediatric formulation. In some situations, the requirement for studies in pediatric populations can be waived if there is no relevant use.

FDA-expedited development and review programs

The FDA has various programs, including orphan drug designation, rare pediatric disease designation, fast track designation, accelerated approval priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and the FDA review of drugs that are intended for the treatment of serious or life-

threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.

To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition, demonstrates the potential to address an unmet medical need, and is actively developing the drug for the disease. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of 10 months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and 10-month review periods are measured from the “filing” date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review, and, if relevant, accelerated approval.

In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.

Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, passed in July 2012, a sponsor can request designation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for priority review and accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. The designation includes all the benefits of a fast track designation. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met.

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, priority review, and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. We may explore some of these opportunities for our product candidates as appropriate.

Post-approval requirements

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.

The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization.

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state and local agencies and are subject to periodic unannounced inspections by government agencies for compliance with cGMP and other requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.

Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

•

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

•

safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warning or other safety information about the product;

•

fines, warning letters, or holds on post-approval clinical trials;

•

refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;

•

product seizure or detention, or refusal to permit the import or export of products; or

•

injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.

Marketing exclusivity

Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the modification for which the drug received approval based on the new clinical investigations and does not prohibit the FDA

from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity and extends patent life of a related patent if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials.

Other healthcare laws and compliance requirements

Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the state, local, and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, and transparency laws and regulations, as well as similar foreign laws in the jurisdictions outside the U.S. State laws may require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, as well as require the registration of pharmaceutical sales representatives and the reporting of pricing information and marketing expenditures. Violations of such laws, or any other governmental regulations that apply, may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting and oversight obligations, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs, and individual imprisonment.

Coverage and reimbursement

Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor’s decision to cover a product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product to each payor separately, and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.

In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are more and more challenging the prices charged, examining the medical necessity, and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.

In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors’ reimbursement policies will not adversely affect the ability of manufacturers to sell products profitably.

Healthcare reform

In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect the pharmaceutical industry. In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions of particular import to the pharmaceutical industry, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and fraud and abuse changes. Additionally, the ACA increases the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; requires collection of rebates for drugs paid by Medicaid managed care organizations; imposes a nondeductible annual fee on pharmaceutical manufacturers or importers who sell “branded prescription drugs” to specified federal government programs; implements a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expands of eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee; identify priorities in, and conducts comparative clinical effectiveness research, along with funding for such research; and establishes a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in December 2018, a U.S. district court judge ruled that the ACA is unconstitutional in its entirety because the Tax Cuts and Jobs Act modified the individual mandate. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court’s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the law.

Legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which was temporarily suspended from May 1, 2020 through March 31, 2021, and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference-pricing systems and publication of discounts and list prices.

Foreign regulation

In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials in those countries, if relevant, and market application approval by foreign countries or economic areas, such as the European Union, or EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.

In the European Economic Area, or EEA, which is comprised of the Member States of the European Union plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of MAs:

•

Community MAs—These are issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune, and viral diseases. The Centralized Procedure is optional for products containing a new active substance

not yet authorized in the EEA; for products that constitute a significant therapeutic, scientific or technical innovation; or for products that are in the interest of public health in the EU.

•

National MAs—These are issued by the competent authorities of the Member States of the EEA and only cover their respective territory and are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State. The competent authority of the Reference Member State prepares a draft assessment report, a draft summary of the product characteristics, or SmPC, and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling or packaging proposed by the Reference Member State, the product is subsequently granted a National MA in all the Member States, i.e., in the Reference Member State and the Member States Concerned.

Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy.

As in the United States, it may be possible in foreign countries to obtain a period of market and/or data exclusivity that would have the effect of postponing the entry into the marketplace of a competitor’s generic product. For example, if any of our products receive marketing approval in the EEA, we expect they will benefit from eight years of data exclusivity and 10 years of marketing exclusivity. An additional noncumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period) we obtain an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. The data exclusivity period begins on the date of the product’s first marketing authorization in the EEA and prevents generics from relying on the marketing authorization holder’s pharmacological, toxicological, and clinical data for a period of eight years. After eight years, a generic product application may be submitted, and generic companies may rely on the marketing authorization holder’s data. However, a generic cannot launch until two years later (or a total of 10 years after the first marketing authorization in the EU of the innovator product), or three years later (or a total of 11 years after the first marketing authorization in the EU of the innovator product) if the marketing authorization holder obtains marketing authorization for a new indication with significant clinical benefit within the eight-year data exclusivity period. In Japan, our products may be eligible for eight years of data exclusivity. There can be no assurance that we will qualify for such regulatory exclusivity, or that such exclusivity will prevent competitors from seeking approval solely on the basis of their own studies.

When conducting clinical trials in the EU, we must adhere to the provisions of the European Union Clinical Trials Directive (Directive 2001/20/EC) and the laws and regulations of the EU Member States implementing them. These provisions require, among other things, that the prior authorization of an Ethics Committee and the competent Member State authority is obtained before commencing the clinical trial. In April 2014, the EU passed the Clinical Trials Regulation (Regulation 536/2014), which will replace the current Clinical Trials Directive. To ensure that the rules for clinical trials are identical throughout the European Union, the EU Clinical Trials Regulation was passed as a regulation that is directly applicable in all EU member states. All clinical trials performed in the European Union are required to be conducted in accordance with the Clinical Trials Directive until the Clinical Trials Regulation becomes applicable. According to the current plans of the EMA, the Clinical Trials Regulation is expected to become applicable sometime in 2020.

Data privacy and security laws

Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including the Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act, or the CCPA, the California Privacy Rights Act, or the CPRA, and the European Union General Data Protection

Regulation, or the GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.

Employees and Human Capital Resources

Employees

As of March 19, 2021, we had 87 employees, including 83 full-time employees. Women represent approximately 46% of our employees with approximately 14% holding senior management level/leadership roles. Thirty-nine percent of our employees have an M.D. or a Ph.D. From time to time, we also retain independent contractors to support our organization. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good.

Diversity & Inclusion

We are committed to creating and maintaining a workplace free from discrimination or harassment on the basis of color, race, sex, national origin, ethnicity, religion, age, disability, sexual orientation, gender identification or expression, or any other status protected by applicable law. Our management team and employees are expected to exhibit and promote honest, ethical and respectful conduct in the workplace. All of our employees must adhere to a code of conduct that sets standards for appropriate behavior and are required to attend training upon hire and at our request to help prevent, identify, report and stop any type of discrimination and harassment. Ongoing acknowledgement of our anti-harassment policy is required on an annual basis. Our recruitment, hiring, development, training, compensation and advancement at our company is based on qualifications, performance, skills and experience without regard to gender, race and ethnicity.

Competitive Pay & Benefits

We strive to provide pay, comprehensive benefits and services that help meet the varying needs of our employees. Our total rewards package includes competitive pay; comprehensive healthcare benefits package for employees, with family member healthcare benefits covered at 90%; a health savings account with company contribution; unlimited paid time off and paid holidays; family medical leave; and flexible work schedules. In addition, we offer every full-time employee, both exempt and non-exempt, the benefit of equity ownership in the company through stock option grants and our employee stock purchase plan. We also sponsor a 401(k) plan with a 5% match.

Employee Development & Training

We focus on attracting, retaining, and cultivating talented individuals. We emphasize employee development and training by providing access to a wide range of online and instructor led development and continual learning programs. Employees are encouraged to attend scientific, clinical and technological meetings and conferences and have access to broad resources they need to be successful.

Safety

The safety, health and wellness of our employees is a top priority. In response to COVID-19, we have implemented a safety protocols including shift work scheduling to reduce number of people in the facility, requirements for the wearing of masks and for social distancing, increased cleaning procedures and readily available hand sanitizer. These protocols are designed to comply with health and safety standards as required by federal, state and local government agencies, taking into consideration guidelines of the Centers for Disease Control and Prevention and other public health authorities. In addition, we have provided work-at-home arrangements for employees who are able to do so.

Our Corporate Information

We were incorporated under the laws of the state of Delaware in November 2014. Our principal executive offices are located at 19 Presidential Way, Woburn, Massachusetts 01801 and our telephone number is (866) 389-1970. In the second quarter of 2021, our principal executive offices will be relocated to 75 Hayden Avenue, Lexington, Massachusetts 02421.

Our corporate website address is www.frequencytx.com. The information contained in, or accessible through, our website is not incorporated by reference into this Annual Report and you should not consider information on our website to be a part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.

Where you can find more information

We are subject to the information requirements of the Securities Exchange Act of 1934, as amended. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically, such as ourselves, with the SEC at http://www.sec.gov.

Item 1A. Risk Factors.

Our future operating results could differ materially from the results described in this Annual Report on Form 10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations in these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See “Forward Looking Statements” for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.

Risks related to our financial position and need for additional capital

We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability. If we are unable to achieve or sustain profitability, the market value of our common stock will likely decline.

We are a clinical-stage biotechnology company with a limited operating history. As a result, we are not profitable and have incurred significant losses since our formation. We had net losses of $26.5 million and $19.8 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $95.4 million. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to licensing technologies and research and development, including our preclinical platform development activities and clinical trials.

We expect to incur significant additional operating losses for the next several years, at least, as we advance FX-322 and any other product candidate through clinical development, complete clinical trials, seek regulatory approval and commercialize FX-322 or any other product candidate, if approved. The costs of advancing product candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any product candidate to marketing approval in even a single jurisdiction are substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any product candidates or achieve or maintain profitability. Our expenses will also increase substantially if and as we:

•

continue our Phase 2a trial of FX-322 in sensorineural hearing loss, or SNHL, our Phase 1b trial of FX-322 in age-related hearing loss, or ARHL, and severe SNHL, and commence additional clinical studies relating to FX-322, and any future pivotal Phase 3 studies;

•

expand our development programs based on our progenitor cell activation, or PCA, platform, including our program for a treatment for multiple sclerosis, or MS, and develop other product candidates;

•

continue to develop our PCA platform;

•

seek regulatory approvals for FX-322 and any other product candidates;

•

expand the target indications and patient population for FX-322;

•

secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any product candidate for which we obtain regulatory approval;

•

establish a sales, marketing and distribution infrastructure to commercialize FX-322 for the treatment of SNHL, if approved, and for any other product candidates for which we may obtain marketing approval;

•

maintain, expand, and protect our intellectual property portfolio;

•

hire additional clinical, scientific, and commercial personnel;

•

add operational, financial, and management personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support operations as a public company; and

•

acquire or in-license other product candidates or technologies.

Furthermore, our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under “—Risks related to development, clinical testing, manufacturing, and regulatory approval” and “—Risks related to commercialization.” As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we successfully commercialize FX-322, we may continue to incur substantial research and development and other expenses to identify and develop other product candidates. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially adversely affected.

We expect to spend substantial amounts to complete the development of, seek regulatory approvals for and, if approved, commercialize FX-322. These expenditures include and will include, as the case may be, costs related to the Phase 2a trial of FX-322 for the treatment of SNHL, the Phase 1b trials of FX-322 for the treatment of ARHL and severe SNHL, respectively, and any additional trials we conduct to support the development of FX-322. In addition, we are obligated to make milestone and royalty payments in connection with the sale of resulting products and licensing revenues under our license agreements with Massachusetts Institute of Technology, or MIT, Massachusetts Eye and Ear, or MEE, the Scripps Research Institute, or Scripps, and Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge), or Cambridge. We also expect to spend substantial amounts to identify and develop new product candidates based on our PCA platform.

We will require additional capital to enable us to develop additional product candidates based on our PCA platform, which we may acquire through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our development efforts.

Based upon our current operating plan, we believe that our existing cash, cash equivalents, short-term investments of $220.3 million will enable us to fund our operating expenses and capital expenditure requirements into 2023. This estimate and our expectation regarding the sufficiency of our current financial resources to advance the clinical development of FX-322 and any other product candidates are based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, or our clinical trials, including our Phase 2a trial of FX-322 for the treatment of SNHL, our Phase 1b trials of FX-322 for the treatment of ARHL and severe SNHL, respectively, and other planned clinical trials of FX-322, may be more expensive, time consuming or difficult to design or implement than we currently anticipate. Changing circumstances, including any unanticipated expenses, could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and scope of activities associated with successful development of FX-322 or any product candidate we may develop is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:

•

the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including the Phase 2a trial and Phase 1b ARHL and severe SNHL trials for FX-322, our other planned clinical trials of FX-322, and the development of any other product candidates including any unforeseen costs we may incur as a result of clinical trials due to the COVID-19 global pandemic or other causes;

•

the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or the FDA, and other comparable foreign regulatory authorities, including any additional clinical trials required by the FDA or other comparable foreign regulatory authorities;

•

the willingness of the FDA and other comparable foreign regulatory authorities to accept our clinical trial designs, as well as data from our completed and planned clinical trials and preclinical studies, as the basis for review and approval of FX-322 and any other product candidates;

•

the cost of filing, prosecuting, defending, and enforcing our patent claims and other intellectual property rights;

•

the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us;

•

the effect of competing technological and market developments;

•

the cost and timing of completion of commercial-scale manufacturing activities;

•

the costs of operating as a public company;

•

the cost of making royalty, milestone or other payments under current and any future in-license agreements;

•

the extent to which we in-license or acquire other product candidates or technologies;

•

the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved;

•

our ability to maintain our collaboration with Astellas Pharma Inc., or Astellas, including achievement of the development milestones and to establish new collaborations; and

•

the initiation, progress, and timing of our commercialization of FX-322, if approved, or any other product candidate.

Depending on our business performance, the economic climate and market conditions, we may be unable to raise additional funds through any sources. Market volatility resulting from the COVID-19 global pandemic could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of FX-322 or any other product candidate, or potentially discontinue operations.

We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.

We were established and began operations in 2014. Our operations to date have been limited to financing and staffing our company, licensing technologies, developing our PCA platform, developing and conducting preclinical and clinical studies of FX-322 for the treatment of SNHL, and developing a pipeline of preclinical and research programs, including our program for the treatment of MS. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.

In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo, which results were unexpected. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.

As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, the results of any quarterly or annual period are not necessarily indicative of future operating performance.

Our ability to use our net operating loss carryforwards to offset future taxable income, or tax credit carryforward to offset future income tax liabilities, may be subject to certain limitations.

As of December 31, 2020, we had net operating loss carryforwards, or NOLs, of $67.9 million for federal income tax purposes and $43.4 million for state income tax purposes, which may be available to offset our future taxable income, if any. Our NOLs begin to expire in various amounts in 2037, provided that federal NOLs generated in taxable years beginning after December 31, 2017 will not be subject to expiration. As of December 31, 2020, we also had federal and state research and development and other tax credit carryforwards of approximately $3.0 million and $1.2 million, respectively, available to reduce future tax liabilities. Our tax credit carryforwards expire at various dates through 2040. These NOLs and tax credit

carryforwards could expire unused, to the extent subject to expiration, and be unavailable to offset future income tax liabilities. In addition, in general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to use its pre-change NOLs and tax credit carryforwards to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation’s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We believe we have experienced an ownership change in 2017 and 2019 and may experience ownership changes in the future as a result of future transactions in our stock, some of which may be outside our control. If we undergo additional ownership changes, our ability to use our NOLs and tax credit carryforwards could be further limited. As a result of the changes in ownership in 2017 and 2019, $0.01 million and $0.04 million of NOL carryforwards are limited under Section 382. For these reasons, we may not be able to use a material portion of our NOLs or tax credit carryforwards, even if we attain profitability. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future tax benefits of such assets. Furthermore, NOLs generated in periods beginning after December 31, 2017 may be carried forward indefinitely but may only be used to offset 80% of our taxable income in years beginning after December 31, 2020, which may require us to pay federal income taxes in future years despite generating federal NOLs in prior years.

Risks related to development, clinical testing, manufacturing, and regulatory approval

We are heavily dependent on the success of FX-322, our lead product candidate, which is still under clinical development, and if FX-322 does not receive regulatory approval or is not successfully commercialized, our business will be materially adversely harmed.

To date, we have invested a significant portion of our efforts and financial resources in the development of FX-322 for the treatment of SNHL. Our future success is substantially dependent on our ability to successfully complete clinical development for, obtain regulatory approval for, and successfully commercialize FX-322, which may never occur. We currently have no products that are approved for commercial sale and may never be able to develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will continue to be devoted to FX-322, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval, establishing commercial scale manufacturing, and significant sales, marketing, and distribution efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities or that, even if it receives regulatory approval, FX-322 will be as effective as anticipated at treating SNHL. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo.

The research, testing, manufacturing, labeling, approval, sale, packaging, marketing, and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market FX-322 in the United States until we receive approval of a New Drug Application, or NDA, from the FDA, or in any foreign countries until our collaborator, Astellas, receives the requisite approval from such countries. We have not submitted an NDA to the FDA and Astellas has not submitted comparable applications to other regulatory authorities for FX-322. We or Astellas may not be in a position to do so for several years, if ever. If we or Astellas are unable to obtain the necessary regulatory approval for FX-322 in a country, including as a result of the COVID-19 pandemic, we or Astellas will not be able to commercialize FX-322 for the treatment of SNHL in that country. As a result, our financial position will be materially adversely affected, and we may not be able to generate sufficient revenue to continue our business.

We utilize our PCA platform to develop product candidates, including FX-322, for the treatment of SNHL. Our PCA platform is designed to identify pathways to activate progenitor cells already present in the body to treat conditions or diseases through cellular regeneration. We have not, nor to our knowledge has any other company, received regulatory approval utilizing this mechanism of cellular regeneration. Given the novelty of our approach, we could encounter a longer than expected regulatory review process, increased development costs, or unexpected delays in, or even prevention of, the regulatory approval and commercialization of our product candidates, and we cannot be certain that our approach will lead to the development of any approvable or marketable products. For example, the FDA-approved treatment options available for patients with SNHL are hearing aids and cochlear implants. Unlike FX-322, which is a therapeutic that targets the underlying

biology of SNHL, these treatment options are medical devices that are designed to target the symptoms of SNHL. As a result, these treatment options are not directly comparable to FX-322, and FDA requirements for marketing authorization of these treatment options may not be relevant for FX-322. While we are developing what we believe are appropriate measurements of efficacy for FX-322, we cannot be certain that the FDA will agree with our measurements or that they will be sufficient for approval. If we were to encounter any of the foregoing, our business and financial prospects could be materially harmed.

Clinical trials are expensive, time consuming, and difficult to design and implement, and involve an uncertain outcome. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and completed clinical trials are not necessarily predictive of future results, and any product candidates we develop may not be further developed or may have additional unfavorable results in later studies or trials. Clinical trial failure may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection, placebo effect, patient enrollment criteria, selection of patients based on patient misrepresentations, and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. Several companies in the pharmaceutical industry have suffered setbacks in the advancement of their drug candidates into later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding favorable results in earlier preclinical studies or clinical trials. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. Based upon negative or inconclusive results or a need for additional information, we may decide, or regulatory authorities may require us, to conduct additional clinical trials or preclinical studies.

We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether our clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, or at all. For example, a number of clinical trial sites for our ongoing Phase 2a clinical trial of FX-322 temporarily halted patient enrollment during the first and second quarter of 2020 in response to the COVID-19 pandemic. While we were able to complete enrollment of our Phase 2 clinical trial in September 2020, enrollment in other ongoing clinical trials could be adversely affected by the pandemic. Clinical trials can be delayed for a variety of reasons, including delays related to:

•

the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;

•

obtaining regulatory approval to commence a trial;

•

reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

•

obtaining Institutional Review Board, or IRB, approval at each site within the United States, or Independent Ethics Committee, or IEC, approval at sites outside the United States;

•

business interruptions resulting from the COVID-19 pandemic;

•

recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;

•

having patients complete a trial or return for post-treatment follow-up;

•

imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites or investigators to adhere to regulatory requirements or follow trial protocols;

•

clinical sites deviating from the trial protocol or dropping out of a trial;

•

addressing patient safety concerns that arise during a trial;

•

adding a sufficient number of clinical trial sites; or

•

manufacturing sufficient quantities of a product candidate for use in clinical trials.

We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the FDA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board, or DSMB, for such trial. Such authorities may impose a suspension or termination or

recommend an alteration due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial.

Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in the section titled “—Risks related to our dependence on third parties.”

Our lead product candidate, FX-322, is still in development and will require the successful completion of one, and possibly more, Phase 3 trials before we are prepared to submit an NDA for regulatory approval by the FDA. In addition, we have been advised by the FDA that, while the nonclinical studies conducted by us to date suggest a pharmacodynamic interaction between the two active components of FX-322, the FDA has indicated that the results of such nonclinical studies do not preclude a human study and that inclusion of a factorial study in humans in future trials of FX-322 would thoroughly assess the effects attributable to each component drug of FX-322 in the combination so as to satisfy the FDA’s combination rule. The design and conduct of a factorial study in humans, including the development of each active component to administer in such study, may cause additional delays in the development of FX-322. We cannot predict with any certainty if or when we might complete the development of FX-322 and submit an NDA for regulatory approval by the FDA of FX-322 or whether any such NDA will be approved by the FDA.

If we experience delays in the commencement or completion of any clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of any product candidate we develop could be harmed, and our ability to generate revenues may be delayed. In addition, any delays in our clinical trials could increase our costs, slow the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may materially harm our business, financial condition, and results of operations. In addition, many of the factors that may cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of a clinical trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of a product candidate.

The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time- consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for FX-322 or any other product candidates, our business will be substantially harmed.

The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate’s clinical development and may vary among jurisdictions. The approval process may also be delayed by changes in government regulation, the impact of the COVID-19 pandemic, future legislation or administrative action. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for any product candidate. We are not permitted to market any of our product candidates in the United States until we receive approval of an NDA from the FDA.

Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. In addition, data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Furthermore, as more competing drug candidates within a class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may

increase or change. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other comparable regulatory authorities.

The FDA or any foreign regulatory authority can delay, limit, or deny approval of FX-322 or any other product candidates that we develop or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:

•

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

•

we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;

•

serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing an active ingredient in our product candidates;

•

negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;

•

we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

•

the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

•

the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;

•

the FDA’s or the applicable foreign regulatory authority’s disagreement regarding the formulation, the labeling, and/or the specifications of our product candidates;

•

the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

•

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, and prospects.

In addition, the FDA or the applicable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or applicable foreign regulatory authority may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing circumstances could materially harm the commercial prospects for our product candidates and our business.

Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials.

Patient enrollment and retention in clinical trials depends on many factors, including:

•

the extent of the ongoing COVID-19 pandemic, see --- The COVID-19 pandemic could adversely impact our business, including our preclinical studies, clinical trials and operations;

•

the patient eligibility criteria defined in the protocol, such as the requirement to establish stable hearing loss in our Phase 2a and Phase 1b clinical trials;

•

the size of the patient population required for analysis of the trial’s primary endpoints;

•

the nature of the trial protocol, trial design, side effects or other results that may arise in development;

•

the existing body of safety and efficacy data with respect to the product candidate;

•

the proximity of patients to clinical sites;

•

our ability to recruit clinical trial investigators with the appropriate competencies, motivation and experience;

•

clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or medical devices that may be approved for the indications we are investigating;

•

competing clinical trials being conducted by other companies or institutions;

•

our ability to obtain and maintain patient consents; and

•

the risk that patients enrolled in clinical trials will drop out of the trials before completion.

In addition, our clinical trials will compete with other clinical trials for product candidates and medical devices that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Furthermore, any negative results we may report in clinical trials of any product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs or program delays, which could have a harmful effect on our ability to develop a product candidate or could render further development impossible.

Results of preclinical studies, clinical trials, or analyses may not be indicative of results that may be obtained in later trials.

The results of preclinical studies, clinical trials, or analyses of the results from such trials, including our prospective and post hoc analyses of the data from the Phase 1/2 trial of FX-322 for the treatment of SNHL, may not be predictive of the results of later clinical trials. Product candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising results. Our interim Phase 2a results, for example, showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and post hoc analysis of results from our Phase 1/2 clinical trial of FX-322 for the treatment of SNHL, may be shown to be incorrect in subsequent clinical trials that have pre-specified end points or may not be considered adequate by regulatory authorities. Even if we complete later clinical trials as planned, we cannot be certain that their results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, our clinical development plans may be materially harmed.

Interim and preliminary “top-line” data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.

From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.

If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

Any product candidate or component of a product candidate that we develop or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales.

Serious adverse events or undesirable side effects caused by any product candidate or component of a product candidate we develop could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects. In our clinical studies to date, subjects treated with FX-322 have experienced adverse events that include ear discomfort and ear pain that are considered to be associated with the intratympanic injection procedure.

If unacceptable side effects arise in the development of any product candidate, we, the FDA, or the IRBs or IECs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may have to train medical personnel regarding the proper administration protocol for our product candidates and to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly.

Additionally, if FX-322 or any other product candidate we develop receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

•

regulatory authorities may suspend, withdraw, or limit approvals of such product, or seek an injunction against its manufacture or distribution;

•

regulatory authorities may require us to recall a product or we may decide to initiate a voluntary recall of a product;

•

regulatory authorities may require additional warnings on the label, such as a “black box” warning or contraindication;

•

additional restrictions may be imposed on the marketing of the product or the manufacturing processes for the product or any component thereof;

•

we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;

•

we may be required to conduct post-market studies or agree to post marketing commitments;

•

we could be sued and held liable for harm caused to patients;

•

the product may become less competitive; and

•

our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations, and prospects.

Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic or issue guidance materially affecting the conduct of clinical trials. If a prolonged government shutdown occurs, or it global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Although we intend to explore additional product candidates based on our PCA platform, we may fail to identify viable new product candidates for clinical development for several reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.

Research programs to develop additional product candidates based on our PCA platform require substantial technical, financial, and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for several reasons, including:

•

the research methodology used may not be successful in identifying potential indications or product candidates;

•

potential product candidates may, after further study, be shown to have harmful or unexpected adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or

•

it may take greater human and financial resources than we possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio.

Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.

Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. For example, we may encounter delays in the process of selecting a product candidate for the treatment of MS and we may not achieve the timeline we currently anticipate for submitting an IND or comparable foreign equivalent. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.

The market opportunities for FX-322, if approved, may be smaller than we anticipate and, as a result, our commercial opportunity may be limited.

We expect to initially seek approval of FX-322 for the treatment of SNHL. Our projections of the number of eligible patients are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations, and market research, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of eligible patients, and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited. For example, even if we obtain FDA approval for FX-322, it may be approved for a target population that is more limited than what we currently anticipate. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are smaller, we may never achieve profitability without obtaining marketing approval for additional indications.

We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate.

We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our product candidates. We believe our approach of activating progenitor cells to treat conditions or diseases through cellular regeneration is novel and, as a result, the process for, and the outcome of, FDA approval is especially uncertain. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.

Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.

Even if we obtain FDA approval for a product candidate in the United States, we or our collaborators may never obtain approval for or commercialize the product candidate in any other jurisdiction, which would limit our ability to realize its full market potential.

In order to market any product in a particular jurisdiction, we or our collaborators must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy on a country-by-country basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our or our collaborators’ ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.

Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time- consuming. Regulatory requirements

can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and we will be unable to realize the full market potential of any product we develop.

Even if we obtain regulatory approval for any product candidate, we will still face extensive and ongoing regulatory requirements and obligations, which may result in significant additional expense, and any product candidates, if approved, may face future development and regulatory difficulties.

Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, and requirements for any clinical trials that we conduct post-approval.

Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If a product candidate receives marketing approval, the accompanying label may limit the approved indicated use of the product, which could limit sales of the product. The FDA may also require costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs, may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.

In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:

•

restrictions on manufacturing such products;

•

restrictions on the labeling or marketing of products;

•

restrictions on product distribution or use;

•

requirements to conduct post-marketing studies or clinical trials;

•

warning letters or untitled letters;

•

refusal to approve pending applications or supplements to approved applications that we submit;

•

recalls or market withdrawals of products;

•

fines, restitution, or disgorgement of profits or revenues;

•

suspension or withdrawal of marketing approvals;

•

refusal to permit the import or export of our products;

•

product seizure; or

•

injunctions, consent decrees, or the imposition of civil or criminal penalties.

Further, the FDA’s policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we

may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects, and ability to achieve or sustain profitability.

We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The policies of the FDA and of other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. For example, the results of the 2020 U.S. Presidential election may impact our business and industry. Namely, the previous presidential administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these actions will be implemented, or whether they will be rescinded and replaced under the new presidential administration. The policies and priorities of the new administration are unknown and could materially impact the regulatory framework governing our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition, and results of operations. Furthermore, noncompliance by us or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in significant financial penalties, which would adversely affect our business.

We received Fast Track designation by the FDA for FX-322 and may seek Fast Track designation by the FDA for any future product candidates, but we might not receive such a designation. However, such designation may not lead to a faster development or regulatory review or approval process.

In October 2019, FX-322 received Fast Track designation by the FDA. If a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, a drug sponsor may qualify for FDA Fast Track designation. Fast Track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. The FDA has broad discretion whether to grant Fast Track designation, and we may not receive such a designation for all of the product candidates for which we may request it. Moreover, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA’s priority review procedures.

We may seek a Breakthrough Therapy designation for FX-322 and our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.

We may seek a Breakthrough Therapy designation for FX-322 if results from our ongoing clinical trials support such designation and we may seek a Breakthrough Therapy designation for other product candidates we may develop. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA.

Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that a product candidate meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such a designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a Breakthrough Therapy, the FDA may later decide that it no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.

The use of any product candidate we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

•

impairment of our business reputation and significant negative media attention;

•

withdrawal of participants from our clinical trials;

•

significant costs to defend the litigation;

•

distraction of management’s attention from our primary business;

•

substantial monetary awards to patients or other claimants;

•

inability to commercialize a product candidate;

•

product recalls, withdrawals or labeling, marketing or promotional restrictions;

•

decreased market demand for any product; and

•

loss of revenue.

The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidate, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any product candidates we develop.

In March 2020, the World Health organization designated the outbreak of the novel strain of coronavirus, known as COVID-19, as a global pandemic. This virus has and continues to spread globally and governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, business closures, quarantines, border closures, significant restrictions on travel, social distancing practices as well as restrictions that prohibit many employees from going to work. The pandemic, and government measures taken in response, have had a significant impact, both direct and indirect, on business and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.

On March 23, 2020, the governor of Massachusetts ordered the closure of all non-essential businesses, effective March 24, 2020 through April 7, 2020, which was subsequently extended through May 18, 2020. The governor of Massachusetts has since implemented a phased re-opening plan. Since December 2020, several vaccines combating COVID-19 have been granted emergency use authorization by the FDA and are being administered.

In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals has been on fighting the virus and vaccinating the public and we have been required to take steps consistent with the FDA’s updated industry guidance for conducting clinical trials issued on March 18, 2020. The majority of our employees have continued to work from home, while nearly a quarter to one-third of our workforce, mainly consisting of laboratory employees, have periodically worked in rotating teams to ensure on the continuation of essential experiments. Our

Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent rate after having paused activity during the state mandated lock down orders previously in effect, however, we have transitioned key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We have also taken steps consistent with the FDA’s updated industry guidance for conducting clinical trials.

It is unknown how long these conditions will last and what the complete effect will be to the Company. If COVID-19 continues to spread in the United States and worldwide, and measures to mitigate the ongoing effects of the pandemic, such as stay home orders and/or advisories persist or are reintroduced, we may continue to experience disruptions and other effects on our business that could severely impact our business, operations, preclinical studies and clinical trials, including:

•

delays, difficulties or postponement in enrolling and retaining patients in our clinical trials;

•

delays, difficulties or postponement in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;

•

diversion of healthcare resources away from the conduct of clinical trials, including the diversion of ENT practices and academic centers serving as our clinical trial sites and staff supporting the conduct of our clinical trials;

•

interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;

•

interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;

•

interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;

•

interruptions in planned trials due to restricted or limited operations at our laboratory facility;

•

continual changes to operating requirements and related expenses, limitations in employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people and resulting losses of productivity and employee work culture;

•

risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;

•

refusal of the FDA, or other government agencies, to accept data from clinical trials in these affected geographies;

•

interruption or delayed to our sourced discovery and clinical activities;

•

inability to obtain additional financing or access the financial markets, and

•

if any of the CMOs involved in the manufacture and supply of FX-322 experience a delay or disruption due to COVID-19, we may not have sufficient quantities of FX-322 for our planned activities and may not be able to transition to a new CMO in a timely or cost-effective manner, or at all, which would negatively impact our ability to develop and potentially commercialize FX-322.

The global outbreak of COVID-19 continues to rapidly evolve and continues to have indeterminable adverse effects on general commercial activity and the world economy. We had previously observed an impact from COVID-19 as a number of clinical trial sites had informed us that they have temporarily halted enrollment, though we completed enrollment on the Phase 2a clinical trial in September 2020. However, due to the uncertain nature of the effects of the outbreak, particularly in the United States, enrollment, participation and retention in our ongoing and planned trials may be reduced, and for a number of the clinical sites, halted for an unknown period of time. Any reduction in enrollment, participation and retention and any halts may delay our ongoing and planned clinical trials and our development plans for FX-322, which could have an adverse impact on our business and results of operations.

The extent to which COVID-19 may continue to impact our business, preclinical studies, clinical trials (including the completion and timing of our Phase 2a clinical trial and Phase 1b clinical trials in ARHL and severe SNHL) and operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ongoing and ultimate geographic spread of the disease, duration of the outbreak, including future waves of infection, new variant strains of the underlying virus, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, availability and effectiveness of vaccines and the effectiveness of actions taken in the United States and other countries to contain, treat and mitigate the spread of COVID-19. In addition, if we or any of the third parties with whom we engage were to experience shutdowns or additional business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted, which could have a material adverse effect on our business and our financial results. The COVID-19 pandemic has resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide, resulting in an economic downturn that could continue to significantly impact our business, financial condition and results of operations. To the extent the COVID-19 pandemic adversely affects our business, financial condition and results of operations, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section.

Risks related to commercialization

We face significant competition from biotechnology, pharmaceutical, and medical device companies, and our operating results will suffer if we fail to compete effectively.

The biotechnology, pharmaceutical, and medical device industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If a product candidate we develop is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies, and early-stage companies, particularly if the early-stage company has a collaborative arrangement with a large and established company. We are aware of several companies developing products to treat SNHL through the regeneration of hair cells or through other mechanisms, and we also anticipate that new companies will enter the SNHL market in the future. If we successfully develop and, if approved, commercialize FX-322 for the treatment of SNHL, it may compete, or potentially be used in conjunction, with currently marketed devices, including the hearing aids and cochlear implants currently available and the next generation of improved hearing aids and cochlear implants, and any new therapies that may become available in the future. Furthermore, changes in the regulatory landscape may increase competition from hearing aids. The FDA Reauthorization Act of 2017 created a new category of over-the-counter, or OTC, hearing aids which are intended to be available to consumers without first requiring a visit to a medical professional. While the final regulations needed to implement this new category of devices have not yet been issued, if and when they are, obtaining hearing aids may become less expensive and more convenient.

Competition could render any product candidate we develop obsolete, less competitive, or uneconomical. Our competitors may, among other things:

•

have significantly greater name recognition and financial, manufacturing, marketing, product development, technical, and human resources than we do, with mergers and acquisitions in the biotechnology, pharmaceutical, and medical device industries resulting in even more resources being concentrated in our competitors;

•

more effectively recruit and retain qualified scientific and management personnel;

•

more effectively establish clinical trial sites and patient registration;

•

develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects;

•

obtain quicker regulatory approval;

•

better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary for, our programs;

•

implement more effective approaches to sales, marketing, pricing, coverage, and reimbursement; or

•

form more advantageous strategic alliances or collaborations.

If we are not able to effectively compete for any of the foregoing reasons, our business will be materially harmed.

The successful commercialization of any product candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our or our collaborators’ ability to market those products and decrease our or our collaborators’ ability to generate revenue.

The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford prescription medications. Our ability to achieve acceptable levels of coverage and reimbursement for products or procedures using our products by governmental authorities, private health insurers and other organizations will influence our ability to successfully commercialize any product candidates we develop. Obtaining adequate coverage and reimbursement for any product candidate we develop that is administered under the supervision of a physician, which is what we anticipate for FX-322, may be particularly difficult because of the higher prices associated with such products. In addition, we believe that FX-322 is a novel approach to treating hearing loss and, as a result, availability of coverage and reimbursement by payors is highly uncertain, particularly because the cost of existing treatments for SNHL, such as hearing aids, are generally not reimbursed by payors. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming we obtain coverage for our product candidates or procedures using our products by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product we commercialize, and any reimbursement that may become available may be decreased or eliminated in the future.

Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and the current presidential administration and Congress have introduced several proposals related to drug pricing. Many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. Although there are currently no FDA approved drugs for the treatment of SNHL, it is possible that a third-party payor may consider FX-322 as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy, pricing of existing drugs and medical devices, such as hearing aids, may limit the amount we will be able to charge for any product we commercialize. Payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize a satisfactory return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates. Additionally, our ability to obtain a satisfactory financial return depends on what, if any, proposals related to drug pricing may be implemented and, if implemented, when they might take effect.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.

No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, and one third-party payor’s decision to cover a product does not ensure that other payors will also provide similar coverage. Additionally, the process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the reimbursement rate that the payor will pay for the product once coverage is approved. As a result, the determination of coverage and reimbursement is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.

Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any product we commercialize. We expect to experience

pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations, and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.

We or our collaborators may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we or our collaborators are able to charge for products we or our collaborators commercialize. Accordingly, in markets outside the United States, the reimbursement for products we or our collaborators commercialize may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

Even if a product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success.

If a product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on several factors, including, but not limited to:

•

the efficacy and potential advantages compared to alternative treatments;

•

effectiveness of sales and marketing efforts;

•

the cost of treatment in relation to alternative treatments, including any similar generic treatments;

•

our ability to offer our products for sale at competitive prices;

•

the convenience and ease of administration compared to alternative treatments;

•

the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

•

the strength of marketing and distribution support;

•

the availability of third-party coverage and adequate reimbursement;

•

the prevalence and severity of any side effects; and

•

any restrictions on the use of our product together with other medications.

Because we expect sales of our product candidates, if approved, to generate substantially all our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.

In order to market and successfully commercialize any product candidate we develop, if approved, we must build our sales and marketing capabilities or enter into collaborations with third parties for these services. We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We intend to directly market and commercialize FX-322 for the treatment of SNHL, if approved, in the United States by developing our own sales and marketing force, targeting ear, nose, and throat doctors and audiologists. There are significant expenses and risks involved with establishing our own sales and marketing capabilities, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales leads and provide our sales and marketing team with adequate access to physicians who may prescribe our product, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. Any failure or delay in the development of a product candidate that affects the expected timing of commercialization of the product candidate or results in the failure of the product candidate to be commercialized could result in us having prematurely or unnecessarily incurred costly

commercialization expenses. Our investment would be lost if we are unable to retain or reposition our sales and marketing personnel.

We may also enter into collaborations for the sales and marketing of our product candidates, if approved. To the extent that we depend on collaborators for sales and marketing activities, any revenues we receive will depend upon the success of those collaborators’ sales and marketing teams and the collaborators’ prioritization of our product and compliance with applicable regulatory requirements, and there can be no assurance that the collaborators’ efforts will be successful. For example, under the License and Collaboration Agreement with Astellas, or the Astellas Agreement, we will depend on Astellas to sell and market FX-322 for the treatment of SNHL, if approved, outside of the United States, and we can have no assurance that it will be successful in its efforts or devote sufficient resources to the sale and marketing of FX-322.

If we are unable to build our own sales and marketing team or enter into a collaboration for the commercialization of product candidates we develop, if approved, we may be forced to delay the commercialization of our product candidates or reduce the scope of our sales or marketing activities, which would have an adverse effect on our business, operating results and prospects.

A variety of risks associated with operating internationally could materially adversely affect our business.

Our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves several risks, including, but not limited to:

•

multiple, conflicting, and changing laws and regulations, such as data privacy and security laws and regulations, tax laws, export and import restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;

•

failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;

•

additional potentially relevant third-party patent rights;

•

complexities and difficulties in obtaining protection and enforcing our intellectual property;

•

difficulties in staffing and managing foreign operations;

•

complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;

•

limits in our ability to penetrate international markets;

•

financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;

•

natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;

•

certain expenses, including, among others, expenses for travel, translation, and insurance; and

•

regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and corruption.

Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.

Risks related to our dependence on third parties

The Astellas Agreement is important to our business. If we or Astellas fail to adequately perform under the Astellas Agreement, or if we or Astellas terminate the Astellas Agreement, the development and commercialization of FX-322 for SNHL outside the United States would be materially delayed and our business would be adversely affected.

Under the Astellas Agreement, Astellas is responsible for the development and commercialization of FX-322 outside of the United States and we are responsible for development and commercialization in the United States. We and Astellas are jointly responsible for conducting global clinical studies and coordinating commercial launch activities.

We have received an upfront payment from Astellas of $80.0 million, and we may also receive development milestone payments up to $230.0 million. If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments plus tiered royalties at rates ranging from low- to mid-teen percentages.

Termination of the Astellas Agreement could cause significant delays in our development and commercialization efforts for FX-322 for the treatment of SNHL outside of the United States. If the Astellas Agreement is terminated, we would need to expand our internal capabilities or enter into another agreement to compensate for the loss in funding and clinical development support from Astellas. Any suitable alternative agreement would take considerable time to negotiate and could also be on less favorable terms to us. Whether or not we identify another suitable collaborator, we may need to seek additional financing to continue the development of FX-322, or we may be forced to discontinue development of FX-322, either of which could have a material adverse effect on our business.

We intend to continue to collaborate with third parties for the development and commercialization of our product candidates. We may not succeed in establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all.

We have entered into the Astellas Agreement for the development and commercialization of FX-322 for the treatment of SNHL outside the United States and may seek collaborations for the development and commercialization of other product candidates. The process of establishing and maintaining collaborative relationships is difficult, time-consuming, and involves significant uncertainty, such as:

•

a collaborator may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale, or downsizing;

•

a collaborator may seek to renegotiate or terminate its relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;

•

a collaborator may cease development in therapeutic areas which are the subject of our collaboration;

•

a collaborator may not devote sufficient capital or resources towards our product candidates, or may fail to comply with applicable regulatory requirements;

•

a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such candidate;

•

a significant delay in initiation of certain development activities by a collaborator will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;

•

a collaborator could develop a product that competes, either directly or indirectly, with our product candidate;

•

a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the marketing, distribution, or sale of a product;

•

a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to meet demand requirements;

•

a collaborator may terminate a strategic alliance;

•

a dispute may arise between us and a collaborator concerning the research, development, or commercialization of a product candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management’s attention and resources; and

•

a collaborator may use our products or technology in such a way as to invite litigation from a third party.

If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense, or find alternative sources of capital, which would have a material adverse impact on our clinical development plans and business.

Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless, or negligent conduct or unauthorized activities that violate applicable laws, rules, and regulations including: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse, and other healthcare laws and regulations; or laws that require the reporting of true, complete, and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these or other laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government agency could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us or them and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.

We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of FX-322 and intend to rely on CMOs for the production of commercial supply of FX-322, if approved, and for clinical and commercial supply of our future product candidates, as well as to supply raw materials necessary to produce our product candidates. Our dependence on CMOs may impair the development of our product candidates and may impair their commercialization, which would adversely impact our business and financial position.

We do not own facilities for manufacturing FX-322 or any product candidate. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials of FX-322 and any product candidates we develop and, in future, for commercial quantities. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. If any CMO we engage is unable to provide sufficient supply of any product candidate we develop, we may be unable to arrange for an alternative supply or to do so on commercially reasonable terms or in a timely manner, which could delay any clinical trials, the commercial launch of our product candidates, if approved, or, regarding any commercial supply, result in a shortage in supply that could negatively impact our revenues. For example, we are substantially dependent on the CMO that supplies us with the proprietary glycogen synthase kinase 3, or GSK3, inhibitor that is a key component of FX-322 and the CMO that lyophilizes FX-322 into a powder. While there are other CMOs who are able to supply the GSK3 inhibitor or lyophilize FX-322, manufacture of the GSK3 inhibitor and the lyophilization process require proprietary knowledge or specialized capabilities that only a limited number of CMOs have. As a result, transitioning to a new CMO for either the supply of the GSK3 inhibitor or to conduct the lyophilization process would be particularly time consuming and costly. We have just begun to engage other CMOs as back-up for the manufacture and supply of FX-322. As a result, if any of the CMOs involved in the manufacture and supply of FX-322 experience a delay or disruption, or if we fail to obtain the appropriate approvals to manufacture and supply FX-322 outside the US (e.g., as a result

of a failure to obtain a waiver under the Bayh-Dole Act), we may not have sufficient quantities of FX-322 for our planned activities and may not be able to transition to a new CMO in a timely or cost-effective manner, or at all, which would negatively impact our ability to develop and potentially commercialize FX-322.

The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign regulatory authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. While we have engaged independent auditors to assess the compliance with the protocol that we co-developed with our CMOs regarding the manufacturing process for FX-322, in general, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and we were not involved in developing our CMOs’ policies and procedures.

If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with laws, regulations, and standards related to manufacturing could subject us to risks, including the risk that we may have to suspend the manufacture of our product candidates, that obtained approvals could be revoked, and that the FDA or another governmental regulatory authority may take enforcement actions, including untitled letters, warning letters, seizures, injunctions, or product recalls. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.

We contract for the supply of the active pharmaceutical ingredient, or API, and other raw material necessary to produce FX-322 and we may contract in the future for the supply of API and other raw material for any other product candidate we develop. Supplies of API or other raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. The extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to mitigate the spread of COVID-19 or treat its effects and may cause delays. In addition, a disruption in the supply of API or other raw material could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues. Growth in the costs and expenses of API or other raw material may also impair our ability to cost-effectively manufacture our product candidates. In addition, there may be a limited number of suppliers for API or other raw material that we may use to manufacture our product candidates, and we cannot be certain that we will be able to engage such suppliers in a timely manner or at all. If we are unable to do so, clinical development of our product candidates, commercialization for any approved product, or our business could be adversely affected.

Finding new CMOs or third-party suppliers involves additional cost and requires our management’s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.

As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved.

We intend to rely on third parties to conduct, supervise, and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.

We rely, and will continue to rely, on CROs, CRO-contracted vendors, and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including our Phase 2a trial and other ongoing and planned clinical trials of FX-322 for the treatment of SNHL. Our reliance on CROs for clinical development activities limits our control over these activities and we were not involved in developing our CRO’s policies and procedures, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards.

We and our CROs will be required to comply with the Good Laboratory Practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.

Our CROs are not our employees, and we do not control whether they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.

If our relationship with any CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management’s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. While the COVID-19 pandemic and government measures taken in response have had a significant impact on our CROs and their ability to conduct clinical trials, there is potential they will face disruption in the future, which may affect our ability to initiate and complete our clinical trials. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects.

Risks related to healthcare laws and other legal compliance matters

Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.

In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of health care. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the biotechnology and pharmaceutical industries include the following:

•

an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents;

•

an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;

•

a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected;

•

a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and

•

establishment of a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

Since its enactment, there have been judicial challenges to certain aspects of the ACA, and we expect there will be additional challenges to the ACA in the future. For example, in December 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was modified as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court’s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or amend some or all aspects of the ACA will impact the law, our business or financial condition.

Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional action is taken by Congress. In addition, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our potential customers and accordingly, our financial operations.

Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been administration efforts, Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be implemented in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing.

In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.

Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties.

Our business operations and current and future arrangements with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws include:

•

the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand;

•

the U.S. federal false claims, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes “any request or demand” for money or property presented to the federal government. In addition, pharmaceutical manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims;

•

the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation:

•

the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices;

•

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

•

federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products;

•

the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (as defined by statute) and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives;

•

analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements

and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities;

•

similar healthcare laws and regulations in the European Union, or EU, and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers; and

•

laws and regulations prohibiting bribery and corruption such as the FCPA, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof.

Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations.

If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to actions including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.

Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.

The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.

As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among

other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the CCPA went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the CPRA recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.

Further, the GDPR applies to companies established in the EEA, as well as to companies that are not established in the EEA and which collect and use personal data in relation to (i) offering goods or services to, or (ii) monitoring the behavior of, individuals located in the EEA. If we conduct clinical trial programs in the EEA (whether the trials are conducted directly by us or through a clinical vendor or collaborator), or enter into research collaborations involving the monitoring of individuals in the EEA, or market our products to individuals in the EEA, we will be subject to the GDPR. The GDPR puts in place stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data (or reliance on another appropriate legal basis), the provision of robust and detailed disclosures to individuals about how personal data is collected and processed (in a concise, intelligible and easily accessible form), a comprehensive individual data rights regime (including access, erasure, objection, restriction, rectification and portability), maintaining a record of data processing, data export restrictions governing transfers of data from the EEA, short timelines for data breach notifications to be given to data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches, and limitations on retention of information. The GDPR also puts in place increased requirements pertaining to health data and other special categories of personal data, as well as a definition of pseudonymized (i.e., key-coded) data. Further, the GDPR provides that EEA member states may establish their own laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use, and share such data and/or could cause our costs to increase. In addition, there are certain obligations if we contract third-party processors in connection with the processing of personal data. If our or our collaborators’ or service providers’ privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data, or fines of up to 20 million Euros or up to 4% of our total worldwide annual revenue of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, including class-action type litigation, negative publicity, reputational harm and a potential loss of business and goodwill. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure.

Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.

We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.

Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.

As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.

Risks related to our intellectual property

If we are unable to obtain, maintain, enforce and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.

Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed.

The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, defend, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain, enforce, and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents, and applications may not be prepared, filed, prosecuted, maintained, defended, and enforced in a manner consistent with the best interests of our business.

The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity,

enforceability, and commercial value of our owned and in-licensed patent rights are uncertain. Moreover, our owned and in-licensed pending and future patent applications may not result in patents being issued that protect our technology and product candidates, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend, and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.

Moreover, we or our licensors may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.

It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.

If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could significantly harm our business, financial condition, results of operations, and prospects.

Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, or delay or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements.

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed.

In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions may be available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations, and prospects could be materially harmed.

It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a United States patent covering any of our product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO.

Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate.

Although we or our licensors are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensors’ issued patents or other intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate, or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable.

An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations, and prospects.

Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs, and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.

The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party’s intellectual property.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may develop may be found to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may develop, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party’s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent or other intellectual property right and could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals, and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.

Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater

financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms, and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations, and prospects.

We are party to license and funding agreements that impose, and we may enter into additional licensing and funding arrangements with third parties that may impose, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Under our existing licensing and funding agreements, we are obligated to pay royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects.

Disputes may arise regarding intellectual property subject to a licensing agreement, including:

•

the scope of rights granted under the license agreement and other interpretation related issues;

•

the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

•

the sublicensing of patent and other rights under our collaborative development relationships;

•

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

•

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and

•

the priority of invention of patented technology.

In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations,

and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents and/or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors’ ownership of our owned or in-licensed patents, trade secrets, or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered and unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trade names or trademarks that incorporate variations of our unregistered trade names

or trademarks. Over the long term, if we are unable to successfully register our trade names and trademarks and establish name recognition based on our trade names and trademarks, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trade names and trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

•

we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;

•

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;

•

it is possible that our owned and in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents;

•

issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;

•

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

•

we cannot ensure that any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;

•

we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;

•

we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;

•

we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own, or license expire;

•

we may not develop additional proprietary technologies that are patentable;

•

the patents of others may harm our business; and

•

we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Risks related to our employees, managing our growth and our operations

Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.

We are highly dependent on the expertise of David L. Lucchino, our President and Chief Executive Officer, as well as the other principal members of our management, scientific, and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.

If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition

to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.

In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by other companies or organizations and may have commitments that limit their availability. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited.

We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

Notwithstanding COVID-19, we have experienced and expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, regulatory affairs, quality and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

We may engage in transactions that could disrupt our business, cause dilution to our shareholders or reduce our financial resources.

In the future, we may enter into transactions to acquire or in-license rights to product candidates, products or technologies, or to acquire other businesses. If we do identify suitable candidates, we may not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions or in-licenses may not strengthen our competitive position, and these transactions may be viewed negatively by analysts, investors, customers, or other third parties with whom we have relationships. We may decide to incur debt in connection with an acquisition, or in-license or issue our common stock or other equity securities as consideration for the acquisition, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely, and nondisruptive manner. Such transactions may also divert management attention from day-to-day responsibilities, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or in-licenses or the effect that any such transactions might have on our operating results.

Our business and operations would suffer in the event of security breaches or system failures.

The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals. In the ordinary course of our business, we and third parties with which we have relationships will continue to collect and store sensitive data, including clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite the implementation of security measures, our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, malfeasance, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication, electrical failures or other disruptions. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. For instance, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with COVID-19 global pandemic. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. A number of proposed and enacted federal, state and international laws and regulations obligate companies to notify individuals

of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors, or other organizations with which we have formed strategic relationships. While we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing, or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we currently rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under data protection laws, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation, and cause a loss of confidence in us and our or such third parties’ ability to conduct clinical trials, which could adversely affect our reputation and delay the clinical development of our product candidates.

Risks related to our common stock

The market price of our common stock has been volatile and fluctuated and may in future fluctuate substantially, which could result in substantial losses for our stockholders.

The market price of our common stock has been highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this section titled “Risk factors” and elsewhere in this Annual Report on Form 10-K, these factors include:

•

any delay in the ultimate completion of our Phase 2a clinical trial, enrollment or ultimate completion of our Phase 1b clinical studies in ARHL and severe SNHL, and other planned clinical trials of FX-322 for the treatment of SNHL;

•

the results of the Phase 2a clinical trial, the Phase 1b clinical studies in ARHL and severe SNHL, or other planned clinical trials of FX-322 for the treatment of SNHL or clinical trials of our competitors for the same or similar indication. For example, the price of our common stock decreased significantly following the announcement of our Phase 2a interim results, showing that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo;

•

our ability to develop additional product candidates based on our PCA platform, including MS;

•

any delay in submitting a regulatory filing and any adverse development or perceived adverse development with respect to the regulatory review of such filing;

•

failure to successfully develop and commercialize FX-322 for the treatment of SNHL or any future product candidate;

•

inability to obtain additional funding;

•

regulatory or legal developments in the United States and other countries applicable to our PCA platform or any product candidate:

•

adverse regulatory decisions;

•

changes in the structure of healthcare payment systems;

•

adverse developments concerning our CMOs or CROs;

•

inability to obtain adequate product supply for our other product candidates, or the inability to do so at acceptable prices;

•

introduction of new products, services or technologies by our competitors;

•

our ability to effectively manage our growth;

•

failure to meet or exceed financial projections we provide to the public;

•

failure to meet or exceed the estimates and projections of the investment community;

•

changes in the market valuations of companies similar to us;

•

market conditions in the biotechnology and pharmaceutical sectors, and the issuance of new or changed securities analysts’ reports or recommendations;

•

announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;

•

the termination of a collaboration agreement, licensing agreement or other strategic arrangement, or the inability to establish additional collaboration arrangements that we need on favorable terms, or at all;

•

significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our product candidates and PCA platform;

•

additions or departures of key scientific or management personnel;

•

sales of our common stock by us or our shareholders in the future;

•

trading volume of our common stock; and

•

general economic, industry and market conditions.

In addition, the trading prices for common stock of biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. The ongoing COVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.

Our directors, executive officers and shareholders affiliated with our directors and executive officers own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant influence over matters subject to shareholder approval.

Our directors, executive officers, and shareholders affiliated with our directors and executive officers exert significant influence on us. As of March 19, 2021, these holders beneficially own approximately 15.1% of the voting power of our outstanding common stock. As a result, these holders, acting together, have significant influence over all matters that require approval of our stockholders, including the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transactions. The interests of these holders may not always coincide with our corporate interests or the interests of other shareholders, and they may act in a manner with which our shareholders may not agree or that may not be in the best interests of our other shareholders.

Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be the sole source of gain on an investment in our common stock for the foreseeable future.

We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.

As a public company, and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur previously. The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and

regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.

Pursuant to Section 404 of SOX, or Section 404, as a public company, we will be required to furnish a report by our senior management on our internal control over financial reporting, and our independent registered public accounting firm will be required to provide an attestation report on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to provide the attestation report. To ensure compliance with Section 404, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction on the price of our common stock in the market due to a loss of confidence in the reliability of our financial statements. Furthermore, if we are unable to conclude that our internal control over financial reporting is effective, our investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline.

We are an “emerging growth company” and a “smaller reporting company” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act, and a “smaller reporting company” as defined under the rules promulgated under the Securities Act. As an emerging growth company and a smaller reporting company we may follow reduced disclosure requirements and do not have to make all the disclosures that public companies that are not emerging growth companies or smaller reporting companies do. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (d) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which means the market value of our voting and non-voting common stock that is held by non-affiliates exceeds $700 million as of the last business day of our second fiscal quarter. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:

•

not being required to comply with the auditor attestation requirements of Section 404;

•

an exemption from compliance with the requirement of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on the financial statements;

•

progressively adding to the number of years of audited financial statements required to be included in our periodic reports; and

•

exemptions from the requirements of holding a nonbinding advisory vote on executive compensation, stockholder approval of any golden parachute payments not previously approved and having to disclose the ratio of the compensation of our chief executive officer to the median compensation of our employees.

•

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700

million measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section 404, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors.

We may choose to take advantage of some, but not all, of the available exemptions for emerging growth companies and smaller reporting companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our shares price may be more volatile.

Provisions in our restated certificate of incorporation and our amended and restated bylaws or Delaware law may discourage, delay or prevent a merger, acquisition or other change in control of our company that our shareholders may consider favorable, including transactions in which our shareholders might otherwise receive a premium for their shares.

Our restated certificate of incorporation and our amended and restated bylaws include certain anti-takeover provisions, including those establishing:

•

a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;

•

no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

•

the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents shareholders from filling vacancies on our board of directors;

•

the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;

•

the ability of our board of directors to alter our bylaws without obtaining stockholder approval;

•

the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors:

•

a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;

•

the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors: and

•

advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a shareholders’ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us.

These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Our restated certificate of incorporation and amended and restated bylaws designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.

Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation, or our amended and restated bylaws, (4) any action to interpret, apply, enforce, or determine the validity of our restated certificate of incorporation or our amended and restated bylaws, or (5) any action asserting a claim governed by the internal affairs doctrine. Under our restated certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. In addition, our amended and restated bylaws specifies that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. For example, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.

General Risk Factors

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial revenues, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, our existing stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. In addition, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts.

Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.

Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs

surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement, or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution, and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.

We may not be able to protect our intellectual property and proprietary rights throughout the world.

Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent or at all, inventions that constitute new methods of treatment.

Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.

We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers, or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.

Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims.

In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. For example, the price of our common stock decreased significantly following the announcement of our Phase 2a interim results, showing that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. As a result, we may be more susceptible to these types of lawsuits and legal proceedings than other companies with more stable security prices. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

If securities or industry analysts issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.

The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

Sales of a substantial number of shares of our common stock, or the perception that substantial sales might occur, could cause the price of our common stock to fall.

Sales of a substantial number of shares of our common stock, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. The shares of common stock that were sold in the initial public offering of our common stock are freely transferable without restrictions or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for any shares acquired by our affiliates, as defined in Rule 144 under the Securities Act. The remaining shares of our common stock that are outstanding are either unrestricted or restricted as a result of securities laws. In addition, there are shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity incentive plans and may become eligible for future sale subject to vesting, and Rule 144 and Rule 701 under the Securities

Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

Item 1B. Unresolved Staff Comments.

None

Item 2. Properties.

Our principal office is located at 19 Presidential Way, Woburn, Massachusetts 01801, where we lease approximately 17,000 square feet of office and laboratory space. We lease this space under a lease that terminates on May 31, 2021. We also lease approximately 2,133 square feet of office and laboratory space at 400 Farmington Avenue, Farmington, Connecticut 06030. This lease is set to terminate on July 31, 2021.

On January 7, 2020, we entered into an indenture of lease for the lease of approximately 61,307 square feet of office and laboratory space located at 75 Hayden Avenue, Lexington, Massachusetts 02421, which, once occupied, will be our new principal office. The lease term commenced on December 11, 2020 and we expect to move to this new location in the second quarter of 2021.

Item 3. Legal Proceedings.

We are not subject to any material legal proceedings.

Item 4. Mine Safety Disclosures.

Not applicable

Management

Executive officers and directors

The following table sets forth information regarding our executive officers and directors as of the date of this Annual Report on Form 10-K.


Name	Age		Position

Executive Officers

David L. Lucchino		52	President, Chief Executive Officer, Director, and Co-Founder

Christopher R. Loose, Ph.D.		40	Chief Scientific Officer and Co-Founder

Peter P. Pfreundschuh		52	Chief Financial Officer

Carl P. LeBel, Ph.D.		62	Chief Development Officer

Dana C. Hilt, M.D.		68	Chief Medical Officer

Quentin McCubbin		51	Chief Manufacturing Officer

Michael D. Bookman		34	General Counsel and Secretary

Wendy S. Arnold		49	Chief People Officer

Non-Employee Directors

Marc A. Cohen		57	Chairman and Director

Timothy J. Barberich		73	Director

Cynthia L. Feldmann		68	Director

Michael Huang		47	Director

Executive officers

David L. Lucchino has served as our President and Chief Executive Officer and a member of our board of directors since November 2014 and was a co-founder of our company with Dr. Robert S. Langer and Dr. Christopher R. Loose. From December 2014 until June 2016, Mr. Lucchino served as the President and Chief Executive Officer of Entrega Bio, a PureTech Health-founded biotechnology company focused on oral drug delivery technology. Prior to that, Mr. Lucchino co-founded Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr. Lucchino oversaw the development of the company’s lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr. Lucchino worked at the investment firm Polaris Partners. Mr. Lucchino is the immediate past chairman of the board of directors of MassBio, a non-profit organization that represents and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Governor Charlie Baker as a member of the Commonwealth’s Economic Planning Council. Mr. Lucchino also serves as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of Advisors of Life Science Cares. Mr. Lucchino holds an MBA from the Massachusetts Institute of Technology’s, or MIT’s, Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University. We believe Mr. Lucchino’s extensive management experience in the biotechnology and pharmaceutical industry qualifies him to serve on our board of directors.

Christopher R. Loose, Ph.D. co-founded our company and has served as our Chief Scientific Officer since January 2016. Prior to our company, Dr. Loose co-founded Semprus with Mr. Lucchino and Dr. Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012. At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr. Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr. Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Since 2014, Dr. Loose has served as an Associate Professor Adjunct of Urology at the Yale School of Medicine. Dr. Loose is also the Executive Director of Yale University’s Center for Biomedical and Interventional Technology. Dr. Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University.

Peter P. Pfreundschuh has served as our Chief Financial Officer since December 2020. He joined our company from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary from August 2018 to October 2020. He brings to our company more than 20 years of finance, business development, commercial and public company leadership experience in the life sciences and medical device industries. Prior to joining UroGen, Mr. Pfreundschuh was the chief financial officer of Sucampo Pharmaceuticals Inc. from March 2017 to February 2018, where he co-led the sale of the company to Mallinckrodt, was EVP and chief financial officer of Immunomedics Inc. from September 2013 to September 2016, and was chief financial officer of the heart pump maker, CircuLite Inc. Mr. Pfreundschuh also has held senior roles across finance, commercial operations and business development within the pharmaceutical industry at AstraZeneca Pharmaceuticals and Johnson & Johnson. He started his career as an auditor at Ernst & Young, LLP. Mr. Pfreundschuh is a certified public accountant and holds a Master of Business Administration in finance from Rider University. He has completed master’s coursework in strategic marketing from Northwestern University’s Kellogg School of Management and received his Bachelor of Science in accounting from Rutgers University.

Carl P. LeBel, Ph.D. has served as our Chief Development Officer since March 2018. In 2017, Dr. LeBel founded LeBel Consulting, LLC, a biopharmaceutical consulting company. Prior to joining our company, from February 2009 until November 2016, Dr. LeBel served as the Chief Scientific Officer of Otonomy, Inc., or Otonomy, a biopharmaceutical company where he was responsible for all research and development activities. From 2008 to 2009, he served as the President and Chief Executive Officer of Akesis Pharmaceuticals, Inc., or Akesis, a virtual metabolic disorders company. Prior to Akesis, Dr. LeBel served as an Executive Director in a variety of research and development management positions for Amgen, Inc., or Amgen, a biopharmaceutical company. Before joining Amgen, Dr. LeBel served as a Research Scientist at Alkermes, Inc. Dr. LeBel is a scientific fellow of the American Academy of Otolaryngology and a full member of the American Association for the Advancement of Science and the Society of Toxicology. Dr. LeBel is a co-inventor on numerous patents in the field of drug delivery for otology-related disorders. He was a National Institute of Environmental

Health Sciences post-doctoral fellow in Molecular Neurotoxicology at the University of California Irvine. Dr. LeBel holds a Ph.D. in Biomedical Sciences and Toxicology from Northeastern University and a B.S. in Chemistry from the University of Detroit.

Dana C. Hilt, M.D. has served as our Chief Medical Officer since August 2019. From October 2016 to August 2019, Dr. Hilt served as Chief Medical Officer for Lysosomal Therapeutics, Inc., or Lysosomal, a life sciences drug development company in the field of neurodegeneration, where he was responsible for all clinical development activity for a product candidate for the treatment of Parkinson’s Disease. Prior to Lysosomal, beginning in 2006, Dr. Hilt served in the roles of Senior Vice President of Drug Development and Chief Medical Officer for FORUM Pharmaceuticals, Inc., or FORUM, where he oversaw the clinical, chemistry manufacture controls, regulatory and quality control activities for therapies focused on the treatment of cognitive impairment in schizophrenia and Alzheimer’s disease. Prior to FORUM, Dr. Hilt served as the Chief Medical Officer and Senior Vice President of Clinical Research, Medical Affairs, and Development for Ascend Therapeutics US, LLC, or Ascend, a specialty pharmaceutical company concentrating on women’s health and transdermal drug delivery. Before joining Ascend, Dr. Hilt served as the Vice President of Clinical Research at Guilford Pharmaceuticals Inc., or Guilford, a biopharmaceutical company engaged in the research, development, and commercialization of drugs that target the acute care market and neurological indications including Parkinson’s disease and brain cancer. Prior to Guilford, he served as a Director of Clinical Development at Amgen, where he established its clinical neuroscience group. Prior to that, Dr. Hilt served on the staff of the National Institute of Health. He holds an M.D. from Tufts University School of Medicine and a B.S. from the University of Maine.

Quentin McCubbin has served as our Chief Manufacturing Officer since January 2021. He joined our company from Cerevel Therapeutics, a clinical-stage biotechnology company, where he served as Head of Technical Operations for two years. Prior to Cerevel, he spent 19 years at Takeda/Millennium Pharmaceuticals in a variety of roles including six years as Vice President of Pharmaceutical Sciences and Global Head of Process Chemistry. He began his career as a chemist, completing a post-doctoral fellowship at Imperial College in London. He earned his B.S. and Ph.D. in Chemistry from Monash University in Australia.

Michael D. Bookman has served as Frequency's General Counsel and Secretary since January 2021 and as its Deputy General Counsel and Secretary from September 2019 to January 2021. Prior to his time at Frequency, from October 2012 to August 2019, Mr. Bookman was an Associate at Latham & Watkins LLP, a leading international law firm where he worked on corporate transactional, securities and general business and governance matters, with an emphasis on representing high-growth technology and life sciences companies. Mr. Bookman is also a member of the Boston Bar Association’s Life Sciences Advisory Committee. He holds a J.D. from the University of Virginia School of Law and a B.B.A., summa cum laude, in finance from the University of Miami.

Wendy S. Arnold has served as our Chief People Officer since February 2020. Ms. Arnold previously served as Senior Vice President, Human Resources at Kaleido Biosciences where she helped to establish the HR infrastructure, compensation, performance and development programs. Prior to Kaleido, she was the head of the HR business partnership function at Moderna Therapeutics, where she helped to lead the HR organization during a period of significant growth, including implementing talent development and engagement initiatives. Prior to that, she was at Celgene Avilomics Research (formerly Avila Therapeutics), where she was responsible for building and developing the HR infrastructure for the company’s early research and development division. She also held senior HR positions at Inotek Pharmaceuticals and Amylin Pharmaceuticals. Ms. Arnold received her Bachelor of Science degree from Colorado State University.

Non-Employee Directors

Marc A. Cohen has served as a member of our board of directors and as Chairman since June 2020 and Executive Chairman from September 2016 to June 2020. Since 2012, Mr. Cohen has served as the Chief Executive Officer of Bublup, Inc., an online knowledge-sharing platform, as well as CoBro Ventures, Inc., an investment management company. Mr. Cohen has also been Executive Chairman of C4 Therapeutics since 2015 and Mana Therapeutics since 2018. Mr. Cohen holds an M.S. in Electrical Engineering from Stanford University and a Bachelor’s degree in Engineering Science from Harvard University. We believe Mr. Cohen’s extensive entrepreneurial experience in the life sciences industry qualifies him to serve on our board of directors.

Timothy J. Barberich has served as a member of our board of directors since September 2016. Mr. Barberich has served on the board of directors of Verastem, Inc. since 2014, and TScan Therapeutics, Inc. since 2019. Mr. Barberich previously served as a director for GI Dynamics, Inc. from 2011 to 2021, Tokai Pharmaceuticals, Inc. from 2009 to 2017, for HeartWare International, Inc. from 2008 to 2016, for Inotek Pharmaceuticals Corporation from 2016 to 2017, and for Neurovance, Inc. from 2010 to 2016. Mr. Barberich is co-founder, and served as the CEO and Chairman of Sepracor Inc.

from 1984 to 2009. He holds a B.S. in Chemistry from Kings College. We believe Mr. Barberich’s extensive experience in the life sciences industry qualifies him to serve on our board of directors.

Cynthia L. Feldmann has served as a member of our board of directors since September 2020. Ms. Feldmann has served as a director of UFPT since June 2017. She chairs the UFPT Audit Committee and serves on the Nominating & Governance Committee. Since 2005, Ms. Feldmann has served on the board of directors of STERIS PLC (NYSE: STE), an NYSE-listed $16 billion provider of infection prevention, decontamination, and health science technologies, products and services. She is a member of STERIS’ Nominating & Governance Committee and Compliance Committee, and was previously Chair of and served on the Audit Committee. Ms. Feldmann also served from 2003 to January 2018 on the board of directors of Hanger Inc. (NYSE: HNGR), a $860 million provider of orthotic and prosthetic services and products, and the largest orthotic and prosthetic managed care network in the U.S. Ms. Feldmann served on the Audit Committee, including as Chair of the Audit Committee, the Compensation Committee and the Quality and Technology Committee of Hanger. Ms. Feldmann currently serves on the board of directors and is the chair of the Finance Committee of Falmouth Academy, an academically rigorous, co-ed college preparatory day school for grades 7 to 12. She was the President and Founder of Jetty Lane Associates, a consulting firm, from 2005 until 2012. Previously, Ms. Feldmann served as Business Development Officer at Palmer & Dodge LLP, a Boston based law firm, with a specialty in serving life sciences companies. From 1994 to 2002, she was a Partner at KPMG LLP, holding various leadership roles in the firm’s Medical Technology and Health Care & Life Sciences industry groups. Ms. Feldmann is a retired CPA and holds a Masters Professional Director Certification from the American College of Corporate Directors. We believe Ms. Feldmann’s extensive expertise in auditing and accounting, particularly her experience in the life sciences industry, qualifies her to serve on our board of directors.

Michael Huang has served as a member of our board of directors since October 2018. Since 2019, Mr. Huang has served as a member of the board of directors of Viracta Therapeutics. Mr. Huang serves as Managing Partner at Taiwania Capital Management Corporation, a venture capital firm. From 2014 to 2017, Mr. Huang served as Chief Executive Officer of NeuroVive Pharmaceutical Asia, Inc., a biopharmaceutical company. Mr. Huang holds an MBA from Rice University, a M.A. in Chemistry from the University of Texas, Arlington, and a B.S. from University of Texas, Austin. We believe Mr. Huang’s extensive investment experience in the life sciences industry qualifies him to serve on our board of directors.

Robert S. Langer, Sc.D., has served as a member of our board of directors since September 2016. Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology since 2005. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc., Moderna, Inc., and Puretech Health plc, and previously served on the board of directors of Momenta Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., Fibrocell Science, Inc. and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from MIT and a B.S. in Chemical Engineering from Cornell University. We believe Dr. Langer’s pioneering academic work, extensive medical and scientific knowledge, and experience serving on public company boards of directors qualify him to serve on our board of directors.

Joel S. Marcus has served as a member of our board of directors since December 2018. Mr. Marcus currently serves as Executive Chairman and Founder of Alexandria Real Estate Equities, Inc., a real estate investment trust, and Alexandria Venture Investments, the company’s strategic venture capital platform. Mr. Marcus served as the Chief Executive Officer of Alexandria from 1997 to 2018 and as its Chairman from 2007 to 2018. Mr. Marcus also currently serves on the boards of directors of Applied Therapeutics, Inc., Intra-Cellular Therapies, Inc., and MeiraGTx Holdings plc. He holds a B.A. and J.D. from the University of California, Los Angeles. We believe Mr. Marcus’ extensive investment experience and service on the boards of directors of public life sciences companies qualify him to serve on our board of directors.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is traded under the symbol “FREQ” on the Nasdaq Global Select Market.

On March 19, 2021, there were approximately 116 registered holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

Dividend Policy

We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.

Equity Compensation Plan Information

The following table provides information on our equity compensation plans as of December 31, 2020.

				Number of Securities
				Remaining Available for Future
	Number of Securities to be			Issuance Under Equity
	Issued Upon Exercise of		Weighted-Average Exercise	Compensation Plans
	Outstanding Options,		Price of Outstanding Options,	(excludes securities
Plan Category	Warrants and Rights		Warrants and Rights	reflected in first column) (1)
Equity compensation plans approved by
security holders (2)	6,816,798(3)	$	10.11(4)	2,099,368(5)
Equity compensation plans not approved by
security holders	—		—	—
Total	6,816,798	$	10.11	2,099,368

(1)

Pursuant to the terms of the 2019 Incentive Award Plan, or the 2019 Plan, the number of shares of common stock available for issuance under the 2019 Plan automatically increases on each January 1 until and including January 1, 2029, by an amount equal to the lesser of: (a) 4% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by our board of directors. Pursuant to the terms of the 2019 Employee Stock Purchase Plan, or the 2019 ESPP, the number of shares of common stock available for issuance under the 2019 ESPP automatically increases on each January 1 until and including January 1, 2029, by an amount equal to the lesser of: (a) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by our board of directors.

(2)	Consists of the 2014 Stock Incentive Plan, or the 2014 Plan, the 2019 Plan, and the 2019 ESPP.

(3)	Includes 3,942,449 outstanding options to purchase shares of common stock under the 2014 Plan and 2,874,349 outstanding options to purchase stock under the 2019 Plan.

(4)	As of December 31, 2020, the weighted-average exercise price of outstanding options under the 2014 Plan was $3.02 and the weighted-average exercise price per share of outstanding options under the 2019 Plan was $19.84.

(5)

As of December 31, 2020, a total of 2,099,368 shares of common stock were available for issuance, consisting of (a) 623,445 shares of common stock available for future issuance under the 2019 ESPP, none of which shares were subject to outstanding purchase rights under the 2019 ESPP and (b) 1,475,923 shares of common stock available for future issuance under the 2019 Plan.

Recent Sales of Unregistered Equity Securities

During the period covered by this Annual Report on Form 10-K, we did not issue any securities which were unregistered under the Securities Act and required to be disclosed herein.

Use of Proceeds

In October 2019, we issued and sold 6,325,000 shares of our common stock in our IPO at a public offering price of $14.00 per share. The offer and sale of all the shares in the IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-233652), as amended, which was declared effective by the SEC on October 2, 2019.

The $79.7 million in net proceeds we received from the IPO have been invested in cash and cash equivalents. There has been no material change in the expected use of the net proceeds from our IPO as described in our final prospectus, dated October 2, 2019, filed with the SEC pursuant to Rule 424(b) relating to our registration statement on Form S-1 on October 4, 2019.

Item 6. Selected Financial Data.

You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K and the section titled “Management’s discussion and analysis of financial condition and results of operations.” We have derived the consolidated statement of operations data for the years ended December 31, 2020 and 2019 and the consolidated balance sheet data as of December 31, 2020 and 2019 from our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of results that may be expected in any future period, and our results for any interim period are not necessarily indicative of results that may be expected for any full year.

	Year ended December 31,
(in thousands, except share and per share amounts)	2020			2019
Consolidated Statements of Operations Data:
Revenue	$	36,984		$	28,947
Operating expenses:
Royalty		—			16,000
Research and development		37,415			18,784
General and administrative		27,119			14,838
Total operating expenses		64,534			49,622
Loss from operations		(27,550	)		(20,675	)
Interest income (expense)		994			1,784
Realized gain on investments		84			138
Foreign exchange (loss) gain		(4	)		7
Loss before income taxes		(26,476	)		(18,746	)
Income taxes		(35	)		—
Net loss		(26,511	)		(18,746	)
Cumulative Series C preferred stock dividends		—			(1,054	)
Net loss attributable to common stockholders		(26,511	)		(19,800	)
Net loss per share attributable to common stockholders, basic and diluted(1)	$	(0.82	)	$	(2.29	)
Weighted-average shares of common stock outstanding, basic and diluted(1)		32,253,227			8,649,245

(1)	See Note 2 within the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for an explanation and details of the method used to calculate the basic and diluted net loss per share of common stock.

	As of December 31,
(in thousands)	2020			2019
Consolidated Balance Sheet Data:
Cash, cash equivalents and short-term investments	$	220,341		$	217,355
Working capital(1)		198,430			168,575
Total assets		264,722			223,218
Total liabilities		72,231			55,860
Accumulated deficit		(95,399	)		(68,888	)
Total stockholders’ (deficit) equity		192,491			167,358

(1)	We define working capital as current assets less current liabilities. See our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further details regarding our current assets and current liabilities.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the section titled “Risk factors” in this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below.

Overview

Our initial therapeutic focus is sensorineural hearing loss, or SNHL, which is the most prevalent type of hearing loss. We are developing FX-322 to treat the underlying cause of SNHL, which is the loss of hair cells. FX-322 is designed to regenerate hair cells through the activation of progenitor cells already present in the ear. In our Phase 1/2 clinical trial evaluating FX-322 in 23 patients with stable SNHL, we observed a statistically significant and clinically meaningful improvement in key measures of hearing loss, including word recognition, and clarity of sounds, and FX-322 was observed to be well-tolerated. We commenced dosing of a Phase 2a clinical trial of FX-322 in patients with SNHL in October 2019. In September 2020, we completed enrollment of 95 patients across 16 sites in the Phase 2a clinical trial. In March 2021, we announced topline, day-90 interim data from the Phase 2a clinical trial. The results showed that four weekly injections in subjects with mild to moderately severe SNHL did not demonstrate improvements in hearing measures versus placebo. While WR scores increased across all groups, repeated weekly injections appeared to dampen the hearing benefit observed compared to other single injection-studies. The interim results also showed an unexpected apparent level of hearing benefit in the placebo group that did not occur in previous trials and exceeded well-established published standards. No treatment-related serious adverse events were observed in the study. We plan to report an analysis of the end of Phase 2a data (210 days) late in the second quarter of 2021. We are also working to identify a product candidate for the treatment of multiple sclerosis, or MS. This program focuses on activating oligodendroglial progenitor cells in the central nervous system to repair the myelin sheath that protects axons and may have the potential to repair damage done by the disease. We established an internal research program using PCA to drive remyelination as a potential therapy for MS and have identified compounds that display promising preliminary preclinical results in an in vivo model of remyelination. Our research efforts are focused on optimizing these compounds and identifying a lead therapeutic candidate to advance into clinical trials. We have obtained worldwide licenses for intellectual property from Scripps and Cambridge Enterprise on approaches to promote remyelination of nerve fibers and are engaged in sponsoring clinical research to validate this approach at Cambridge University.

We commenced a Phase 1b clinical trial of FX-322 for age-related hearing loss in October 2020. The clinical trial is a double-blind, placebo-controlled, randomized multicenter safety study of up to 30 individuals aged 66-85 with mild to moderately severe age-related hearing loss. The primary objectives of the Phase 1b study are to assess the local and systemic safety of a single dose of FX-322 and evaluate hearing responses in an older adult cohort. Study participants will be randomized 4:1 to receive either FX-322 or placebo in one ear. Validated measures of hearing including WR, words-in-noise, or WIN, and pure tone audiometry will be used. Safety, otologic and audiologic assessments will be conducted at day 30 and 90 following administration of FX-322 or placebo. We expect to share results from this clinical trial in the second quarter of 2021.

We also commenced a Phase 1b clinical trial of FX-322 in patients aged 18-65 with severe SNHL in November 2020. Severe SNHL is defined as a pure tone average deficit between 71-90 dB. Many patients with this clinical

profile typically would be candidates for cochlear implants. This clinical trial has a similar design to the age-related Phase 1b clinical trial that completed enrollment in October 2020. We expect to share results for the age-related Phase 1b study second quarter 2021 and SNHL Phase 1b study in the third quarter of 2021.

In October 2019, we completed the initial public offering of our common stock, or the IPO. In the IPO, we issued and sold 6,325,000 shares of our common stock at a price to the public of $14.00 per share, inclusive of the underwriters’ exercise in part of their over-allotment option. We received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In July 2019, we closed our Series C convertible preferred stock financing in which we issued and sold 39,492,960 shares of our Series C convertible preferred stock for aggregate gross proceeds of approximately $61.7 million. In July 2019, we also entered into a License and Collaboration Agreement, or the Astellas Agreement, with Astellas Pharma Inc., or Astellas, pursuant to which Astellas paid us an upfront payment of $80.0 million.

In July 2020, we completed a private placement of our common stock to new and existing investors, or the Private Placement. In the Private Placement, we issued and sold 2,350,108 shares of our common stock at a purchase price of $18.00 per share. We received approximately $40.1 million in net proceeds, after deducting placement agent fees and other offering expenses. In connection with the Private Placement, we entered into a Registration Rights Agreement, or the Registration Rights Agreement, with the investors purchasing shares in the Private Placement. Pursuant to the Registration Rights Agreement, we filed a registration statement with the Securities and Exchange Commission, or the SEC, which was declared effective on September 3, 2020, registering the resale of the shares sold in the Private Placement.

Since our formation in 2014, we have devoted substantially all our resources to developing our PCA platform, conducting research and development activities, including product candidate development, recruiting skilled personnel, establishing our intellectual property portfolio, and providing general and administrative support for these operations. We have financed our operations primarily through proceeds from the sale of convertible notes, convertible preferred stock, the common stock and the Astellas Agreement.

Since our formation, we have incurred significant operating losses and have not generated any revenue from the sale of products. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $26.5 million and $18.7 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $95.4 million.

We expect our operating expenses to increase substantially in connection with the expansion of our product development programs and capabilities. In addition, we expect to continue to incur significant additional costs associated with operating as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval for, and successfully commercialize our product candidates, or until our collaborators do so, which could result in milestone payments or royalties to us. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing and distribution.

As a result of these anticipated expenditures, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We cannot be sure that we will ever generate sufficient revenue to achieve profitability.

Because of the numerous risks and uncertainties associated with the development of therapeutics, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we can generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be required to raise additional capital on terms that are unfavorable to us or we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

COVID-19

worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. Thus, while we have resumed experiments at our Farmington site, we have transitioned certain key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We have also taken steps consistent with the FDA’s updated industry guidance for conducting clinical trials. The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operates, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, COVID-19 may cause significant disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue.

License and collaboration agreements

Astellas Pharma Inc.

In July 2019, we entered into the Astellas Agreement with Astellas, under which we granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek, and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, or the Astellas licensed products, including our product candidate FX-322, outside of the United States. We and Astellas have agreed to jointly develop the Astellas licensed products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in SNHL and in age-related hearing loss, in each case in one major Asian country and one major European country. We have agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in the United States. Astellas has the sole right to commercialize the Astellas licensed products outside of the United States and we have the sole right to commercialize the Astellas licensed products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas licensed products in a major Asian country and a major European country following receipt of regulatory approval in such countries.

As a consideration for the licensed rights under the Astellas Agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestones up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments and tiered royalties at rates ranging from low to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. Pursuant to our Exclusive Patent License Agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, we are required to pay MIT a royalty on sublicense revenues. A royalty of $16.0 million related to the $80.0 million upfront payment received from Astellas was expensed in the quarter ended September 30, 2019 and paid in November 2019. The $80.0 million upfront payment received from Astellas in July 2019 has been recorded as deferred revenue and is being recognized as revenue, using the input method, over the period in which we will be conducting Phase 2a clinical trials for FX-322. As of December 31, 2020, we have recognized $65.9 million of the $80.0 million since the agreement was executed in 2019.

Massachusetts Institute of Technology

In December 2016, we entered into the MIT License, with MIT under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, or the MIT licensed products, and to develop and perform processes, or the MIT licensed processes, which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. We are required to use diligent efforts to develop and commercialize the MIT licensed products or processes, and to make such products or processes reasonably available to the public. We are also subject to certain development obligations with regards to a first MIT licensed product. We have satisfied certain obligations related to preclinical studies and the filing of an IND for a first MIT licensed product with our development activities related to FX-322. Our future development obligations are: (i) to commence a Phase II clinical trial for such product within two years of the IND filing for such product, (ii) to commence a Phase III clinical trial for such product within five years of the IND filing for such product,

(iii) to file a New Drug Application, or NDA, or equivalent with the FDA or comparable European regulatory agency for such product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such product within 11 years of the IND filing for such product. We also have certain development obligations with regards to a second MIT licensed product.

Upon entering into the MIT License, we paid a $50 thousand license fee payment and issued shares of our common stock equal to 5% of our then-outstanding capital stock to MIT. We are required to pay certain annual license maintenance fees ranging from $30 thousand to $0.1 million per year prior to first commercial sale of a MIT licensed product and an annual license maintenance fee of $0.2 million every year afterwards, which may be credited to running royalties during the same calendar year, if any. We are also required to make potential milestone payments in an aggregate amount of up to $2.9 million on each MIT licensed product or process. In addition, we agreed to pay a low single-digit royalty on the MIT licensed products and processes and a low-twenties royalty on sub-license revenues. In the year ended December 31, 2019, we paid MIT a $16.0 million royalty on the upfront license fee received from Astellas. See “Business—License and collaboration agreements—Massachusetts Institute of Technology.”

Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary)

In February 2019, we entered into an Non-Exclusive Patent License Agreement, or the MEE License, with the Massachusetts Eye and Ear, or MEE, under which we received a non-exclusive, non-sub-licensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, and to develop and perform processes that incorporate the licensed technology for the treatment or prevention of hearing loss, or the MEE licensed products. We are obligated to use diligent efforts to develop and commercialize the MEE licensed products. We are also subject to milestone timeline obligations to dose a first patient in a Phase II trial by December 31, 2020 and to dose a first patient in a Phase III trial by December 31, 2024.

Upon entering into the MEE License, we made a $20 thousand license fee payment. We are obligated to pay certain annual license maintenance fees between $5 thousand and $7.5 thousand per each MEE patent family case number included in the licensed MEE patent rights prior to first commercial sale of an MEE licensed product. We are also obligated to pay a minimum annual royalty payment of $15 thousand per each MEE patent family case number included in the licensed MEE patent rights after first commercial sale of an MEE licensed product. We are also obligated to make milestone payments up to $350 thousand on each product or process that incorporates the licensed patent rights. In addition, we have agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. See “Business—License and collaboration agreements—Massachusetts Eye and Ear.”

The Scripps Research Institute (California Institute for Biomedical Research)

In September 2018, we entered into a license agreement, or the CALIBR License, with the California Institute for Biomedical Research, or CALIBR, a division of Scripps, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the CALIBR licensed products, which incorporate licensed technology for the treatment of MS. We have agreed to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR licensed product. We are also subject to certain milestone timeline obligations, which may be extended in certain circumstances as described in the CALIBR License, to: (i) submit an IND (or equivalent) for a CALIBR licensed product by the 30th month after the effective date of the CALIBR License, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR licensed product by the fourth anniversary of the effective date of the CALIBR License, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR licensed product by the sixth anniversary of the effective date of the CALIBR License.

Upon entering into the CALIBR License, we made a $1.0 million license fee payment, and are required to make milestone payments in an aggregate amount of up to $26.0 million for each category of CALIBR licensed products. Category 1 is any CALIBR licensed products containing a compound that modulates any muscarinic receptor, and Category 2 is any CALIBR licensed products not included in Category 1 that could differentiate oligodendrocyte precursor cells from in vitro studies and/or are active in animal models relevant to MS. We are also required to pay a mid-single-digit royalty on CALIBR licensed products and a royalty on sub-license revenues ranging from a low-teen percentage to 50%. See “Business—License and collaboration agreements—The Scripps Research Institute (California Institute for Biomedical Research).”

The Scripps Research Institute

In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we are required to make funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement.

The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement. We have the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt. See “Business—License and collaboration agreements—The Scripps Research Institute (California Institute for Biomedical Research).”

In September 2020, we extended the term of the option agreement through the end of December 2021. As consideration for this extension, we are required to make additional funding payments of $0.6 million to Scripps through December 2021.

We have the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt.

Cambridge Enterprise Limited

In December 2019, we entered into an Exclusive Patent License Agreement, or the Cambridge License, with Cambridge, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the Cambridge licensed products, which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant sublicenses under the Cambridge License. Cambridge reserves the right to use for itself (as well as the investors and the funder) and the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.

We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge licensed product. Upon entering into the Cambridge License, we made a $50 thousand license fee payment. We are obligated to pay an annual license fee of $50 thousand. We are also obligated to make milestone payments up to $10.5 million on each Cambridge licensed product. In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.

Components of our results of operations

Revenue

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, Revenue Recognition, we are recognizing the $80.0 million as revenue over the period that research and development services and the Phase 2a clinical study for FX-322 are being provided using the input method. For the purpose of revenue recognition, this is the period from execution of the Astellas Agreement to, based on management’s best estimate, the completion date of the Phase 2a clinical study. In the year ended December 31, 2020, we recognized $37.0 million of the $80.0 million upfront fee as revenue. In the year ended December 31, 2019, we recognized $28.9 million of the upfront fee as revenue. The 2019 amount reflects revenue of $16.0 million equal to the royalty expense under the MIT License as well as $12.9 million from applying the input method to the remaining $64.0 million of the upfront payment.

Royalty

We are required to pay royalties under the MIT License on the receipt of fees for the sublicense of the MIT intellectual property. We expensed the $16.0 million royalty due MIT on the $80.0 million license fee pursuant to the Astellas Agreement in the third quarter of 2019. There were no royalties paid in the year ended December 31, 2020.

Research and development expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and for the development of our product candidate, FX-322. These include the following:

•

salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;

•

expenses incurred under agreements with third parties, including contract research organizations, or CROs, and other third parties that conduct preclinical research and development activities and clinical trials on our behalf;

•

costs to manufacture our clinical trial material for use in our preclinical studies and clinical trials;

•

costs of outside consultants, including their fees and related travel expenses;

•

costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;

•

option and license payments made to third parties, including MIT, Scripps, MEE and Cambridge, for intellectual property used in research and development activities; and

•

facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically, identifiable to research activities.

We expense research and development costs as incurred.

We track external research and development costs, including the cost of services, outsourced research and development, clinical trials, contract manufacturing, laboratory equipment and maintenance, and certain other development costs, by product candidate when the costs are specifically identifiable to a product candidate. Internal and external costs associated with infrastructure resources, other research and development costs, facility-related costs, and depreciation and amortization that are not identifiable to a specific product candidate are included in the platform development, early-stage research, and unallocated expenses category in the table below.

The following table summarizes our research and development expenses by product candidate or development program for the years ended December 31, 2020, and 2019:

	Years ended December 31
	2020		2019

Direct research and development expenses by product candidate:
FX-322 external development costs	$	9,392	$	4,294
Platform development, early-stage research and unallocated expenses:
Employee-related costs		17,140		8,249
Laboratory supplies		388		395
Outsourced research and development		6,694		4,241
Facility-related costs		1,392		1,155
Depreciation and amortization		759		450
Other research and development costs		1,650		—
Platform development, early-stage research and unallocated expenses total		28,023		14,490
Total research and development expenses	$	37,415	$	18,784

We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we complete our Phase 2a clinical trial and additional clinical trials for FX-322 and continue to discover and develop additional product candidates. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to increased scale, duration and the higher costs associated with later stage clinical trials.

We cannot determine with certainty the duration and costs of future clinical trials of FX-322 or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. The duration, costs, and timing of clinical trials and development of FX-322 and any other product candidate we may develop will depend on a variety of factors, including:

•

the scope, rate of progress, expense and results of clinical trials of FX-322, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;

•

the actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability, and commercial viability;

•

significant and changing government regulation and regulatory guidance;

•

the timing and receipt of any marketing approvals;

•

the progress of the development efforts of parties with whom we may enter into collaboration agreements;

•

our ability to secure manufacturing supply through relationships with third parties;

•

the commercialization of our product candidates, if and when approved; and

•

the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate.

General and administrative expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which

include direct depreciation costs and expenses for rent and maintenance of facilities, and other operating costs that are not specifically attributable to research and development activities.

We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued research activities and development of product candidates. In addition, due to our IPO in October 2019, we expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with the requirements of The Nasdaq Stock Market LLC and the SEC; director and officer insurance costs; and investor and public relations costs.

Interest income

Interest income consists of interest earned on cash equivalents and short-term investments.

Realized gain on investments

Realized gain on investments represents the gain realized on our marketable securities in the years ended December 31, 2020 and 2019.

Foreign exchange (loss) gain

Foreign exchange (loss) gain represents the gain or loss recorded as a result of remeasuring the financial statements of our foreign subsidiaries.

Income taxes

Since our inception in 2014, we have generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods.

As of December 31, 2020, we had federal net operating loss carryforwards of approximately $67,868 and Massachusetts state operating loss carryforwards of approximately $43,386 which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $45,469 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2040. As of December 31, 2020, we also had federal and Massachusetts research and development tax credit carryforwards of $3,014 and $1,211, respectively, which are available to offset federal and state tax liabilities through 2040 and 2035, respectively. Realization of future tax benefits is dependent on many factors, including our ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. We have completed several financings and have conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and have determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, we may utilize approximately $10,800 of our pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership. Additionally, we have determined an ownership changed occurred in October of 2019 as a result of the IPO. Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382. We have determined we will be able to utilize the entire $46,123 of our pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.

Results of operations

Comparison of years ended December 31, 2020 and 2019

The following table summarizes our results of operations for the years ended December 31, 2020 and 2019:

	Year Ended December 31,
	2020			2019			Increase (Decrease)
	(in thousands)
Revenue	$	36,984		$	28,947		$	8,037
Operating expenses:
Royalty		—			16,000			(16,000	)
Research and development		37,415			18,784			18,631
General and administrative		27,119			14,838			12,281
Total operating expenses		64,534			49,622			14,912
Loss from operations		(27,550	)		(20,675	)		(6,875	)
Interest income		994			1,784			(790	)
Realized gain on investments		84			138			(54	)
Foreign exchange (loss) gain		(4	)		7			(11	)
Loss before income taxes		(26,476	)		(18,746	)		(7,730	)
Income taxes		(35	)		—			(35	)
Net loss	$	(26,511	)	$	(18,746	)	$	(7,765	)

Revenue

Revenue was $37.0 million for the year ended December 31, 2020 compared to $28.9 million for the year ended December 31, 2019. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, we are recognizing the $80.0 million as revenue over the period that research and development services and the Phase 2a clinical study for FX-322 are being provided using the input method. In the year ended December 31, 2020, we recognized revenue of $37.0 million applying the input method to the upfront payment. In the year ended December 31, 2019 we recognized revenue of $28.9 million applying the input method to the upfront payment. We expect to recognize the remaining revenue under the Astellas Agreement in 2021.

Royalty Expense

We are required to pay royalties under the MIT License on the receipt of fees for the sublicense of the MIT intellectual property. In the year ended December 31, 2019, we expensed the $16.0 million royalty due MIT on the $80.0 million upfront fee received from Astellas. No royalties were due in the year ended December 31, 2020.

Research and development expenses

	Years ended December 31,				Increase
	2020		2019		(Decrease)
					(in thousands)
Direct research and development expenses by product candidate:
FX-322 external development costs	$	9,392	$	4,294	$	5,098
Platform development, early-stage research and unallocated expenses:
Employee-related costs		17,140		8,249		8,891
Laboratory supplies		388		395		(7	)
Outsourced research and development		6,694		4,241		2,453
Facility-related costs		1,392		1,155		237
Depreciation and amortization		759		450		309
Other research and development costs		1,650		—		1,650
Platform development, early-stage research and unallocated expenses total		28,023		14,490		13,533
Total research and development expenses	$	37,415	$	18,784	$	18,631

Research and development expenses for the year ended December 31, 2020 were $37.4 million, compared to $18.8 million for the year ended December 31, 2019. The increase of $18.6 million was primarily due to an increase of $13.5 million in platform development, early-stage research and unallocated expenses and an increase of $5.1 million in FX-322 external research and development costs.

The $9.4 million of FX-322 external development costs incurred for the year ended December 31, 2020 consisted primarily of $8.9 million of clinical and development costs associated with the Phase 2a and other related clinical trials of FX-322, including $2.2 million related to drug manufacturing and development, and $0.4 million of third party consulting costs. The $4.3 million of FX-322 external development costs incurred for the year ended December 31, 2019 consisted primarily of $2.1 million of clinical development costs including manufacturing costs for FX-322 to be used in clinical trials, $0.7 million of outside consulting costs, $1.1 million in clinical trial costs and $0.3 million in milestone payments under the MIT License.

The $28.0 million of platform development, early-stage research and unallocated expenses incurred for the year ended December 31, 2020 consisted primarily of $17.1 million of employee-related costs, including $4.0 million of stock compensation expense, $6.7 million of outsourced research and development expense, and $1.7 million of other research and development costs. This increase of $13.5 million from the year ended December 31, 2019 is primarily attributable to an increase of $8.9 million in employee-related expenses associated with increased headcount to support pre-clinical and clinical development of FX-322 and research on our PCA platform developments and a $1.7 million increase in other research and development expenses, primarily related to consulting on programs excluding FX-322.

General and administrative expenses

General and administrative expenses were $27.1 million for the year ended December 31, 2020, compared to $14.8 million for the year ended December 31, 2019. General and administrative expenses increased $12.3 million due to an increase of $8.0 million in employee-related costs, including $4.1 million in stock compensation expense, as we increase our general and administrative headcount to manage our growth and the impact of being a public company, and increases of $2.3 million and $1.4 million in directors and officers insurance and public relations expense, respectively.

Interest income

Interest income was $1.0 million for the year ended December 31, 2020 compared to $1.8 million for the year ended December 31, 2019, due to a decrease in interest rates in the current year.

Realized gain on investments

Realized gain on investments was $84 thousand for the year ended December 31, 2020 compared to $138 thousand for the year ended December 31, 2019 due to a decrease in interest rates in the current year.

Foreign exchange (loss) gain

Foreign exchange loss was $4 thousand for the year ended December 31, 2020 compared to a gain of $7 thousand for the year ended December 31, 2019. The decrease of $11 thousand was due to differences in foreign exchange remeasurement of the financial statements of our foreign subsidiaries.

Liquidity and capital resources

Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will continue to increase, including in connection with conducting preclinical studies and clinical trials for our product candidates, contracting with contract manufacturing organizations, or CMOs, to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations particularly as we continue to operate as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources.

We do not currently have any approved products and have never generated any revenue from product sales. We have financed our operations primarily through proceeds from the sale of our convertible notes, convertible preferred stock, our IPO, our Private Placement, the upfront payment under the Astellas Agreement, and a Term Loan. To date, we have raised approximately $376.9 million through a combination of convertible notes, convertible preferred stock, the upfront payment under the Astellas Agreement, grants, the IPO, our Private Placement, option exercises and Term Loan. Our cash, cash equivalents and short-term investments totaled $220.3 million as of December 31, 2020. As of December 31, 2020, we had $15.0 million of debt related to the Term Loan.

Cash flows

The following table summarizes our sources and uses of cash for the periods presented:

	Year Ended December 31,
	2020			2019
	(in thousands)
Net cash (used in) provided by operating activities	$	(45,188	)	$	34,216
Net cash provided by (used in) investing activities		10,402			(18,261	)
Net cash provided by financing activities		56,688			142,015
Increase in cash and cash equivalents	$	21,902		$	157,970

Cash flows for the year ended December 31, 2020

Operating activities

Net cash used by operating activities for the year ended December 31, 2020 was $45.2 million, consisting of a net loss of $26.5 million as we incurred expenses associated with our FX-322 program, platform development and early-stage research, and general and administrative expenses. In addition, we had non-cash charges of $11.6 million for depreciation, stock-based compensation expense, and non-cash lease expense. Net cash used in operating activities was also impacted by a net $30.2 million decrease in operating assets and liabilities, including a decrease of $37.0 million in deferred revenues from the upfront payment under the Astellas Agreement, and increases in accounts payable, accrued expenses and prepaid expense and other current assets of $4.3 million, $3.1 million, and $0.6 million, respectively.

Investing activities

Net cash provided by investing activities for the year ended December 31, 2020 was $10.4 million, which was attributable to $43.4 million of redemptions of available for sale securities, partially offset by $26.3 million of available for sale securities and $6.7 million of purchases of property and equipment, $2.6 million of which is related to the buildout of the Company’s new Lexington office.

Financing activities

Net cash provided by financing activities for the year ended December 31, 2020 was $56.7 million, primarily attributable to $40.1 million in net proceeds from the July 2020 Private Placement, $15.0 million in proceeds from the Term Loan, and $1.5 million in proceeds from the exercise of stock options.

Cash flows for the year ended December 31, 2019

Operating activities

Net cash provided by operating activities for the year ended December 31, 2019 was $34.2 million, primarily consisting of a net loss of $18.7 million as we incurred expenses associated with our FX-322 program, platform development and early-stage research, and general and administrative expenses. In addition, we had non-cash charges of $4.3 million primarily for depreciation, stock-based compensation expense and deferred lease incentives. Net cash used in operating activities was also impacted by a net $48.7 million change in operating assets and liabilities, including an increase of $51.1 million in deferred revenues from the upfront payment under the Astellas Agreement and a $1.5 million increase accrued expenses, which were partially offset by an increase of $3.3 million in prepaid expenses and other current assets and a $.6 million decrease in accounts payable.

Investing activities

Net cash used in investing activities for the year ended December 31, 2019 was $18.3 million, which was attributable to $1.1 million of purchases of property and equipment and $17.2 million of net purchases of marketable securities.

Financing activities

Net cash provided by financing activities for the year ended December 31, 2019 was $142.0 million, consisting of proceeds from our IPO of $79.7 million, the issuance of our Series C convertible preferred stock of $61.7 million, the issuance of additional shares of our Series B convertible preferred stock of $0.3 million, and $0.3 million of proceeds from the exercise of stock options.

Funding requirements

Our operating expenses increased substantially in the years ended December 31, 2020 and 2019 and are expected to increase substantially in the future in connection with our ongoing activities, particularly as we advance FX-322 through clinical trials and as we research and develop additional product candidates including preclinical activities, studies for INDs, and initiation of human clinical trials. In addition, we expect to incur additional general and administrative costs to build the infrastructure necessary to manage the growth of our research and development efforts and the increased costs associated with operating as a public company.

Specifically, our costs and expenses will increase as we:

•

advance the clinical development of FX-322;

•

pursue the preclinical and clinical development of other product candidates using our PCA platform, including our program for the treatment of MS;

•

in-license or acquire the rights to other products, product candidates or technologies;

•

maintain, expand, and protect our intellectual property portfolio;

•

hire additional personnel in research, manufacturing, and regulatory and clinical development, as well as management personnel; and

•

expand our operational, financial, investor relations, and management systems and increase personnel, including personnel to support our operations as a public company.

100

We believe that our existing cash, cash equivalents, and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements into 2023. We have based this estimate on assumptions that may prove to be incorrect, and we could utilize our available capital resources sooner than we expect.

Because of the numerous risks and uncertainties associated with the research, development, and commercialization of therapeutics, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including:

•

the progress, costs, and results of our clinical development and clinical trials for FX-322;

•

the progress, costs, and results of our additional research and preclinical development programs, including our program for the treatment of MS;

•

the outcome, timing and cost of meeting regulatory requirements established by the FDA and comparable foreign regulatory authorities, if applicable, for our product candidates;

•

the costs and timing of internal process development, manufacturing activities, and clinical trial management associated with FX-322 and other product candidates we advance through preclinical and clinical development;

•

our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements;

•

the scope, progress, results, and costs of any product candidates that we may derive from our PCA platform or any other product candidates we may develop alone or with collaborators;

•

the extent to which we in-license or acquire rights to other products, product candidates, or technologies;

•

additions or departures of key scientific or management personnel;

•

the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and protecting our intellectual property rights, and defending against any intellectual property-related claims; and

•

the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution for any product candidates for which we or our collaborators obtain marketing approval.

Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other sources, such as collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, product development, and research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.

Contractual obligations and commitments

The following is a summary of our contractual obligations and commitments as of December 31, 2020:

	Payments due by period (in thousands)
	Total		Less than 1 year		1 - 3 years		4 - 6 years		More than 6 years

Operating lease obligations (1)	$	47,456	$	2,986	$	12,855	$	14,048	$	17,567

(1)

Represents future minimum lease payments under our operating leases for office and laboratory space at our Woburn, Massachusetts, Lexington, Massachusetts and Farmington, Connecticut facilities (see Note 17 of notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information on these lease agreements).

101

We have not included future milestone payments under our collaboration and license agreements in the table above since the payment obligations under these agreements are contingent upon future events, such as the achievement of specified product development milestones or generating product sales, and we are unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. We are also required to spend certain minimum amounts on research and development of licensed products or processes under the MIT License, and may have certain funding obligations under the Scripps option agreement, which are not included in the table above. See “—License and collaboration agreements” for more information regarding our payment obligations under these agreements.

We also enter into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon completion of a manufacturing run. These payments are not included in the table above as the amount and timing of such payments are not known or are not material.

Critical accounting policies and use of estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our audited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.

Revenue recognition

We account for contracts with customers in accordance with Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“ASC 606”), including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. Our disclosure in the accompanying consolidated financial statements reflects the Company’s accounting policies in compliance with this standard.

Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies its performance obligations. We only apply the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.

We assess whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, we consider factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the “customer” in this type of arrangement) and the

102

availability of the associated expertise in the general marketplace. We also consider the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, we identify all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services.

In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.

If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue and sales-based milestone payments at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, we adjust the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company’s customer with a significant benefit of financing the transfer of goods and services. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. We assess each of its revenue generating arrangements in order to determine whether a significant financing component exists. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, we measure progress toward completion of its performance obligations using an input method based on our efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.

Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.

Accrued research and development expenses

As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Most of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to the following:

•

CROs and other third parties in connection with performing research and development activities and conducting preclinical studies and clinical trials on our behalf;

103

•

Vendors in connection with preclinical development activities; and

•

CMOs and other vendors in connection with product manufacturing and development and distribution of preclinical supplies.

We base our expenses related to preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage preclinical studies and clinical trials and CMOs that manufacture product for our research and development activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may cause us to report amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.

Leases

The Company elected to early adopt ASC 842, Leases, as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (“ROU”) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.

For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component.

Stock-based compensation

We measure stock options and other stock-based awards granted to our employees, directors, consultants, advisors based on the fair value on the date of the grant, awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed.

We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield.

104

Determination of fair value of common stock

Prior to the IPO, there had been no public market for our common stock and as such, the estimated fair value of our common stock had been determined by our board of directors as of the date of each option grant, with input from management, taking into consideration our most recently available third-party valuations of common stock at the time of the grants, as well as our board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Third-party valuations, or valuation reports, were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.

Our common stock valuation reports were prepared using a market approach, utilizing either the guideline M&A or guideline public company methodologies. Under the guideline M&A methodology, a set of mergers and acquisitions within the biotechnology and pharmaceutical industries for similar stage companies were reviewed and an applicable equity value was selected to apply to our company. Under the guideline public company methodology, the market capitalizations of similar public companies were analyzed, and an applicable capitalization for our company was selected based on qualitative and quantitative factors.

For each valuation report, an option pricing allocation method, or OPM, was selected to allocate the total equity value across the various securities outstanding at the time of the valuation. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes.

In addition to considering the results of the valuation reports, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including:

•

the prices at which we sold shares of convertible preferred stock and the superior rights and preferences of the convertible preferred stock relative to our common stock at the time of each grant;

•

the progress of our research and development programs, including the status and results of preclinical studies and clinical trials for our product candidates;

•

our stage of development and commercialization and our business strategy;

•

external market conditions affecting the biotechnology industry and trends within that industry;

•

our financial position, including cash on hand, and our historical and forecasted performance and operating results;

•

the lack of an active public market for our common stock and our convertible preferred stock;

•

the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company considering prevailing market conditions; and

•

the analysis of IPOs and the market performance of similar companies in the biotechnology industry.

The assumptions underlying these valuations represented management’s best estimate, which involved inherent uncertainties and the application of management’s judgment. As a result, if we had used different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different.

Recent accounting pronouncements

A description of recent accounting pronouncements that may potentially impact our financial position, results of operations, or cash flows is disclosed below:

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of

105

previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements.

There are no other recent accounting pronouncements that we believe will have a material impact on our consolidated financial statements.

Off-balance sheet arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents and short-term investments, which are denominated in U.S. dollars. We had cash, cash equivalents and short-term investments of $220.3 million, or 83.2% of our total assets, at December 31, 2020. Interest income earned on these assets was $1.0 million for the year ended December 31, 2020. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. Such interest-earning instruments carry a degree of interest rate risk however, if a change by 10% in interest rates were to have immediately occurred on December 31, 2020, such change would not have had a material impact on our financial position or results of operations. We had $15.0 million of debt outstanding as of December 31, 2020.

Item 8. Financial Statements and Supplementary Data.

Our consolidated financial statements, together with the reports of our independent registered public accounting firms, appear at pages F-1 through F-33 of this Annual Report on Form 10-K for the year ended December 31, 2020. An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. Based on the evaluation of our disclosure controls and procedures as of December 31, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

106

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

Our management, with the participation of Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), conducted an evaluation of the effectiveness of our internal control over financial reporting based on the criteria set forth in “Internal Control –Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2020.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

None

107

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 11. Executive Compensation.

The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.

Item 14. Principal Accounting Fees and Services.

The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.

108

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(1) Financial Statements

The following documents are included on pages F-1 through F-33 attached hereto and are filed as part of this Annual Report on Form 10-K.


Report of an Independent Registered Public Accounting Firm	F-2
Consolidated financial statements As of December 31, 2020 and 2019
Consolidated balance sheets	F-3
Consolidated statements of operations	F-4
Consolidated statements of comprehensive income		F-5
Consolidated statements of convertible preferred stock, non-controlling interest and stockholders’ deficit	F-6
Consolidated statements of cash flows	F-7
Notes to consolidated financial statements	F-8

(2) Financial Statement Schedules:

All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the Consolidated Financial Statements or the Notes thereto set forth below beginning on page F-1.

(3) Exhibits.

The following is a list of exhibits filed as part of this Annual Report on Form 10-K.

Incorporated by Reference

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing

Date

Filed/

Furnished

Herewith

3.1

Restated Certificate of Incorporation of Frequency Therapeutics, Inc.

8-K

001-39062

3.1

10/7/19

3.2

Amended and Restated Bylaws of Frequency Therapeutics, Inc.

8-K

001-39062

3.1

9/25/20

4.1

Form of Specimen Common Stock Certificate

S-1/A

333-233652

4.1

9/23/19

4.2

Second Amended and Restated Investors’ Rights Agreement, dated as of July 17, 2019

S-1

333-233652

4.2

9/6/19

4.3

Form of Indenture

S-3

333-250099

4.3

11/16/20

4.4

Description of Frequency Therapeutics, Inc. Securities

10-K

001-39062

4.3

3/26/20

10.1†

2014 Stock Incentive Plan, as amended and form of option agreements thereunder

S-1

333-233652

10.1

9/6/19

10.2†

2019 Incentive Award Plan and form of option agreements thereunder

S-1/A

333-233652

10.2

9/23/19

10.3†

Non-Employee Director Compensation Program

S-1/A

333-233652

10.3

9/23/19

10.4

Form of Indemnification Agreement for Directors and Officers

S-1/A

333-233652

10.5

9/23/19

109



10.5.1	Lease Agreement, dated as of August 24, 2016, as amended, between ARE-MA Region No. 20 and Frequency Therapeutics, Inc.	10-K	001-39062	10.5.1	3/26/20

10.5.2	Agreement for Termination of Lease and Voluntary Surrender of Premises, dated as of December 11, 2020, between ARE-MA Region No. 20 and Frequency Therapeutics, Inc.	8-K	001-39062	10.1	12/16/20

10.6	Second Amended and Restated Executive Employment Agreement, dated as of September 20, 2019, between David L. Lucchino and Frequency Therapeutics, Inc.	S-1/A	333-233652	10.7	9/23/19

10.7	Exclusive Patent License Agreement, dated as of December 13, 2016, as amended, between Massachusetts Institute of Technology and Frequency Therapeutics, Inc.	S-1	333-233652	10.10	9/6/19

10.8	Non-Exclusive Patent License Agreement, dated as of February 7, 2019, between Massachusetts Eye and Ear Infirmary and Frequency Therapeutics, Inc.	S-1	333-233652	10.11	9/6/19

10.9	License and Collaboration Agreement, dated as of July 16, 2019, between Astellas Pharma, Inc. and Frequency Therapeutics, Inc.	S-1	333-233652	10.12	9/6/19

10.10†	2019 Employee Stock Purchase Plan	S-1/A	333-233652	10.13	9/23/19

10.11	Indenture of Lease, effective as of January 7, 2020 between HCP/KING 75 Hayden LLC and Frequency Therapeutics, Inc.	10-K	001-39062	10.13	3/26/20

10.12	Securities Purchase Agreement, dated July 17, 2020, by and among Frequency Therapeutics, Inc. and the Investors named therein.	8-K	001-39062	10.1	7/21/20

10.13	Registration Rights Agreement, dated July 17, 2020, by and among Frequency Therapeutics, Inc. and the Investors named therein.	8-K	001-39062	10.2	7/21/20

10.14	Employment Agreement, effective December 1, 2020, by and between Frequency Therapeutics, Inc. and Peter P. Pfreundschuh.	8-K	001-39062	10.1	12/1/20

10.15	Loan and Security Agreement, dated December 11, 2020, by and between Frequency Therapeutics, Inc. and Silicon Valley Bank.	8-K	001-39062	10.1	12/15/20

10.16	Employment Agreement, effective February 3, 2020, by and between Frequency Therapeutics, Inc. and Wendy S. Arnold.					*

21.1	Subsidiaries of Frequency Therapeutics, Inc.					*

23.1	Consent of RSM US, LLP, Independent Registered Public Accounting Firm					*

110

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document

***

101.SCH

XBRL Taxonomy Extension Schema Document

***

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

***

101.DEF

XBRL Extension Definition Linkbase Document

***

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

***

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

***

*	Filed herewith

**	Furnished herewith

***	Submitted electronically herewith

†	A management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to Item 15(a)(3) of Form 10‑K.

Item 16. Form 10-K Summary

None.

111

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	FREQUENCY THERAPEUTICS, INC.

Date: March 29, 2021	By:	/s/ David L. Lucchino
		David L. Lucchino
		President, Chief Executive Officer and Director (Principal Executive Officer)

POWER OF ATTORNEY

Each person whose individual signature appears below hereby authorizes and appoints David L. Lucchino and Peter P. Pfreundschuh, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Name	Title	Date

/s/ David L. Lucchino	President, Chief Executive Officer and Director (Principal Executive Officer)	March 29, 2021
David L. Lucchino

/s/ Peter P. Pfreundschuh	Chief Financial Officer (Principal Financial and Accounting Officer)	March 29, 2021
Peter P. Pfreundschuh

/s/ Marc A. Cohen	Chairman and Director	March 29, 2021
Marc A. Cohen

/s/ Cynthia L. Feldmann	Director	March 29, 2021
Cynthia L. Feldmann

/s/ Timothy J. Barberich	Director	March 29, 2021
Timothy J. Barberich

/s/ Michael Huang	Director	March 29, 2021
Michael Huang

/s/ Robert S. Langer	Director	March 29, 2021
Robert S. Langer, Sc.D.

/s/ Joel S. Marcus	Director	March 29, 2021
Joel S. Marcus

112

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of an Independent Registered Public Accounting Firm	F-2
Consolidated financial statements
Consolidated balance sheets	F-3
Consolidated statements of operations	F-4
Consolidated statements of comprehensive loss	F-5
Consolidated statements of convertible preferred stock, non-controlling interest and stockholder’s equity (deficit)	F-6
Consolidated statements of cash flows	F-7
Notes to consolidated financial statements	F-8

F-1

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Frequency Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Frequency Therapeutics, Inc. and its subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, convertible preferred stock, non-controlling interest, and stockholders’ equity (deficit) and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

We have served as the Company's auditor since 2017.

/s/ RSM US LLP

Boston, Massachusetts

March 29, 2021

F-2

Frequency Therapeutics, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	December 31, 2020			December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$	220,341		$	200,158
Short-term marketable securities		—			17,197
Prepaid expenses and other current assets		4,723			4,000
Total current assets		225,064			221,355
Property and equipment, net		7,287			1,762
Right of use assets		30,551			—
Restricted cash		1,820			101
Total assets	$	264,722		$	223,218
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	5,506		$	1,219
Accrued expenses		6,663			3,239
Deferred revenue		14,068			48,152
Lease liabilities		397			—
Other current liabilities		—			170
Total current liabilities		26,634			52,780
Deferred revenue, net of current portion		—			2,900
Lease liabilities, net of current portion		30,597			—
Term Loan		15,000			—
Long-term liabilities		—			180
Total liabilities		72,231			55,860
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019, respectively		—			—
Common stock, $0.001 par value; 200,000,000 shares authorized, 33,964,000 and 30,844,507 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		34			31
Additional paid-in capital		287,829			236,161
Accumulated other comprehensive income		27			54
Accumulated deficit		(95,399	)		(68,888	)
Total stockholders’ equity		192,491			167,358
Total liabilities and stockholders’ equity	$	264,722		$	223,218

See accompanying notes.

F-3

Frequency Therapeutics, Inc.

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

	Year Ended December 31,
	2020			2019
Revenue	$	36,984		$	28,947
Operating expenses:
Royalty		—			16,000
Research and development		37,415			18,784
General and administrative		27,119			14,838
Total operating expenses		64,534			49,622
Loss from operations		(27,550	)		(20,675	)
Interest income		994			1,784
Realized gain on investments		84			138
Foreign exchange (loss) gain		(4	)		7
Loss before income taxes		(26,476	)		(18,746	)
Provision for income taxes		(35	)		-
Net loss		(26,511	)		(18,746	)
Cumulative Series C convertible preferred stock dividends		—			(1,054	)
Net loss attributable to common stockholders	$	(26,511	)	$	(19,800	)
Net loss per share attributable to common stockholders-basic and diluted	$	(0.82	)	$	(2.29	)
Weighted-average shares of common stock outstanding-basic and diluted		32,253,227			8,649,245

See accompanying notes.

F-4

Frequency Therapeutics, Inc.

Consolidated Statements of Comprehensive Loss

(in thousands, except share and per share amounts)

	Year Ended December 31,
	2020			2019
Net loss	$	(26,511	)	$	(18,746	)
Other comprehensive (loss) gain:
Unrealized (loss) gain on marketable securities		(27	)		54
Total comprehensive (loss) gain		(27	)		54
Comprehensive loss	$	(26,538	)	$	(18,692	)

See accompanying notes.

F-5

Frequency Therapeutics, Inc.

Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder’s Equity (Deficit)

(in thousands, except share and per share amounts)

	Series C convertible preferred shares issued	Series C convertible preferred value			Series B convertible preferred shares issued	Series B convertible preferred value			Series B-1 convertible preferred shares issued	Series B-1 convertible preferred value			Series A convertible preferred shares issued	Series A convertible preferred value			Series A-1 convertible preferred shares issued	Series A-1 convertible preferred value			Non- controlling interest			Common shares issued	Common par value		Additi- onal paid-in capital		Accumulated other comprehensive income			Accumu- lated deficit			Total stock- holders’ equity (deficit)
Balance, December 31, 2018	-	$	—		41,857,005	$	38,224		10,000	$	9		62,528,507	$	46,694		10,000	$	8		$	3,773		2,084,710	$	2	$	804	$	—		$	(49,088	)	$	(48,282	)
Stock-based compensation expense	-	-			-	-			-	-			-	-			-	-			-			-		—		3,609		—			—			3,609
Issuance of common stock upon exercise of stock options	-	-			-	-			-	-			-	-			-	-			-			357,170		1		365		—			—			366
Issuance of Series B convertible preferred stock	-	-			288,991		266		-	-			-	-			-	-			-			-		—		—		—			—			—
Issuance of Series C convertible preferred stock	39,492,960		61,687		-	-			-	-			-	-			-	-			-			-		—		—		—			—			—
Accretion of Series C preferred dividend	-		1,054		-	-			-	-			-	-			-	-			-			-		—		—		—			(1,054	)		(1,054	)
Initial public offering of common stock	-	-			-	-			-	-			-	-			-	-			-			6,325,000		6		79,690		—			—			79,696
Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO	(39,492,960)		(62,741	)	(42,145,996)		(38,490	)	(10.000)		(9	)	(62,528,507)		(46,694	)	(10,000)		(8	)		(3,773	)	22,077,627		22		151,693		—			—			151,715
Other comprehensive income	-	-			-	-			-	-			-	-			-	-			-			-		—		—		54			—			54
Net Loss	-	-			-	-			-	-			-	-			-	-			-			-		—		—		—			(18,746	)		(18,746	)
Balance, December 31, 2019	-	$	—		-	$	—		-	$	—		-	$	—		-	$	—		$	—		30,844,507	$	31	$	236,161	$	54		$	(68,888	)	$	167,358
Stock-based compensation expense	-	-			-	-			-	-			-	-			-	-			-			-		—		9,983		—			—			9,983
Issuance of common stock upon exercise of stock options	-	-			-	-			-	-			-	-			-	-			-			769,385		1		1,544		—			—			1,545
Issuance of common stock in Private Placement, net	-	-			-	-			-	-			-	-			-	-			-			2,350,108		2		40,141		—			—			40,143
Other comprehensive (loss)	-	-			-	-			-	-			-	-			-	-			-			-		—		—		(27	)		—			(27	)
Net loss	-	-			-	-			-	-			-	-			-	-			-			-		—		—		—			(26,511	)		(26,511	)
Balance, December 31, 2020	-	$	—		-	$	—		-	$	—		-	$	—		-	$	—		$	—		33,964,000	$	34	$	287,829	$	27		$	(95,399	)	$	192,491

See accompanying notes

F-6

Frequency Therapeutics, Inc.

Consolidated Statements of Cash Flows

(in thousands)

	Year Ended December 31,
	2020			2019
Cash flows from operating activities:
Net loss	$	(26,511	)	$	(18,746	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation		9,983			3,609
Depreciation expense		1,146			813
Issuance of common stock for license agreement		—			54
Non-cash lease expense		434			—
Deferred lease incentives		—			(160	)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(626	)		(3,252	)
Accounts payable		4,287			(644	)
Deferred revenue		(36,984	)		51,052
Accrued expenses		3,083			1,490
Net cash (used in) provided by operating activities		(45,188	)		34,216
Cash flows from investing activities:
Purchases of property and equipment		(6,671	)		(1,064	)
Purchase of available for sale securities		(26,345	)		(282,618	)
Redemption of available for sale securities		43,418			265,421
Net cash provided by (used in) investing activities		10,402			(18,261	)
Cash flows from financing activities:
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs		—			266
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs		—			61,687
Proceeds from issuance of common stock		1,545			80,062
Proceeds from Private Placement, net of issuance costs		40,143			—
Proceeds from Term Loan		15,000			—
Net cash provided by financing activities		56,688			142,015
Net increase in cash, cash equivalents, short-term investments, and restricted cash		21,902			157,970
Cash, cash equivalents, short-term investments and restricted cash at beginning of period		200,259			42,289
Cash, cash equivalents, short-term investments, and restricted cash at end of period	$	222,161		$	200,259
Non-cash items:
Right-of-use assets in exchange for lease liabilities	$	31,335		$	—
Cumulative Series C convertible preferred stock dividends	$	—		$	1,054
Conversion of preferred stock and non-controlling interest into common stock	$	—		$	151,715
Purchases of property and equipment included in accounts payable and accrued expenses	$	2,145		$	—

See accompanying notes

F-7

Frequency Therapeutics, Inc.

Notes to Consolidated Financial Statements

(Amounts in thousands, except share and per share amounts)

1. Organization and basis of presentation

Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.

On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements.

In October 2019, the Company completed the initial public offering of its common stock (the “IPO”). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters’ exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited.

On July 20, 2020, the Company issued and sold an aggregate of 2,350,108 shares of its common stock, par value $0.001 per share, at a purchase price of $18.00 per share to new and existing investors in a private placement for net proceeds of $40.1 million after deducting placement agent fees and offering expenses (the “Private Placement”). In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within 60 days after the closing of the Private Placement (the “Initial Filing Date”) for purposes of registering the resale of the Shares. The Company filed a registration statement (the “Registration Statement”) which was declared effective by the SEC on September 3, 2020.

The Company has also agreed, among other things, to indemnify the investors, their officers, directors, managers, employees, agents and any person who controls any investor under the Registration Statement from certain liabilities and to pay all fees and expenses (excluding any underwriting discounts and commissions) incident to the Company’s obligations under the Registration Rights Agreement.

Uncertainties

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.

F-8

while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. While we have resumed experiments at our Farmington site, we have transitioned certain key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We are also have taken steps consistent with the FDA’s updated industry guidance for conducting clinical trials.

The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, while no significant disruptions have occurred, the COVID-19 pandemic may cause such disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact the our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue.

Liquidity and capital resources

The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December 31, 2020, the Company had an accumulated deficit of $95,399. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued.

2. Summary of significant accounting policies

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC).

Principles of consolidation

The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements.

Use of estimates

The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates.

F-9

The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date.

Comprehensive income (loss)

Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities.

Segment information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker, the Company’s chief executive officer, views the Company’s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue.

Foreign currency

All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December 31, 2020 and 2019 the Company recorded $(4), and $7 of foreign currency exchange (losses) gains, respectively.

Cash and cash equivalents

The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December 31, 2020 and 2019 consists entirely of cash and money market funds.

Restricted Cash

The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company's future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company's Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company's Woburn, Massachusetts facility.

Short-term marketable debt securities

Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders’ equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).

F-10

Concentration of credit risk and off-balance sheet risk

Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.

The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.

Significant suppliers

The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs.

Fair value measurements

Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3

Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company’s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020.

Property and equipment

Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

		Estimated useful life
Lab equipment		3 years
Software		3 years
Furniture and office equipment		3 years
Leasehold improvements		Shorter of the estimated useful life or lease term

Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.

F-11

Impairment of long-lived assets

The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December 31, 2020 and 2019.

Research and development costs and accruals

Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.

Leases

The Company elected to early adopt ASC 842, Leases (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (“ROU”) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.

Collaborative arrangements

The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company’s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, Revenue from Contracts with Customers (“ASC 606”). For those

F-12

elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company’s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense.

The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor’s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products.

The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods.

Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer’s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time.

Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.

The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (“Astellas”), as further described in Note 16 of notes to consolidated financial statements.

Revenue recognition

The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company’s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company’s accounting policies in compliance with this new standard.

Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a

F-13

good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.

The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the “customer” in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services.

In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.

If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company’s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company’s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.

F-14

Patent costs

The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.

Stock-based compensation

The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided.

The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.

There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.

The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period.

Income taxes

The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, Income Taxes (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13).

Net loss per share

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of

F-15

potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December 31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods.

The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2020 and 2019.

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

	Year Ended December 31,
	2020			2019
Numerator:
Net loss attributable to common stockholders	$	(26,511	)	$	(19,800	)
Denominator:
Weighted-average shares of common stock outstanding- basic and diluted		32,253,227			8,649,245
Net loss per share attributable to common stockholders- basic and diluted	$	(0.82	)	$	(2.29	)

The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect.

	Year Ended December 31,
	2020		2019
Unvested restricted Common Stock		3,093		70,366
Series C Preferred (as converted to common stock)		—		1,172,676
Series B Preferred (as converted to common stock)		—		4,759,079
Series A Preferred (as converted to common stock)		—		7,070,574
Conversion of Frequency Japan preferred stock		—		513,047
Outstanding stock options (as converted to common stock)		6,816,798		5,968,672
Total		6,819,891		19,554,414

Recently adopted accounting pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.

In July 2018, the FASB also issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC

F-16

842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time.

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets. The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements.

Recently issued accounting pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

3. Fair value measurements

The Company’s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows:

		December 31, 2020
	Fair Value	Amortization		Unrealized		Fair Market
	Hierarchy	Cost		Gain		Value
Money market funds	Level 1	$	214,522	$	27	$	214,549
		$	214,522	$	27	$	214,549

F-17

		December 31, 2019
	Fair Value	Amortization		Unrealized			Fair Market
	Hierarchy	Cost		(Loss) Gain			Value
Money market funds	Level 1	$	200,131	$	(12	)	$	200,119
U.S. Government treasury securities	Level 1		17,131		66			17,197
		$	217,262	$	54		$	217,316

4. Prepaid expenses

Prepaid expenses and other current assets consisted of the following:

	December 31,		December 31,
	2020		2019
Rent and deposits		-	63
Research and development expenses		1,729	801
Grant receivable		-		805
Accounts receivable		340		-
Insurance		2,552		2,132
Other		102		199
Total	$	4,723	$	4,000

5. Property and equipment

Property and equipment include the following:

	December 31,			December 31,
	2020			2019
Lab equipment	$	4,166		$	1,846
Furniture and office equipment		283			257
Software		291			—
Leasehold improvements		1,419			1,419
Construction in progress		4,340			306
Total		10,499			3,828
Accumulated depreciation		(3,212	)		(2,066	)
Property and equipment, net	$	7,287		$	1,762

The Company recognized $1,146 and $813 of depreciation expense for the years ended December 31, 2020 and 2019, respectively.

6. Accrued expenses

Accrued expenses consist of the following:

	December 31,		December 31,
	2020		2019
Payroll and employee related expenses	$	5,062	$	2,686
Professional fees		647		435
Third-party research and development expenses		874		118
Taxes and other		80		—
Total	$	6,663	$	3,239

F-18

7. Debt

On December 11, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with a commercial bank for a Term Loan with a principal balance of $15 million. The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”). Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in The Wall Street Journal, subject to an interest rate floor of zero) or (ii) 4.75%. Interest related to the Loan Agreement was immaterial for the year ended December 31, 2020.

The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the Term Loan Facility is refinanced by the Bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date.

The Company will pay a final payment of $150,000, which will occur on the earliest of: (i) the Loan Maturity Date; (ii) the date that the Company prepays all of the outstanding principal in full; (iii) the date the loan payments are accelerated due to an event of default; or (iv) the termination of the Loan Agreement. The Company is recording the final payment as interest expense over the term of the loan. The Term Loan Facility is secured by substantially all of the Company’s assets, excluding intellectual property.

8. Convertible preferred stock

As of December 31, 2018, the Company had issued 62,528,507 shares of Series A Preferred Stock, 10,000 shares of Series A-1 Preferred Stock, 41,857,005 shares of Series B Preferred Stock, and 10,000 shares of Series B-1 Preferred Stock. In 2019, the Company also issued 288,911 shares of Series B Preferred Stock. On July 17, 2019, the Company authorized and issued 39,492,960 shares of Series C Preferred for net proceeds of $61,687.

The Company evaluated the tranched nature of the issuance of these preferred shares as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation.

In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock.

9. Non-controlling Interest

In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation.

In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company’s Series A-1 Preferred Stock and 10,000 shares of the Company’s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock.

On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of an initial public offering of the Company’s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred shares were forfeited in conjunction with the IPO.

F-19

10. Stockholders’ equity

Preferred stock

The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of December 31, 2020.

Common stock

The Company has authorized 200,000,000 shares of $0.001 par value common stock of which 33,964,000 were issued and outstanding as of December 31, 2020. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.

The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019:

	December 31,		December 31,
	2020		2019
Stock options outstanding		6,816,798		5,968,672
Shares available for future grant under stock option plan		1,475,923		1,859,654
		8,292,721		7,828,326

11. Stock-based compensation

On November 13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company’s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December 31, 2020, there were no shares of common stock available for future grants under the 2014 Plan.

On September 17, 2019, the Company’s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (“the “2019 Plan”) which became effective on the day prior to the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company’s subsidiaries. A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company’s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company’s board of directors.

All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company’s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant.

F-20

Stock options

A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows:

	Number of shares			Weighted average exercise		Weighted average remaining contractual term		Aggregate intrinsic		Number of shares			Weighted average exercise		Weighted average remaining contractual term		Aggregate intrinsic
	2019 Plan			price		(in years)		value		2014 Plan			price		(in years)		value
Outstanding as of December 31, 2018		—		$	-		—				2,089,334		$	0.61		—		—
Granted		1,247,338			14.09		—				3,015,381			4.17		—		—
Exercised		—			-		—				(357,170	)		1.02		—		—
Forfeited		—			-		—				(26,211	)		1.09		—		—
Outstanding as of December 31, 2019		1,247,338		$	14.09		9.76	$	4,287		4,721,334		$	2.85		8.89	$	65,051
Granted		1,645,859			24.22		—				—			—		—		—
Exercised		(1,851	)		18.93		—				(767,534	)		1.94		—		—
Forfeited		(16,997	)		22.72		—				(11,351	)		6.89		—		—
Outstanding as of December 31, 2020		2,874,349		$	19.84		9.09	$	44,325		3,942,449		$	3.02		7.98	$	127,090
Options exercisable as of December 31, 2020		564,617		$	17.48		8.90	$	10,042		2,337,828		$	2.57		7.88	$	76,416
Options unvested as of December 31, 2020		2,309,732						$	34,283		1,604,621						$	50,674

Stock option valuation

The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:

	December 31,			December 31,
	2020			2019
Risk-free interest rate		1.1	%		2.0	%
Expected term (in years)		6.0			5.9
Expected volatility		79.1	%		79.4	%
Expected dividend yield		0.0	%		0.0	%

Risk-Fee Interest Rate: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant.

Expected Term: The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).

Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available.

Expected Dividend Yield: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. During the years ended December 31, 2020 and 2019, 769,385 and 357,170 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $16,667 and $5,896 respectively.

F-21

The weighted-average grant date fair value of options granted to employees during the years ended December 31, 2020 and 2019 was $16.41 and $4.05 respectively.

The total grant date fair value of options vested during the years ended December 31, 2020 and 2019 was $7,907 and $2,990, respectively.

Restricted common stock

The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder.

A summary of the status of restricted common stock as of December 31, 2020 and 2019 is presented below:


	Number of shares			Weighted average fair value
Unvested, December 31, 2019		70,366		$	0.36
Awarded		—			—
Vested		(67,273	)		0.29
Forfeited		—			—
Unvested, December 31, 2020		3,093		$	1.75

The total value of restricted stock awards that vested during the years ended December 31, 2020 and 2019, based on estimated fair values of the stock underlying the restricted stock awards was $20 and $73, respectively.

Stock-based compensation

Stock-based compensation expense of $9,983 and $3,609 for the years ended December 31, 2020 and 2019 respectively, is included in research and development and general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss.

As of December 31, 2020 and 2019, total unrecognized stock-based compensation expense relating to unvested stock options was $31,006 and $13,820, respectively. This amount is expected to be recognized over a weighted-average period of 3.08 years and 2.76 years, respectively.

12. Employee stock purchase plan

On September 20, 2019, the Company’s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the “ESPP”) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company’s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. No shares were issued under the ESPP at December 31, 2020.

F-22

13. Income taxes

Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods.

As of December 31, 2020, the Company had federal net operating loss carryforwards of approximately $67,868 and Massachusetts state operating loss carryforwards of approximately $43,386 which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $45,469 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2040. As of December 31, 2020, the Company also had federal and Massachusetts research and development tax credit carryforwards of $3,014 and $1,211, respectively, which are available to offset federal and state tax liabilities through 2040 and 2035, respectively.

Realization of future tax benefits is dependent on many factors, including the Company’s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership. Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO. Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382. The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.

ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2020 and 2019 because the Company’s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $26,995 and $16,204 as of December 31, 2020 and 2019 has been established.

The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December 31, 2020 and 2019.

F-23

The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.

A reconciliation of the Company’s pre-tax income for the years ended December 31, 2020 and 2019 is as follows:

	2020			2019
Domestic	$	(25,744	)	$	(19,086	)
Foreign		(732	)		(714	)
Total	$	(26,476	)	$	(19,800	)

The Company’s provision at December 31, 2020 and 2019 consist of the following:

	2020		2019
Current:
Federal	$	35	$	-
State		-		-
Foreign		-		-
Total current	$	35	$	-
Deferred:
Federal		-		-
State		-		-
Foreign		-		-
Total Deferred	$	-	$	-
Total provision (benefit)	$	35	$	-

A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate for the years ended December 31, 2020 and 2019 is as follows:

	2020		2019
U.S federal statutory income tax rate		21.0%		21.0	%
Permanent differences		(0.2)		(2.8	)
State income taxes, net of federal benefit		3.0		4.0
Research and development tax credits		11.2		1.8
Stock compensation deductions		5.1		0.0
Other items		0.6		(1.0	)
Change in deferred tax asset valuation allowance		(40.7)		(23.0	)
Effective income tax rate	—%		—%

F-24

The Company’s deferred tax assets at December 31, 2020 and 2019 consist of the following:

	2020			2019
Net operating loss carryforwards	$	17,885		$	13,253
Research and development tax credits		3,992			1,138
Intangibles		360			358
Stock compensation		850			686
Accrued expenses		-			48
Deferred revenue		3,606			496
Other		142			189
Fixed assets		56			36
Lease liability		7,285			-
Right of use asset		(7,181	)		-
Total deferred tax asset		26,995			16,204
Valuation allowance		(26,995	)		(16,204	)
Net deferred tax assets	$	—		$	—

14. Research and license agreements

Massachusetts Institute of Technology

In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement.

The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company’s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90) days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations.

Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15.

F-25

The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.

In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product.

The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Pursuant to MIT’s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively. Refer to Note 18 for all related party disclosures.

The Scripps Research Institute (California Institute for Biomedical Research)

In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes.

The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations , which may be extended under certain circumstances as outlined in the CALIBR License Agreement, to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement.

Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%.

The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1) the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2) ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to

F-26

terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.

The Scripps Research Institute

In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we made funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement.

In September 2020, the Company extended the term of the option agreement through the end of December 2021. As consideration for this extension, the Company is required to make additional funding payments of $0.6 million to Scripps through December 2021.

The Company has the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt.

Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary)

In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss.

The Company is required to use diligent efforts to develop and commercialize the licensed products and MEE has control over the filing, prosecution, enforcement and defense of any licensed patent rights. We met one of our milestone timeline obligations by dosing a first patient in a Phase II trial by December 31, 2020. We are still subject to a milestone timeline obligation to dose a first patient in a Phase III trial by December 31, 2024.

Upon entering into the MEE License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale.

The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights.

The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60) business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights.

Cambridge Enterprise Limited

In December 2019, we entered into an Exclusive Patent License Agreement ( the “Cambridge License”) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge) (“Cambridge”) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the “Cambridge License Product”) which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.

F-27

The Company has agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product. Upon entering into the Cambridge License, the Company made a $50 license fee payment. The Company is obligated to pay an annual license fee of $50. The Company is also obligated to make milestone payments up to $10.5 million on each Cambridge License Product. In addition, the Company has agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.

The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon 90 days’ prior to written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.

Department of Defense

In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company’s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $323 and $845 as a reduction in research and development expenses for the years ended December 31, 2020 and 2019, respectively.

15. Collaboration agreement

In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States.

The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries.

The collaboration is governed by a joint steering committee (“JSC”) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party’s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC.

As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments up to $230.0 million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone

F-28

payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315.0 million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan.

The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days’ written notice. Each party has the right to terminate the Astellas Agreement due to the other party’s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt.

The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808.

The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation.

Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019.

The $80.0 million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2020, the Company recognized $37.0 million of revenue under the Astellas Agreement. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MIT and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322.

The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its

F-29

evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee’s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the years ended December 31, 2020 and 2019, the Company invoiced Astellas $1,046 and $186 for joint costs, respectively.

16. Commitments and contingencies

Operating leases

In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company’s primary office and laboratory space in Woburn, Massachusetts. The lease was extended in November 2019 and expires in February 2025. Additionally, the Company amended the lease in November 2019 to add additional laboratory and office space. The commencement date of the additional space occurred in February 2020 and expires in February 2025. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2021.

On December 11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the “Lease Termination Agreement”) with ARE-MA Region No. 20, LLC (the “Landlord”). The Lease Termination Agreement provides that the Lease Agreement, dated as of August 14, 2016, by and between the Company and Landlord (as the same may have been amended, the “Lease”) will terminate on March 31, 2021, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May 31, 2021.

As consideration for the Landlord’s agreement to enter into the Lease Termination Agreement and accelerate the expiration date of the term of the Lease, the Company has agreed to pay to Landlord a fee of approximately $0.2 million.

On January 7, 2020 the Company entered into an indenture of lease (the “Lexington Lease”) with HCP/KING 75 Hayden LLC, for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the “Lexington Premises”). The Lexington Lease commenced on December 11, 2020, (the “Commencement Date”). The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses. The term of the Lexington Lease, (the “ Initial Term”), is ten years from the rent commencement date (which is five months following the Commencement Date) and the Initial Term is expected to end on May 31, 2031. The Company also has the option to extend the Initial Term for two additional terms of five years each.

As of December 31, 2020, the Company has $30,551 of operating lease ROU assets, and $397 and $30,597 of current and non-current lease liabilities, respectively, recorded on the consolidated balance sheets. For the year ended December 31, 2020 the Company recorded $470 of operating lease cost, $510 of variable lease cost, and $106 of short-term lease cost. The lease expense for the years ended December 31, 2020 and 2019 are $835 and $269, respectively. Cash paid for amounts included in the measurement of lease liabilities for year ended December 31, 2020 is $484.

Other information	December 31, 2020
Weighted-average remaining lease term	10.3 years
Weighted-average discount rate (1)		8.5	%

(1)

Rate includes the Company’s Woburn and Lexington leases.

F-30

The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020.

2021		2,928
2022		4,159
2023		4,284
2024		4,412
2025		4,545
Thereafter		27,070
Total minimum lease payments		47,398
Less: amount of lease payments representing interest		(16,404	)
Present value of future lease payments		30,994
Less: current lease liabilities		(397	)
Noncurrent lease liabilities	$	30,597

Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows:

2021	$	2,986
2022		4,159
2023		4,284
2024		4,412
2025		4,545
2026 and beyond		27,070
Total minimum lease payments	$	47,456

Contract commitments

The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $0.6 million through December 2021.

The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run.

Guarantees

The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees.

As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid.

The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.

F-31

The Company leases office space in Woburn, Massachusetts under a five-year non-cancelable operating lease, and has entered into a facility lease in Lexington, Massachusetts. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease.

As of December 31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established.

17. Employee benefit plan

Employees of the Company are eligible to participate in the Company’s 401(k) retirement plan (the “401(k) Plan”). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches 100% of the first 5% of employee contributions and vests 100% at time of match. For the years ended December 31, 2020 and 2019, the Company made matching contributions of $0.4 million and $0.2 million, respectively.

18. Related party transactions

The Company’s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company’s directors and shareholders.

As disclosed in Note 14, the Company entered into the MIT License Agreement in December 2016. The patents in-licensed by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively.

19. Subsequent events

The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 29, 2021, the date which the consolidated financial statements were available to be issued. The identified subsequent events are as follows;

On February 18, 2021, the Company completed the liquidation and dissolution of Frequency Therapeutics Japan KK, the Company’s Japanese subsidiary.

On March 23, 2021, the Company announced topline, day-90 data from its FX-322 Phase 2a study. The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study.

The Company also announced new preliminary data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The single dose showed efficacy that was clinically meaningful and statistically significant compared to the untreated ear, had a favorable safety profile and was well tolerated.

F-32

20. Selected Quarterly Data (Unaudited)

The following table contains quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

	2020
	March 31,			June 30,			September 30,			December 31,			Total
	(in thousands, except per share amounts)
Total revenue	$	7,264		$	8,523		$	11,247		$	9,950		$	36,984
Total expenses		12,177			14,548			16,588			20,182		$	63,495
Net loss		(4,913	)		(6,025	)		(5,341	)		(10,232	)	$	(26,511	)
Cumulative series C convertible preferred stock dividends		—			—			—			—			—
Net loss attributable to common stockholders		(4,913	)		(6,025	)		(5,341	)		(10,232	)	$	(26,511	)
Net loss per share attributable to common shareholders - basic and diluted	$	(0.16	)	$	(0.19	)	$	(0.16	)	$	(0.30	)	$	(0.82	)

	2019
	March 31,			June 30,			September 30,			December 31,			Total
	(in thousands, except per share amounts)
Total revenue	$	—		$	—		$	24,238		$	4,709		$	28,947
Total expenses		5,826			6,852			24,813			10,202		$	47,693
Net loss		(5,826	)		(6,852	)		(575	)		(5,493	)	$	(18,746	)
Cumulative series C convertible preferred stock dividends		—			—			(1,014	)		(40	)	$	(1,054	)
Net loss attributable to common stockholders		(5,826	)		(6,852	)		(1,589	)		(5,533	)	$	(19,800	)
Net loss per share attributable to common shareholders - basic and diluted	$	(3.24	)	$	(3.42	)	$	(0.73	)	$	(0.19	)	$	(2.29	)

F-33

EX-10.16 2 freq-ex1016_1057.htm EX-10.16 freq-ex1016_1057.htm

Exhibit 10.16

19 Presidential Way, Suite 203

Woburn, MA 01801

December 19, 2019

Wendy S. Arnold

64 East Street

Ipswich, MA 01938

Re: Employment Terms

Dear Wendy:

On behalf of us at Frequency Therapeutics, Inc. (the “Company”), I am pleased to offer you full-time employment, subject to the terms and conditions below. We expect that your employment with the Company will commence no later than February 3, 2020 in the Company’s Woburn, MA offices. You will be employed as Chief People Officer, reporting to David Lucchino, Chief Executive Officer.

Your responsibilities will include but not be limited to:

•

Reinforce and build upon a “check your ego at the door” culture. (This means supporting our team/teammates, even when one might not get the bulk of the credit one feels they might otherwise deserve.) This approach is fundamental to our culture as team Frequency’s number one mission is to help patients regain hearing while building value for shareholders.

•

Develop the overall strategic HR plan and prioritize and implement key HR initiatives. Participate in the development of the organization's plans and programs as a strategic partner, bringing a business perspective as well as the perspective of people and organization. Evaluate and advise on the impact of strategic and growth initiatives on attracting, motivating, developing and retaining our talent.

•

Act as a trusted advisor and coach to leaders, managers, and employees.

•

Develop and execute the recruitment strategy and workforce plan to enable our rapid growth.

•

Coach hiring managers to identify and recruit strong and diverse talent. Design and implement effective and nimble recruiting procedures and practices.

•

Work with the Leadership Team to design the structure and roles to achieve strategic and growth goals. Advise leaders on optimal staffing and team structure.

•

Champion, promote, and embed an innovative and inclusive company culture. Implement programs and practices to sustain the culture as the company grows.

•

Evaluate Frequency’s current people-related practices and identifies opportunities for improvement. Partners with the CEO, CFO, and General Counsel to develop progressive and competitive compensation and benefits programs to provide motivation, incentives and rewards for strong performance. Contribute to the development of presentations to the Compensation Committee of the Board of Directors. Coordinate with Frequency’s external compensation consultant to support analyses for the Compensation Committee.

US-DOCS\110928677.1

•

Manage and facilitate Frequency’s goal setting and performance assessment process.

•

Supports continuous leader, manager, and employee development by implementing learning programs to ensure skill development needed to build a high-performing company. Ensure strong people management practices, including feedback and assessment. Work with managers to create career paths that grow and retain talent.

•

Partner with Legal to develop appropriate policies and programs for effective and compliant management of the people resources of the organization, including employee relations, affirmative action, sexual harassment, employee complaints, external education and career development. Stay abreast of and ensures compliance with new laws and regulations.

•

Oversee the development and management of HR operations, systems, and processes that will scale as Frequency rapidly grows. Manage the human resource information database (HRIS) and production of necessary reports while ensuring the confidentiality of HR data.

•

Structure, develop and oversee the HR resources to provide maximum benefit to the organization as it grows.

•

Identify, hire, and oversee external resources effectively when outside expertise is necessary.

1.Your compensation will be $25,666.67 per month subject to tax and other withholdings as required by law. In addition, you will be eligible for an annual performance-based bonus with a target amount equal to 35% of your annualized base salary, based on your individual performance and the Company’s performance during the applicable fiscal year, in accordance with certain milestones to be determined by the board of directors of the Company (the “Board”). The Company also agrees to pay the equivalent of your 2019 annual bonus at your previous employer, which is an amount equal to $52,272. Your salary may be adjusted from time to time in accordance with normal business practice and at the sole discretion of the Company. The actual amount of any such annual bonus payable to you will be determined by the Board in its discretion. You must be an active employee of the Company on the date any bonus is paid in order to be eligible for payment of an annual bonus.

2.You will be eligible for Frequency Health, Dental, Vision and Disability insurance, in addition to participation in the Company’s 401(k) the first of the month following your first day of employment.

3.You will be eligible for a maximum 15 Paid Time Off days (PTO) per calendar year to be taken at such times as may be approved by the Company. These PTO days are accrued monthly at a rate of 10 hours per month.

4.You will be required to execute an Employee Proprietary Information and Inventions Assignment Agreement in the form attached as Exhibit B, as a condition of employment.

5.You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.

US-DOCS\110928677.1

6.In connection with entering into this letter agreement, following the commencement of your employment with the Company, the Company will recommend to the Board of Directors or its designee that it grant you an option to purchase 130,000 shares of the Company’s common stock (the “Stock Option”) at a per-share exercise price equal to the fair market value of a share of the Company’s common stock on the date of grant (as determined under the Plan (as defined below)), provided that you are employed by the Company on the date of grant Subject to your continued employment with the Company through the applicable vesting date, 25% of the shares underlying the Stock Option will vest on the first anniversary of the date you commence employment with the Company and 1/48th of the total number of shares initially underlying the Stock Option will vest on each monthly anniversary thereafter. The Stock Option will otherwise be subject to the terms and conditions of the Company’s 2019 Incentive Award Plan (the “Plan”) and a stock option agreement to be entered into between you and the Company.

7.You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work in the United States. If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company.

8.This offer set forth in this letter is contingent upon the Company completing a background check on you to its satisfaction in accordance with applicable laws. The Company engages a third-party provider to perform background checks and such provider will be reaching out to you under separate cover to provide the background check disclosure and required authorization forms for your review and execution.

9.The Company shall have the right to terminate your employment without “Cause” (as defined on Exhibit A hereto). Termination “Without Cause” means the Company’s termination of your employment for any reason other than for Cause, death or as a result of you becoming permanently disabled (within the meaning of Section 22(e) of the Internal Revenue Code of 1986, as amended (the “Code”)). If the Company terminates your employment with the Company Without Cause or you terminate your employment with the Company with Good Reason (as defined on Exhibit A hereto), you shall be entitled to payment of your unpaid base salary earned for the period up to the date of such termination, amounts accrued or payable under any benefit plans and programs of the Company applicable to you up to the date of such termination, subject to and in accordance with the terms of such plans and programs, and amounts payable on account of any unreimbursed business expenses incurred in accordance with Company policy up to the date of such termination. In addition, in the event you deliver to the Company a general release of claims against the Company and its affiliates in a form reasonably acceptable to the Company that becomes effective and irrevocable within sixty (60) days following such termination of employment (“Release Condition”) and subject to your compliance with the terms of any confidentiality, non-competition, non-solicitation or other similar restrictive covenants with the Company to which you are subject, the Company will (i) continue to pay your then current base salary, less all applicable withholding taxes and authorized deductions, for a period of twelve (12) months following the date of termination (“Severance Period”), (ii) an amount equal to 100% of your annual bonus opportunity, less all applicable taxes and withholdings, in one lump sum within

US-DOCS\110928677.1

14 days of the satisfaction of the Release Condition, and (iii) should you timely elect and be eligible to continue receiving group medical and dental coverage pursuant to COBRA, and so long as the Company can provide such benefit without violating the non-discrimination requirements of the law, the Company will pay the portion of the premium for such coverage that is paid by the Company for active and similarly situated employees who receive the same type of coverage, such payment to be made for coverage from the termination date through the earliest of (x) the end of the Severance Period, (y) the date you are no longer eligible for COBRA coverage or (z) the date you become eligible for healthcare coverage from a subsequent employer (and you agree to promptly notify the Company of such eligibility). The remaining balance of any premium cost shall timely be paid by you.

10.Notwithstanding Section 9 hereof, if the Company terminates your employment with the Company Without Cause or you terminate your employment with the Company with Good Reason during the twelve (12) month period commencing on a Change in Control (as defined on Exhibit A hereto), then, subject to your compliance with the Release Condition and with the terms of any confidentiality, non-competition, non-solicitation or other similar restrictive covenants with the Company to which you are subject, in lieu of (and not in addition to) the amounts in Section 9 hereof, (i) the Company will pay you (x) the same benefits as set forth in Section 9 hereof, except that the Severance Period will be twelve (12) months and (y) an amount equal to 100% of your target annual bonus for the year in which the termination occurs, less all applicable taxes and withholdings, in one lump sum within 14 days of the execution of the Release Agreement, and (ii) the vesting and, to the extent applicable, exercisability of each equity award, including all unvested stock options, held by you as of the date the termination occurs will accelerate in respect of one hundred percent (100%) of the shares subject thereto.

11.Nothing in this letter or any other prior agreement between you and the Company (collectively, the “Subject Documents”) prevents you from reporting possible violations of law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies). Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in any Subject Document: (a) you shall not be in breach of any Subject Document, and shall not be held criminally or civilly liable under any federal or state trade secret law (i) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (ii) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (b) if you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney, and may use the trade secret information in the court proceeding, if you file any document containing the trade secret under seal, and do not disclose the trade secret, except pursuant to court order.

12.This letter shall be interpreted to avoid any additional tax under Section 409A of the Code (“Section 409A”). If any payment or benefit cannot be provided or made at the time

US-DOCS\110928677.1

specified without incurring sanctions under Section 409A, then such benefit or payment shall be provided in full at the earliest time thereafter, when such sanctions will not be imposed.

Notwithstanding anything in this letter to the contrary, any compensation or benefit payable under this letter upon your termination of employment shall be payable only upon your “separation from service” with the Company within the meaning of Section 409A (a “Separation from Service”) and, except as provided below, any such compensation or benefits shall not be paid, or, in the case of installments, shall not commence payment, until the sixtieth (60th) day following your Separation from Service (the “First Payment Date”). Any installment payments that would have been made to you during the sixty (60) day period immediately following your Separation from Service but for the preceding sentence shall be paid to you on the First Payment Date and the remaining payments shall be made as provided in this letter. The right to receive any installment payments under this letter, including without limitation any continuation salary payments that are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment as permitted under Section 409A. Except as otherwise permitted under Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or interest pursuant to Section 409A.

Notwithstanding any other provision of this letter to the contrary, and solely if and to the extent necessary for compliance with Section 409A and not otherwise eligible for exclusion from the requirements of Section 409A, if as of the date of your Separation from Service from the Company, you are deemed to be a “specified employee” (within the meaning of Section 409A), no payment or other distribution required to be made to you hereunder (including any payment of cash, any transfer of property and any provision of taxable benefits) as a result of your Separation from Service shall be made until the date that is the earlier of (1) the expiration of the six-month period measured from the date of your Separation from Service or (2) the date of your death. Upon the expiration of the foregoing delay period, all payments and benefits delayed pursuant to the foregoing shall be paid to you in a lump sum, and all remaining payments and benefits due under this letter shall be paid or provided in accordance with the normal payment dates specified for them herein.

13.Notwithstanding any other provisions of this letter, in the event that any payment or benefit made by the Company or otherwise to you or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section 9 and Section 10 hereof, being hereinafter referred to as the “Total Payments”), would be subject (in whole or in part) to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Total Payments shall be reduced (in the order provided in this Section below) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (a) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (b) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which you would be subject in

US-DOCS\110928677.1

respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments). The Total Payments shall be reduced in the following order: (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A, (ii) reduction on a pro-rata basis any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time. All determinations regarding the application of this Section shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the “Independent Advisors”). For purposes of these determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (x) does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (y) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the “base amount” (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company. In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this Section, the excess amount shall be returned immediately by you to the Company.

14.This letter shall be interpreted and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to any conflicts of laws principles that would result in the application of the laws of another state. While other terms and conditions of your employment may change in the future, the at-will nature of your employment may not be changed, except in a subsequent letter or written agreement, signed by you and the Chief Executive Officer of the Company. This letter may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same agreement. Signatures delivered by facsimile or PDF shall be deemed effective for all purposes. This letter contains the entire agreement between you and the Company with respect to the matters covered herein. This letter supersedes all prior and contemporaneous agreements and understanding, oral or written, between you and the Company with respect to the matters herein. This letter may not be amended, nor may any of your rights or obligations as set forth herein be altered, except by a written instrument executed by you, on the one hand, and a duly-authorized officer of the Company acting with the written authorization of the Board, on the other hand.

US-DOCS\110928677.1

15.If you agree with the employment provisions of this letter, please sign this letter in the space provided below and return it to David L. Lucchino, President and CEO. Please return this signed offer letter by December 27, 2019 by 5PM (EST) or the offer will become null and void.


	Sincerely,

	FREQUENCY THERAPEUTICS, INC.



	By:	/s/ David L. Lucchino
	Name:	David L. Lucchino
	Title:	President and CEO

Accepted and agreed by:


/s/ Wendy S. Arnold
Wendy S. Arnold

US-DOCS\110928677.1

19 Presidential Way, Suite 203

Woburn, MA 01801

Exhibit A

When used in the letter to which this Exhibit A is attached, the following terms shall have the meanings set forth below.

(1) “Cause” means any of:

(a) your conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (b) a good faith finding by the Company that you have (i) engaged in willful misconduct or gross negligence that is materially harmful to the business or reputation of the Company, (ii) breached or threatened to breach the terms of any restrictive covenants or confidentiality agreement or any similar agreement with the Company, and/or (iii) materially failed to perform your assigned duties, provided, however, in the case of (iii) that the Company provided you with written notice of such failure and a period of 30 days to cure, but you failed to cure such failure.

(2) “Good Reason” means the occurrence, without your prior written consent, of any of the following events:

(a) a material reduction in your authority, duties, or responsibilities (other than in connection with a corporate transaction where you continue to hold substantially the same position with respect to the Company’s business, substantially as such business exists prior to the date of consummation of such corporate transaction, but do not hold such position with respect to the successor or surviving entity in the transaction); (b) the relocation by at least 50 miles of the principal place at which you provide services to the Company; or (c) a material reduction in your base salary (other than a reduction of less than 10% that is implemented in connection with a contemporaneous reduction in base salaries proportionately affecting other similarly situated employees of the Company).

To be treated as a resignation for Good Reason, (x) you must provide written notice to the Company of your intention to terminate your employment for Good Reason, describing the grounds for such action, no later than 90 days after the occurrence of such circumstances, (y) you must provide the Company with at least 30 days in which to cure the circumstances, and (z) if the Company is not successful in curing the circumstances, you must end your employment within 30 days following the cure period in (y).

(3) “Change in Control” means a Change in Control as defined in the Company’s 2019 Incentive Award Plan, as in effect on the date hereof.

US-DOCS\110928677.1

Exhibit B

Employee Proprietary Information and Inventions Assignment Agreement

US-DOCS\110928677.1

EX-21.1 3 freq-ex211_19.htm EX-21.1 freq-ex211_19.htm

Exhibit 21.1

Subsidiaries of Frequency Therapeutics, Inc.


Legal Name of Subsidiary		Jurisdiction of Organization
Frequency Therapeutics Pty Ltd		Australia
Frequency Therapeutics Securities Corporation		Massachusetts

EX-23.1 4 freq-ex231_7.htm EX-23.1 freq-ex231_7.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (No. 333-233652 and 333-248474) on Form S-1 and Form S-3 (No. 333-250099) of Frequency Therapeutics, Inc. of our report dated March 29, 2021, relating to the consolidated financial statements of Frequency Therapeutics, Inc. and Subsidiaries, appearing in this Annual Report on Form 10-K of Frequency Therapeutics, Inc. for the year ended December 31, 2020.

/s/ RSM US LLP

Boston, Massachusetts

March 29, 2021

EX-31.1 5 freq-ex311_16.htm EX-31.1 freq-ex311_16.htm

Exhibit 31.1

CERTIFICATIONS

I, David L. Lucchino, certify that:

1.	I have reviewed this Annual Report on Form 10-K of Frequency Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 29, 2021

By:

/s/ David L. Lucchino

David L. Lucchino

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 6 freq-ex312_22.htm EX-31.2 freq-ex312_22.htm

Exhibit 31.2

CERTIFICATIONS

I, Peter Pfreundschuh, certify that:

1.	I have reviewed this Annual Report on Form 10-K of Frequency Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 29, 2021

By:

/s/ Peter Pfreundschuh

Peter Pfreundschuh

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 7 freq-ex321_8.htm EX-32.1 freq-ex321_8.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Frequency Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David L. Lucchino, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: March 29, 2021	By:	/s/ David L. Lucchino
		David L. Lucchino
		President and Chief Executive Officer

EX-32.2 8 freq-ex322_14.htm EX-32.2 freq-ex322_14.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Frequency Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Pfreundschuh, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: March 29, 2021	By:	/s/ Peter Pfreundschuh
		Peter Pfreundschuh
		Chief Financial Officer

GRAPHIC 9 gyycud3vz5ad000011.jpg GRAPHIC begin 644 gyycud3vz5ad000011.jpg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end GRAPHIC 10 gyycud3vz5ad000001.jpg GRAPHIC begin 644 gyycud3vz5ad000001.jpg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�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�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end GRAPHIC 11 gyycud3vz5ad000015.jpg GRAPHIC begin 644 gyycud3vz5ad000015.jpg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end GRAPHIC 12 gyycud3vz5ad000006.jpg GRAPHIC begin 644 gyycud3vz5ad000006.jpg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
R,L=K)#9RB*5%!/^KT0,#(9C M=9-6CM<3,2YWZK:7D=41;3N,<^1HE3,7;VSAG5E@PLR,@D(.0BVQ.4TX-/ B M*I>^,.]W=V/7FF6!IAU#D1P2/-.5>&8,R,ZIAS9D4/=[(9)&9]EJKE50(,1) M$T@CQ& -TB+%&I$D6$*J[785D3]'33L.Q69-!*"?$\#0R*#-9ME&],D;ZW]& MMTK("W/>D499I&C@BHA]0@1C&)[C!R"\(WJI)(.&,L74P.Y50K'[+,I!-'?3[?XB7N-P*3Z2JMT2(D&@ZPL2)6RYJ_IT_U@"D&+$IYWQHVH_0CY29K..U'P_#/ M92QI;M>Z?(0UQI8?$D14 BZT:0LILKNW^W% DB0.P @]GE+&;/LM6EBN(Y&G M%K>+E8K_ &^20,?-;ZE&H(NK><9665D>4 _6]>(*L=8?3GVM)G->;T)I]1#I MVAB-M.O]/-X&L+*AEF]EE5H*Q\4)>?TE5/YJKJAN1Z^Q M&0/A%4*[KQ*^-\ M'Z\;34)?"E]>K>-'&)])O3M26XLR2H@NH<*]K>V[#V>ZM9TBECGVND8ANHDA MSO$>E">TCU^UMFMEED,6H6P)>."[^T7MY>4GM)U(FMIXGD1XRZ,[202/)W5S MJ%:13BE.*4XI3BE.*4XI3BE.*4XI3BE%^$_IQ2O-KO4YR)Y5J>/W*GA%=\^4 M:OA/4B)X\JGE/*^E%540LK%%9Q(YJJUS)+A\XU!%+&_P -F%6T4Z+SY414 M1>:9JWCWPUI):-[WVV=0?J-.471!'!5IPRVJ,#PR-.)!D'96QV'A36K\!Q;> MRPGM->DP @]BL6UKAU([.D)0_P U2#JOMRA[7"M"*D*RJS*:86.QK;1HJS1Q MG(0H14,X1)0\PY*AEQM\OB(9*+,D@[(E@FGSO#7BC3_$]O/-9)/"]K(B7$%P MJ!TZ@9HG#1NZ,D@1\$$,"C J!M9L;6M"N]#FBBN6BD6=6:*:%F*-L($B$.J, MKIN0D%<8=2".*.25L4R 6@M1=_:ER5$0LUGBOP^NOZ>$B*I?VC-/92L2%+E=LEM*0">A< MJ KG!ZQ'$$,#+-K>R*IM>=%[!X9[3M'6O!+B17-80.4Q8)%B?+ ]S?< M&FG@=%*_YUEC=;6]A:-DE3V^W>)QATF26>)XV'.&$BLN02I'F4LI&>Q1.IEM MY ZNC>RRK(IRCQND4B.I(^RR$,-P! .&"L"!W)USNZ7=9VN/K7/'*;75TAU4 M4Z-#0?N18Y!WN1CG,)#*9Y>#8#+((6QKVL>TB D>#Z6T#7+'7;"*YLWPPCCZ M]NY436[LF0LBCNK $QR*"DBJ2IR& XGJNF76EW4D%PO&]^G*H/3E4'NI(X(R M-Z'#(2,C!4GP[#V4^:#'!JDB=?6J3((^9ON0UPL*-0FTGA^$G]E\L$(HOK:I M14S5=_JHYCX\'Q7XA&@V2F$*]_=%DM$?E%"@=2XD7(+1Q;E 0$%Y'09V!V7* MT'2#JMT5D++:PX:=UP&.<[(D)[-)M.6P=J*S8SM!YPBA]MT\TDLQ19D[BCSR MY%F-/+>UC'E%SJB+++[<<<,;41L(PT, 8L4 @X\$7!YYYKJ:2XN97GGF;?+- M(=SNW;). ,*B* D:!8T5455'5X88[>)(846.*-=J1H,*JY)P!SW))8DEF8 MEV)9B3$L;!&VGM*J5$=]GI=>)-"JHOH'-T-G9A1/1/PDE38@R(G\XY6K^%3F M#;J!&\9'V9[@$$8\K3.Z9 ].DZ=OZ8K*E.7#<^:.$C[UB1&P?7SJW/OS65E) M"",W4Q2S.C*KQW4Y[D:USG'TDTE.>Y%D1S?#C 9W-7TKZFJUR?"IRZ GHQ@G ME 4?(Y+1DQ-Z\>=&/;M@Y((JV3&]L< G1HSS534X MY/LHY8(9#$?K*6-162E20CL>2CEA8LTT<:ND1'.1%\\S]*_^*Z62C28U/3ST MU**9/[9 -@:1E0%R0HWL%)/) R:QM0_[A?#<$S97@W$,0H]FE&XA%9L+PQV@ MD8_"NF'=DU\"/^ZS>S"]M?3Y-S\HL;W>/EL,TT[89D:J>%?%(^/QXT;=OF,8*J3M+*V<91T66(*;B M5%R-Q$ $YC7C]\-\?1)SY5DPS+YU4H03O?XGU3O"LJ<\J+\_^6;'^OC^5&]% M\?U\IY_HG+_VW>\XL[0^_P#MDO'_ /B?UI^S+?UN)O\ \$?_ /W%?'\5:]J+ MXS^;G7QY3_QILQE_P1$_A I%\_XJWY\>/SP-=9'#[@@I) M*#6$)=VWU4&6CMXQ6R64EE96:6T4+;9XOTJBI_=0-Z)\ M)ZUY5-+OB,F>SMSVV]">\]W\?7L#GWCI_P"EDFHVJG:8KB7G[0EBMB2<]UZ5 MYQR.S=^]9D%%V"&GN-ML9>/3QX#6CN\K[B^/E'6?Z_L?:;_BE1*OC_+RN=#I MVHQC/M%C.5SM0V]Q9 \>LWM-_CX_4,>1]U8K7MH^[ZFZAP3EQ/#QAKB-70+?6I98 MI"BB[1V*'39#?[7J74 ]==G0PE1V:R,R>AJ GC4&V''3URIF0&.G_AS: "L= M+:=9I+,'=0,DL< ^(B%,Y;^^G:OJ>A7T6CZXJL)R?8+VWC*6>J(@RPLXEWBR MU.) 3-HNXQW2JTVDE67V.6EYIUCJEK)J6E,R=+;[7:RN'N+!W/!N)#M]IL9& M.V/4L![=L1Z@"&%Q'V&&8+8"CFA3PE"%0QD#D02-EAFAE:CXY8I&*K'QO:J. M8]JJCFJBHO.AQR1RHLD3K(CJ'1T8,K*PR&4C(*D$$$<$7U;7/_U6@/LOII[U%B:KY&]6[(QC6IY575M*78HJ)_5/ MM?/^[BE7)F3V6N;S]I$[UQV5'4GQO_Y;# !R&.__ FR(O\ OXI6\XI7-V!% M03J#MBJ8B>L'=?4*4 MXI7RYS6-<][FM8UJNYR METHL8ET!&6P>;[H*=LDXEA6F)')$P^IM Y1[*HL8XY9616%:4*;$V1[8YVH] MR*I4$L)B\B-.!M2(M5UT?$\ R]NQPY2Z$2=N7M"7>EF"MSIG22QU MIOW@L]0OX_=*4=05EK&GY\I'1D*BIX1%3PO%*^V[6QIIH8][GX,N M&7(R$70@77Z_F(B9$7V@[BSEK*0NBG(>U8Q2K*KCHR"'#U[;E+8X"N)4J2Z* MK(N*UK:TJ(.V")&M*4Z5CI8(; -_KB:2R-S)) #X'3UEDR"2.>6L.,C@EBE> MR1JE:.H"//L83;"@+SL8<[K604FR L82- 2(77$3U?V)9;8*]!2299I9(JR> MQ(+A*EKAB?U!"%*D\@);[6 YME+&'% D;JUL?]G+*B%M=*^7W?2K9/N('.8Z M!TK) !U@GACE+B)4KP*HX2I154HV,6!]B\@%L[GCG+9N>^=I*R^Y-[;72S)% M%'*R**&5T$4;(VQ)$I7-G8V0L.O,+LLY0Q3E]/Z//W=8M5!!*43TP99 %QCW M%(*-'*8;U8&=) 49G0X"3NO8DE(S\4N(A92Y",UFP.J:1J>FA@K7UA=VB.WV M4DG@DC1VP"=JNRL< GCL:S-.NO8=0LKP@L+6[MYV5?M,D4J.ZC.!EE! R<<\ MD5P"%52EZ&"@/LZW,2>D^6RM+%([8($.MSANH^Y@;76$(UM ?5P1'UQ@-I]B M;4%1W(1!PKAV%?*)T>XAU232=0==-N(.MUS.O4$0AMWN,A4D02K)$G41HY<- M$3(F_A6[_P#M.!]/74;-3>PRB$1")]C2-)*D(4EHW,;([!75HPZRCIG:W:6D M]5[^-P8OZ$XZ>PJH;%80R1HY0VDSE0,%-B.E"?"7$R&&4STK**&\I@TI2R(C MG^\OAS5(WB6*+K]2(2$*\<9C#NZA'$KIA@JJSXR$W[6.[!/C%KMC(KEY3"58 MA=RLX<*JDLAC5@0265=A7)0'!I@]-U M3JP*@BVE3(WY$H5/<%-;/G+"T+ECGK![Z.)&?P[>G*A-:\\#V!;JT- LFP6/ MI*I:W'@2;3[A8FD8VTI*12-@Q/(Y!19<#ZF9\-'O3"RN\;[6YB3UE:.[A:1$ M7KQ@,\8)$G3 *LT9_P!ZB95RC!FC0,-R#ZQKP.JY-%ZQ#Z0JL@LJ\ZLT,SC: M_P!)U>6!.*HXTM<=,5(3"6^":O-)%%E%'C*]O[>0AX[Y5D,NY'C9 ZLDQ)3+ M(49=JLC%B5;:48[=H4GC)%1X;8A\H LC2X1IK$D,5L9Z1RP# U<)"L MCKLE8J))(W565R1&5=RC!U#>4 M$C'"@G*YY9B,U]W=A)6$22@A!SVDT#VQDV!3O(X_GU23R,C8] :2%8&O+GD) MKXY9F1QP1'6RBK%D,KWFEMI+I65%@0RH'':>.(+/85 MY7CWPS[.Q@J R0A)?9>V6TZ]Z&H6>Q4ABFF]G=Y(VN9A#0R;%:1E)!VUU= MB\OG>NJ.PWFH"CJBR(Q71AOA:8;5 Q>[!55_I%B=/WM?*PL@A[?2Z6OJ2A:F'UR!$27L<;#I> M;:YXTU/57>*UDDTVQ!Q'%;N8[F1?1KBYC;>I;UAMV2-02CO. '.[:7X9L;%5 M>X6.]N>"SRIN@0XY6*%QM(4\"296=L$#E:BV[.S)5;G0(ZCL XF MO85!6Q&6%;LJ2@W9Q\R2QLEG'?K]/JJX:23W$5*UT*.]43FMU2\6W?V>5Q$9 M9H%ZVY4R7@DDMU!)SN;HQ1,"4 MD*T5A'-TG!8]*1O;82S[!O1^FBRKN*@;)$2NN_ ]GI?BE-1N]/ M35(-%8ZGHLR:I9W.GWUI<(Z6ZL+RTE>8V%X8;JS,T6V"WDE$O3=(R\8KTT(V M=O=26$NIA;'4XFL+F&\M;FW=7FVFVN8UB%U"LL%P(Y TDL:;!(C.J.<=@92^ M U.8SVEJRF&UN@I:VY +C1&M)#L@X3!YD:U51BR13-V[B2"[MH;F%QV>.>-94;N<;E8'&>.WI6HW-O+:7-Q:S(8YK>:6"5#W6 M2)RCKZ=F4C..>];_ )EUX4XI3BE.*4XI3BE.*4XI3BE.*4XI7Y\^4^4]/A?* M>%\JOQZ?"^?"(G[O**B^?*>%3POE2OWBE5EW0DZ]2]BN'>]CXDO\ ;5R/ MD'% F)+@16^'>"!8IH'>/]F14Y >*A(?#>N](D.-*O6RO!*I [NO_,BLI^!- M2VA;/VUI74"LIO[52&&5RTR*I(YSAB#@C''-?R:)F]*.5?*I\(B)^57X:UJ> M?">554:GX3^JHB>>?)K-YB1VSV'/F/<<>[T^%=\09( XQ[^>!Z\^[\\X^^I] MUKVUK>L/XD_AX&FD72"UD+Y[1"27U\U5+8/&)'''>/'/ZXK,N*6">9&>[]J0 MU[HX)1B]F\->+[_PO'J,=G;VTSWZP_63]0]&6 R['"(4$BE9I%9&8>?8X)UKPW:ZXUF;F::);-IO)%L'56;I[U+D-L8-$IW!6R"PV@D,MK6GU6]D&UM M6, '0T]D+Y=:VD([SH[A[7)[3(:XQKF5(SF(YI<;"CR9WN:\4RO:Q8G[-<_2 MOKDMO:I;VMG;7,9S=SA6F2YVD86*&3_NR,N1("\SYVF.2, AH.'Z/M-CGG>: MXN9X&!%O""L3PY!\TDPSUF7^'$<2]MP?D4PVV&V-WN2&B?IWZE?D:(>MDE9- M[,-DC!K&.-[61MG:EH&0>1(UB>EUO"DJ(]_EVN7&J0ZMJ6IWL4)MUN[HW:P, MRL4$J*)1E>&W3*\C' _>C/)-2\-A)IUE8VLD@F:"W$+2J"%8QL2F,DGB)D0# M/ 3CBL7K_25U'8LP?ZL32;/$2/J:@A?(9-EG_@J@DK"B62!7D,U VN;<5;VE MQI8 %*8 Z,2&?GGH^JS:7%Q(6Z;C!,;#G#,M6O?::\M+%MC> MA,*6.O%"4ZEBDU"*Y?\ \Y+#(S144:?A&1#Y2MG=_64UZ_E57GB@VSW QP_1F!][,C0L M#]RV\9P.!O\ 4Y->C,R6N>G*0?L3$,IXP M)0N&CQZ;T0.H QN64DY90:8W)G.3'W&/]V6R&_Y78JQ)[-&%&%.-A:QRK+"8 M*R> \5)&0DM&:8/./*YCIPBH8I4(4>98HI&R,]F6">**5DCV).-/>^<@@,&& M0"%W J<%@V#V.!Z@KWSC5(9, MY!8!>][XMYNVJ;,+?[ V.''Q!!V@#W@!C6=<4)']G?V9JP1#V EPL!@\K"J^ M*0*]K;1@!?I@A)E[)X?O3XCT^9]3U*5$L-MO=6YZ5N)8S']7=W,O[N6*Y42; M@8QTKF*=4E)C%TVQ]KV2TF7V2RM(X;4LJO*Z.;RZ:,J%R[ W?U1";@9%FC(07ESIL>T MR>-ND\;>T7$[O.-Q2-"@MH X.[:B8@^LR> C1. W0@O3NZ>WI*[2#G!C_J,D MTL0S&@8FMAI *D"'VWPQFVQPE8^>LJX(_#0Z^ @[[:2*6&$S43L'2'QM+6ZD MGCBB9F"(.G9QI;1Q(,;1)/(D1:"%5QTH%,NTA@LMZ>DR7SSP)&SNH!+9:9FF M9V.2QCC0R8D=BO/U31*!_=PQ';>WK64-SK::4F*X%"OH@[ X2=:P=U7; MPB#DS1"E(*660#;/)&0112YEB'?I\E[>65U/;7<23I%/)'NA1 MHIUB5V$3F-I&2X:2+9*=C6W#?5(Y(4[ EM# M/:VY ")LD9+JIXL&FMZZ[!C/JRHRQGJYBO8CV/BFC563#$CRMC(#,'>BPE!% M10E"3M? 3#%,Q[&RT$L5RBRP.)8B2-PSP5X9'! *NA!5XW"NC HZJX*B+FC> M*4)(I5AS@\]^Q5@2'5NZLI*NN&!(8&M\/X]2?]GX\_R_^?\ /$O)&+(!.?? MCOWQC_+X?=6,Q.QNW/Y]N?\ 3_6LDZGK+T$RIN !;*M,8L)01L+)QYF(YDC/ M5%(BM]4V36WANK>2"XB2:&0;7CD4,C#.1D'(R#RI M[A@".0",,RR02)+$[1R)@HZ$AE/(.".V02#Z$$@Y!P:*WN7KVYJPP?:/ZE?] M8V"1OH]][LTVCZ^LAW-?6SZ"U8R8T62E)1#*/LA6HP../[39RLEC?>7\!JMA M UE+I6M=6YT6;!MM2W$W>E31^:![F< O$UL_UEKK!'U97IWY!_M-S+V%U(+J M*^TOIP:G%D3V.%6WU")@1*MO#E4<3I]7/IN6,A(:R!4^SV\4^G_LD\*[O.K- MA=5ES?44PTS+ZKG@DJ]357,KOX?[ J?M72!L!U4OJK-0,-.Z&F[!C]/JFDV, M$86%X3UB6.XNM#U&ZAN+VS:(BZ@*M!J%M=,WL>K6_3+(([\@PWB*VVWU96^U M[?&L>7X@TR,Q0:K902P6MTL@-O*&$MG/!@7&G2[P'+VJ_6VSN T^GD-@>R2, MW8W.AUJ%1W84,>IR6HS$WI6'1YV[H94?_=6.WK":]_J_]7TD+Y_P\\4JIOI; MT,NG^G;INT(]7WD6"HJ2Q]?GUI:9@9,U:I)Y^4E;8U!22HORDB.1?E%XI5]\ M4JD:@-:LCOZHG_;$9<2:L"'^3:G1]>T04TB)\?$^EH-0]?GYD]S$XXI5W<4 MIQ2HALV??UX6=\/]&JM(*0M6>43])]@JTOH9'M5'PL.HZVQK8YXW-DB).'=& M]DGH3&D7Y\^B6&;L6/^2(B>XOSY\N3QQ2LZ+5 M:\;RRYZUN?4U?+R\S?9F^K6QIY\O;^J6.7O)51/GVH:"25WGPQCG?'%*^HNS MH0R>-R_W'N3PJJ5MQ=O MBSF^L+7YG_;Q2O$S;8-C'C'Z[(L9,QT4D!E_3-9+'(U M6/C?%,6B2,>U5:YCFJUS55JHJ*J<4JM4N*W,ENFZQ8MQ4&1M;+DJW/ZTG(_> M,\MC-SNFS>?O*+,RSL_;8U_V\M/82,'-1*@N2QL+)2MB[<]K>TLJ]0UM;&WP MJSW_ &=35XZL7_;:^OI+F=O\E]! T#T141[6/\L12O.+L3;^XC)LSUNYZKX6 M(3M^*65J_GQZ9\6-ZG(GGX_;Y7^:)RW:.%9)3LB0R.J!I'((1 6&3R?0 D@'^-G8M5OA2;'L6IQ=H3C-;*38! M97)U%A;LQY0:RM"-PXM7&23, TUDDMQCD$&FMU(L;;'@3-4K/W?S1K]SJ'BB M\.JM826TMSY-*:'+P&*$LD-M<2*=J3,^\BYFZ23,TD3HMMM>'M>DQ66AVO[/ M%XD\=N2;X3;8Y!)(N9IH4;[:*H4="-I6BVHZDSAED_H7'V?B";BHM&:>E+I# M:TBMJ[VH.$MZ&6XFD".MZXN[KIRA!)A@(Z0T+[EPPY(I99#9YDA3V=LGU"UM M[E!;E:XMYW4LL$L:K#M2;9G=+R=AVP$5M<2Q;HH7_;A,X#5S]WEFBJ79)J_<<91[;[*.$U7MECKKJNJ MHQHZAKT\^D&QK*];6KK".6-!)$V<=7V@-YGCW;/X?NT>W-F0J2P%W'&.K"SEF<^^2.1RC \B(P@ M ['*Q//;8RE!DH[6N'TV3(B4>:C.;!*\<5RM]4(7W;9!2!/0CD;4G(@OJ]I@ MQ5?!&Z.2"@O6B0Q2H)X"NWIN 2!QE5W#!7':-_@ ZKQ4K/9B1NI&QCE!W;@< M*3SWP 5/8[U)Y'*Y.ZI6G8V_U1^7(D94#YPB4\2"%$0N;(Z4='C=HY%,>W:J^W<]E6137EIS&N6$, KTDR>IDK?L*XLB M&:$7V_>+M)8#?,$=8-,MT=Q)97$-W&,M"SMW [Q.@<[@PVPNXD4!=QE"L&39 MNKSE@6YB>W?.A*\%>7V["2?L$J V]A70'9UPMYLEJFR>NMQS!T= MJ>$746@##)9Y&KY5SJ_/6%>P&5OI1/URTC>CGL8L?0OI"U5Y]1CTF-_J+&.. M:= <;[R=-Z!_>(;5XVCYP3O\/W5.IAV 1K94\?B%GF0RN%;_8&P-55G>,,U6QPVD2>J2-\3&.->S[( MQ%5T! >$<(NY. .2JC@CUPH[/Z@@9;&PYR-N3G/Y![>H.8: M=/6QA:FJ1Q)V=D;>@QCO_P#*8L4+EL:E%3S')%>U+RZYGNMEAAG)&/;&LX8[ MV2&G:A+I=[;:C 6+6T@D9%..O!VG@;N"LT)=!G(5RDF-T:D8M[:)?6L]I(!B M>,HK-_NI>\4OK@QR!6;;@L@9,E6(/3DF)Z\T0S#Y_\ [.TF]03&QLI3*H83""(2,K %2)44 M2;2,$>;&.>>]KO^#_ &?8^#A\N5WIKLSN[\&BC:KE5WHBH$K(V>57]K4\*J?"1_@E>AH2 MZ?SC2-2UC24S_P"#8ZI=Q6H'P%I[. ])6?<-9$A3R(VQ3.A5/>D6(=")6+"JQ2. MA:L$.@K8[FANZ>5/,5M4V-9(B^%18SPYA7HJ+X145LJHJ+\* MGGSS&O(%NK2ZMF^S<6\\#9&1MEB:-N#P>&/?BO:WE,%Q!,.\,T4HP2#F-U<8 M(Y';N.:_BK&Z22&#[A'-G:UJ$1N14DB(C3T3Q2M5/+9(9DDCE8Y$-JRIO74T.B9GKN3.DD/%%NH E+%(G82\-R-'#>190CN+C>,.> M4 /7F3K%$$62\@9)O?V"_:W6\%G<-;2,529$WASO,>1&A:94+@JLCQ)$[8$; ML2 ?,WUFL[V[7$:SH/-&S;<84.1O<"(L%(+(DC.!G @4B% M[HIQ3!YPRQY6+X?"2*3'$0/,Q?A\4\3)6+\.8B_',5T>-F21'C=3ADD1HW4^ MYD<*ZM[U8 CU K(1UD021LKJP+(Z,KJ1[T9K&$0.5)!SCAU'\ M2'[0[]^S+D\.%)[8KQGA6>(IG![H3CA@?+[^.2N1D8)SVQ5O=FX^+;U=9MLK M&RTL1 XO4+"J-?H*-)G&1C0+(Z+V;NF,?*=3+,L;XB7V-:_[:<]I84G?VPNH MTNK<"614&U0?WT6[<%&2,21,3)%G!#=2/*-)O2/M9_9W>&;*QL3G(STY,;2Q M'.4=0$D4#+ *W(7:VIZM[!OCI9J@F232"# M-$=(YS-)&*,2\*T8]Y/MMM'U M,\M;$0)8.%O6N))]<]F;#]HEFGWDLF4=NL%4,N?WVU699 22-[1G8&1]LN6R M69^#=>01Q[74;-Q(;',62JLA&,A%D D(V;H_+P$4\7GZ*K0B1%P2>YX]QHIT M"/&L )VN]$S&.DC84"5#*Q83 B(V/:^.00\942:!9,,.*CR"#[CQ[F!'<=CAAZ@@D8.5/.:C+?U>22JUM>/';$1 &TEO7#3P M"+;AQV35@MJB\ L&+;5(:X*(\LS()\<+4&5HRME8Y7M9!)$W['X M9(55"Y9PYX! VHB*S.[9\H\J8#,TBJK$>,TK1J-D3RNS;55=H ."Q9V8@(@] M6YYP &8@'4?KXM;= V,@DEE').RJM)@T/;+$V1A#Z5L4U7]PP>5MK,/%[ WW MMM&\HYM9IZ_WY:\K8-$O;6ROHT$$LD-Q]5([R2+//*JLUIM@@R(D65B/();C M,C+#>C<87A=3MI[JUDD,R+)#YXT1%,,0+(MR#++MZKE &.[9'Y 9;9@ ZVW5 M8MUO<@4:,:EH%/67>JL$8)-#D1@I4-HN:;1%$7BN?X:U71PV5S,#E>-04P)[4:U&OCD8YJ(GI5/ M">/!%6([HE6)AR'A41/G &0\>U@< #@C@"O9_K!MD)D7^5R77!))&UB1@DDD M8PR2EO2SAF2>N6FTY)5V&0U?F1D-N4^;0UTS_#602)8'UH2* MYR49/PSFP:?XEU:P8 W#WL&1OM[QC*6 Y)2Z;?,';[1!EE FA#+N(C<)*&C70M1T#4K63 @>XAS]7?CPU3B!TI'.VPNWP"3TH))< >IZ: ML /B<"N?^Z\]D(J$+NSJ\?.G7G6I9=[HX[.9;FU@GCD66.:*.2.9/L31NH:.9?3;*A5P!P-V M/2M7N(FAFEA=&C>*1HWC;.Z-T8J\;9YRC J3ZXS6]YDUXURY]-*_PZ;WEU3) MXB3KON72G4H:?"#8_LM@_8N?9&G\X8R;^Y#B5/A/LG1_#HW(BE=1\4JKM",\ M+:2$M=X@U^ N*&9'?#'VF8(FM*0=CO\ TT]?H=5.YOCRL->KOQ&OA2K/8J.8 MUR+Y1S6JBI_-%1%1?]Z<4KZXI4?+:C]-1M=\I%4Z$EB+^$F83GQFR>/^4V$P MB-')\HV5[47P]R*I4@XI3BE1&PE^SV>=D559%;U-]4/^51)C17UUO7,5/PKH M@AK][//X1\GA4\JCE*DY(PQH\X9@\!8A4,@Y(I,4)/*D)N,L-46TOA\MB?40 &M>J_L5FIK?6 M*I#O[S6B7;R6_P"TC'HJ(I6:/E88VK+1ZK5 Q2_N56WW\20N7_[T[70:7V6_ ME$C%=#&GX1B>$\*5[/J-;$J(%L(9&_*K^M9L,Z1?S\>JH-SK$:GQX_LO/POE MR^4\*5JC,I?V;_Z,_P!' MA6I^J+4-\IX5?6F;AI$F1?'RR=)8U3RGH\.=YM;..*5YOS-#&K9F4]>XAGS] MS,+"06YWRGK>7.R0F1_[E\ODF<[Y7ROYYB3(SJ<,<]P,GDXQWS^G/->L;G^2)X5$3Q^/3_)43X\?'A/SR N(R,GG@X/Q^_[ MO\./6I2)QPV/OX^ YS^7?D>GK4,+KQVJKD'A1R+ZOB*-%54^/SZ4^6^/Z^?" M?'(*Y1P3@G:<=R6.1GKY@VBH]Y)#*F0]N9(FS MAE,C%0P/#+A)%9&4J0< M,#G%6<5;1;-%K%@UQC_\ D+:/.CGT(I(B M1QPR,T"Q-;[-9&7V2SG0;ED@B$L0(4!E)C::/=PI=D,DL:X1B6D0=0N)KVS> MQJI:*PZZ[!*F9A[P=(@;U'+]QC+6*5A->:V96R?;5L1T4!@AKV*/1V8\4A3' M5194E=DZ9J<#VTVCZLY]AN%V13D@&TD!!3SD?5H'57BD)"P2J-_U3L8_"_L9 M4G34].7-W$VYX5&1<#@/A ?,Y!9)(QYIHW)4F15#ZJLI\>-BJS2:?;0E6AXS M7PY/)0AS:(]_JZ MEU&D7^UZI7[_IG@?Q9KT-M>:3X3U2Q2!,6< ME]?VVDZ2 HW@3W%GJGBW3+R>5 MB;F'3;*ZU?4R5(4VS>R0WEC:)$5)1)Y T)PRP#*@2[Z=.TZ3LCL*\!.OB(M+ M5P17555&9H7,6%A4J*?7%"R?9R1AF#5)=L8:0*.!'8%R&5%G<65C-6-]J-UW MPAXL\+3P_P"TT$"I>.\EA=6AMY8).E$ZRVKSVQV))&)FFZ+QI+<)MN#)<>SR M&.1\->-_"'BY+E?#-S>YJJX#HQ]'0G[@P)_05O9K,.ZN-!< SQE M#VMK'8PDQKY:0&;4U9-3+Y_/A])+6.C\^/[%8_"(GCD[XDF2YUW4KB)Q)'/) M;S1R#L\4ME:R0L/@86C(^%16BQ/!I5G Z['A6:)T]4D2YG$JGOAA*'S\:U@B M*HI\+%\$QEV;7HB_N;*1/*4+ZE_JHI(CV_/[6.8B>$1.02]F'KE\Y[AB2R_H M5'NQ^=2A]?=@=O@H!_'.37V\4&0@"R:.,\H6*<,,ET35(@$/>*I@P\OCW(8Y MG@ARDPI^V10HO=9ZH8W1W[CMVACM8@E<\%ER 2/>H+8SR,G&,FK=JY#8&Y<@ M'U&<9 ]V>*]XFHPLN-OPUT8Q*I_+W9G$Q2.:B_#4X,Z#/N1RH_( =@T/4+ MYM'THQ3VBG]G6(^NMII6R+:,9+)?0 DD#'E!;U)[US?5+.W74M0WQSL/;;LD M1SQH,=9^!NM92I'/.6&,8''+Z8CB[+,=C'FD"&3$=W=H?ZX '-7@EI%=M@<4 M$&098SCBDRQ230QR6!KD8]%^YF\^M97P+-)<:?J\\C)(TGB;7")(HVBBD"W7 M3+Q1M+,R(S(S*#+(<$'>V,)HFE I(XD=";8,%=U2)67-XMI\FDGTF8F:VAMC<02/RUOMEBB,.X\]%NKOC4D]-E8( KMB)='7[-+'284U M)88>MZMIZB.1S8+V62W(BR]DDC7(PD>@"'=]T',URMT;PK-\4:@TY1&J^&KQ M+V"WL6)0Z7"KNGI.QE86DO'=(8T;*$\7.R0KF*-S.ZS:O;SRW(PRWDS!&XS& M-BM<1X_A:1VPK#']G!3)ZDJBV;7KK%WNL/)O*1IIED.-:L)8=9!R+(!")43P MD)7&B,DA8/#5N%;.R57O>:GE&1(U9JXTK3KJZ=[FU66210^_=(I.Q4B(8QNN M0%$>S<.X?NH%1L-[>P1[(;B2.)25"#ILH#%GRH=6VDL9,E<'&WU-5_W0N,Q^ M6'S-=DZAEIIH3HZR:"O$'_2HZY0VF7JEI LSSP9;$% V))]P440UTTB"1&/2 M*\0MI^G:?[-'90"2\62. )"B"+8%5[C>%)$D1D0Q\[WD8#(7>RR&DQW=W>+, M;F79;-&\Q:1W,@9B5@";N5E".&! 14!'VBE4KAMR1D27C%-F*SQ4JR$CQHZ6 M>MG>J>NP B;ZGRQO^7'U\3?40O\ K8:*&W.Q\F%B2<9)0_S*,$D M$_:0#G[2^;(;9[JUZHW)^] ^&' SPWN/\K$G^5B!@K9N@Q$%T8!V'UU85P&I MBD;813^XYV*4V!J1M(A+> @4C-:K*RWEFZ M+< [PV=?*9 K,,#<'VJ%P(YRJ-;3JS0G@J?WL+9R'CW'C:3N MZ;85LD93-F"ACMCF'H,.T+NS*O8.Z !1N98U&!X[3C:DJ ML.< ,R>I/'5" ,W/ .5;D'E688Q[P3%+!7HL?VT8JE)ZG(48UTD%=$C'(XE6(YC MG/55;&P>.89Y/ERK.R.&1[(@^F N1SN;!"#!\V#Z^@&1D]SC)$AZ^OX>OP/Y MY'?MVK5"5/OK+[BE-%G>DADY"K%9WY0!CW>IHPW<'MSD#MWSW_ *GN?4FM;;1H436QB'#4 M4-?8B$9XF6-C0V7M80VY6\D%]T>,JNST ,Q;!7RP-M"_=@AD9/\ I\T^78=2 M34+,Q3+;R)3IEAUF7:#D@G%O3%':3]2)IHS" M\)A08+"<=#8K8.PN)-FX A%)., BNWLI3@9?.PM25JJ^*2TM;,J9KI"RR4<6 M;8&EO5/<<]SGODGD5/+461ZHOJ7GT?8V\5E9H-W\+33S.VXR2/F26:60XW$D MDEVQQWKC5S*]Q.S8[D1QQJ.%5<)'&BCL % [US9I-*3O+1EL1[D= '*Y^8 MJY&NC:C?"QMT9T#_ "JVI\2N<"R9&RTU;,@S81CR[;WN)>*?$DNNW1CB=ETR MV?%K%@J)W4D>VRJ<'>P_<(PS%&W97:3=T_0-%32X>I*H:]F7ZYR 3$#C^SQG MT4=I64XE;C)C6/.JGGA&B?//(R*)GCU/>J-:BNQD?%,[U?*/;7Q M1OD]"M5/V%$!$L>KF20,5J^;V0>_\H&>W8$H>>>V#7CX_@.!^9'K MGL".QSS1SKF%%=[=>=_-6,<17O3QX\HSU_J$?".D1/+N"6'HK M?<2A_7>,GTY49]15/GW_ .7SSSVKW$/A+=)$C98"8/3[X9+$C)B1_E&/5K7/ MCFA>K7LC*&EG%DDCECCG>^&5K*@@Y'(([@\$ ^OJ"/3*DC.1G(.'Y?@?S^/Y M@=P>Q%?I,!/NBV%86M;=UDCB*BS;'[JBSN1$?$1 DD7WE:8QJ#V=<^6.,P5R MM22 A@Y,&3:7=Q8W$5W:RF&>%MR/CX3J0R##*" P]S(Q!V2(>4<#*G@Y4LK=$X[5W>JST%L"%3/,;),!;5!AQ ME;)56XBI&:$\F$2Y4B%5])0)#A1T/K"0K"-C8#(UYWK1]5DU;3H+ZU6W?J!E ME@EDDB:">-MLL+NL=P&*G+*W3 EC:*0 )(&KDFI6"Z?>RVMPTR["&CEC1)!+ M"W*2JI:(#/V2H8[) Z$EDQ4:O,O3V,DT^EZ"K;XV1DC'6="W"64_M/:J.5ME M>'Y*Z8Y8_AR#CK(OGQ'ZN>=U96\Y+7OA:"Z=EP9K4:5.Y!P&'5NI+"Y^R2"% M7G[//&[TAN9H@!;:]+ H((CF]NC&021F.!+J$D'D%FQSG(.0(]]+MA.%B=#U MR:-8 D]2[>]Q88=LR-EG%E9_M]/B?NHXBBHF>SE=!65T:Q$SQO\ TYRMD7Y1 M,/P/*\6FWFC/'+&_A_4[K38XY\+.MBVR^TS> S@[;"[@A!#L"86.365XH0/> M6VI(T;KK%C!?.\))B-XNZUU *2JGF]MYI"-HQU!QC!/3/-VK6JY:MO&$^K+, MVSO["F[SZVL,>2K?+8I=WUF7-I*-Y"_W?N#LA;Z$:!S_ ^1E.R%BN]*-:I7 M4O%*KGL_V@LY!IY4R ;_P#Q"$#-1$3_ M !CK)5_R1?CY^%*VG%*<4JNMO*^+1]1HQ/\ CNP["!_C_P!$[JSLN5R+\IY; MZX8W>%\IZFM7QY1%12K%XI3BE.*5XM&'9(LK((6RN\JLK8F-D551455>C4W%*<4IQ2G%*Y,[=^J2MZA[ -QVBR-E^BQ5_2I 6UA(D)J2;3 MM7LS0XFRS18((!=E7W--G._N! M_*JCW]N?U X_(X_/[ZJZN^O3K>]*S=>SJGZC0+'1VS0Y +#IN]:104\J]>(- MK;S[68N*+-$KV?FFL+!E/(>L=I[0DJ15GZM'7%J9"S+M QZ]SW/^6"?]:S(I M=GQ!X.#Z'W9X[Y[U$[?ZW*$6_@A?UCO)\Y:]>]?;O-OJH*73[/61=G:R;*X^ M.FQ^2N+^2$6R>X(QZ7=A478D;S8R:.-X\'W<1-II>-OK%#*[*2P940* 2VY@ M,A1NY&5/O R:SX;S8=I4E2,@KC.GI5TU^V!U./Q/;U0%?U%7[ M(^A.J]'43TU^%F+0>0+1!7E5,LDX9%%%*EZ4,.\IA1>=':%,6.1#/+JEX#87 M$,H:>)88*\16EW#_MIH"6%_9U MIMT )*Z, :XJJZR9%,;!# 3C>)]/BN]/>7#[K8"8,K+M$2>:?R.K+((X4:YC M3RQQW$$=PJM( C^FAWC6UZD8VE+CZH@@Y,C<0@,"#'OE,<4CJ0S02RQDJCL1 MPXRU.T$YVDM(X(;/1FRW1\ S9&P#3%LC;&'&DJND7[(:(<-[W>E99('R^W$C MTB9P^YGENKF>YG18YYY&DE122J,< ("Q).Q0J$\9*D[1G%=8MH8X((H(R7CB M0(CG:"XY;>0"0 Q8L!DX5@I+$$GQ//"JPRK&Q*& !!'D*,-,EC'%$%@8Z28@ M@B5S(H8(8VNDDDD>UC&-5SG(B*O+8()KJ:*VMXI)YYY$AA@A1I99I9&"I''& MH+22.QPJ*"S'@"EU"F]N.FHF%C:GLR1BJBO+]CV3Z[-D-=X@JE<,I0 MG@NY(@81'!7_ &3]&_T0P>';:WU76;6'4/$\P$D44RI/:Z,#@J(T(>*6\3&7 MNR#TF)B@(C#R3_#_ -*'TUR^([JZTS2KZ;2O"%LQCN)HI&MKW7,%@[3..G)# M9/PD5D"#*H62[/5=8K;MW#?4-:=;Y-V2ZKZEZUZ^J)!VBO>:"1<6I43&JC9# M&4!N9AA*7\R?<6^@<[X5Y4CE\IV8^#GO'$^H:C.7'(CB"^4'C&79E'8#RJO M& #7$&^F.#2;9['P_H%GTV&QKBZ+J9 ,^;;"(Y&)_FDE9CZD]ZXR[@N-]7:2 M#O"LO:VNTF2E=<0+55)@<4:"PSSRBL&?9VDEHVU1/TI]5-*C3ONV"Q)(3)"U MV'XK\$:;K/AVYT>\9S;RD20W+(K75A=0QR-;7ELV,">-_JPF L\++/6;6!(+T.L,D$4K+9WUK/(BW%E>!O,+:1"9'D).>[UQ,6@KD97:&LD2JV>7ED13L[?PL3[@>2-R^X\ GY(K#/" MQE"N3P]98IFL^'=C:K$(KRT?[2Y,%U;N3T+VT9N9+6X"ML;DQR MI-:S".YMIHT_1CPSXDTSQ9HUGKFD2]2TNT&Z-BIGM+E54SV-TJDA+BW++NQY M9HGANH2UO<0N]Y@*ZB$BALZV"3PUZP MF!"0V=>*[W5'^UN(X7Q PABP>0RLA!)*R\QYQY&1%5HP?M$;%5D#9**CJ&"+ M&BW'!4<8*\,>?-DY#GT#9.UB,;R58YD9V:231303N,%9[WN-8PH5'LC6;T+X MCGA<]6QH3&Q5C5)'1L(B]IDDT?V\7+R"/,.3_$/4@#C&<#([2R&1#.1%^'+%/*KD^8VR?S9'HIS_ ,./OR2 /US[ MLTQ7Y+,E8(78&JLLG_&OC@1TCG._;$+7A,5$?+)(]S(!XT:CRC)W/9%&\CVF MB0BEF^\@<^N HXYSP!QR3VH/0=LG\,GN3WQ\3Z =\"M?,1)G,P4:2BDF UY= M@1'"BO<9:2I*9- ,Q$]4DAMC*Z$6)J>M[YHXV(KE3EO,49.-S*K-@#EW))P M>[.[84'G+ ?=4 $X)VJ3RQX"J/4^X*HR3V&"35DP3V&>RU1B\X^ S3 9VOJ! M%6-2!*:,*N8&_37C(G(X>FK6CR&N;(^&2VGACIZY9+$T>->GV4#-)NVY (B#&9\1HQ-I=*8R#!]?UN>@BDB^W-N))FS2)-.LSK0N-RD$ M)^XHGT11_<%2*KR)?5)Y5')SH'AS3(](TJ&SC4KLDG+;CN;]?4+^6Z=@Q=8P,#"[1&F-JX\BY)VH/L@[><9JV>3M1E.*4XI M3BE.*4XI3BE.*4XI7C(DGA?3*V/^BJUJI_\ W+_]?CBJ<_Z_/S_2M.1]\GJ6 M&[$C=X_:R> =6>I?QZO2YLBI_@CD5?Z\ID>\?G5>?GY^ZM:Y=FGI]FQR,K4_ MO+,%9M^5_+DXS]WPY^?C2M>?9Z:L$F)*L*6P6(ZH7?(1-S ;W8 [47.6.#@ G!K^:]J7V)WD=8[%H; M[$6KC5H-2,<,Z.M'*_MWBB_ MXGP]Q=F,DRD>4,=N\Q0+EECC0MW+ON)9AMNDJ^UJMO8Z&UKK*BHZ?&W@]S9W MU<=2!#N(LJ Z*&22T@$:LT$%2862Y/4E<-"KC5&0P9)\?PO;75O?W%Q<0S6U MM%8S++)<1R0(&,MO(!]:J X6)V.=9-^[J!(**QGG21H5+26[-'/;D;)D;.FS9W9..#[,QZ,J3 WV8COUG+6LSG#!HQ*%8*=Z;MT,JEXI"NX!'+J"Z M)5;&\?3[H2%6V@]*YB(VN8]PW##8*R(P#IG&2NTY1F5N$X9))$D80/,&6/,0 M(<"4SVR@3@YGC&A$Q_*-G$)BE@E1KGL5S%=&]\;FN7D[*Z,R2(T^%.*CFL)!N/4CV*I9BP<%5&YA,D$,@I+'C74. M1N&0QHHN=?+ZP!9J#3K[SHD.XKB;IX,+B.XEF9.FDC%B RLH2=;27 4B '*+ M%27ML C-)@,3%O'UB!X4C#AW3R@X9<&$W,9/>;D,ULT][$]L@DLDI5:_P,> M_P!QDX3U5TK7H*2UDH%D(Z9T[(IHH9?+Y(9V>W/(U<^QU%[?=97O4FT^0=&Y MM9-Q: $EA/;QR_N+J!G::(@+O+21R$QS29Q+FS28"ZM#''>(>K!<(%VRG 4Q M3,G[V"546-\EMH5)$\\:FO T3[8F4:1S)?9D:YDC/*QRLNR6-DE3/.UAGFLNWF6XAC MF *[QYE/VD=25DC/]Z-PR-SW!%8SE\-5?2KOA?VM\>7?X)ZE:WROX^7(G]51 M/GF/7O4(N@29)XG0M:ID@I$$Z^VV> &DFB<%+60>IGADMJ03#+++Z8W3I7K* MQR.J@DBHKO$^^/'4:.2/E0P6.9#"R ?S.'.6 !RJL.8T862(LBA7)"B2-SM) M',;B12?> 4 /H02I&'8&_=;>2D]3]?U"*CI=I39YMHUWESEH8:(>TN?6SPC9 M1K"5 : UCU1%&O'KXZ;'JKJJV M[^F+GT.,.P^KT^:YE4<;>J+@Q0C/H8R6G3'
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end GRAPHIC 13 gyycud3vz5ad000010.jpg GRAPHIC begin 644 gyycud3vz5ad000010.jpg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end GRAPHIC 14 gyycud3vz5ad000016.jpg GRAPHIC begin 644 gyycud3vz5ad000016.jpg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end GRAPHIC 15 gqmjb0hqad4j000001.jpg GRAPHIC begin 644 gqmjb0hqad4j000001.jpg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gyycud3vz5ad000012.jpg GRAPHIC begin 644 gyycud3vz5ad000012.jpg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end GRAPHIC 17 gyycud3vz5ad000013.jpg GRAPHIC begin 644 gyycud3vz5ad000013.jpg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ⅅ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end GRAPHIC 18 gyycud3vz5ad000007.jpg GRAPHIC begin 644 gyycud3vz5ad000007.jpg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gyycud3vz5ad000009.jpg GRAPHIC begin 644 gyycud3vz5ad000009.jpg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gyycud3vz5ad000014.jpg GRAPHIC begin 644 gyycud3vz5ad000014.jpg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end GRAPHIC 22 gyycud3vz5ad000005.jpg GRAPHIC begin 644 gyycud3vz5ad000005.jpg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ú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gyycud3vz5ad000008.jpg GRAPHIC begin 644 gyycud3vz5ad000008.jpg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end GRAPHIC 24 gyycud3vz5ad000004.jpg GRAPHIC begin 644 gyycud3vz5ad000004.jpg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end GRAPHIC 25 gyycud3vz5ad000002.jpg GRAPHIC begin 644 gyycud3vz5ad000002.jpg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�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end EX-101.INS 26 freq-20201231.xml XBRL INSTANCE DOCUMENT iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft freq:Term 0001703647 2020-01-01 2020-12-31 0001703647 2020-06-30 0001703647 2021-03-19 0001703647 2020-12-31 0001703647 2019-12-31 0001703647 2019-01-01 2019-12-31 0001703647 freq:SeriesBConvertiblePreferredStockMember 2018-12-31 0001703647 freq:SeriesB1ConvertiblePreferredStockMember 2018-12-31 0001703647 freq:SeriesAConvertiblePreferredStockMember 2018-12-31 0001703647 freq:SeriesA1ConvertiblePreferredStockMember 2018-12-31 0001703647 us-gaap:NoncontrollingInterestMember 2018-12-31 0001703647 us-gaap:CommonStockMember 2018-12-31 0001703647 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001703647 us-gaap:RetainedEarningsMember 2018-12-31 0001703647 2018-12-31 0001703647 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001703647 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001703647 freq:SeriesBConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001703647 freq:SeriesCConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001703647 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001703647 freq:SeriesB1ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001703647 freq:SeriesAConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001703647 freq:SeriesA1ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001703647 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001703647 us-gaap:CommonStockMember 2019-12-31 0001703647 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001703647 us-gaap:RetainedEarningsMember 2019-12-31 0001703647 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001703647 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001703647 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001703647 us-gaap:CommonStockMember 2020-12-31 0001703647 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001703647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001703647 us-gaap:RetainedEarningsMember 2020-12-31 0001703647 2019-09-19 2019-09-20 0001703647 2019-09-20 0001703647 us-gaap:CommonStockMember us-gaap:IPOMember 2019-10-01 2019-10-31 0001703647 us-gaap:CommonStockMember us-gaap:IPOMember 2019-10-31 0001703647 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-07-20 2020-07-20 0001703647 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2020-07-20 0001703647 freq:LexingtonMassachusettsFacilityMember 2020-12-31 0001703647 freq:WoburnMassachusettsFacilityMember 2020-12-31 0001703647 freq:WoburnMassachusettsFacilityMember 2019-12-31 0001703647 freq:LabEquipmentMember 2020-01-01 2020-12-31 0001703647 us-gaap:SoftwareDevelopmentMember 2020-01-01 2020-12-31 0001703647 freq:FurnitureAndOfficeEquipmentMember 2020-01-01 2020-12-31 0001703647 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001703647 freq:UnvestedRestrictedCommonStockMember 2020-01-01 2020-12-31 0001703647 freq:UnvestedRestrictedCommonStockMember 2019-01-01 2019-12-31 0001703647 freq:SeriesCPreferredAsConvertedToCommonStockMember 2019-01-01 2019-12-31 0001703647 freq:SeriesBPreferredAsConvertedToCommonStockMember 2019-01-01 2019-12-31 0001703647 freq:SeriesAPreferredAsConvertedCommonStockMember 2019-01-01 2019-12-31 0001703647 freq:ConversionOfFrequencyJapanPreferredStockMember 2019-01-01 2019-12-31 0001703647 freq:OutstandingStockOptionsAsConvertedToCommonStockMember 2020-01-01 2020-12-31 0001703647 freq:OutstandingStockOptionsAsConvertedToCommonStockMember 2019-01-01 2019-12-31 0001703647 2020-01-01 0001703647 2020-12-11 0001703647 freq:WoburnMassachusettsFacilityMember 2020-01-01 2020-03-31 0001703647 us-gaap:AccountingStandardsUpdate201811Member 2020-12-31 0001703647 us-gaap:AccountingStandardsUpdate201601Member 2020-12-31 0001703647 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001703647 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001703647 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001703647 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001703647 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001703647 us-gaap:EquipmentMember 2020-12-31 0001703647 us-gaap:EquipmentMember 2019-12-31 0001703647 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001703647 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001703647 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0001703647 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001703647 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001703647 us-gaap:ConstructionInProgressMember 2020-12-31 0001703647 us-gaap:ConstructionInProgressMember 2019-12-31 0001703647 freq:LoanAndSecurityAgreementMember freq:TermLoanMember 2020-12-11 0001703647 freq:LoanAndSecurityAgreementMember freq:TermLoanMember 2020-01-01 2020-12-31 0001703647 freq:LoanAndSecurityAgreementMember freq:TermLoanMember 2020-12-11 2020-12-11 0001703647 freq:LoanAndSecurityAgreementMember freq:TermLoanMember us-gaap:PrimeRateMember 2020-12-11 2020-12-11 0001703647 freq:LoanAndSecurityAgreementMember freq:TermLoanMember freq:PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember 2020-12-11 2020-12-11 0001703647 freq:LoanAndSecurityAgreementMember freq:TermLoanMember freq:PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember 2020-12-11 2020-12-11 0001703647 freq:LoanAndSecurityAgreementMember freq:TermLoanMember freq:PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember 2020-12-11 2020-12-11 0001703647 freq:SeriesBConvertiblePreferredStockMember 2019-12-31 0001703647 freq:SeriesCConvertiblePreferredStockMember 2019-07-17 0001703647 srt:SubsidiariesMember 2018-12-31 0001703647 srt:SubsidiariesMember 2018-01-01 2018-12-31 0001703647 freq:SeriesA1ConvertiblePreferredStockMember freq:DelawareLimitedLiabilityCompanyMember 2018-01-01 2018-12-31 0001703647 freq:SeriesB1ConvertiblePreferredStockMember freq:DelawareLimitedLiabilityCompanyMember 2018-01-01 2018-12-31 0001703647 freq:SeriesA1ConvertiblePreferredStockMember freq:DelawareLimitedLiabilityCompanyMember 2020-01-01 2020-12-31 0001703647 freq:SeriesB1ConvertiblePreferredStockMember freq:DelawareLimitedLiabilityCompanyMember 2020-01-01 2020-12-31 0001703647 us-gaap:EmployeeStockOptionMember 2020-12-31 0001703647 us-gaap:EmployeeStockOptionMember 2019-12-31 0001703647 us-gaap:StockCompensationPlanMember 2020-12-31 0001703647 us-gaap:StockCompensationPlanMember 2019-12-31 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2014-11-13 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2020-12-31 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2019-09-17 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2020-01-01 2020-12-31 0001703647 srt:MaximumMember 2020-01-01 2020-12-31 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2018-12-31 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2019-01-01 2019-12-31 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2019-01-01 2019-12-31 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2019-12-31 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2019-12-31 0001703647 freq:TwoThousandAndFourteenStockIncentivePlanMember 2020-01-01 2020-12-31 0001703647 freq:TwoThousandAndNineteenIncentiveAwardPlanMember 2020-12-31 0001703647 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001703647 us-gaap:RestrictedStockMember 2019-12-31 0001703647 us-gaap:RestrictedStockMember 2020-12-31 0001703647 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001703647 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001703647 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001703647 us-gaap:EmployeeStockMember 2019-09-19 2019-09-20 0001703647 us-gaap:EmployeeStockMember 2019-09-20 0001703647 us-gaap:EmployeeStockMember 2020-12-30 2020-12-31 0001703647 us-gaap:DomesticCountryMember 2020-12-31 0001703647 us-gaap:StateAndLocalJurisdictionMember stpr:MA 2020-12-31 0001703647 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001703647 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001703647 us-gaap:StateAndLocalJurisdictionMember stpr:MA 2020-01-01 2020-12-31 0001703647 us-gaap:ResearchMember us-gaap:DomesticCountryMember 2020-12-31 0001703647 us-gaap:ResearchMember us-gaap:StateAndLocalJurisdictionMember stpr:MA 2020-12-31 0001703647 srt:MinimumMember us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001703647 us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001703647 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2017-02-28 0001703647 us-gaap:InternalRevenueServiceIRSMember 2017-03-31 0001703647 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2019-10-31 0001703647 freq:MassachusettsInstituteOfTechnologyMember freq:PatentLicenseAgreementMember 2016-12-01 2016-12-31 0001703647 freq:MassachusettsInstituteOfTechnologyMember 2020-01-01 2020-12-31 0001703647 freq:MassachusettsInstituteOfTechnologyMember 2016-12-31 0001703647 freq:MassachusettsInstituteOfTechnologyMember 2016-12-01 2016-12-31 0001703647 srt:MaximumMember freq:MassachusettsInstituteOfTechnologyMember 2016-12-01 2016-12-31 0001703647 freq:MassachusettsInstituteOfTechnologyMember us-gaap:RoyaltyMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2019-01-01 2019-12-31 0001703647 srt:DirectorMember 2020-01-01 2020-12-31 0001703647 srt:DirectorMember 2019-01-01 2019-12-31 0001703647 freq:CaliforniaInstituteForBiomedicalResearchMember freq:PatentLicenseAgreementMember 2018-09-01 2018-09-30 0001703647 freq:CaliforniaInstituteForBiomedicalResearchMember 2018-09-30 0001703647 freq:CaliforniaInstituteForBiomedicalResearchMember srt:MaximumMember 2018-09-01 2018-09-30 0001703647 freq:CaliforniaInstituteForBiomedicalResearchMember 2018-09-01 2018-09-30 0001703647 freq:CaliforniaInstituteForBiomedicalResearchMember 2020-01-01 2020-12-31 0001703647 freq:ScrippsOptionAgreementMember 2018-09-01 2018-09-30 0001703647 freq:ScrippsOptionAgreementMember 2020-09-01 2020-09-30 0001703647 freq:ScrippsOptionAgreementMember srt:ScenarioForecastMember 2020-09-01 2021-12-31 0001703647 freq:ScrippsOptionAgreementMember 2020-01-01 2020-12-31 0001703647 freq:NonExclusivePatentLicenseAgreementMember freq:MassachusettsEyeAndEarMember 2019-02-01 2019-02-28 0001703647 freq:MassachusettsEyeAndEarMember 2019-02-28 0001703647 freq:MassachusettsEyeAndEarMember srt:MaximumMember 2019-02-01 2019-02-28 0001703647 freq:MassachusettsEyeAndEarMember 2020-01-01 2020-12-31 0001703647 freq:MassachusettsEyeAndEarMember 2019-02-01 2019-02-28 0001703647 freq:CambridgeEnterpriseLimitedMember freq:PatentLicenseAgreementMember 2019-12-01 2019-12-31 0001703647 freq:CambridgeEnterpriseLimitedMember 2019-12-31 0001703647 freq:CambridgeEnterpriseLimitedMember 2019-12-01 2019-12-31 0001703647 srt:MaximumMember freq:CambridgeEnterpriseLimitedMember 2019-12-01 2019-12-31 0001703647 freq:CambridgeEnterpriseLimitedMember 2020-01-01 2020-12-31 0001703647 freq:ResearchAndDevelopmentMember us-gaap:GrantMember 2018-06-01 2018-06-30 0001703647 us-gaap:GrantMember 2020-01-01 2020-12-31 0001703647 us-gaap:GrantMember 2019-01-01 2019-12-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2019-07-01 2019-07-31 0001703647 freq:LicenseAndCollaborationAgreementMember srt:MaximumMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2019-07-01 2019-07-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember freq:Phase2bClinicalTrialMember srt:EuropeMember 2019-07-01 2019-07-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember freq:Phase2bClinicalTrialMember srt:AsiaMember 2019-07-01 2019-07-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember freq:Phase3ClinicalTrailMember srt:EuropeMember 2019-07-01 2019-07-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember freq:Phase3ClinicalTrailMember srt:AsiaMember 2019-07-01 2019-07-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2020-01-01 2020-12-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2020-12-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2019-07-01 2019-09-30 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2019-07-01 2020-12-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2019-01-01 2019-12-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember us-gaap:RoyaltyMember 2019-01-01 2019-12-31 0001703647 freq:LicenseAndCollaborationAgreementMember freq:AstellasPharmaLimitedLiabilityCompanyMember 2019-12-31 0001703647 stpr:MA 2016-12-31 0001703647 stpr:CT 2020-01-01 2020-12-31 0001703647 stpr:MA 2020-01-01 2020-12-31 0001703647 freq:AREMARegionNo20LLCMember freq:LeasesTerminationAgreementMember 2020-12-11 2020-12-11 0001703647 freq:LeasesTerminationAgreementMember 2020-01-01 2020-12-31 0001703647 freq:HaydenLLCMember freq:LexingtonLeaseMember 2020-01-07 0001703647 freq:HaydenLLCMember freq:LexingtonLeaseMember 2020-01-07 2020-01-07 0001703647 2020-01-01 2020-03-31 0001703647 2020-04-01 2020-06-30 0001703647 2020-07-01 2020-09-30 0001703647 2020-10-01 2020-12-31 0001703647 2019-07-01 2019-09-30 0001703647 2019-10-01 2019-12-31 0001703647 2019-01-01 2019-03-31 0001703647 2019-04-01 2019-06-30 10-K false true 2020-12-31 false 2020 --12-31 FY 0001703647 001-39062 Frequency Therapeutics, Inc. DE 47-2324450 19 Presidential Way 2nd Floor Woburn MA 01801 866 389-1970 Common Stock, $0.001 par value per share FREQ NASDAQ Yes No Yes Yes Non-accelerated Filer true true false false 625800000 34177771 false 220341000 200158000 17197000 4723000 4000000 225064000 221355000 7287000 1762000 30551000 1820000 101000 264722000 223218000 5506000 1219000 6663000 3239000 14068000 48152000 397000 170000 26634000 52780000 2900000 30597000 15000000 180000 72231000 55860000 34000 31000 287829000 236161000 27000 54000 -95399000 -68888000 192491000 167358000 264722000 223218000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 200000000 200000000 33964000 30844507 33964000 30844507 36984000 28947000 16000000 37415000 18784000 27119000 14838000 64534000 49622000 -27550000 -20675000 994000 1784000 84000 138000 -4000 7000 -26476000 -18746000 35000 -26511000 -18746000 1054000 -26511000 -19800000 -0.82 -2.29 32253227 8649245 -27000 54000 -27000 54000 -26538000 -18692000 41857005 38224000 10000 9000 62528507 46694000 10000 8000 3773000 2084710 2000 804000 -49088000 -48282000 3609000 3609000 357170 1000 365000 366000 288991 266000 39492960 61687000 1054000 1054000 1054000 6325000 6000 79690000 79696000 -39492960 -62741000 -42145996 -38490000 -10.000 -9000 -62528507 -46694000 -10000 -8000 -3773000 22077627 22000 151693000 151715000 54000 54000 -18746000 30844507 31000 236161000 54000 -68888000 9983000 9983000 769385 1000 1544000 1545000 2350108 2000 40141000 40143000 -27000 -27000 -26511000 33964000 34000 287829000 27000 -95399000 -26511000 -18746000 9983000 3609000 1146000 813000 54000 434000 160000 626000 3252000 4287000 -644000 -36984000 51052000 3083000 1490000 -45188000 34216000 6671000 1064000 26345000 282618000 43418000 265421000 10402000 -18261000 266000 61687000 1545000 80062000 40143000 15000000 56688000 142015000 21902000 157970000 200259000 42289000 222161000 31335000 1054000 151715000 2145000 Portions of the Proxy Statement for the registrant’s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. 1. Organization and basis of presentation Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.   On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. In October 2019, the Company completed the initial public offering of its common stock (the “IPO”). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters’ exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 20, 2020, the Company issued and sold an aggregate of 2,350,108 shares of its common stock, par value $0.001 per share, at a purchase price of $18.00 per share to new and existing investors in a private placement for net proceeds of $40.1 million after deducting placement agent fees and offering expenses (the “Private Placement”). In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within 60 days after the closing of the Private Placement (the “Initial Filing Date”) for purposes of registering the resale of the Shares. The Company filed a registration statement (the “Registration Statement”) which was declared effective by the SEC on September 3, 2020. The Company has also agreed, among other things, to indemnify the investors, their officers, directors, managers, employees, agents and any person who controls any investor under the Registration Statement from certain liabilities and to pay all fees and expenses (excluding any underwriting discounts and commissions) incident to the Company’s obligations under the Registration Rights Agreement. Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. Our offices are located in states that are currently operating under a phased re-opening plan in response to the COVID-19 pandemic. As of the date of the filing of this Annual Report, the majority of our employees continue to work from home, while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. While we have resumed experiments at our Farmington site, we have transitioned certain key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We are also have taken steps consistent with the FDA’s updated industry guidance for conducting clinical trials. The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, while no significant disruptions have occurred, the COVID-19 pandemic may cause such disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact the our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue. Liquidity and capital resources The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December 31, 2020, the Company had an accumulated deficit of $95,399. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued.   2. Summary of significant accounting policies Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). Principles of consolidation The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. Use of estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. Comprehensive income (loss) Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities.   Segment information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker, the Company’s chief executive officer, views the Company’s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. Foreign currency All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December 31, 2020 and 2019 the Company recorded $(4), and $7 of foreign currency exchange (losses) gains, respectively. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December 31, 2020 and 2019 consists entirely of cash and money market funds. Restricted Cash The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company's future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company's Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company's Woburn, Massachusetts facility. Short-term marketable debt securities Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders’ equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense). Concentration of credit risk and off-balance sheet risk Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Significant suppliers The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. Fair value measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.86%;white-space:nowrap">  </td> <td valign="top" style="width:9.38%;white-space:nowrap"> Level 1</td> <td valign="top"> Quoted prices in active markets for identical assets or liabilities.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.86%;white-space:nowrap">  </td> <td valign="top" style="width:9.38%;white-space:nowrap"> Level 2</td> <td valign="top"> Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable,     such as quoted market prices, interest rates and yield curves.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.86%;white-space:nowrap">  </td> <td valign="top" style="width:9.38%;white-space:nowrap"> Level 3</td> <td valign="top"> Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</td></tr></table></div> To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company’s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. Property and equipment Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" style="width:72%;">  </td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="width:72%;"> Lab equipment</td> <td valign="top" bgcolor="#CFF0FC" style="width:1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" style="width:72%;"> Software</td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="width:72%;"> Furniture and office equipment</td> <td valign="top" bgcolor="#CFF0FC" style="width:1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" style="width:72%;"> Leasehold improvements</td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</td> </tr> </table>   Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.</div> Impairment of long-lived assets The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December 31, 2020 and 2019. Research and development costs and accruals Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. Leases The Company elected to early adopt ASC 842, Leases (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (“ROU”) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component. Collaborative arrangements The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company’s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, Revenue from Contracts with Customers (“ASC 606”). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company’s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor’s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer’s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (“Astellas”), as further described in Note 16 of notes to consolidated financial statements. Revenue recognition The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company’s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company’s accounting policies in compliance with this new standard.   Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the “customer” in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company’s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.  For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company’s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. Patent costs The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. Stock-based compensation The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period.   Income taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, Income Taxes (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). Net loss per share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December 31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2020 and 2019. Basic and diluted net loss per share attributable to common stockholders was calculated as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding- <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders- <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table>   The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,819,891</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div></div>   Recently adopted accounting pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. In July 2018, the FASB also issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC 842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets. The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements. 3. Fair value measurements The Company’s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss) Gain</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,131</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,119</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government treasury securities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,131</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,262</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,316</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>   4. Prepaid expenses Prepaid expenses and other current assets consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent and deposits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant receivable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,552</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,132</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,723</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>    </div> 5. Property and equipment Property and equipment include the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,166</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,340</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,828</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,212</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,066</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,287</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The Company recognized $1,146 and $813 of depreciation expense for the years ended December 31, 2020 and 2019, respectively.   6. Accrued expenses Accrued expenses consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,062</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,686</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">874</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes and other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,663</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> 7. Debt <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with a commercial bank for a Term Loan with a principal balance of $15 million. The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”). Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in The Wall Street Journal, subject to an interest rate floor of zero) or (ii) 4.75%. Interest related to the Loan Agreement was immaterial for the year ended December 31, 2020. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the Term Loan Facility is refinanced by the Bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date. <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay a final payment of $150,000, which will occur on the earliest of: (i) the Loan Maturity Date; (ii) the date that the Company prepays all of the outstanding principal in full; (iii) the date the loan payments are accelerated due to an event of default; or (iv) the termination of the Loan Agreement. The Company is recording the final payment as interest expense over the term of the loan. The Term Loan Facility is secured by substantially all of the Company’s assets, excluding intellectual property. 8. Convertible preferred stock As of December 31, 2018, the Company had issued 62,528,507 shares of Series A Preferred Stock, 10,000 shares of Series A-1 Preferred Stock, 41,857,005 shares of Series B Preferred Stock, and 10,000 shares of Series B-1 Preferred Stock. In 2019, the Company also issued 288,911 shares of Series B Preferred Stock. On July 17, 2019, the Company authorized and issued 39,492,960 shares of Series C Preferred for net proceeds of $61,687. The Company evaluated the tranched nature of the issuance of these preferred shares as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation. In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock.   9. Non-controlling Interest In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation. In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company’s Series A-1 Preferred Stock and 10,000 shares of the Company’s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock. On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of an initial public offering of the Company’s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred shares were forfeited in conjunction with the IPO. 10. Stockholders’ equity Preferred stock        The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of December 31, 2020. Common stock The Company has authorized 200,000,000 shares of $0.001 par value common stock of which 33,964,000 were issued and outstanding as of December 31, 2020. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors. The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under stock option plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,475,923</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859,654</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,292,721</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828,326</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> 11. Stock-based compensation On November 13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company’s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December 31, 2020, there were no shares of common stock available for future grants under the 2014 Plan. On September 17, 2019, the Company’s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (“the “2019 Plan”) which became effective on the day prior to the IPO.  Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company’s subsidiaries.  A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan.  The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan.  In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company’s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company’s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. Stock options A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,015,381</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357,170</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,211</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.76</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721,334</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,051</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,645,859</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.22</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,851</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.93</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(767,534</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.94</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,997</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.72</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,351</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.89</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,874,349</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.84</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.09</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,325</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,942,449</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.98</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,090</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,617</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.48</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,042</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,337,828</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.88</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,416</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309,732</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,283</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604,621</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,674</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Stock option valuation The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   Risk-Fee Interest Rate: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant.   Expected Term:  The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).   Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.  The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available.   Expected Dividend Yield: The Company has not paid and does not anticipate paying any dividends in the near future.  Therefore, the expected dividend yield was zero.   The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. During the years ended December 31, 2020 and 2019, 769,385 and 357,170 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $16,667 and $5,896 respectively. The weighted-average grant date fair value of options granted to employees during the years ended December 31, 2020 and 2019 was $16.41 and $4.05 respectively. The total grant date fair value of options vested during the years ended December 31, 2020 and 2019 was $7,907 and $2,990, respectively. Restricted common stock The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder. A summary of the status of restricted common stock as of December 31, 2020 and 2019 is presented below: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:72.52%;"> <tr style="height:8.85pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:20.95pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.85pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.85pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awarded</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.5pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,273</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.85pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.5pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> The total value of restricted stock awards that vested during the years ended December 31, 2020 and 2019, based on estimated fair values of the stock underlying the restricted stock awards was $20 and $73, respectively. Stock-based compensation Stock-based compensation expense of $9,983 and $3,609 for the years ended December 31, 2020 and 2019 respectively, is included in research and development and general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss. As of December 31, 2020 and 2019, total unrecognized stock-based compensation expense relating to unvested stock options was $31,006 and $13,820, respectively. This amount is expected to be recognized over a weighted-average period of 3.08 years and 2.76 years, respectively. 12. Employee stock purchase plan On September 20, 2019, the Company’s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the “ESPP”) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company’s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. No shares were issued under the ESPP at December 31, 2020. 13. Income taxes Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. As of December 31, 2020, the Company had federal net operating loss carryforwards of approximately $67,868 and Massachusetts state operating loss carryforwards of approximately $43,386 which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $45,469 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2040. As of December 31, 2020, the Company also had federal and Massachusetts research and development tax credit carryforwards of $3,014 and $1,211, respectively, which are available to offset federal and state tax liabilities through 2040 and 2035, respectively. Realization of future tax benefits is dependent on many factors, including the Company’s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.  Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO.  Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382.  The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2020 and 2019 because the Company’s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $26,995 and $16,204 as of December 31, 2020 and 2019 has been established. The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December 31, 2020 and 2019. The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. A reconciliation of the Company’s pre-tax income for the years ended December 31, 2020 and 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56.02%;"> <tr style="height:10.65pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.7pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,744</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,086</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr style="height:12.7pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(732</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(714</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr style="height:13.45pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> The Company’s provision at December 31, 2020 and 2019 consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.74%;"> <tr style="height:10.3pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Federal</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:13.05pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     State</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:13.05pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Foreign</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:13.05pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Federal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     State</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:13.05pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Foreign</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Deferred</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate for the years ended December 31, 2020 and 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:52.54%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="border:none;padding:0;"></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S federal statutory income tax rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation deductions</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40.7)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.0</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="border:none;padding:0;"></td> </tr> </table></div>   The Company’s deferred tax assets at December 31, 2020 and 2019 consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,885</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,253</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,992</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,606</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,285</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,181</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,995</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,204</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,995</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,204</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>     14. Research and license agreements Massachusetts Institute of Technology In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company’s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90) days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations. Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15. The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Pursuant to MIT’s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively. Refer to Note 18 for all related party disclosures. The Scripps Research Institute (California Institute for Biomedical Research) In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes. The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations , which may be extended under certain circumstances as outlined in the CALIBR License Agreement, to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement. Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%. The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1) the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2) ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.   The Scripps Research Institute In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we made funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement. In September 2020, the Company extended the term of the option agreement through the end of December 2021. As consideration for this extension, the Company is required to make additional funding payments of $0.6 million to Scripps through December 2021. The Company has the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt. Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss. The Company is required to use diligent efforts to develop and commercialize the licensed products and MEE has control over the filing, prosecution, enforcement and defense of any licensed patent rights. We met one of our milestone timeline obligations by dosing a first patient in a Phase II trial by December 31, 2020. We are still subject to a milestone timeline obligation to dose a first patient in a Phase III trial by December 31, 2024. Upon entering into the MEE License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale. The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60) business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. Cambridge Enterprise Limited In December 2019, we entered into an Exclusive Patent License Agreement ( the “Cambridge License”) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge) (“Cambridge”) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the “Cambridge License Product”) which incorporate licensed technology for the treatment of demyelinating diseases.  We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.   The Company has agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product.  Upon entering into the Cambridge License, the Company made a $50 license fee payment.  The Company is obligated to pay an annual license fee of $50. The Company is also obligated to make milestone payments up to $10.5 million on each Cambridge License Product.  In addition, the Company has agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances. The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier.  We have the right to terminate for any reason upon 90 days’ prior to written notice.  Each party has the right to terminate immediately if the other party ceases to carry on its business.  Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.  Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed. Department of Defense In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company’s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $323 and $845 as a reduction in research and development expenses for the years ended December 31, 2020 and 2019, respectively. 15. Collaboration agreement In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. The collaboration is governed by a joint steering committee (“JSC”) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party’s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments up to $230.0 million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315.0 million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days’ written notice. Each party has the right to terminate the Astellas Agreement due to the other party’s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019. The $80.0 million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2020, the Company recognized $37.0 million of revenue under the Astellas Agreement. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MIT and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322. The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee’s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the years ended December 31, 2020 and 2019, the Company invoiced Astellas $1,046 and $186 for joint costs, respectively. 16. Commitments and contingencies Operating leases In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company’s primary office and laboratory space in Woburn, Massachusetts. The lease was extended in November 2019 and expires in February 2025. Additionally, the Company amended the lease in November 2019 to add additional laboratory and office space. The commencement date of the additional space occurred in February 2020 and expires in February 2025. The lease agreements do not contain any material residual value guarantees or material restrictive covenants.  The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2021.   On December 11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the “Lease Termination Agreement”) with ARE-MA Region No. 20, LLC (the “Landlord”). The Lease Termination Agreement provides that the Lease Agreement, dated as of August 14, 2016, by and between the Company and Landlord (as the same may have been amended, the “Lease”) will terminate on March 31, 2021, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May 31, 2021. As consideration for the Landlord’s agreement to enter into the Lease Termination Agreement and accelerate the expiration date of the term of the Lease, the Company has agreed to pay to Landlord a fee of approximately $0.2 million. On January 7, 2020 the Company entered into an indenture of lease (the “Lexington Lease”) with HCP/KING 75 Hayden LLC, for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the “Lexington Premises”).  The Lexington Lease commenced on December 11, 2020, (the “Commencement Date”).  The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses.  The term of the Lexington Lease, (the “ Initial Term”), is ten years from the rent commencement date (which is five months following the Commencement Date) and the Initial Term is expected to end on May 31, 2031.  The Company also has the option to extend the Initial Term for two additional terms of five years each. As of December 31, 2020, the Company has $30,551 of operating lease ROU assets, and $397 and $30,597 of current and non-current lease liabilities, respectively, recorded on the consolidated balance sheets. For the year ended December 31, 2020 the Company recorded $470 of operating lease cost, $510 of variable lease cost, and $106 of short-term lease cost. The lease expense for the years ended December 31, 2020 and 2019 are $835 and $269, respectively. Cash paid for amounts included in the measurement of lease liabilities for year ended December 31, 2020 is $484.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other information</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate (1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.86%;white-space:nowrap">  </td> <td valign="top" style="width:3.57%;white-space:nowrap"> (1)</td> <td valign="top"> Rate includes the Company’s Woburn and Lexington leases. </td></tr></table></div></div> The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,398</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount of lease payments representing interest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,404</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current lease liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(397</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent lease liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,986</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026 and beyond</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,456</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Contract commitments The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $0.6 million through December 2021.       The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. Guarantees The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees. As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. The Company leases office space in Woburn, Massachusetts under a five-year non-cancelable operating lease, and has entered into a facility lease in Lexington, Massachusetts. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. As of December 31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. 17. Employee benefit plan Employees of the Company are eligible to participate in the Company’s 401(k) retirement plan (the “401(k) Plan”). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches 100% of the first 5% of employee contributions and vests 100% at time of match. For the years ended December 31, 2020 and 2019, the Company made matching contributions of $0.4 million and $0.2 million, respectively. 18. Related party transactions The Company’s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company’s directors and shareholders. As disclosed in Note 14, the Company entered into the MIT License Agreement in December 2016. The patents in-licensed by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively.   19. Subsequent events <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 29, 2021, the date which the consolidated financial statements were available to be issued. The identified subsequent events are as follows;   On February 18, 2021, the Company completed the liquidation and dissolution of Frequency Therapeutics Japan KK, the Company’s Japanese subsidiary. On March 23, 2021, the Company announced topline, day-90 data from its FX-322 Phase 2a study. The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. The Company also announced new preliminary data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The single dose showed efficacy that was clinically meaningful and statistically significant compared to the untreated ear, had a favorable safety profile and was well tolerated.   20. Selected Quarterly Data (Unaudited) <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table contains quarterly financial information for 2020 and 2019.  The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.  The operating results for any quarter are not necessarily indicative of results for any future period.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,264</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,523</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,247</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,950</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36,984</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,177</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,548</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,588</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,182</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">63,495</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   dividends</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders - <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,238</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28,947</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,826</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,813</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,202</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47,693</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,746</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   dividends</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,054</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,800</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders - <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.42</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.73</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2.29</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>  </div> Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). Principles of consolidation The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. Use of estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. Comprehensive income (loss) Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities.   Segment information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker, the Company’s chief executive officer, views the Company’s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. Foreign currency All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December 31, 2020 and 2019 the Company recorded $(4), and $7 of foreign currency exchange (losses) gains, respectively. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December 31, 2020 and 2019 consists entirely of cash and money market funds. Restricted Cash The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company's future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company's Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company's Woburn, Massachusetts facility. Short-term marketable debt securities Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders’ equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense). Concentration of credit risk and off-balance sheet risk Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Significant suppliers The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. Fair value measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.86%;white-space:nowrap">  </td> <td valign="top" style="width:9.38%;white-space:nowrap"> Level 1</td> <td valign="top"> Quoted prices in active markets for identical assets or liabilities.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.86%;white-space:nowrap">  </td> <td valign="top" style="width:9.38%;white-space:nowrap"> Level 2</td> <td valign="top"> Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable,     such as quoted market prices, interest rates and yield curves.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.86%;white-space:nowrap">  </td> <td valign="top" style="width:9.38%;white-space:nowrap"> Level 3</td> <td valign="top"> Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</td></tr></table></div> To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company’s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. Property and equipment Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" style="width:72%;">  </td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="width:72%;"> Lab equipment</td> <td valign="top" bgcolor="#CFF0FC" style="width:1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" style="width:72%;"> Software</td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="width:72%;"> Furniture and office equipment</td> <td valign="top" bgcolor="#CFF0FC" style="width:1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" style="width:72%;"> Leasehold improvements</td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</td> </tr> </table></div>   Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations. Impairment of long-lived assets The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December 31, 2020 and 2019. Research and development costs and accruals Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. Leases The Company elected to early adopt ASC 842, Leases (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (“ROU”) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component. Collaborative arrangements The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company’s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, Revenue from Contracts with Customers (“ASC 606”). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company’s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor’s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer’s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (“Astellas”), as further described in Note 16 of notes to consolidated financial statements. Revenue recognition The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company’s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company’s accounting policies in compliance with this new standard.   Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the “customer” in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company’s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.  For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company’s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. Patent costs The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. Stock-based compensation The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. Income taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, Income Taxes (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). Net loss per share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December 31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2020 and 2019. Basic and diluted net loss per share attributable to common stockholders was calculated as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding- <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders- <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>   The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,819,891</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Recently adopted accounting pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. In July 2018, the FASB also issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC 842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets. The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements. Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" style="width:72%;">  </td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="width:72%;"> Lab equipment</td> <td valign="top" bgcolor="#CFF0FC" style="width:1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" style="width:72%;"> Software</td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="width:72%;"> Furniture and office equipment</td> <td valign="top" bgcolor="#CFF0FC" style="width:1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> </tr> <tr> <td valign="top" style="width:72%;"> Leasehold improvements</td> <td valign="top" style="width:1%;">  </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</td> </tr> </table></div> Basic and diluted net loss per share attributable to common stockholders was calculated as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,511</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding- <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,253,227</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders- <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.82</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.06%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,819,891</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.66%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The Company’s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,522</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,549</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.74%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss) Gain</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,131</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,119</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government treasury securities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,131</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.04%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,262</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,316</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Prepaid expenses and other current assets consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent and deposits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,729</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant receivable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,552</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,132</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,723</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>     Property and equipment include the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,166</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,340</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,828</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,212</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,066</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,287</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Accrued expenses consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,062</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,686</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">874</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes and other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,663</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,816,798</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under stock option plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,475,923</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859,654</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,292,721</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828,326</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,015,381</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357,170</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,211</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.76</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721,334</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,051</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,645,859</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.22</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,851</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.93</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(767,534</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.94</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,997</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.72</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,351</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.89</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,874,349</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.84</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.09</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,325</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,942,449</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.98</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,090</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,617</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.48</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,042</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,337,828</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.88</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,416</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.76%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309,732</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,283</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.7%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604,621</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.7%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,674</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> A summary of the status of restricted common stock as of December 31, 2020 and 2019 is presented below: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:72.52%;"> <tr style="height:8.85pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:20.95pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.85pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.85pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Awarded</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.5pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,273</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.85pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:8.5pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested, December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   A reconciliation of the Company’s pre-tax income for the years ended December 31, 2020 and 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56.02%;"> <tr style="height:10.65pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.7pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,744</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,086</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr style="height:12.7pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(732</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(714</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr style="height:13.45pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,476</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> The Company’s provision at December 31, 2020 and 2019 consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:55.74%;"> <tr style="height:10.3pt;"> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Federal</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:13.05pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     State</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:13.05pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Foreign</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:13.05pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Federal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     State</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:13.05pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Foreign</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Deferred</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.35pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate for the years ended December 31, 2020 and 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:52.54%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="border:none;padding:0;"></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S federal statutory income tax rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation deductions</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40.7)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.0</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="border:none;padding:0;"></td> </tr> </table></div> The Company’s deferred tax assets at December 31, 2020 and 2019 consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,885</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,253</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,992</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,606</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,285</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,181</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,995</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,204</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,995</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,204</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other information</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate (1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.86%;white-space:nowrap">  </td> <td valign="top" style="width:3.57%;white-space:nowrap"> (1)</td> <td valign="top"> Rate includes the Company’s Woburn and Lexington leases. </td></tr></table></div> The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,398</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount of lease payments representing interest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,404</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current lease liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(397</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent lease liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,597</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,986</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,159</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,284</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,412</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026 and beyond</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.56%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,456</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table contains quarterly financial information for 2020 and 2019.  The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.  The operating results for any quarter are not necessarily indicative of results for any future period.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,264</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,523</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,247</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,950</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36,984</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,177</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,548</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,588</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,182</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">63,495</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   dividends</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,913</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,341</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,232</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(26,511</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders - <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.30</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,238</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28,947</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,826</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,813</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,202</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47,693</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,746</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   dividends</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,054</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,800</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders - <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.42</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.73</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2.29</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>   2014-11-30 0.148467 1-for-6.7355 100000000 148724922 0.001 6325000 14.00 79700000 22077627 2350108 0.001 18.00 40100000 1700000 100000 100000 0 P1M P3Y P3Y P3Y Shorter of the estimated useful life or lease term 0 0 3093 70366 1172676 4759079 7070574 513047 6816798 5968672 6819891 19554414 1200000 1700000 1500000 1700000 1000000 1000000 true 2020-01-01 true 2020-01-01 true 214522000 214522000 27000 27000 214549000 214549000 200131000 12000 200119000 17131000 217262000 66000 54000 17197000 217316000 63000 1729000 801000 805000 340000 2552000 2132000 102000 199000 4166000 1846000 283000 257000 291000 1419000 1419000 4340000 306000 10499000 3828000 3212000 2066000 5062000 2686000 647000 435000 874000 118000 80000 15000000 The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”) monthly 2022-11-30 2024-05-01 0.0150 0.00 0.0475 0.020 0.010 0.000 150000000 62528507 10000 41857005 288911 10000 39492960 39492960 61687000 673605 0.70 10000 10000 Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock Each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock 6816798 5968672 1475923 1859654 8292721 7828326 8550415 0 3100000 P10Y 0.04 In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company’s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. P4Y P10Y 2089334 1247338 3015381 357170 26211 1247338 4721334 1645859 1851 767534 16997 11351 2874349 3942449 564617 2337828 2309732 1604621 0.61 14.09 4.17 1.02 1.09 14.09 2.85 24.22 18.93 1.94 22.72 6.89 19.84 3.02 17.48 2.57 P9Y9M3D P8Y10M20D P9Y1M2D P7Y11M23D P8Y10M24D P7Y10M17D 4287000 65051000 44325000 127090000 10042000 76416000 34283000 50674000 0.011 0.020 P6Y P5Y10M24D 0.791 0.794 0.000 0.000 769385 357170 16667 5896 16.41 4.05 7907 2990 P4Y 70366 67273 3093 0.36 0.29 1.75 73000 20000 9983000 3609000 31006000 13820000 P3Y29D P2Y9M3D 0.15 315000 P10Y 0.01 0 0 67868000 43386000 22400000 2037 45469000 2040 2040 2035 3014000 1211000 0.50 P3Y 12400000 10800000 1600000 180000 1600000 46123000 0 0 26995000 16204000 0 0 0 0 -25744000 -19086000 -732000 -714000 -26476000 -19800000 35000 35000 0.210 0.210 -0.002 -0.028 0.030 0.040 0.112 0.018 0.051 0.000 0.006 -0.010 -0.407 -0.230 17885000 13253000 3992000 1138000 360000 358000 850000 686000 48000 3606000 496000 142000 189000 56000 36000 7285000 7181000 26995000 16204000 2016-12 The Company’s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. 50000 0.05 2900000 16000000 The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. P3M P90D P30D 1980000 10000 2018-09 1000000 26000000 0.50 The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. P30D P90D P30D 2018-09 700000 P1Y 2021-12 600000 The Company has the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt. P90D P10D P60D 2019-02 20000 350000 The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60) business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. P30D P30D P45D P60D 2019-12 50000 50000 10500 We have the right to terminate for any reason upon 90 days’ prior to written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed. P90D P30D 1596000 P2Y 323000 845000 80000000 230000000 315000000 65000000 25000000 100000000 40000000 315000000 P60D P90D P45D 80000000 16000000 16000000 80000000 28900000 37000000 16000000 12900000 64000000 1046000 186000 P5Y 2021 The lease was extended in November 2019 and expires in February 2025. 2019-11 2020-02 2025-02 2021-03-31 200000 61307 2020-12-11 P10Y 2031-05-31 2 P5Y 470000 510000 106000 835000 269000 484000 P10Y3M18D 0.085 2928000 4159000 4284000 4412000 4545000 27070000 47398000 16404000 30994000 2986000 4159000 4284000 4412000 4545000 27070000 47456000 600000 P5Y 0 0 0.90 1.00 0.05 1.00 400000 200000 7264000 8523000 11247000 9950000 12177000 14548000 16588000 20182000 63495000 -4913000 -6025000 -5341000 -10232000 -4913000 -6025000 -5341000 -10232000 -0.16 -0.19 -0.16 -0.30 24238000 4709000 5826000 6852000 24813000 10202000 47693000 -5826000 -6852000 -575000 -5493000 1014000 40000 -5826000 -6852000 -1589000 -5533000 -3.24 -3.42 -0.73 -0.19 EX-101.SCH 27 freq-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Organization and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Prepaid Expenses link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Convertible Preferred Stock link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Non-controlling Interest link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Stock-based Compensation link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Employee Stock Purchase Plan link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Research and License Agreements link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Collaboration Agreement link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Employee Benefit Plan link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Selected Quarterly Data (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Prepaid Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Stock-based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Selected Quarterly Data (Unaudited) (Tables) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Property and Equipment - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Debt - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Convertible Preferred Stock - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Non-controlling Interest - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Stockholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Stock-based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock (Details) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Income Taxes - Schedule of Reconciliation Pre-tax Income (Details) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Income Taxes - Schedule of Provision (Details) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Research and License Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Collaboration Agreement - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100660 - Disclosure - Commitments and Contingencies - Schedule of Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100670 - Disclosure - Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details) link:calculationLink link:presentationLink link:definitionLink 100680 - Disclosure - Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details)2 link:calculationLink link:presentationLink link:definitionLink 100690 - Disclosure - Commitments and Contingencies - Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100700 - Disclosure - Employee Benefit Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100710 - Disclosure - Related Party Transactions - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100720 - Disclosure - Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 28 freq-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 29 freq-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 30 freq-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Operating and non-operating expenses net. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Document Fiscal Year Focus Document Fiscal Year Focus Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address City Or Town Entity Address City Or Town Entity Address State Or Province Entity Address State Or Province Entity Address Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Public Float Entity Public Float Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term marketable securities Available For Sale Securities Debt Securities Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Right of use assets Operating Lease Right Of Use Asset Restricted cash Restricted Cash Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Deferred revenue Contract With Customer Liability Current Lease liabilities Operating Lease Liability Current Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Deferred revenue, net of current portion Contract With Customer Liability Noncurrent Lease liabilities, net of current portion Operating Lease Liability Noncurrent Term Loan Long Term Loans From Bank Long-term liabilities Long Term Debt Noncurrent Total liabilities Liabilities Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019, respectively Preferred Stock Value Common stock, $0.001 par value; 200,000,000 shares authorized, 33,964,000 and 30,844,507 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, authorized shares Preferred Stock Shares Authorized Preferred stock, issued shares Preferred Stock Shares Issued Preferred stock, outstanding shares Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, authorized shares Common Stock Shares Authorized Common stock, issued shares Common Stock Shares Issued Common stock, outstanding shares Common Stock Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Royalty Royalty Expense Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest income Investment Income Interest Realized gain on investments Realized Investment Gains Losses Foreign exchange (loss) gain Foreign Currency Transaction Gain Loss Before Tax Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income taxes Income Tax Expense Benefit Net loss Net Income Loss Cumulative Series C convertible preferred stock dividends Temporary Equity Dividends Adjustment Net loss attributable to common stockholders Net Income Loss Available To Common Stockholders Basic Net loss per share attributable to common stockholders-basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares of common stock outstanding-basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Net loss Other comprehensive (loss) gain: Comprehensive Income Net Of Tax [Abstract] Unrealized (loss) gain on marketable securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Total comprehensive (loss) gain Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Comprehensive loss Comprehensive Income Net Of Tax Temporary equity, stock issued during period, shares, new issues. Convertible preferred stock accretion of dividend. Temporary equity stock shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering. Temporary equity stock value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering. Stock issued during period shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering. Stock issued during period value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series C convertible preferred stock. Series C Convertible Preferred Stock Series C Convertible Preferred Stock [Member] Series B convertible preferred stock. Series B Convertible Preferred Stock Series B Convertible Preferred Stock [Member] Series B-1 convertible preferred stock. Series B-1 Convertible Preferred Stock Series B1 Convertible Preferred Stock [Member] Series A convertible preferred stock. Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Series A-1 convertible preferred stock. Series A-1 Convertible Preferred Stock Series A1 Convertible Preferred Stock [Member] Accumulated Other Comprehensive Income Statement Equity Components [Axis] Equity Component Equity Component [Domain] Non-controlling Interest Noncontrolling Interest [Member] Common Stock Common Stock [Member] Additional-paid in Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Beginning Balance Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests Beginning Balance (in shares) Temporary Equity Shares Outstanding Beginning Balance Beginning Balance (in shares) Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation expense (in shares) Stock Issued During Period Shares Share Based Compensation Gross Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of options (in shares) Stock Issued During Period Shares Stock Options Exercised Issuance of convertible preferred stock Temporary Equity Stock Issued During Period Value New Issues Issuance of convertible preferred stock (in shares) Temporary Equity Stock Issued During Period Shares New Issues Accretion of Series C preferred dividend Convertible Preferred Stock Accretion Of Dividend Accretion of Series C preferred dividend Temporary Equity Accretion Of Dividends Issuance of common stock in initial public offering or private placement Stock Issued During Period Value New Issues Issuance of common stock in initial public offering or private placement (in shares) Stock Issued During Period Shares New Issues Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO Stock Issued During Period Value Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares) Temporary Equity Stock Shares Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO Temporary Equity Stock Value Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares) Stock Issued During Period Shares Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering Other comprehensive income (loss) Other Comprehensive Income Loss Net Of Tax Ending Balance Ending Balance (in shares) Ending Balance Ending Balance (in shares) Non cash lease expenses. Deferred lease incentives. Non cash dividend on cumulative convertible preferred stock. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation Share Based Compensation Depreciation expense Depreciation Issuance of common stock for license agreement Issuance Of Stock And Warrants For Services Or Claims Non-cash lease expense Non Cash Lease Expenses Deferred lease incentives Deferred Lease Incentives Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Deferred revenue Increase Decrease In Contract With Customer Liability Accrued expenses Increase Decrease In Accrued Liabilities Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Purchase of available for sale securities Payments To Acquire Available For Sale Securities Debt Redemption of available for sale securities Proceeds From Sale Of Available For Sale Securities Debt Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of convertible preferred stock, net of issuance costs Proceeds From Issuance Of Convertible Preferred Stock Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Proceeds from Private Placement, net of issuance costs Proceeds From Issuance Of Private Placement Proceeds from Term Loan Proceeds From Issuance Of Long Term Debt Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents, short-term investments, and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents, short-term investments and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents, short-term investments, and restricted cash at end of period Non-cash items: Noncash Investing And Financing Items [Abstract] Right-of-use assets in exchange for lease liabilities Right Of Use Asset Obtained In Exchange For Operating Lease Liability Cumulative Series C convertible preferred stock dividends Non Cash Dividend On Cumulative Convertible Preferred Stock Conversion of preferred stock and non-controlling interest into common stock Conversion Of Stock Amount Issued1 Purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred But Not Yet Paid Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Basis of Presentation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Basis Of Presentation And Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Prepaid expenses and other current assets. Prepaid Expense And Other Assets Current [Abstract] Prepaid Expenses Prepaid Expenses And Other Current Assets [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Expenses Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Temporary equity. Temporary Equity Disclosure [Abstract] Convertible Preferred Stock Temporary Equity [Text Block] Noncontrolling Interest [Abstract] Non-controlling Interest Minority Interest Disclosure [Text Block] Equity [Abstract] Stockholders' Deficit Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Employee stock purchase plan disclosure. Compensation And Retirement Disclosure [Abstract] Employee Stock Purchase Plan Employee Stock Purchase Plan Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Research and license agreements disclosure text block. Research And Development [Abstract] Research and License Agreements Research And License Agreements Disclosure [Text Block] Collaboration Agreement Collaborative Arrangement Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Employee Benefit Plan Pension And Other Postretirement Benefits Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Quarterly Financial Information Disclosure [Abstract] Selected Quarterly Data (Unaudited) Quarterly Financial Information [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Comprehensive Income (loss) Comprehensive Income Policy Policy [Text Block] Segment Information Segment Reporting Policy Policy [Text Block] Foreign Currency Foreign Currency Transactions And Translations Policy [Text Block] Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Short-term Marketable Debt Securities Marketable Securities Policy Concentration of Credit Risk and Off-balance Sheet Risk Concentration Risk Credit Risk Significant suppliers. Significant Suppliers Significant Suppliers Policy [Text Block] Fair Value Measurements Fair Value Of Financial Instruments Policy Property and Equipment Property Plant And Equipment Policy [Text Block] Impairment of Long-Lived Assets Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Research and Development Costs and Accruals Research And Development Expense Policy Leases Lessee Leases Policy [Text Block] Collaborative Arrangements Collaborative Arrangement Accounting Policy Revenue Recognition Revenue Recognition Policy [Text Block] Patent costs. Patent Costs Patent Costs Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Income Taxes Income Tax Policy [Text Block] Net Loss Per Share Earnings Per Share Policy [Text Block] Recently Adopted Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Property and equipment. Property And Equipment Property And Equipment Table [Text Block] Schedule of Basic and Diluted Net Loss per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Computation of Diluted Net Loss per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Financial Assets Measured at Fair Value on Recurring Basis Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Summary of prepaid expenses and other current assets. Summary of Prepaid Expenses and Other Current Assets Summary Of Prepaid Expenses And Other Current Assets Table [Text Block] Schedule of Property and Equipment Property Plant And Equipment [Text Block] Schedule of Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Schedule of common stock shares reserved for future issuance. Schedule of Common Stock Shares Reserved for Future Issuance Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block] Summary of Stock Option Activity under 2014 Plan and 2019 Plan Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Status of Restricted Common Stock Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block] Schedule of Reconciliation Pre-tax Income Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block] Schedule of Provision Schedule Of Components Of Income Tax Expense Benefit Table [Text Block] Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Deferred Tax Assets Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Leases Lease Cost Table [Text Block] Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet Lessee Operating Lease Liability Maturity Table [Text Block] Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Schedule of Quarterly Financial Information Schedule Of Quarterly Financial Information Table [Text Block] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] IPO I P O [Member] Private Placement Private Placement [Member] Subsidiary Sale Of Stock [Line Items] Subsidiary Sale Of Stock [Line Items] Date of incorporation Entity Incorporation Date Of Incorporation Reverse stock split ratio Stockholders Equity Note Stock Split Conversion Ratio1 Reverse stock split, description Stockholders Equity Reverse Stock Split Common stock shares issued and sold Share price per share Shares Issued Price Per Share Net proceeds from issuance of common stock Proceeds From Issuance Initial Public Offering Number of common stock issued upon conversion of preferred stock Stock Issued During Period Shares Conversion Of Convertible Securities Net proceeds from issuance of common stock Accumulated deficit Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] Lexington Massachusetts facility. Lexington Massachusetts facility Lexington Massachusetts Facility [Member] Woburn Massachusetts facility. Woburn Massachusetts Facility Woburn Massachusetts Facility [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] Accounting Standards Update 2018-11 Accounting Standards Update201811 [Member] Accounting Standards Update 2016-01 Accounting Standards Update201601 [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Foreign currency exchange (losses) gains Fair value of term loan. Fair value of term loan issued term. Fair value of term loan Fair Value Of Term Loan Fair value of term loan issued term Fair Value Of Term Loan Issued Term Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Lab equipment. Lab Equipment Lab Equipment [Member] Software Software Development [Member] Furniture and office equipment. Furniture and Office Equipment Furniture And Office Equipment [Member] Leasehold Improvements Leasehold Improvements [Member] Property and equipment, estimated useful lives Property Plant And Equipment Useful Life Leasehold improvements, estimated useful lives Property Plant And Equipment Estimated Useful Lives Impairment losses Impairment Of Long Lived Assets Held For Use Numerator: Net Income Loss Available To Common Stockholders Basic [Abstract] Net loss attributable to common stockholders Denominator: Earnings Per Share Basic And Diluted Other Disclosures [Abstract] Weighted-average shares of common stock outstanding- basic and diluted Earnings Per Share [Abstract] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Unvested Restricted Common Stock [Member]. Unvested Restricted Common Stock Unvested Restricted Common Stock [Member] Series C Preferred As Converted To Common Stock [Member]. Series C Preferred (as converted to common stock) Series C Preferred As Converted To Common Stock [Member] Series B Preferred as converted to common stock member. Series B Preferred (as converted to common stock) Series B Preferred As Converted To Common Stock [Member] Series A Preferred as converted to common stock member. Series A Preferred (as converted to common stock) Series A Preferred As Converted Common Stock [Member] Conversion of Frequency Japan preferred stock member. Conversion of Frequency Japan Preferred Stock Conversion Of Frequency Japan Preferred Stock [Member] Outstanding stock options as converted to common stock member. Outstanding Stock Options (as converted to common stock) Outstanding Stock Options As Converted To Common Stock [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Increase (decrease) in operating lease right of use assets. Increase (decrease) in operating lease liability. Lease liability Operating Lease Liability Increase in right-of-use asset Increase Decrease In Operating Lease Right Of Use Assets Increase in lease liability Increase Decrease In Operating Lease Liability Change in accounting principle, accounting standards update, adopted Change In Accounting Principle Accounting Standards Update Adopted Change in accounting principle, accounting standards update, adoption date Change In Accounting Principle Accounting Standards Update Adoption Date Change in accounting principle, accounting standards update, immaterial effect Change In Accounting Principle Accounting Standards Update Immaterial Effect Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Money Market Funds Money Market Funds [Member] U.S. Government Treasury Securities U S Treasury Securities [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Recurring Basis Fair Value Measurements Recurring [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Amortization Cost Available For Sale Debt Securities Amortized Cost Basis Unrealized Loss Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Unrealized Gain Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Fair Market Value Available For Sale Securities Debt Securities Rent and deposits. Prepaid research and development expense current. Prepaid accounts receivable current. Rent and deposits Prepaid Rent And Deposits Current Research and development expenses Prepaid Research And Development Expense Current Grant receivable Grants Receivable Current Accounts receivable Prepaid Accounts Receivable Current Insurance Prepaid Insurance Other Other Assets Current Total Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Lab Equipment Equipment [Member] Furniture and Office Equipment Furniture And Fixtures [Member] Software Software And Software Development Costs [Member] Construction in Progress Construction In Progress [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Total Property Plant And Equipment Gross Accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Depreciation expense Accrued third-party research and development expenses current. Accrued income taxes and other accrued liabilities, current. Payroll and employee related expenses Employee Related Liabilities Current Professional fees Accrued Professional Fees Current Third-party research and development expenses Accrued Third Party Research And Development Expenses Current Taxes and other Accrued Income Taxes And Other Accrued Liabilities Current Total Debt instrument floor interest rate percentage. Debt instrument interest only payment maturity date. Debt Instrument [Table] Debt Instrument [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Loan and security agreement. Loan Agreement Loan And Security Agreement [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Term loan. Term Loan Term Loan [Member] Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] Prime Rate Prime Rate [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Prepayment Occurs on or Prior to First Anniversary of Closing Date. Prepayment Occurs on or Prior to First Anniversary of Closing Date Prepayment Occurs On Or Prior To First Anniversary Of Closing Date [Member] Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date. Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date Prepayment Occurs After First Anniversary Of Closing Date And On Or Prior To Second Anniversary Of Closing Date [Member] Prepayment Occurs After Second Anniversary of Closing Date. Prepayment Occurs After Second Anniversary of Closing Date Prepayment Occurs After Second Anniversary Of Closing Date [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Principal balance Debt Instrument Face Amount Payment terms, description Debt Instrument Payment Terms Frequency of interest-only payments Debt Instrument Frequency Of Periodic Payment Monthly interest only payments due Debt Instrument Interest Only Payment Maturity Date Loan maturity date Debt Instrument Maturity Date Debt instrument, Interest rate Debt Instrument Basis Spread On Variable Rate1 Interest rate floor percentage Debt Instrument Floor Interest Rate Percentage Debt instrument prepayment premium percentage. Debt instrument prepayment premium percentage Debt Instrument Prepayment Premium Percentage Debt instrument final payment Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Temporary Equity By Class Of Stock [Table] Temporary Equity By Class Of Stock [Table] Series A Preferred Stock Series B Preferred Stock Series C Convertible Preferred Stock Series A-1 Preferred Stock Series B-1 Preferred Stock Temporary Equity [Line Items] Temporary Equity [Line Items] Convertible preferred stock, issued shares Temporary Equity Shares Issued Convertible preferred stock, authorized shares Temporary Equity Shares Authorized Preferred stock, net proceeds from shares issued Temporary Equity Carrying Amount Attributable To Parent Percentage of vote of the holders of preferred stock. Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Consolidated Entities Consolidated Entities [Axis] Consolidated Entities Consolidated Entities [Domain] Frequency Japan Subsidiaries [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Delaware Limited Liability Company. LLC(FT-FJ) Delaware Limited Liability Company [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Convertible preferred Stock, shares issued upon conversion Convertible Preferred Stock Shares Issued Upon Conversion Voting percentage of preferred stock holder Percentage Of Vote Of Holders Of Preferred Stock Preferred stock, shares purchased. Preferred stock, shares purchased Preferred Stock Shares Purchased Preferred stock, voting rights Preferred Stock Voting Rights Preferred stock, shares authorized Preferred Stock, value per share Preferred stock, outstanding shares Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock Options Outstanding Employee Stock Option [Member] Shares Available for Future Grant Under Stock Option Plan Stock Compensation Plan [Member] Shares of common stock reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand and fourteen stock incentive plan. 2014 Plan Two Thousand And Fourteen Stock Incentive Plan [Member] Two thousand and nineteen incentive award plan. 2019 Plan Two Thousand And Nineteen Incentive Award Plan [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum [Member] Minimum [Member] Restricted Common Stock Restricted Stock [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] General and Administrative General And Administrative Expense [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Common stock, shares reserved for issuance Common stock, shares available for future grants Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Period for automatic increase in common stock available for future issuance. Number of authorized shares reserved for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Period for automatic increase in common stock available for future issuance Period For Automatic Increase In Common Stock Available For Future Issuance Percentage of shares issued from outstanding number of shares Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum Common stock future issuance, description Share Based Compensation Arrangement By Share Based Payment Award Description Options vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Options expiration period Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Number of shares, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Number of shares, Exercised Number of shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Number of shares, Ending balance Number of shares, Options exercisable as of December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Number of shares, Options unvested as of December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Weighted average exercise price, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted average exercise price, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted average exercise price, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted average exercise price, Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Weighted average exercise price, Ending balance Weighted average exercise price, Options exercisable as of December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted average exercise price, Options unvested as of December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Weighted average remaining contractual term (in years), Outstanding Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2020 Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Aggregate intrinsic value, Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Aggregate intrinsic value, Options exercisable as of December 31, 2020 Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Aggregate intrinsic value, Options unvested as of December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Expected term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Options exercised Aggregate intrinsic value of stock options exercised Weighted-average grant date fair value of stock options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Total grant date fair value of stock options vested Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value Number of shares, Unvested, December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Number of shares, Awarded Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Number of shares, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Number of shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Number of shares, Unvested, December 31, 2020 Weighted average fair value, Unvested, December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Weighted average fair value, Awarded Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Weighted average fair value, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted average fair value, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Weighted average fair value, Unvested, December 31, 2020 Total value of restricted stock awards, vested based on estimated fair value of stock Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value Stock-based compensation expense Allocated Share Based Compensation Expense Total unrecognized stock-based compensation expense relating to unvested stock options Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Unrecognized unvested stock options, weighted-average period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Percentage of eligible employee compensation. 2019 Employee Stock Purchase Plan Employee Stock [Member] Percentage of eligible employee compensation Percentage Of Eligible Employee Compensation Period for automatic increase in common available for future issuance Shares issued Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Income taxes disclosure. Income taxes disclosure. Income Taxes Disclosure [Table] Income Taxes Disclosure [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal Domestic Country [Member] State State And Local Jurisdiction [Member] Massachusetts MASSACHUSETTS Tax Credit Carryforward Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name Tax Credit Carryforward Name [Domain] Research and Development Research [Member] Income Tax Authority, Name Income Tax Authority Name [Axis] Income Tax Authority, Name Income Tax Authority Name [Domain] Internal Revenue Service Internal Revenue Service I R S [Member] Minimum Income Taxes Disclosure [Line Items] Income Taxes Disclosure [Line Items] Net tax benefit Tax credit carryforward expiration year. Net operating loss carryforwards expiration with limitation. Operating loss carryforwards expiration year. Net operating loss carryforwards expiration without limitation. Net operating loss carryforwards Operating Loss Carryforwards Net operating loss carryforwards expire through 2037 Net Operating Loss Carryforwards Expiration With Limitation Operating loss carryforwards expiration year Operating Loss Carryforwards Expiration Year Net operating loss carryforwards without expiration Net Operating Loss Carryforwards Expiration Without Limitation Tax credit carryforwards expiration year Tax Credit Carryforward Expiration Year Tax credit carryforwards Tax Credit Carryforward Amount Operating Loss Carryforwards Usage After Ownership Change. Operating loss carryforwards annual usage for next each five years after ownership change. Operating loss carryforwards annual usage for next each after five years and thereafter after ownership change. Remaining pre ownership change in operating loss carryforwards written off due to expiration. Cumulative change in ownership percentage. Period of cumulative change in ownership. Cumulative change in ownership percentage Cumulative Change In Ownership Percentage Period of cumulative change in ownership Period Of Cumulative Change In Ownership Operating loss carryforwards, utilization after ownership change Operating Loss Carryforwards Usage After Ownership Change Operating loss carryforwards, utilization after five years after ownership change Operating Loss Carryforwards Annual Usage For Next Each Five Years After Ownership Change Operating loss carryforwards, utilization after 15 years thereafter after ownership change Operating Loss Carryforwards Annual Usage For Next Each After Five Years And Thereafter After Ownership Change Remaining pre ownership change in operating loss carryforwards written off due to expiration Remaining Pre Ownership Change In Operating Loss Carryforwards Written Off Due To Expiration Federal and state deferred tax benefits Deferred Federal State And Local Tax Expense Benefit Valuation allowance Deferred Tax Assets Valuation Allowance Unrecognized tax benefits Unrecognized Tax Benefits Interest and penalties Unrecognized Tax Benefits Income Tax Penalties And Interest Expense Domestic Income Loss From Continuing Operations Before Income Taxes Domestic Foreign Income Loss From Continuing Operations Before Income Taxes Foreign Total Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Current: Current Federal State And Local Tax Expense Benefit [Abstract] Federal Current Federal Tax Expense Benefit State Current State And Local Tax Expense Benefit Foreign Current Foreign Tax Expense Benefit Total current Current Income Tax Expense Benefit Deferred: Deferred Federal State And Local Tax Expense Benefit [Abstract] Federal Deferred Federal Income Tax Expense Benefit State Deferred State And Local Income Tax Expense Benefit Foreign Deferred Foreign Income Tax Expense Benefit Total Deferred Deferred Income Tax Expense Benefit Total provision (benefit) U.S federal statutory income tax rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Permanent differences Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential State income taxes, net of federal benefit Effective Income Tax Rate Reconciliation State And Local Income Taxes Research and development tax credits Effective Income Tax Rate Reconciliation Tax Credits Research Stock compensation deductions Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost Other items Effective Income Tax Rate Reconciliation Other Reconciling Items Percent Change in deferred tax asset valuation allowance Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Effective income tax rate Effective Income Tax Rate Continuing Operations Deferred tax assets liabilities property plant and equipment. Deferred tax assets leasing arrangements. Deferred tax assets right of use assets. Net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Research and development tax credits Deferred Tax Assets Tax Credit Carryforwards Research Intangibles Deferred Tax Assets Goodwill And Intangible Assets Stock compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Accrued expenses Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Deferred revenue Deferred Tax Assets Deferred Income Other Deferred Tax Assets Other Fixed assets Deferred Tax Assets Liabilities Property Plant And Equipment Lease liability Deferred Tax Assets Leasing Arrangements Right of use asset Deferred Tax Assets Right Of Use Assets Total deferred tax asset Deferred Tax Assets Gross Valuation allowance Net deferred tax assets Deferred Tax Assets Net License agreement entered date. Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Massachusetts Institute of Technology. MIT Massachusetts Institute Of Technology [Member] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Patent license agreement. Patent License Agreement Patent License Agreement [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Astellas pharma limited liability company. Astellas Pharma LLC Astellas Pharma Limited Liability Company [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Royalty Royalty [Member] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Dr. Langer Director [Member] California Institute for Biomedical Research. CALIBR California Institute For Biomedical Research [Member] Scripps option agreement. Scripps Option Agreement Scripps Option Agreement [Member] Scenario Statement Scenario [Axis] Scenario Scenario Unspecified [Domain] Scenario Forecast Scenario Forecast [Member] Non-exclusive patent license agreement. Non-Exclusive Patent License Agreement Non Exclusive Patent License Agreement [Member] Massachusetts eye and ear. MEE Massachusetts Eye And Ear [Member] Cambridge Enterprise Limited. Cambridge Cambridge Enterprise Limited [Member] Research and Development. Research and Development Research And Development [Member] Grant Grant [Member] Research And Development Arrangement Contract To Perform For Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] License agreement entered date License Agreement Entered Date Description of future development obligations. Description of future development obligations Description Of Future Development Obligations License fee payment. Percentage of shares of common stock issued. Milestone payments. License fee payment License Fee Payment Percentage of shares of common stock issued Percentage Of Shares Of Common Stock Issued Milestone payments Milestone Payments Right to terminate agreement upon prior written notice. Right to terminate agreement if breach remains uncured. Right to terminate agreement incase of nonpayment. Description of conditions to terminate license agreement. Description of conditions to terminate license agreement Description Of Conditions To Terminate License Agreement Right to terminate agreement upon prior written notice Right To Terminate Agreement Upon Prior Written Notice Right to terminate agreement if breach remains uncured Right To Terminate Agreement If Breach Remains Uncured Right to terminate agreement incase of nonpayment Right To Terminate Agreement Incase Of Nonpayment Payment to director Payment For Management Fee Right to terminate licensed patents upon prior written notice. Right to terminate licensed patents upon prior written notice Right To Terminate Licensed Patents Upon Prior Written Notice Funding payments made as consideration to support research activities. Term of agreement. Funding payments as consideration to support research activities Funding Payments Made As Consideration To Support Research Activities Agreement term Term Of Agreement License agreement extended date. Additional funding payments made as consideration to support research activities. License agreement extended date License Agreement Extended Date Additional funding payments made as consideration to support research activities Additional Funding Payments Made As Consideration To Support Research Activities Right to terminate agreement upon prior written notice if insolvent. Right to terminate agreement upon prior written notice if insolvent Right To Terminate Agreement Upon Prior Written Notice If Insolvent Annual license fee Annual license fee Annual License Fee Increase (decrease) in research and development expenses. Amount of funding received as grant. Grant term period. Amount of funding received as grant Amount Of Funding Received As Grant Grant term period Grant Term Period Decrease in research and development expenses Increase Decrease In Research And Development Expense Contract with customer liability revenue recognized from commercialization milestones. Revenue recognition potential commercial milestone payments eligible upon successful commercialization. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] License and collaboration agreement. License and Collaboration Agreement License And Collaboration Agreement [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Phase 2b clinical trial. Phase 2b Clinical Trial Phase2b Clinical Trial [Member] Phase 3 clinical trail. Phase 3 Clinical Trial Phase3 Clinical Trail [Member] Europe Europe [Member] Asia Asia [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Payments received under collaboration agreement Proceeds From Collaborators Revenue recognized potential development milestone payments to receive Contract With Customer Liability Revenue Recognized Revenue recognized commercialization milestone payments to receive Contract With Customer Liability Revenue Recognized From Commercialization Milestones Potential commercial milestone payments eligible to receive upon successful commercialization Revenue Recognition Potential Commercial Milestone Payments Eligible Upon Successful Commercialization Agreement termination notice period. Agreement termination notice period Agreement Termination Notice Period Revenue recognition transaction price. Upfront fee recognized as revenue. Transaction price allocated to single combined performance obligation Revenue Recognition Transaction Price Accrued upfront payment related to sub License revenue Accrued Royalties Current Upfront fee recognized as revenue Upfront Fee Recognized As Revenue Revenue from contract with customer application input method. Revenue from contract with customer application input method Revenue From Contract With Customer Application Input Method Revenue remaining performance obligation Revenue Remaining Performance Obligation Lease expiration year. Operating lease agreement amended date. Operating lease agreement commencement date. Operating lease agreement expiration date. Lessee Lease Description [Table] Lessee Lease Description [Table] Connecticut CONNECTICUT Lease termination agreement. Lease Termination Agreement Leases Termination Agreement [Member] ARE-MA Region No. 20, LLC. ARE-MA Region No. 20, LLC A R E M A Region No20 L L C [Member] Hayden LLC. Hayden LLC Hayden L L C [Member] Lease Contractual Term Lease Contractual Term [Axis] Lease Contractual Term Lease Contractual Term [Domain] Lexington lease. Lexington Lease Lexington Lease [Member] Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Operating lease term Lessee Operating Lease Term Of Contract Lease, expiration year Lease Expiration Year Lease, description of option to extend Lessee Operating Lease Option To Extend Lease agreement amended date Operating Lease Agreement Amended Date Lease commencement date Operating Lease Agreement Commencement Date Lease expiration date Operating Lease Agreement Expiration Date Lease expiration date Lease Expiration Date1 Operating lease termination fee. Payment of fee to landlord Operating Lease Termination Fee Operating lease commencement date. Operating lease number of additional extension terms. Operating leases additional extension term. Rentable area of office space Net Rentable Area Lease commencement date Operating Lease Commencement Date Number of additional lease extension terms Operating Lease Number Of Additional Extension Terms Lease extension term Operating Leases Additional Extension Term Operating lease ROU assets Current lease liabilities Non-current lease liabilities Operating lease cost Operating Lease Cost Variable lease cost Variable Lease Cost Short term lease cost Short Term Lease Cost Lease expense Operating Lease Expense Cash paid for amounts included in the measurement of lease liabilities Operating Lease Payments Weighted-average remaining lease term Operating Lease Weighted Average Remaining Lease Term1 Weighted-average discount rate Operating Lease Weighted Average Discount Rate Percent 2021 Lessee Operating Lease Liability Payments Due Next Twelve Months 2022 Lessee Operating Lease Liability Payments Due Year Two 2023 Lessee Operating Lease Liability Payments Due Year Three 2024 Lessee Operating Lease Liability Payments Due Year Four 2025 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total minimum lease payments Lessee Operating Lease Liability Payments Due Less: amount of lease payments representing interest Lessee Operating Lease Liability Undiscounted Excess Amount Present value of future lease payments Less: current lease liabilities Noncurrent lease liabilities 2021 Operating Leases Future Minimum Payments Due Current 2022 Operating Leases Future Minimum Payments Due In Two Years 2023 Operating Leases Future Minimum Payments Due In Three Years 2024 Operating Leases Future Minimum Payments Due In Four Years 2025 Operating Leases Future Minimum Payments Due In Five Years 2026 and beyond Operating Leases Future Minimum Payments Due Thereafter Total minimum lease payments Operating Leases Future Minimum Payments Due Commitment payments related to research Long Term Purchase Commitment Amount Losses related to indemnification obligations Loss Contingency Loss In Period Maximum percentage of employee contribution to retirement plan Defined Contribution Plan Maximum Annual Contributions Per Employee Percent Percentage of employer matching contribution Defined Contribution Plan Employer Matching Contribution Percent Of Match Percentage of employee annual compensation matched by the employer Defined Contribution Plan Employer Matching Contribution Percent Employers matching contribution vesting percentage Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage Employers matching contribution Defined Contribution Plan Employer Discretionary Contribution Amount Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Total revenue Total expenses Operating And Non Operating Expenses Net EX-101.PRE 31 freq-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 32 R1.htm IDEA: XBRL DOCUMENT v3.21.1 Document and Entity Information - USD ($) $ in Millions 12 Months Ended Dec. 31, 2020 Mar. 19, 2021 Jun. 30, 2020 Cover [Abstract] Document Type 10-K Amendment Flag false Document Annual Report true Document Period End Date Dec. 31, 2020 Document Transition Report false Document Fiscal Year Focus 2020 Current Fiscal Year End Date --12-31 Document Fiscal Period Focus FY Entity Central Index Key 0001703647 Entity File Number 001-39062 Entity Registrant Name Frequency Therapeutics, Inc. Entity Incorporation State Country Code DE Entity Tax Identification Number 47-2324450 Entity Address Address Line 19 Presidential Way Entity Address, Address Line Two 2nd Floor Entity Address City Or Town Woburn Entity Address State Or Province MA Entity Address Postal Zip Code 01801 City Area Code 866 Local Phone Number 389-1970 Title of 12(b) Security Common Stock, $0.001 par value per share Trading Symbol FREQ Security Exchange Name NASDAQ Entity Well-known Seasoned Issuer Yes Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Non-accelerated Filer Entity Small Business true Entity Emerging Growth Company true Entity Ex Transition Period false Entity Shell Company false Entity Public Float $ 625.8 Entity Common Stock, Shares Outstanding 34,177,771 ICFR Auditor Attestation Flag false Documents Incorporated by Reference Portions of the Proxy Statement for the registrant’s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an annual report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_DocumentAnnualReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionDocuments incorporated by reference. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-23 + Details Name: dei_DocumentsIncorporatedByReferenceTextBlock Namespace Prefix: dei_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. + ReferencesNo definition available. + Details Name: dei_EntityPublicFloat Namespace Prefix: dei_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. + ReferencesNo definition available. + Details Name: dei_EntityVoluntaryFilers Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. + ReferencesNo definition available. + Details Name: dei_EntityWellKnownSeasonedIssuer Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_IcfrAuditorAttestationFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 33 R2.htm IDEA: XBRL DOCUMENT v3.21.1 Consolidated Balance Sheets - USD ($) $ in Thousands Dec. 31, 2020 Dec. 31, 2019 Current assets: Cash and cash equivalents $ 220,341 $ 200,158 Short-term marketable securities 17,197 Prepaid expenses and other current assets 4,723 4,000 Total current assets 225,064 221,355 Property and equipment, net 7,287 1,762 Right of use assets 30,551 Restricted cash 1,820 101 Total assets 264,722 223,218 Current liabilities: Accounts payable 5,506 1,219 Accrued expenses 6,663 3,239 Deferred revenue 14,068 48,152 Lease liabilities 397 Other current liabilities 170 Total current liabilities 26,634 52,780 Deferred revenue, net of current portion 2,900 Lease liabilities, net of current portion 30,597 Term Loan 15,000 Long-term liabilities 180 Total liabilities 72,231 55,860 Stockholders’ equity: Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019, respectively Common stock, $0.001 par value; 200,000,000 shares authorized, 33,964,000 and 30,844,507 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively 34 31 Additional paid-in capital 287,829 236,161 Accumulated other comprehensive income 27 54 Accumulated deficit (95,399) (68,888) Total stockholders’ equity 192,491 167,358 Total liabilities and stockholders’ equity $ 264,722 $ 223,218 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (bb) -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 + Details Name: us-gaap_LongTermLoansFromBank Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 210 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 17 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 23 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(1) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 5 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793 Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(1) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(3) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(2) Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(3) + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 34 R3.htm IDEA: XBRL DOCUMENT v3.21.1 Consolidated Balance Sheets (Parenthetical) - $ / shares Dec. 31, 2020 Dec. 31, 2019 Sep. 20, 2019 Statement Of Financial Position [Abstract] Preferred stock, par value $ 0.001 $ 0.001 $ 0.001 Preferred stock, authorized shares 10,000,000 10,000,000 148,724,922 Preferred stock, issued shares 0 0 Preferred stock, outstanding shares 0 0 Common stock, par value $ 0.001 $ 0.001 Common stock, authorized shares 200,000,000 200,000,000 100,000,000 Common stock, issued shares 33,964,000 30,844,507 Common stock, outstanding shares 33,964,000 30,844,507 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R4.htm IDEA: XBRL DOCUMENT v3.21.1 Consolidated Statements of Operations - USD ($) 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Statement Of Income And Comprehensive Income [Abstract] Revenue $ 36,984,000 $ 28,947,000 Operating expenses: Royalty 16,000,000 Research and development 37,415,000 18,784,000 General and administrative 27,119,000 14,838,000 Total operating expenses 64,534,000 49,622,000 Loss from operations (27,550,000) (20,675,000) Interest income 994,000 1,784,000 Realized gain on investments 84,000 138,000 Foreign exchange (loss) gain (4,000) 7,000 Loss before income taxes (26,476,000) (18,746,000) Provision for income taxes (35,000) 0 Net loss (26,511,000) (18,746,000) Cumulative Series C convertible preferred stock dividends (1,054,000) Net loss attributable to common stockholders $ (26,511,000) $ (19,800,000) Net loss per share attributable to common stockholders-basic and diluted $ (0.82) $ (2.29) Weighted-average shares of common stock outstanding-basic and diluted 32,253,227 8,649,245 X - DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256 + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 35 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 10 -Section 45 -Paragraph 17 -URI http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 940 -SubTopic 20 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 20 -Section 45 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.3(a)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details Name: us-gaap_RealizedInvestmentGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details Name: us-gaap_RoyaltyExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAccretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends). + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityDividendsAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). + ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 36 R5.htm IDEA: XBRL DOCUMENT v3.21.1 Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Statement Of Income And Comprehensive Income [Abstract] Net loss $ (26,511) $ (18,746) Other comprehensive (loss) gain: Unrealized (loss) gain on marketable securities (27) 54 Total comprehensive (loss) gain (27) 54 Comprehensive loss $ (26,538) $ (18,692) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683 + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 10A -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R6.htm IDEA: XBRL DOCUMENT v3.21.1 Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) - USD ($) $ in Thousands Total Non-controlling Interest Common Stock Additional-paid in Capital Accumulated Other Comprehensive Income Accumulated Deficit Series C Convertible Preferred Stock Series B Convertible Preferred Stock Series B-1 Convertible Preferred Stock Series A Convertible Preferred Stock Series A-1 Convertible Preferred Stock Beginning Balance at Dec. 31, 2018 $ 3,773 $ 38,224 $ 9 $ 46,694 $ 8 Beginning Balance (in shares) at Dec. 31, 2018 41,857,005 10,000 62,528,507 10,000 Beginning Balance at Dec. 31, 2018 $ (48,282) $ 2 $ 804 $ (49,088) Beginning Balance (in shares) at Dec. 31, 2018 2,084,710 Stock-based compensation expense 3,609 3,609 Issuance of common stock upon exercise of stock options $ 366 $ 1 365 Issuance of common stock upon exercise of options (in shares) 357,170 357,170 Issuance of convertible preferred stock $ 61,687 $ 266 Issuance of convertible preferred stock (in shares) 39,492,960 288,991 Accretion of Series C preferred dividend $ (1,054) (1,054) Accretion of Series C preferred dividend $ 1,054 Issuance of common stock in initial public offering or private placement 79,696 $ 6 79,690 Issuance of common stock in initial public offering or private placement (in shares) 6,325,000 Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO 151,715 $ 22 151,693 Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares) (39,492,960) (42,145,996) (10.000) (62,528,507) (10,000) Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO $ (3,773) $ (62,741) $ (38,490) $ (9) $ (46,694) $ (8) Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares) 22,077,627 Other comprehensive income (loss) 54 $ 54 Net loss (18,746) (18,746) Ending Balance at Dec. 31, 2019 $ 167,358 $ 31 236,161 54 (68,888) Ending Balance (in shares) at Dec. 31, 2019 30,844,507 30,844,507 Stock-based compensation expense $ 9,983 9,983 Issuance of common stock upon exercise of stock options $ 1,545 $ 1 1,544 Issuance of common stock upon exercise of options (in shares) 769,385 769,385 Issuance of common stock in initial public offering or private placement $ 40,143 $ 2 40,141 Issuance of common stock in initial public offering or private placement (in shares) 2,350,108 Other comprehensive income (loss) (27) (27) Net loss (26,511) (26,511) Ending Balance at Dec. 31, 2020 $ 192,491 $ 34 $ 287,829 $ 27 $ (95,399) Ending Balance (in shares) at Dec. 31, 2020 33,964,000 33,964,000 X - DefinitionConvertible preferred stock accretion of dividend. + ReferencesNo definition available. + Details Name: freq_ConvertiblePreferredStockAccretionOfDividend Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock issued during period shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering. + ReferencesNo definition available. + Details Name: freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering Namespace Prefix: freq_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering. + ReferencesNo definition available. + Details Name: freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTemporary equity, stock issued during period, shares, new issues. + ReferencesNo definition available. + Details Name: freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues Namespace Prefix: freq_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTemporary equity stock shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering. + ReferencesNo definition available. + Details Name: freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering Namespace Prefix: freq_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTemporary equity stock value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering. + ReferencesNo definition available. + Details Name: freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 17 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 55 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 17 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 23 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (f)(1) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 45 -Paragraph 5 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793 Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (f)(1) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(3) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(2) Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (d)(3) + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of accretion of temporary equity during the period due to unpaid dividends. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityAccretionOfDividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.27(b)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details Name: us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionValue of new stock classified as temporary equity issued during the period. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 38 R7.htm IDEA: XBRL DOCUMENT v3.21.1 Consolidated Statements of Cash Flows - USD ($) $ in Thousands 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Cash flows from operating activities: Net loss $ (26,511) $ (18,746) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Stock-based compensation 9,983 3,609 Depreciation expense 1,146 813 Issuance of common stock for license agreement 54 Non-cash lease expense 434 Deferred lease incentives (160) Changes in operating assets and liabilities: Prepaid expenses and other current assets (626) (3,252) Accounts payable 4,287 (644) Deferred revenue (36,984) 51,052 Accrued expenses 3,083 1,490 Net cash (used in) provided by operating activities (45,188) 34,216 Cash flows from investing activities: Purchases of property and equipment (6,671) (1,064) Purchase of available for sale securities (26,345) (282,618) Redemption of available for sale securities 43,418 265,421 Net cash provided by (used in) investing activities 10,402 (18,261) Cash flows from financing activities: Proceeds from issuance of common stock 1,545 80,062 Proceeds from Private Placement, net of issuance costs 40,143 Proceeds from Term Loan 15,000 Net cash provided by financing activities 56,688 142,015 Net increase in cash, cash equivalents, short-term investments, and restricted cash 21,902 157,970 Cash, cash equivalents, short-term investments and restricted cash at beginning of period 200,259 42,289 Cash, cash equivalents, short-term investments, and restricted cash at end of period 222,161 200,259 Non-cash items: Right-of-use assets in exchange for lease liabilities 31,335 Cumulative Series C convertible preferred stock dividends 1,054 Conversion of preferred stock and non-controlling interest into common stock 151,715 Purchases of property and equipment included in accounts payable and accrued expenses $ 2,145 Series B Convertible Preferred Stock Cash flows from financing activities: Proceeds from issuance of convertible preferred stock, net of issuance costs 266 Series C Convertible Preferred Stock Cash flows from financing activities: Proceeds from issuance of convertible preferred stock, net of issuance costs $ 61,687 X - DefinitionDeferred lease incentives. + ReferencesNo definition available. + Details Name: freq_DeferredLeaseIncentives Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon cash dividend on cumulative convertible preferred stock. + ReferencesNo definition available. + Details Name: freq_NonCashDividendOnCumulativeConvertiblePreferredStock Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon cash lease expenses. + ReferencesNo definition available. + Details Name: freq_NonCashLeaseExpenses Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586 + Details Name: us-gaap_ConversionOfStockAmountIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 20: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R8.htm IDEA: XBRL DOCUMENT v3.21.1 Organization and Basis of Presentation 12 Months Ended Dec. 31, 2020 Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Basis of Presentation 1. Organization and basis of presentation Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. In October 2019, the Company completed the initial public offering of its common stock (the “IPO”). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters’ exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited. On July 20, 2020, the Company issued and sold an aggregate of 2,350,108 shares of its common stock, par value $0.001 per share, at a purchase price of $18.00 per share to new and existing investors in a private placement for net proceeds of $40.1 million after deducting placement agent fees and offering expenses (the “Private Placement”). In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within 60 days after the closing of the Private Placement (the “Initial Filing Date”) for purposes of registering the resale of the Shares. The Company filed a registration statement (the “Registration Statement”) which was declared effective by the SEC on September 3, 2020. The Company has also agreed, among other things, to indemnify the investors, their officers, directors, managers, employees, agents and any person who controls any investor under the Registration Statement from certain liabilities and to pay all fees and expenses (excluding any underwriting discounts and commissions) incident to the Company’s obligations under the Registration Rights Agreement. Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. Our offices are located in states that are currently operating under a phased re-opening plan in response to the COVID-19 pandemic. As of the date of the filing of this Annual Report, the majority of our employees continue to work from home, while nearly a quarter to one-third of our workforce, consisting of mainly laboratory personnel, have periodically worked in rotating teams to ensure the continuation of essential experiments. Our Farmington, CT research site, co-located with the University of Connecticut, has resumed activity at a fifty percent level after a period of paused activity due to state lock down orders previously in effect. While we have resumed experiments at our Farmington site, we have transitioned certain key experiments to our offices in Woburn, MA and third parties and contract research organizations have been engaged to advance certain projects. We are also have taken steps consistent with the FDA’s updated industry guidance for conducting clinical trials. The COVID-19 pandemic, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which we operate, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. In addition, while no significant disruptions have occurred, the COVID-19 pandemic may cause such disruptions in our business or operations, as well as the business and operations of our CMOs, CROs and other third parties with whom we conduct business. The COVID-19 pandemic may also adversely impact the our clinical trials, which could impede, delay, limit or prevent the clinical development of our product candidates and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely affect our business and operations, including our ability to generate revenue. Liquidity and capital resources The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December 31, 2020, the Company had an accumulated deficit of $95,399. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -URI http://asc.fasb.org/topic&trid=2122149 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -URI http://asc.fasb.org/topic&trid=2197479 + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 40 R9.htm IDEA: XBRL DOCUMENT v3.21.1 Summary of Significant Accounting Policies 12 Months Ended Dec. 31, 2020 Accounting Policies [Abstract] Summary of Significant Accounting Policies 2. Summary of significant accounting policies Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). Principles of consolidation The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. Use of estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. Comprehensive income (loss) Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities. Segment information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker, the Company’s chief executive officer, views the Company’s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. Foreign currency All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December 31, 2020 and 2019 the Company recorded $(4), and $7 of foreign currency exchange (losses) gains, respectively. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December 31, 2020 and 2019 consists entirely of cash and money market funds. Restricted Cash The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company's future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company's Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company's Woburn, Massachusetts facility. Short-term marketable debt securities Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders’ equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense). Concentration of credit risk and off-balance sheet risk Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Significant suppliers The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. Fair value measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company’s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. Property and equipment Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: Estimated useful life Lab equipment 3 years Software 3 years Furniture and office equipment 3 years Leasehold improvements Shorter of the estimated useful life or lease term Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations. Impairment of long-lived assets The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December 31, 2020 and 2019. Research and development costs and accruals Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. Leases The Company elected to early adopt ASC 842, Leases (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (“ROU”) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component. Collaborative arrangements The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company’s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, Revenue from Contracts with Customers (“ASC 606”). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company’s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor’s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer’s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (“Astellas”), as further described in Note 16 of notes to consolidated financial statements. Revenue recognition The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company’s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company’s accounting policies in compliance with this new standard. Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the “customer” in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company’s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company’s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. Patent costs The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. Stock-based compensation The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. Income taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, Income Taxes (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). Net loss per share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December 31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2020 and 2019. Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year Ended December 31, 2020 2019 Numerator: Net loss attributable to common stockholders $ (26,511 ) $ (19,800 ) Denominator: Weighted-average shares of common stock outstanding- basic and diluted 32,253,227 8,649,245 Net loss per share attributable to common stockholders- basic and diluted $ (0.82 ) $ (2.29 ) The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. Year Ended December 31, 2020 2019 Unvested restricted Common Stock 3,093 70,366 Series C Preferred (as converted to common stock) — 1,172,676 Series B Preferred (as converted to common stock) — 4,759,079 Series A Preferred (as converted to common stock) — 7,070,574 Conversion of Frequency Japan preferred stock — 513,047 Outstanding stock options (as converted to common stock) 6,816,798 5,968,672 Total 6,819,891 19,554,414 Recently adopted accounting pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. In July 2018, the FASB also issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC 842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets. The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 41 R10.htm IDEA: XBRL DOCUMENT v3.21.1 Fair Value Measurements 12 Months Ended Dec. 31, 2020 Fair Value Disclosures [Abstract] Fair Value Measurements 3. Fair value measurements The Company’s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows: December 31, 2020 Fair Value Amortization Unrealized Fair Market Hierarchy Cost Gain Value Money market funds Level 1 $ 214,522 $ 27 $ 214,549 $ 214,522 $ 27 $ 214,549 December 31, 2019 Fair Value Amortization Unrealized Fair Market Hierarchy Cost (Loss) Gain Value Money market funds Level 1 $ 200,131 $ (12 ) $ 200,119 U.S. Government treasury securities Level 1 17,131 66 17,197 $ 217,262 $ 54 $ 217,316 X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 42 R11.htm IDEA: XBRL DOCUMENT v3.21.1 Prepaid Expenses 12 Months Ended Dec. 31, 2020 Prepaid Expense And Other Assets Current [Abstract] Prepaid Expenses 4. Prepaid expenses Prepaid expenses and other current assets consisted of the following: December 31, December 31, 2020 2019 Rent and deposits - 63 Research and development expenses 1,729 801 Grant receivable - 805 Accounts receivable 340 - Insurance 2,552 2,132 Other 102 199 Total $ 4,723 $ 4,000 X - DefinitionPrepaid expenses and other current assets. + ReferencesNo definition available. + Details Name: freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R12.htm IDEA: XBRL DOCUMENT v3.21.1 Property and Equipment 12 Months Ended Dec. 31, 2020 Property Plant And Equipment [Abstract] Property and Equipment 5. Property and equipment Property and equipment include the following: December 31, December 31, 2020 2019 Lab equipment $ 4,166 $ 1,846 Furniture and office equipment 283 257 Software 291 — Leasehold improvements 1,419 1,419 Construction in progress 4,340 306 Total 10,499 3,828 Accumulated depreciation (3,212 ) (2,066 ) Property and equipment, net $ 7,287 $ 1,762 The Company recognized $1,146 and $813 of depreciation expense for the years ended December 31, 2020 and 2019, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -URI http://asc.fasb.org/topic&trid=2155823 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 44 R13.htm IDEA: XBRL DOCUMENT v3.21.1 Accrued Expenses 12 Months Ended Dec. 31, 2020 Payables And Accruals [Abstract] Accrued Expenses 6. Accrued expenses Accrued expenses consist of the following: December 31, December 31, 2020 2019 Payroll and employee related expenses $ 5,062 $ 2,686 Professional fees 647 435 Third-party research and development expenses 874 118 Taxes and other 80 — Total $ 6,663 $ 3,239 X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R14.htm IDEA: XBRL DOCUMENT v3.21.1 Debt 12 Months Ended Dec. 31, 2020 Debt Disclosure [Abstract] Debt 7. Debt On December 11, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with a commercial bank for a Term Loan with a principal balance of $15 million. The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”). Advances under the Loan Agreement will bear an interest rate equal to the greater of either (i) 1.50% plus the Prime Rate (as reported in The Wall Street Journal, subject to an interest rate floor of zero) or (ii) 4.75%. Interest related to the Loan Agreement was immaterial for the year ended December 31, 2020. The Company may prepay the advance made under the Loan Agreement in whole, at any time subject to a prepayment premium equal to: (a) 2.0% of the then-outstanding principal amount of the advance, if such prepayment occurs on or prior to the first anniversary of the Closing Date; (b) 1.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date; and (c) 0.0% of the then-outstanding principal amount of the advance, if such prepayment occurs after the second anniversary of the Closing Date. The prepayment premium is waived if the Term Loan Facility is refinanced by the Bank (in its sole and absolute discretion) on or prior to the Loan Maturity Date. The Company will pay a final payment of $150,000, which will occur on the earliest of: (i) the Loan Maturity Date; (ii) the date that the Company prepays all of the outstanding principal in full; (iii) the date the loan payments are accelerated due to an event of default; or (iv) the termination of the Loan Agreement. The Company is recording the final payment as interest expense over the term of the loan. The Term Loan Facility is secured by substantially all of the Company’s assets, excluding intellectual property. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -URI http://asc.fasb.org/topic&trid=2208564 + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 46 R15.htm IDEA: XBRL DOCUMENT v3.21.1 Convertible Preferred Stock 12 Months Ended Dec. 31, 2020 Temporary Equity Disclosure [Abstract] Convertible Preferred Stock 8. Convertible preferred stock As of December 31, 2018, the Company had issued 62,528,507 shares of Series A Preferred Stock, 10,000 shares of Series A-1 Preferred Stock, 41,857,005 shares of Series B Preferred Stock, and 10,000 shares of Series B-1 Preferred Stock. In 2019, the Company also issued 288,911 shares of Series B Preferred Stock. On July 17, 2019, the Company authorized and issued 39,492,960 shares of Series C Preferred for net proceeds of $61,687. The Company evaluated the tranched nature of the issuance of these preferred shares as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation. In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock. X - DefinitionTemporary equity. + ReferencesNo definition available. + Details Name: freq_TemporaryEquityTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R16.htm IDEA: XBRL DOCUMENT v3.21.1 Non-controlling Interest 12 Months Ended Dec. 31, 2020 Noncontrolling Interest [Abstract] Non-controlling Interest 9. Non-controlling Interest In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation. In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company’s Series A-1 Preferred Stock and 10,000 shares of the Company’s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock. On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of an initial public offering of the Company’s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred shares were forfeited in conjunction with the IPO. X - DefinitionThe entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -URI http://asc.fasb.org/topic&trid=2197479 + Details Name: us-gaap_MinorityInterestDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R17.htm IDEA: XBRL DOCUMENT v3.21.1 Stockholders' Equity 12 Months Ended Dec. 31, 2020 Equity [Abstract] Stockholders' Deficit 10. Stockholders’ equity Preferred stock The Company has authorized 10,000,000 shares of $0.001 par value preferred stock of which no shares were issued or outstanding as of December 31, 2020. Common stock The Company has authorized 200,000,000 shares of $0.001 par value common stock of which 33,964,000 were issued and outstanding as of December 31, 2020. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors. The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019: December 31, December 31, 2020 2019 Stock options outstanding 6,816,798 5,968,672 Shares available for future grant under stock option plan 1,475,923 1,859,654 8,292,721 7,828,326 X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 49 R18.htm IDEA: XBRL DOCUMENT v3.21.1 Stock-based Compensation 12 Months Ended Dec. 31, 2020 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-based Compensation 11. Stock-based compensation On November 13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company’s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December 31, 2020, there were no shares of common stock available for future grants under the 2014 Plan. On September 17, 2019, the Company’s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (“the “2019 Plan”) which became effective on the day prior to the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company’s subsidiaries. A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company’s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company’s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. Stock options A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: Number of shares Weighted average exercise Weighted average remaining contractual term Aggregate intrinsic Number of shares Weighted average exercise Weighted average remaining contractual term Aggregate intrinsic 2019 Plan price (in years) value 2014 Plan price (in years) value Outstanding as of December 31, 2018 — $ - — 2,089,334 $ 0.61 — — Granted 1,247,338 14.09 — 3,015,381 4.17 — — Exercised — - — (357,170 ) 1.02 — — Forfeited — - — (26,211 ) 1.09 — — Outstanding as of December 31, 2019 1,247,338 $ 14.09 9.76 $ 4,287 4,721,334 $ 2.85 8.89 $ 65,051 Granted 1,645,859 24.22 — — — — — Exercised (1,851 ) 18.93 — (767,534 ) 1.94 — — Forfeited (16,997 ) 22.72 — (11,351 ) 6.89 — — Outstanding as of December 31, 2020 2,874,349 $ 19.84 9.09 $ 44,325 3,942,449 $ 3.02 7.98 $ 127,090 Options exercisable as of December 31, 2020 564,617 $ 17.48 8.90 $ 10,042 2,337,828 $ 2.57 7.88 $ 76,416 Options unvested as of December 31, 2020 2,309,732 $ 34,283 1,604,621 $ 50,674 Stock option valuation The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: December 31, December 31, 2020 2019 Risk-free interest rate 1.1 % 2.0 % Expected term (in years) 6.0 5.9 Expected volatility 79.1 % 79.4 % Expected dividend yield 0.0 % 0.0 % Risk-Fee Interest Rate: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant. Expected Term: The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available. Expected Dividend Yield: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. During the years ended December 31, 2020 and 2019, 769,385 and 357,170 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $16,667 and $5,896 respectively. The weighted-average grant date fair value of options granted to employees during the years ended December 31, 2020 and 2019 was $16.41 and $4.05 respectively. The total grant date fair value of options vested during the years ended December 31, 2020 and 2019 was $7,907 and $2,990, respectively. Restricted common stock The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder. A summary of the status of restricted common stock as of December 31, 2020 and 2019 is presented below: Number of shares Weighted average fair value Unvested, December 31, 2019 70,366 $ 0.36 Awarded — — Vested (67,273 ) 0.29 Forfeited — — Unvested, December 31, 2020 3,093 $ 1.75 The total value of restricted stock awards that vested during the years ended December 31, 2020 and 2019, based on estimated fair values of the stock underlying the restricted stock awards was $20 and $73, respectively. Stock-based compensation Stock-based compensation expense of $9,983 and $3,609 for the years ended December 31, 2020 and 2019 respectively, is included in research and development and general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss. As of December 31, 2020 and 2019, total unrecognized stock-based compensation expense relating to unvested stock options was $31,006 and $13,820, respectively. This amount is expected to be recognized over a weighted-average period of 3.08 years and 2.76 years, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R19.htm IDEA: XBRL DOCUMENT v3.21.1 Employee Stock Purchase Plan 12 Months Ended Dec. 31, 2020 Compensation And Retirement Disclosure [Abstract] Employee Stock Purchase Plan 12. Employee stock purchase plan On September 20, 2019, the Company’s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the “ESPP”) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company’s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. No shares were issued under the ESPP at December 31, 2020. X - DefinitionEmployee stock purchase plan disclosure. + ReferencesNo definition available. + Details Name: freq_EmployeeStockPurchasePlanDisclosureTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R20.htm IDEA: XBRL DOCUMENT v3.21.1 Income Taxes 12 Months Ended Dec. 31, 2020 Income Tax Disclosure [Abstract] Income Taxes 13. Income taxes Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. As of December 31, 2020, the Company had federal net operating loss carryforwards of approximately $67,868 and Massachusetts state operating loss carryforwards of approximately $43,386 which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $45,469 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2040. As of December 31, 2020, the Company also had federal and Massachusetts research and development tax credit carryforwards of $3,014 and $1,211, respectively, which are available to offset federal and state tax liabilities through 2040 and 2035, respectively. Realization of future tax benefits is dependent on many factors, including the Company’s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership. Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO. Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382. The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2020 and 2019 because the Company’s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $26,995 and $16,204 as of December 31, 2020 and 2019 has been established. The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December 31, 2020 and 2019. The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. A reconciliation of the Company’s pre-tax income for the years ended December 31, 2020 and 2019 is as follows: 2020 2019 Domestic $ (25,744 ) $ (19,086 ) Foreign (732 ) (714 ) Total $ (26,476 ) $ (19,800 ) The Company’s provision at December 31, 2020 and 2019 consist of the following: 2020 2019 Current: Federal $ 35 $ - State - - Foreign - - Total current $ 35 $ - Deferred: Federal - - State - - Foreign - - Total Deferred $ - $ - Total provision (benefit) $ 35 $ - A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate for the years ended December 31, 2020 and 2019 is as follows: 2020 2019 U.S federal statutory income tax rate 21.0% 21.0 % Permanent differences (0.2) (2.8 ) State income taxes, net of federal benefit 3.0 4.0 Research and development tax credits 11.2 1.8 Stock compensation deductions 5.1 0.0 Other items 0.6 (1.0 ) Change in deferred tax asset valuation allowance (40.7) (23.0 ) Effective income tax rate —% —% The Company’s deferred tax assets at December 31, 2020 and 2019 consist of the following: 2020 2019 Net operating loss carryforwards $ 17,885 $ 13,253 Research and development tax credits 3,992 1,138 Intangibles 360 358 Stock compensation 850 686 Accrued expenses - 48 Deferred revenue 3,606 496 Other 142 189 Fixed assets 56 36 Lease liability 7,285 - Right of use asset (7,181 ) - Total deferred tax asset 26,995 16,204 Valuation allowance (26,995 ) (16,204 ) Net deferred tax assets $ — $ — X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 270 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -URI http://asc.fasb.org/topic&trid=2144680 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 52 R21.htm IDEA: XBRL DOCUMENT v3.21.1 Research and License Agreements 12 Months Ended Dec. 31, 2020 Research And Development [Abstract] Research and License Agreements 14. Research and license agreements Massachusetts Institute of Technology In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company’s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90) days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations. Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15. The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. The patents in-licensed by the Company from MIT pursuant to the MIT License claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Pursuant to MIT’s policy on the ownership, distribution and commercial development of MIT technology, or the MIT Policy, inventors of intellectual property invented at MIT, including the inventors of patents licensed to the Company under the MIT License, are entitled to a portion of the net royalty income derived by MIT from such inventions, but not amounts received by MIT from the sale of common stock previously issued by the Company to MIT pursuant to the MIT License. Accordingly, pursuant to the MIT Policy, Dr. Langer is entitled to receive a portion of the amounts the Company pays to MIT under the MIT License, including the Astellas Royalty Payment and future milestone payments or royalties, if any, that the Company may receive pursuant to the Astellas Agreement. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively. Refer to Note 18 for all related party disclosures. The Scripps Research Institute (California Institute for Biomedical Research) In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes. The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations , which may be extended under certain circumstances as outlined in the CALIBR License Agreement, to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement. Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors). The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%. The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1) the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2) ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. The Scripps Research Institute In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we made funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement. In September 2020, the Company extended the term of the option agreement through the end of December 2021. As consideration for this extension, the Company is required to make additional funding payments of $0.6 million to Scripps through December 2021. The Company has the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt. Massachusetts Eye and Ear (Formerly Massachusetts Eye and Ear Infirmary) In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEE License Agreement) with the Massachusetts Eye and Ear (MEE) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss. The Company is required to use diligent efforts to develop and commercialize the licensed products and MEE has control over the filing, prosecution, enforcement and defense of any licensed patent rights. We met one of our milestone timeline obligations by dosing a first patient in a Phase II trial by December 31, 2020. We are still subject to a milestone timeline obligation to dose a first patient in a Phase III trial by December 31, 2024. Upon entering into the MEE License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale. The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. The MEE License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60) business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. Cambridge Enterprise Limited In December 2019, we entered into an Exclusive Patent License Agreement ( the “Cambridge License”) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge) (“Cambridge”) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the “Cambridge License Product”) which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care. The Company has agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product. Upon entering into the Cambridge License, the Company made a $50 license fee payment. The Company is obligated to pay an annual license fee of $50. The Company is also obligated to make milestone payments up to $10.5 million on each Cambridge License Product. In addition, the Company has agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances. The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon 90 days’ prior to written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed. Department of Defense In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company’s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $323 and $845 as a reduction in research and development expenses for the years ended December 31, 2020 and 2019, respectively. X - DefinitionResearch and license agreements disclosure text block. + ReferencesNo definition available. + Details Name: freq_ResearchAndLicenseAgreementsDisclosureTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ResearchAndDevelopmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 53 R22.htm IDEA: XBRL DOCUMENT v3.21.1 Collaboration Agreement 12 Months Ended Dec. 31, 2020 Organization Consolidation And Presentation Of Financial Statements [Abstract] Collaboration Agreement 15. Collaboration agreement In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. The collaboration is governed by a joint steering committee (“JSC”) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party’s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments up to $230.0 million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315.0 million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days’ written notice. Each party has the right to terminate the Astellas Agreement due to the other party’s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019. The $80.0 million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2020, the Company recognized $37.0 million of revenue under the Astellas Agreement. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MIT and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322. The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee’s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the years ended December 31, 2020 and 2019, the Company invoiced Astellas $1,046 and $186 for joint costs, respectively. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -URI http://asc.fasb.org/topic&trid=5833765 + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 54 R23.htm IDEA: XBRL DOCUMENT v3.21.1 Commitments and Contingencies 12 Months Ended Dec. 31, 2020 Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies 16. Commitments and contingencies Operating leases In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company’s primary office and laboratory space in Woburn, Massachusetts. The lease was extended in November 2019 and expires in February 2025. Additionally, the Company amended the lease in November 2019 to add additional laboratory and office space. The commencement date of the additional space occurred in February 2020 and expires in February 2025. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2021. On December 11, 2020, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the “Lease Termination Agreement”) with ARE-MA Region No. 20, LLC (the “Landlord”). The Lease Termination Agreement provides that the Lease Agreement, dated as of August 14, 2016, by and between the Company and Landlord (as the same may have been amended, the “Lease”) will terminate on March 31, 2021, unless the Company elects to extend the term of the Lease. The Company exercised the option to extend the lease until May 31, 2021. As consideration for the Landlord’s agreement to enter into the Lease Termination Agreement and accelerate the expiration date of the term of the Lease, the Company has agreed to pay to Landlord a fee of approximately $0.2 million. On January 7, 2020 the Company entered into an indenture of lease (the “Lexington Lease”) with HCP/KING 75 Hayden LLC, for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the “Lexington Premises”). The Lexington Lease commenced on December 11, 2020, (the “Commencement Date”). The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses. The term of the Lexington Lease, (the “ Initial Term”), is ten years from the rent commencement date (which is five months following the Commencement Date) and the Initial Term is expected to end on May 31, 2031. The Company also has the option to extend the Initial Term for two additional terms of five years each. As of December 31, 2020, the Company has $30,551 of operating lease ROU assets, and $397 and $30,597 of current and non-current lease liabilities, respectively, recorded on the consolidated balance sheets. For the year ended December 31, 2020 the Company recorded $470 of operating lease cost, $510 of variable lease cost, and $106 of short-term lease cost. The lease expense for the years ended December 31, 2020 and 2019 are $835 and $269, respectively. Cash paid for amounts included in the measurement of lease liabilities for year ended December 31, 2020 is $484. Other information December 31, 2020 Weighted-average remaining lease term 10.3 years Weighted-average discount rate (1) 8.5 % (1) Rate includes the Company’s Woburn and Lexington leases. The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020. 2021 2,928 2022 4,159 2023 4,284 2024 4,412 2025 4,545 Thereafter 27,070 Total minimum lease payments 47,398 Less: amount of lease payments representing interest (16,404 ) Present value of future lease payments 30,994 Less: current lease liabilities (397 ) Noncurrent lease liabilities $ 30,597 Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows: 2021 $ 2,986 2022 4,159 2023 4,284 2024 4,412 2025 4,545 2026 and beyond 27,070 Total minimum lease payments $ 47,456 Contract commitments The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. In September 2020, the Company extended the term of this contract through December 2021. As consideration for this extension, the Company committed to total payments of $0.6 million through December 2021. The Company enters into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. Guarantees The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees. As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. The Company leases office space in Woburn, Massachusetts under a five-year non-cancelable operating lease, and has entered into a facility lease in Lexington, Massachusetts. The Company has standard indemnification arrangements under these leases that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. As of December 31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -URI http://asc.fasb.org/topic&trid=2127136 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -URI http://asc.fasb.org/topic&trid=2144648 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308 + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 55 R24.htm IDEA: XBRL DOCUMENT v3.21.1 Employee Benefit Plan 12 Months Ended Dec. 31, 2020 Compensation And Retirement Disclosure [Abstract] Employee Benefit Plan 17. Employee benefit plan Employees of the Company are eligible to participate in the Company’s 401(k) retirement plan (the “401(k) Plan”). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. Under the 401(k) Plan Safe Harbor Match, the Company matches 100% of the first 5% of employee contributions and vests 100% at time of match. For the years ended December 31, 2020 and 2019, the Company made matching contributions of $0.4 million and $0.2 million, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for retirement benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 55 -Paragraph 17 -URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section S99 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (d)(i) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (o) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (p) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 70 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -URI http://asc.fasb.org/topic&trid=2235017 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 60 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(03) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (q) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (r)(1) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (d)(iii) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (l) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (r)(2) -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920 + Details Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 56 R25.htm IDEA: XBRL DOCUMENT v3.21.1 Related Party Transactions 12 Months Ended Dec. 31, 2020 Related Party Transactions [Abstract] Related Party Transactions 18. Related party transactions The Company’s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company’s directors and shareholders. As disclosed in Note 14, the Company entered into the MIT License Agreement in December 2016. The patents in-licensed by the Company from MIT pursuant to the MIT License Agreement claim inventions created by, among others, Dr. Langer, one of the Company’s directors. Accordingly, Dr. Langer has received $1.98 million and $0.01 million from MIT under the MIT Policy during the years ended December 31, 2020 and 2019, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -URI http://asc.fasb.org/topic&trid=2122745 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 57 R26.htm IDEA: XBRL DOCUMENT v3.21.1 Subsequent Events 12 Months Ended Dec. 31, 2020 Subsequent Events [Abstract] Subsequent Events 19. Subsequent events The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 29, 2021, the date which the consolidated financial statements were available to be issued. The identified subsequent events are as follows; On February 18, 2021, the Company completed the liquidation and dissolution of Frequency Therapeutics Japan KK, the Company’s Japanese subsidiary. On March 23, 2021, the Company announced topline, day-90 data from its FX-322 Phase 2a study. The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. The Company also announced new preliminary data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The single dose showed efficacy that was clinically meaningful and statistically significant compared to the untreated ear, had a favorable safety profile and was well tolerated. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -URI http://asc.fasb.org/topic&trid=2122774 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 58 R27.htm IDEA: XBRL DOCUMENT v3.21.1 Selected Quarterly Data (Unaudited) 12 Months Ended Dec. 31, 2020 Quarterly Financial Information Disclosure [Abstract] Selected Quarterly Data (Unaudited) 20. Selected Quarterly Data (Unaudited) The following table contains quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. 2020 March 31, June 30, September 30, December 31, Total (in thousands, except per share amounts) Total revenue $ 7,264 $ 8,523 $ 11,247 $ 9,950 $ 36,984 Total expenses 12,177 14,548 16,588 20,182 $ 63,495 Net loss (4,913 ) (6,025 ) (5,341 ) (10,232 ) $ (26,511 ) Cumulative series C convertible preferred stock dividends — — — — — Net loss attributable to common stockholders (4,913 ) (6,025 ) (5,341 ) (10,232 ) $ (26,511 ) Net loss per share attributable to common shareholders - basic and diluted $ (0.16 ) $ (0.19 ) $ (0.16 ) $ (0.30 ) $ (0.82 ) 2019 March 31, June 30, September 30, December 31, Total (in thousands, except per share amounts) Total revenue $ — $ — $ 24,238 $ 4,709 $ 28,947 Total expenses 5,826 6,852 24,813 10,202 $ 47,693 Net loss (5,826 ) (6,852 ) (575 ) (5,493 ) $ (18,746 ) Cumulative series C convertible preferred stock dividends — — (1,014 ) (40 ) $ (1,054 ) Net loss attributable to common stockholders (5,826 ) (6,852 ) (1,589 ) (5,533 ) $ (19,800 ) Net loss per share attributable to common shareholders - basic and diluted $ (3.24 ) $ (3.42 ) $ (0.73 ) $ (0.19 ) $ (2.29 ) X - ReferencesNo definition available. + Details Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details Name: us-gaap_QuarterlyFinancialInformationTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 59 R28.htm IDEA: XBRL DOCUMENT v3.21.1 Summary of Significant Accounting Policies (Policies) 12 Months Ended Dec. 31, 2020 Accounting Policies [Abstract] Basis of Presentation Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC). Principles of Consolidation Principles of consolidation The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics Securities Corporation, Frequency Therapeutics PTY, LTD and Frequency Japan. All intercompany transactions and balances have been eliminated. Frequency Japan was closed down in February 2021, as further described in Note 19 of notes to consolidated financial statements. Use of Estimates Use of estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, revenue recognition, fair value of common stock, valuation of share-based awards, present value of lease liabilities and income taxes. Actual results could differ from those estimates. The Company utilized significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. Comprehensive Income (loss) Comprehensive income (loss) Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders which for the years ended December 31, 2020 and 2019 consist of unrealized gain on marketable securities. Segment Information Segment information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker, the Company’s chief executive officer, views the Company’s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. Foreign Currency Foreign currency All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December 31, 2020 and 2019 the Company recorded $(4), and $7 of foreign currency exchange (losses) gains, respectively. Cash and Cash Equivalents Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December 31, 2020 and 2019 consists entirely of cash and money market funds. Restricted Cash Restricted Cash The Company has $1.8 million of restricted cash as of December 31, 2020 which represents a $1.7 million security deposit on the Company's future Lexington, Massachusetts facility and a $0.1 million security deposit on the Company's Woburn, Massachusetts facility. The $0.1 million restricted cash at December 31, 2019 represented the security deposit on the Company's Woburn, Massachusetts facility. Short-term Marketable Debt Securities Short-term marketable debt securities Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. Short-term marketable investments mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders’ equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense). Concentration of Credit Risk and Off-balance Sheet Risk Concentration of credit risk and off-balance sheet risk Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained. The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Significant Suppliers Significant suppliers The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. Fair Value Measurements Fair value measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (ASC 820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the Company’s Term Loan is not materially different from the carry value as presented given the Term Loan was issued within one month of December 31, 2020. Property and Equipment Property and equipment Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: Estimated useful life Lab equipment 3 years Software 3 years Furniture and office equipment 3 years Leasehold improvements Shorter of the estimated useful life or lease term Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations. Impairment of Long-Lived Assets Impairment of long-lived assets The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December 31, 2020 and 2019. Research and Development Costs and Accruals Research and development costs and accruals Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. Leases Leases The Company elected to early adopt ASC 842, Leases (ASC 842) as of January 1, 2020 and elected the transition method under ASU 2016-02 whereby the Company records a right-to-use asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. The Company also elected to apply the package of practical expedients intended to ease transition. Accordingly, the Company has only applied ASC 842 to leases existing at January 1, 2020. The Company determines if an arrangement is, or contains, a lease at inception. Operating leases are included in operating lease right-of-issue (“ROU”) assets, other current liabilities, and operating lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments to be made over the lease term. The ROU asset also includes any lease payments made at or before the lease commencement date and excludes lease incentives received. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirements of ASC 842 for short-term leases, which is defined as a lease that, at the lease commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For real estate lease agreements entered into or modified after the adoption of ASC 842 that include lease and non-lease components, the Company has elected to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component. Collaborative Arrangements Collaborative arrangements The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company’s ordinary activities in exchange for a consideration and therefore within the scope of ASC 606, Revenue from Contracts with Customers (“ASC 606”). For those elements of the arrangement that are accounted for pursuant to ASC 606, including those to which ASC 606 is applied by analogy, the Company applies the five-step model described in the Company’s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. The Company enters into out-licensing agreements that are within the scope of ASC 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor’s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer’s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (“Astellas”), as further described in Note 16 of notes to consolidated financial statements. Revenue Recognition Revenue recognition The Company accounts for contracts with customers in accordance with ASC 606, including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company’s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company’s accounting policies in compliance with this new standard. Under ASC 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer. The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the “customer” in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company’s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company’s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation. Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets. Patent Costs Patent costs The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. Stock-Based Compensation Stock-based compensation The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (ASC 718). ASC 718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company treats non-employee grants in a manner consistent with employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. Income Taxes Income taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, Income Taxes (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2020 and 2019, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). Net Loss Per Share Net loss per share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December 31, 2020 and 2019 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. The Company’s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2020 and 2019. Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year Ended December 31, 2020 2019 Numerator: Net loss attributable to common stockholders $ (26,511 ) $ (19,800 ) Denominator: Weighted-average shares of common stock outstanding- basic and diluted 32,253,227 8,649,245 Net loss per share attributable to common stockholders- basic and diluted $ (0.82 ) $ (2.29 ) The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. Year Ended December 31, 2020 2019 Unvested restricted Common Stock 3,093 70,366 Series C Preferred (as converted to common stock) — 1,172,676 Series B Preferred (as converted to common stock) — 4,759,079 Series A Preferred (as converted to common stock) — 7,070,574 Conversion of Frequency Japan preferred stock — 513,047 Outstanding stock options (as converted to common stock) 6,816,798 5,968,672 Total 6,819,891 19,554,414 Recently Adopted Accounting Pronouncements Recently adopted accounting pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), as amended by various subsequently issued ASUs. The standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. In July 2018, the FASB also issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which permits entities to continue applying legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year that the entity adopts the new leasing standard. The Company adopted the standard on January 1, 2020 using the optional transition method. As such, the consolidated balance sheets and statements of operations for prior periods will not be comparable in the year of adoption of ASC 842. The Company elected the package of practical expedients permitted under the transition guidance within the standard. Accordingly, the Company did not reassess the conclusion of whether the existing arrangements contain a lease, lease classification and initial direct costs under ASC 842. As a result of the adoption of ASC 842, the Company recorded $1.2 million of ROU assets and a total of $1.5 million of lease liabilities on the consolidated balance sheets as of January 1, 2020. In addition, in the first quarter of 2020 the Company expanded and amended the lease for its Woburn, Massachusetts facility and increased both the ROU asset and lease liability by $1.0 million. On December 11, 2020, the Company terminated this lease and remeasured the existing ROU asset and lease liability based on this lease modification, resulting in a $1.7 million impact to both the ROU asset and lease liability. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which commenced December 11, 2020. In accordance with ASU No. 2016-02, the Company recognized a right-of-use asset and related lease liability at such time. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amended certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's statements of operations. Prior to adoption of ASU 2016-01, companies recognized changes in fair value in accumulated other comprehensive income (loss), net. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. In addition, a valuation allowance should be evaluated on deferred tax assets related to available- for-sale debt securities in combination with other deferred tax assets. The Company adopted this new standard on January 1, 2020, using the modified retrospective method, and determined that it did not have a material impact on its financial statements. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2023. The Company is still evaluating the impact of this standard on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12 amending accounting guidance that simplifies the accounting for income taxes, as part of its initiative to reduce complexity in the accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. This standard will become effective for the Company on January 1, 2021. The Company is still evaluating the impact of this standard on its consolidated financial statements. X - DefinitionPatent costs. + ReferencesNo definition available. + Details Name: freq_PatentCostsPolicyTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSignificant suppliers. + ReferencesNo definition available. + Details Name: freq_SignificantSuppliersPolicyTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for collaborative arrangements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details Name: us-gaap_CollaborativeArrangementAccountingPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 60 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -URI http://asc.fasb.org/topic&trid=2175825 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 05 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 740 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803 + Details Name: us-gaap_MarketableSecuritiesPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13(a)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 60 R29.htm IDEA: XBRL DOCUMENT v3.21.1 Summary of Significant Accounting Policies (Tables) 12 Months Ended Dec. 31, 2020 Accounting Policies [Abstract] Property And Equipment Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: Estimated useful life Lab equipment 3 years Software 3 years Furniture and office equipment 3 years Leasehold improvements Shorter of the estimated useful life or lease term Schedule of Basic and Diluted Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year Ended December 31, 2020 2019 Numerator: Net loss attributable to common stockholders $ (26,511 ) $ (19,800 ) Denominator: Weighted-average shares of common stock outstanding- basic and diluted 32,253,227 8,649,245 Net loss per share attributable to common stockholders- basic and diluted $ (0.82 ) $ (2.29 ) Computation of Diluted Net Loss per Share The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. Year Ended December 31, 2020 2019 Unvested restricted Common Stock 3,093 70,366 Series C Preferred (as converted to common stock) — 1,172,676 Series B Preferred (as converted to common stock) — 4,759,079 Series A Preferred (as converted to common stock) — 7,070,574 Conversion of Frequency Japan preferred stock — 513,047 Outstanding stock options (as converted to common stock) 6,816,798 5,968,672 Total 6,819,891 19,554,414 X - DefinitionProperty and equipment. + ReferencesNo definition available. + Details Name: freq_PropertyAndEquipmentTableTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 61 R30.htm IDEA: XBRL DOCUMENT v3.21.1 Fair Value Measurements (Tables) 12 Months Ended Dec. 31, 2020 Fair Value Disclosures [Abstract] Schedule of Financial Assets Measured at Fair Value on Recurring Basis The Company’s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2020 and 2019 are summarized as follows: December 31, 2020 Fair Value Amortization Unrealized Fair Market Hierarchy Cost Gain Value Money market funds Level 1 $ 214,522 $ 27 $ 214,549 $ 214,522 $ 27 $ 214,549 December 31, 2019 Fair Value Amortization Unrealized Fair Market Hierarchy Cost (Loss) Gain Value Money market funds Level 1 $ 200,131 $ (12 ) $ 200,119 U.S. Government treasury securities Level 1 17,131 66 17,197 $ 217,262 $ 54 $ 217,316 X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 62 R31.htm IDEA: XBRL DOCUMENT v3.21.1 Prepaid Expenses (Tables) 12 Months Ended Dec. 31, 2020 Prepaid Expense And Other Assets Current [Abstract] Summary of Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: December 31, December 31, 2020 2019 Rent and deposits - 63 Research and development expenses 1,729 801 Grant receivable - 805 Accounts receivable 340 - Insurance 2,552 2,132 Other 102 199 Total $ 4,723 $ 4,000 X - DefinitionSummary of prepaid expenses and other current assets. + ReferencesNo definition available. + Details Name: freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 63 R32.htm IDEA: XBRL DOCUMENT v3.21.1 Property and Equipment (Tables) 12 Months Ended Dec. 31, 2020 Property Plant And Equipment [Abstract] Schedule of Property and Equipment Property and equipment include the following: December 31, December 31, 2020 2019 Lab equipment $ 4,166 $ 1,846 Furniture and office equipment 283 257 Software 291 — Leasehold improvements 1,419 1,419 Construction in progress 4,340 306 Total 10,499 3,828 Accumulated depreciation (3,212 ) (2,066 ) Property and equipment, net $ 7,287 $ 1,762 X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 64 R33.htm IDEA: XBRL DOCUMENT v3.21.1 Accrued Expenses (Tables) 12 Months Ended Dec. 31, 2020 Payables And Accruals [Abstract] Schedule of Accrued Expenses Accrued expenses consist of the following: December 31, December 31, 2020 2019 Payroll and employee related expenses $ 5,062 $ 2,686 Professional fees 647 435 Third-party research and development expenses 874 118 Taxes and other 80 — Total $ 6,663 $ 3,239 X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 65 R34.htm IDEA: XBRL DOCUMENT v3.21.1 Stockholders' Equity (Tables) 12 Months Ended Dec. 31, 2020 Equity [Abstract] Schedule of Common Stock Shares Reserved for Future Issuance The Company has reserved the following shares of common stock for future issuance as of December 31, 2020 and 2019: December 31, December 31, 2020 2019 Stock options outstanding 6,816,798 5,968,672 Shares available for future grant under stock option plan 1,475,923 1,859,654 8,292,721 7,828,326 X - DefinitionSchedule of common stock shares reserved for future issuance. + ReferencesNo definition available. + Details Name: freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock Namespace Prefix: freq_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 66 R35.htm IDEA: XBRL DOCUMENT v3.21.1 Stock-based Compensation (Tables) 12 Months Ended Dec. 31, 2020 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Summary of Stock Option Activity under 2014 Plan and 2019 Plan A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: Number of shares Weighted average exercise Weighted average remaining contractual term Aggregate intrinsic Number of shares Weighted average exercise Weighted average remaining contractual term Aggregate intrinsic 2019 Plan price (in years) value 2014 Plan price (in years) value Outstanding as of December 31, 2018 — $ - — 2,089,334 $ 0.61 — — Granted 1,247,338 14.09 — 3,015,381 4.17 — — Exercised — - — (357,170 ) 1.02 — — Forfeited — - — (26,211 ) 1.09 — — Outstanding as of December 31, 2019 1,247,338 $ 14.09 9.76 $ 4,287 4,721,334 $ 2.85 8.89 $ 65,051 Granted 1,645,859 24.22 — — — — — Exercised (1,851 ) 18.93 — (767,534 ) 1.94 — — Forfeited (16,997 ) 22.72 — (11,351 ) 6.89 — — Outstanding as of December 31, 2020 2,874,349 $ 19.84 9.09 $ 44,325 3,942,449 $ 3.02 7.98 $ 127,090 Options exercisable as of December 31, 2020 564,617 $ 17.48 8.90 $ 10,042 2,337,828 $ 2.57 7.88 $ 76,416 Options unvested as of December 31, 2020 2,309,732 $ 34,283 1,604,621 $ 50,674 Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis: December 31, December 31, 2020 2019 Risk-free interest rate 1.1 % 2.0 % Expected term (in years) 6.0 5.9 Expected volatility 79.1 % 79.4 % Expected dividend yield 0.0 % 0.0 % Summary of Status of Restricted Common Stock A summary of the status of restricted common stock as of December 31, 2020 and 2019 is presented below: Number of shares Weighted average fair value Unvested, December 31, 2019 70,366 $ 0.36 Awarded — — Vested (67,273 ) 0.29 Forfeited — — Unvested, December 31, 2020 3,093 $ 1.75 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 67 R36.htm IDEA: XBRL DOCUMENT v3.21.1 Income Taxes (Tables) 12 Months Ended Dec. 31, 2020 Income Tax Disclosure [Abstract] Schedule of Reconciliation Pre-tax Income A reconciliation of the Company’s pre-tax income for the years ended December 31, 2020 and 2019 is as follows: 2020 2019 Domestic $ (25,744 ) $ (19,086 ) Foreign (732 ) (714 ) Total $ (26,476 ) $ (19,800 ) Schedule of Provision The Company’s provision at December 31, 2020 and 2019 consist of the following: 2020 2019 Current: Federal $ 35 $ - State - - Foreign - - Total current $ 35 $ - Deferred: Federal - - State - - Foreign - - Total Deferred $ - $ - Total provision (benefit) $ 35 $ - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate for the years ended December 31, 2020 and 2019 is as follows: 2020 2019 U.S federal statutory income tax rate 21.0% 21.0 % Permanent differences (0.2) (2.8 ) State income taxes, net of federal benefit 3.0 4.0 Research and development tax credits 11.2 1.8 Stock compensation deductions 5.1 0.0 Other items 0.6 (1.0 ) Change in deferred tax asset valuation allowance (40.7) (23.0 ) Effective income tax rate —% —% Schedule of Deferred Tax Assets The Company’s deferred tax assets at December 31, 2020 and 2019 consist of the following: 2020 2019 Net operating loss carryforwards $ 17,885 $ 13,253 Research and development tax credits 3,992 1,138 Intangibles 360 358 Stock compensation 850 686 Accrued expenses - 48 Deferred revenue 3,606 496 Other 142 189 Fixed assets 56 36 Lease liability 7,285 - Right of use asset (7,181 ) - Total deferred tax asset 26,995 16,204 Valuation allowance (26,995 ) (16,204 ) Net deferred tax assets $ — $ — X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319 + Details Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319 + Details Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 + Details Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of income before income tax between domestic and foreign jurisdictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details Name: us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 68 R37.htm IDEA: XBRL DOCUMENT v3.21.1 Commitments and Contingencies (Tables) 12 Months Ended Dec. 31, 2020 Commitments And Contingencies Disclosure [Abstract] Schedule of Leases Other information December 31, 2020 Weighted-average remaining lease term 10.3 years Weighted-average discount rate (1) 8.5 % (1) Rate includes the Company’s Woburn and Lexington leases. Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet The table below reconciles the undiscounted cash flows to the operating lease liability recorded on the consolidated balance sheet as of December 31, 2020. 2021 2,928 2022 4,159 2023 4,284 2024 4,412 2025 4,545 Thereafter 27,070 Total minimum lease payments 47,398 Less: amount of lease payments representing interest (16,404 ) Present value of future lease payments 30,994 Less: current lease liabilities (397 ) Noncurrent lease liabilities $ 30,597 Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases Future aggregate minimum payments under the noncancelable operating leases and short term leases, including the Lexington, MA lease and Connecticut lease, which is not subject to ASC 842, as of December 31, 2020 are as follows: 2021 $ 2,986 2022 4,159 2023 4,284 2024 4,412 2025 4,545 2026 and beyond 27,070 Total minimum lease payments $ 47,456 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 + Details Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 69 R38.htm IDEA: XBRL DOCUMENT v3.21.1 Selected Quarterly Data (Unaudited) (Tables) 12 Months Ended Dec. 31, 2020 Quarterly Financial Information Disclosure [Abstract] Schedule of Quarterly Financial Information The following table contains quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. 2020 March 31, June 30, September 30, December 31, Total (in thousands, except per share amounts) Total revenue $ 7,264 $ 8,523 $ 11,247 $ 9,950 $ 36,984 Total expenses 12,177 14,548 16,588 20,182 $ 63,495 Net loss (4,913 ) (6,025 ) (5,341 ) (10,232 ) $ (26,511 ) Cumulative series C convertible preferred stock dividends — — — — — Net loss attributable to common stockholders (4,913 ) (6,025 ) (5,341 ) (10,232 ) $ (26,511 ) Net loss per share attributable to common shareholders - basic and diluted $ (0.16 ) $ (0.19 ) $ (0.16 ) $ (0.30 ) $ (0.82 ) 2019 March 31, June 30, September 30, December 31, Total (in thousands, except per share amounts) Total revenue $ — $ — $ 24,238 $ 4,709 $ 28,947 Total expenses 5,826 6,852 24,813 10,202 $ 47,693 Net loss (5,826 ) (6,852 ) (575 ) (5,493 ) $ (18,746 ) Cumulative series C convertible preferred stock dividends — — (1,014 ) (40 ) $ (1,054 ) Net loss attributable to common stockholders (5,826 ) (6,852 ) (1,589 ) (5,533 ) $ (19,800 ) Net loss per share attributable to common shareholders - basic and diluted $ (3.24 ) $ (3.42 ) $ (0.73 ) $ (0.19 ) $ (2.29 ) X - ReferencesNo definition available. + Details Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306 + Details Name: us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 70 R39.htm IDEA: XBRL DOCUMENT v3.21.1 Organization and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands 1 Months Ended 12 Months Ended Jul. 20, 2020 USD ($) $ / shares shares Sep. 20, 2019 $ / shares shares Oct. 31, 2019 USD ($) $ / shares shares Dec. 31, 2020 USD ($) $ / shares shares Dec. 31, 2019 USD ($) $ / shares shares Subsidiary Sale Of Stock [Line Items] Date of incorporation Nov. 30, 2014 Reverse stock split ratio 0.148467 Reverse stock split, description 1-for-6.7355 Common stock, authorized shares 100,000,000 200,000,000 200,000,000 Preferred stock, authorized shares 148,724,922 10,000,000 10,000,000 Preferred stock, par value | $ / shares $ 0.001 $ 0.001 $ 0.001 Common stock, par value | $ / shares $ 0.001 $ 0.001 Net proceeds from issuance of common stock | $ $ 1,545 $ 80,062 Accumulated deficit | $ $ 95,399 $ 68,888 Common Stock Subsidiary Sale Of Stock [Line Items] Common stock shares issued and sold 2,350,108 6,325,000 Common Stock | IPO Subsidiary Sale Of Stock [Line Items] Common stock shares issued and sold 6,325,000 Share price per share | $ / shares $ 14.00 Net proceeds from issuance of common stock | $ $ 79,700 Number of common stock issued upon conversion of preferred stock 22,077,627 Common Stock | Private Placement Subsidiary Sale Of Stock [Line Items] Common stock shares issued and sold 2,350,108 Share price per share | $ / shares $ 18.00 Common stock, par value | $ / shares $ 0.001 Net proceeds from issuance of common stock | $ $ 40,100 X - DefinitionDate when an entity was incorporated + ReferencesNo definition available. + Details Name: dei_EntityIncorporationDateOfIncorporation Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R40.htm IDEA: XBRL DOCUMENT v3.21.1 Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) 3 Months Ended 12 Months Ended Mar. 31, 2020 Dec. 31, 2020 Dec. 31, 2019 Dec. 11, 2020 Jan. 01, 2020 Summary Of Significant Accounting Policies [Line Items] Foreign currency exchange (losses) gains $ (4,000) $ 7,000 Restricted cash 1,820,000 101,000 Fair value of term loan $ 0 Fair value of term loan issued term 1 month Impairment losses $ 0 0 Right of use assets 30,551,000 $ 1,700,000 $ 1,200,000 Lease liability $ 30,994,000 $ 1,700,000 $ 1,500,000 Accounting Standards Update 2018-11 Summary Of Significant Accounting Policies [Line Items] Change in accounting principle, accounting standards update, adopted true Change in accounting principle, accounting standards update, adoption date Jan. 01, 2020 Accounting Standards Update 2016-01 Summary Of Significant Accounting Policies [Line Items] Change in accounting principle, accounting standards update, adopted true Change in accounting principle, accounting standards update, adoption date Jan. 01, 2020 Change in accounting principle, accounting standards update, immaterial effect true Lexington Massachusetts facility Summary Of Significant Accounting Policies [Line Items] Restricted cash $ 1,700,000 Woburn Massachusetts Facility Summary Of Significant Accounting Policies [Line Items] Restricted cash $ 100,000 $ 100,000 Increase in right-of-use asset $ 1,000,000 Increase in lease liability $ 1,000,000 X - DefinitionFair value of term loan. + ReferencesNo definition available. + Details Name: freq_FairValueOfTermLoan Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of term loan issued term. + ReferencesNo definition available. + Details Name: freq_FairValueOfTermLoanIssuedTerm Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionIncrease (decrease) in operating lease liability. + ReferencesNo definition available. + Details Name: freq_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in operating lease right of use assets. + ReferencesNo definition available. + Details Name: freq_IncreaseDecreaseInOperatingLeaseRightOfUseAssets Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSummary Of Significant Accounting Policies [Line Items] + ReferencesNo definition available. + Details Name: freq_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: freq_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether accounting standards update was adopted. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 20 -Section 65 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 65 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 65 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 65 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (a) + Details Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: instant X - DefinitionDate accounting standards update was adopted, in CCYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 20 -Section 65 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 65 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 65 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079 Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 40 -Section 65 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 65 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (a) + Details Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - DefinitionIndicates (true false) whether effect from applying amendment to accounting standards is immaterial. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section S99 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 10 -Section 65 -Paragraph 4 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 65 -Paragraph 8 -Subparagraph (e)(3) + Details Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: instant X - DefinitionAmount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 35 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 10 -Section 45 -Paragraph 17 -URI http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 210 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201811Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=freq_LexingtonMassachusettsFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R41.htm IDEA: XBRL DOCUMENT v3.21.1 Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) 12 Months Ended Dec. 31, 2020 Lab Equipment Summary Of Significant Accounting Policies [Line Items] Property and equipment, estimated useful lives 3 years Software Summary Of Significant Accounting Policies [Line Items] Property and equipment, estimated useful lives 3 years Furniture and Office Equipment Summary Of Significant Accounting Policies [Line Items] Property and equipment, estimated useful lives 3 years Leasehold Improvements Summary Of Significant Accounting Policies [Line Items] Leasehold improvements, estimated useful lives Shorter of the estimated useful life or lease term X - DefinitionSummary Of Significant Accounting Policies [Line Items] + ReferencesNo definition available. + Details Name: freq_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: freq_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescribes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 35 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 + Details Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R42.htm IDEA: XBRL DOCUMENT v3.21.1 Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 12 Months Ended Dec. 31, 2020 Sep. 30, 2020 Jun. 30, 2020 Mar. 31, 2020 Dec. 31, 2019 Sep. 30, 2019 Jun. 30, 2019 Mar. 31, 2019 Dec. 31, 2020 Dec. 31, 2019 Numerator: Net loss attributable to common stockholders $ (10,232) $ (5,341) $ (6,025) $ (4,913) $ (5,533) $ (1,589) $ (6,852) $ (5,826) $ (26,511) $ (19,800) Denominator: Weighted-average shares of common stock outstanding- basic and diluted 32,253,227 8,649,245 Net loss per share attributable to common stockholders-basic and diluted $ (0.30) $ (0.16) $ (0.19) $ (0.16) $ (0.19) $ (0.73) $ (3.42) $ (3.24) $ (0.82) $ (2.29) X - DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256 + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). + ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 74 R43.htm IDEA: XBRL DOCUMENT v3.21.1 Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share 6,819,891 19,554,414 Unvested Restricted Common Stock Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share 3,093 70,366 Series C Preferred (as converted to common stock) Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share 1,172,676 Series B Preferred (as converted to common stock) Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share 4,759,079 Series A Preferred (as converted to common stock) Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share 7,070,574 Conversion of Frequency Japan Preferred Stock Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share 513,047 Outstanding Stock Options (as converted to common stock) Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share 6,816,798 5,968,672 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesCPreferredAsConvertedToCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesBPreferredAsConvertedToCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesAPreferredAsConvertedCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_ConversionOfFrequencyJapanPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsAsConvertedToCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R44.htm IDEA: XBRL DOCUMENT v3.21.1 Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) - Recurring Basis - USD ($) $ in Thousands Dec. 31, 2020 Dec. 31, 2019 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Amortization Cost $ 214,522 $ 217,262 Unrealized Gain 27 54 Fair Market Value 214,549 217,316 Money Market Funds | Level 1 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Amortization Cost 214,522 200,131 Unrealized Loss (12) Unrealized Gain 27 Fair Market Value $ 214,549 200,119 U.S. Government Treasury Securities | Level 1 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Amortization Cost 17,131 Unrealized Gain 66 Fair Market Value $ 17,197 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (aa) -URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R45.htm IDEA: XBRL DOCUMENT v3.21.1 Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands Dec. 31, 2020 Dec. 31, 2019 Prepaid Expense And Other Assets Current [Abstract] Rent and deposits $ 63 Research and development expenses $ 1,729 801 Grant receivable 805 Accounts receivable 340 Insurance 2,552 2,132 Other 102 199 Total $ 4,723 $ 4,000 X - DefinitionPrepaid accounts receivable current. + ReferencesNo definition available. + Details Name: freq_PrepaidAccountsReceivableCurrent Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRent and deposits. + ReferencesNo definition available. + Details Name: freq_PrepaidRentAndDepositsCurrent Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid research and development expense current. + ReferencesNo definition available. + Details Name: freq_PrepaidResearchAndDevelopmentExpenseCurrent Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_GrantsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g)(1) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 77 R46.htm IDEA: XBRL DOCUMENT v3.21.1 Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands Dec. 31, 2020 Dec. 31, 2019 Property Plant And Equipment [Line Items] Total $ 10,499 $ 3,828 Accumulated depreciation (3,212) (2,066) Property and equipment, net 7,287 1,762 Lab Equipment Property Plant And Equipment [Line Items] Total 4,166 1,846 Furniture and Office Equipment Property Plant And Equipment [Line Items] Total 283 257 Software Property Plant And Equipment [Line Items] Total 291 Leasehold Improvements Property Plant And Equipment [Line Items] Total 1,419 1,419 Construction in Progress Property Plant And Equipment [Line Items] Total $ 4,340 $ 306 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.14) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R47.htm IDEA: XBRL DOCUMENT v3.21.1 Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Property Plant And Equipment [Abstract] Depreciation expense $ 1,146 $ 813 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 79 R48.htm IDEA: XBRL DOCUMENT v3.21.1 Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands Dec. 31, 2020 Dec. 31, 2019 Payables And Accruals [Abstract] Payroll and employee related expenses $ 5,062 $ 2,686 Professional fees 647 435 Third-party research and development expenses 874 118 Taxes and other 80 Total $ 6,663 $ 3,239 X - DefinitionAccrued income taxes and other accrued liabilities, current. + ReferencesNo definition available. + Details Name: freq_AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued third-party research and development expenses current. + ReferencesNo definition available. + Details Name: freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 80 R49.htm IDEA: XBRL DOCUMENT v3.21.1 Debt - Additional Information (Details) - Loan Agreement - Term Loan - USD ($) $ in Thousands 12 Months Ended Dec. 11, 2020 Dec. 31, 2020 Debt Instrument [Line Items] Principal balance $ 15,000 Payment terms, description The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”) Frequency of interest-only payments monthly Monthly interest only payments due Nov. 30, 2022 Loan maturity date May 01, 2024 Debt instrument, Interest rate 4.75% Interest rate floor percentage 0.00% Debt instrument final payment $ 150,000 Prepayment Occurs on or Prior to First Anniversary of Closing Date Debt Instrument [Line Items] Debt instrument prepayment premium percentage 2.00% Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date Debt Instrument [Line Items] Debt instrument prepayment premium percentage 1.00% Prepayment Occurs After Second Anniversary of Closing Date Debt Instrument [Line Items] Debt instrument prepayment premium percentage 0.00% Prime Rate Debt Instrument [Line Items] Debt instrument, Interest rate 1.50% X - DefinitionDebt instrument floor interest rate percentage. + ReferencesNo definition available. + Details Name: freq_DebtInstrumentFloorInterestRatePercentage Namespace Prefix: freq_ Data Type: num:percentItemType Balance Type: na Period Type: instant X - DefinitionDebt instrument interest only payment maturity date. + ReferencesNo definition available. + Details Name: freq_DebtInstrumentInterestOnlyPaymentMaturityDate Namespace Prefix: freq_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument prepayment premium percentage. + ReferencesNo definition available. + Details Name: freq_DebtInstrumentPrepaymentPremiumPercentage Namespace Prefix: freq_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of the frequency of periodic payments (monthly, quarterly, annual). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823 + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDescription of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823 + Details Name: us-gaap_DebtInstrumentPaymentTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of payment greater than the preceding installment payments to be paid at final maturity date of debt. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=freq_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=freq_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursOnOrPriorToFirstAnniversaryOfClosingDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterFirstAnniversaryOfClosingDateAndOnOrPriorToSecondAnniversaryOfClosingDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=freq_PrepaymentOccursAfterSecondAnniversaryOfClosingDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R50.htm IDEA: XBRL DOCUMENT v3.21.1 Convertible Preferred Stock - Additional Information (Details) - USD ($) $ in Thousands Dec. 31, 2019 Jul. 17, 2019 Dec. 31, 2018 Series A Preferred Stock Temporary Equity [Line Items] Convertible preferred stock, issued shares 62,528,507 Series B Preferred Stock Temporary Equity [Line Items] Convertible preferred stock, issued shares 288,911 41,857,005 Series C Convertible Preferred Stock Temporary Equity [Line Items] Convertible preferred stock, issued shares 39,492,960 Convertible preferred stock, authorized shares 39,492,960 Preferred stock, net proceeds from shares issued $ 61,687 Series A-1 Preferred Stock Temporary Equity [Line Items] Convertible preferred stock, issued shares 10,000 Series B-1 Preferred Stock Temporary Equity [Line Items] Convertible preferred stock, issued shares 10,000 X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_TemporaryEquitySharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_TemporaryEquitySharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R51.htm IDEA: XBRL DOCUMENT v3.21.1 Non-controlling Interest - Additional Information (Details) - shares 12 Months Ended Dec. 31, 2020 Dec. 31, 2018 Series A-1 Preferred Stock | LLC(FT-FJ) Class Of Stock [Line Items] Preferred stock, shares purchased 10,000 Preferred stock, voting rights Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock Series B-1 Preferred Stock | LLC(FT-FJ) Class Of Stock [Line Items] Preferred stock, shares purchased 10,000 Preferred stock, voting rights Each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock Frequency Japan Class Of Stock [Line Items] Convertible preferred Stock, shares issued upon conversion 673,605 Voting percentage of preferred stock holder 70.00% X - DefinitionPercentage of vote of the holders of preferred stock. + ReferencesNo definition available. + Details Name: freq_PercentageOfVoteOfHoldersOfPreferredStock Namespace Prefix: freq_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPreferred stock, shares purchased. + ReferencesNo definition available. + Details Name: freq_PreferredStockSharesPurchased Namespace Prefix: freq_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued for each share of convertible preferred stock that is converted. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644 + Details Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDescription of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 + Details Name: us-gaap_PreferredStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=freq_DelawareLimitedLiabilityCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R52.htm IDEA: XBRL DOCUMENT v3.21.1 Stockholders' Equity - Additional Information (Details) - $ / shares Dec. 31, 2020 Dec. 31, 2019 Sep. 20, 2019 Equity [Abstract] Preferred stock, shares authorized 10,000,000 10,000,000 148,724,922 Preferred Stock, value per share $ 0.001 $ 0.001 $ 0.001 Preferred stock, issued shares 0 0 Preferred stock, outstanding shares 0 0 Common stock, authorized shares 200,000,000 200,000,000 100,000,000 Common stock, par value $ 0.001 $ 0.001 Common stock, issued shares 33,964,000 30,844,507 Common stock, outstanding shares 33,964,000 30,844,507 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 84 R53.htm IDEA: XBRL DOCUMENT v3.21.1 Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) - shares Dec. 31, 2020 Dec. 31, 2019 Class Of Stock [Line Items] Shares of common stock reserved for future issuance 8,292,721 7,828,326 Stock Options Outstanding Class Of Stock [Line Items] Shares of common stock reserved for future issuance 6,816,798 5,968,672 Shares Available for Future Grant Under Stock Option Plan Class Of Stock [Line Items] Shares of common stock reserved for future issuance 1,475,923 1,859,654 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R54.htm IDEA: XBRL DOCUMENT v3.21.1 Stock-based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Sep. 17, 2019 Nov. 13, 2014 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Common stock, shares reserved for issuance 8,292,721 7,828,326 Options vesting period 4 years Expected dividend yield 0.00% 0.00% Options exercised 769,385 357,170 Aggregate intrinsic value of stock options exercised $ 16,667 $ 5,896 Weighted-average grant date fair value of stock options granted 16.41 4.05 Total grant date fair value of stock options vested $ 7,907 $ 2,990 Total unrecognized stock-based compensation expense relating to unvested stock options $ 31,006 $ 13,820 Unrecognized unvested stock options, weighted-average period 3 years 29 days 2 years 9 months 3 days Research and Development Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Stock-based compensation expense $ 9,983 General and Administrative Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Stock-based compensation expense $ 3,609 Restricted Common Stock Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Options vesting period 4 years Total value of restricted stock awards, vested based on estimated fair value of stock $ 20 $ 73 Maximum Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Options expiration period 10 years 2014 Plan Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Common stock, shares reserved for issuance 8,550,415 Common stock, shares available for future grants 0 Options exercised 767,534 357,170 Aggregate intrinsic value of stock options exercised $ 1.94 $ 1.02 2019 Plan Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Number of authorized shares reserved for issuance 3,100,000 Period for automatic increase in common stock available for future issuance 10 years Percentage of shares issued from outstanding number of shares 4.00% Common stock future issuance, description In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company’s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. Options exercised 1,851 Aggregate intrinsic value of stock options exercised $ 18.93 X - DefinitionPeriod for automatic increase in common stock available for future issuance. + ReferencesNo definition available. + Details Name: freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R55.htm IDEA: XBRL DOCUMENT v3.21.1 Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details) - USD ($) $ / shares in Units, $ in Thousands 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Number of shares, Exercised (769,385) (357,170) Weighted average exercise price, Exercised $ 16,667 $ 5,896 2019 Plan Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Number of shares, Beginning balance 1,247,338 Number of shares, Granted 1,645,859 1,247,338 Number of shares, Exercised (1,851) Number of shares, Forfeited (16,997) Number of shares, Ending balance 2,874,349 1,247,338 Number of shares, Options exercisable as of December 31, 2020 564,617 Number of shares, Options unvested as of December 31, 2020 2,309,732 Weighted average exercise price, Beginning balance $ 14.09 Weighted average exercise price, Granted 24.22 $ 14.09 Weighted average exercise price, Exercised 18.93 Weighted average exercise price, Forfeited 22.72 Weighted average exercise price, Ending balance 19.84 $ 14.09 Weighted average exercise price, Options exercisable as of December 31, 2020 $ 17.48 Weighted average remaining contractual term (in years), Outstanding 9 years 1 month 2 days 9 years 9 months 3 days Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2020 8 years 10 months 24 days Aggregate intrinsic value, Outstanding $ 44,325 $ 4,287 Aggregate intrinsic value, Options exercisable as of December 31, 2020 10,042 Aggregate intrinsic value, Options unvested as of December 31, 2020 $ 34,283 2014 Plan Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Number of shares, Beginning balance 4,721,334 2,089,334 Number of shares, Granted 3,015,381 Number of shares, Exercised (767,534) (357,170) Number of shares, Forfeited (11,351) (26,211) Number of shares, Ending balance 3,942,449 4,721,334 Number of shares, Options exercisable as of December 31, 2020 2,337,828 Number of shares, Options unvested as of December 31, 2020 1,604,621 Weighted average exercise price, Beginning balance $ 2.85 $ 0.61 Weighted average exercise price, Granted 4.17 Weighted average exercise price, Exercised 1.94 1.02 Weighted average exercise price, Forfeited 6.89 1.09 Weighted average exercise price, Ending balance 3.02 $ 2.85 Weighted average exercise price, Options exercisable as of December 31, 2020 $ 2.57 Weighted average remaining contractual term (in years), Outstanding 7 years 11 months 23 days 8 years 10 months 20 days Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2020 7 years 10 months 17 days Aggregate intrinsic value, Outstanding $ 127,090 $ 65,051 Aggregate intrinsic value, Options exercisable as of December 31, 2020 76,416 Aggregate intrinsic value, Options unvested as of December 31, 2020 $ 50,674 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R56.htm IDEA: XBRL DOCUMENT v3.21.1 Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details) 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Risk-free interest rate 1.10% 2.00% Expected term (in years) 6 years 5 years 10 months 24 days Expected volatility 79.10% 79.40% Expected dividend yield 0.00% 0.00% X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2) -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 88 R57.htm IDEA: XBRL DOCUMENT v3.21.1 Stock-based Compensation - Summary of Status of Restricted Common Stock (Details) - Restricted Common Stock 12 Months Ended Dec. 31, 2020 $ / shares shares Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Number of shares, Unvested, December 31, 2019 | shares 70,366 Number of shares, Vested | shares (67,273) Number of shares, Unvested, December 31, 2020 | shares 3,093 Weighted average fair value, Unvested, December 31, 2019 | $ / shares $ 0.36 Weighted average fair value, Vested | $ / shares 0.29 Weighted average fair value, Unvested, December 31, 2020 | $ / shares $ 1.75 X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 89 R58.htm IDEA: XBRL DOCUMENT v3.21.1 Employee Stock Purchase Plan - Additional Information (Details) - shares Dec. 31, 2020 Sep. 20, 2019 Dec. 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Shares of common stock reserved for future issuance 8,292,721 7,828,326 2019 Employee Stock Purchase Plan Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Percentage of eligible employee compensation 15.00% Shares of common stock reserved for future issuance 315,000 Period for automatic increase in common available for future issuance 10 years Percentage of shares issued from outstanding number of shares 1.00% Shares issued 0 X - DefinitionPercentage of eligible employee compensation. + ReferencesNo definition available. + Details Name: freq_PercentageOfEligibleEmployeeCompensation Namespace Prefix: freq_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod for automatic increase in common stock available for future issuance. + ReferencesNo definition available. + Details Name: freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R59.htm IDEA: XBRL DOCUMENT v3.21.1 Income Taxes - Additional Information (Details) - USD ($) 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Oct. 31, 2019 Mar. 31, 2017 Feb. 28, 2017 Income Taxes Disclosure [Line Items] Net tax benefit $ 35,000 $ 0 Federal and state deferred tax benefits 0 0 Valuation allowance 26,995,000 16,204,000 Unrecognized tax benefits 0 0 Interest and penalties $ 0 $ 0 Internal Revenue Service Income Taxes Disclosure [Line Items] Period of cumulative change in ownership 3 years Operating loss carryforwards, utilization after ownership change $ 10,800,000 Operating loss carryforwards, utilization after five years after ownership change 1,600,000 Operating loss carryforwards, utilization after 15 years thereafter after ownership change 180,000 Remaining pre ownership change in operating loss carryforwards written off due to expiration $ 1,600,000 Internal Revenue Service | Minimum Income Taxes Disclosure [Line Items] Cumulative change in ownership percentage 50.00% Federal Income Taxes Disclosure [Line Items] Net operating loss carryforwards $ 67,868,000 Net operating loss carryforwards expire through 2037 $ 22,400,000 Operating loss carryforwards expiration year 2037 Net operating loss carryforwards without expiration $ 45,469,000 Tax credit carryforwards expiration year 2040 Federal | Internal Revenue Service Income Taxes Disclosure [Line Items] Net operating loss carryforwards $ 46,123,000 $ 12,400,000 Federal | Research and Development Income Taxes Disclosure [Line Items] Tax credit carryforwards $ 3,014,000 State Income Taxes Disclosure [Line Items] Operating loss carryforwards expiration year 2040 State | Massachusetts Income Taxes Disclosure [Line Items] Net operating loss carryforwards $ 43,386,000 Tax credit carryforwards expiration year 2035 State | Massachusetts | Research and Development Income Taxes Disclosure [Line Items] Tax credit carryforwards $ 1,211,000 X - DefinitionCumulative change in ownership percentage. + ReferencesNo definition available. + Details Name: freq_CumulativeChangeInOwnershipPercentage Namespace Prefix: freq_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionIncome taxes disclosure. + ReferencesNo definition available. + Details Name: freq_IncomeTaxesDisclosureLineItems Namespace Prefix: freq_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet operating loss carryforwards expiration with limitation. + ReferencesNo definition available. + Details Name: freq_NetOperatingLossCarryforwardsExpirationWithLimitation Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNet operating loss carryforwards expiration without limitation. + ReferencesNo definition available. + Details Name: freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOperating loss carryforwards annual usage for next each after five years and thereafter after ownership change. + ReferencesNo definition available. + Details Name: freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOperating loss carryforwards annual usage for next each five years after ownership change. + ReferencesNo definition available. + Details Name: freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOperating loss carryforwards expiration year. + ReferencesNo definition available. + Details Name: freq_OperatingLossCarryforwardsExpirationYear Namespace Prefix: freq_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating Loss Carryforwards Usage After Ownership Change. + ReferencesNo definition available. + Details Name: freq_OperatingLossCarryforwardsUsageAfterOwnershipChange Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod of cumulative change in ownership. + ReferencesNo definition available. + Details Name: freq_PeriodOfCumulativeChangeInOwnership Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRemaining pre ownership change in operating loss carryforwards written off due to expiration. + ReferencesNo definition available. + Details Name: freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTax credit carryforward expiration year. + ReferencesNo definition available. + Details Name: freq_TaxCreditCarryforwardExpirationYear Namespace Prefix: freq_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesNo definition available. + Details Name: us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319 + Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 20 -Section 45 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319 + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319 + Details Name: us-gaap_TaxCreditCarryforwardAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 10B -URI http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319 + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319 + Details Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_MA Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R60.htm IDEA: XBRL DOCUMENT v3.21.1 Income Taxes - Schedule of Reconciliation Pre-tax Income (Details) - USD ($) $ in Thousands 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Income Tax Disclosure [Abstract] Domestic $ (25,744) $ (19,086) Foreign (732) (714) Total $ (26,476) $ (19,800) X - DefinitionThe portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.3) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.3) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 92 R61.htm IDEA: XBRL DOCUMENT v3.21.1 Income Taxes - Schedule of Provision (Details) - USD ($) 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Current: Federal $ 35,000 Total current 35,000 Deferred: Total provision (benefit) $ 35,000 $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319 + Details Name: us-gaap_CurrentFederalTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.2) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details Name: us-gaap_CurrentIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 20 -Section 45 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 93 R62.htm IDEA: XBRL DOCUMENT v3.21.1 Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details) 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Income Tax Disclosure [Abstract] U.S federal statutory income tax rate 21.00% 21.00% Permanent differences (0.20%) (2.80%) State income taxes, net of federal benefit 3.00% 4.00% Research and development tax credits 11.20% 1.80% Stock compensation deductions 5.10% 0.00% Other items 0.60% (1.00%) Change in deferred tax asset valuation allowance (40.70%) (23.00%) X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.4) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.4) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.4) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.4) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments. + ReferencesNo definition available. + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.4) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.4) -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 94 R63.htm IDEA: XBRL DOCUMENT v3.21.1 Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands Dec. 31, 2020 Dec. 31, 2019 Income Tax Disclosure [Abstract] Net operating loss carryforwards $ 17,885 $ 13,253 Research and development tax credits 3,992 1,138 Intangibles 360 358 Stock compensation 850 686 Accrued expenses 48 Deferred revenue 3,606 496 Other 142 189 Fixed assets 56 36 Lease liability 7,285 Right of use asset (7,181) Total deferred tax asset 26,995 16,204 Valuation allowance $ (26,995) $ (16,204) X - DefinitionDeferred tax assets leasing arrangements. + ReferencesNo definition available. + Details Name: freq_DeferredTaxAssetsLeasingArrangements Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDeferred tax assets liabilities property plant and equipment. + ReferencesNo definition available. + Details Name: freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDeferred tax assets right of use assets. + ReferencesNo definition available. + Details Name: freq_DeferredTaxAssetsRightOfUseAssets Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319 + Details Name: us-gaap_DeferredTaxAssetsDeferredIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill. + ReferencesNo definition available. + Details Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319 + Details Name: us-gaap_DeferredTaxAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319 + Details Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319 + Details Name: us-gaap_DeferredTaxAssetsOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319 + Details Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319 + Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319 + Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319 + Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 95 R64.htm IDEA: XBRL DOCUMENT v3.21.1 Research and License Agreements - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 12 Months Ended 16 Months Ended Sep. 30, 2020 Dec. 31, 2019 Feb. 28, 2019 Sep. 30, 2018 Jun. 30, 2018 Dec. 31, 2016 Dec. 31, 2020 Sep. 30, 2020 Jun. 30, 2020 Mar. 31, 2020 Dec. 31, 2019 Sep. 30, 2019 Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2021 Research And Development Arrangement Contract To Perform For Others [Line Items] Revenue $ 9,950,000 $ 11,247,000 $ 8,523,000 $ 7,264,000 $ 4,709,000 $ 24,238,000 $ 36,984,000 $ 28,947,000 Dr. Langer Research And Development Arrangement Contract To Perform For Others [Line Items] Payment to director 1,980,000 10,000 Grant Research And Development Arrangement Contract To Perform For Others [Line Items] Decrease in research and development expenses $ 323,000 845,000 Research and Development | Grant Research And Development Arrangement Contract To Perform For Others [Line Items] Amount of funding received as grant $ 1,596,000 Grant term period 2 years MIT Research And Development Arrangement Contract To Perform For Others [Line Items] Description of future development obligations The Company’s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. License fee payment $ 50,000 Percentage of shares of common stock issued 5.00% Description of conditions to terminate license agreement The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. Right to terminate agreement upon prior written notice 3 months Right to terminate agreement if breach remains uncured 90 days Right to terminate agreement incase of nonpayment 30 days MIT | Astellas Pharma LLC | Royalty Research And Development Arrangement Contract To Perform For Others [Line Items] Revenue 16,000,000 MIT | Maximum Research And Development Arrangement Contract To Perform For Others [Line Items] Milestone payments $ 2,900,000 MIT | Patent License Agreement Research And Development Arrangement Contract To Perform For Others [Line Items] License agreement entered date 2016-12 CALIBR Research And Development Arrangement Contract To Perform For Others [Line Items] License fee payment $ 1,000,000 Percentage of shares of common stock issued 50.00% Description of conditions to terminate license agreement The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. Right to terminate agreement upon prior written notice 30 days Right to terminate agreement if breach remains uncured 30 days Right to terminate licensed patents upon prior written notice 90 days CALIBR | Maximum Research And Development Arrangement Contract To Perform For Others [Line Items] Milestone payments $ 26,000,000 CALIBR | Patent License Agreement Research And Development Arrangement Contract To Perform For Others [Line Items] License agreement entered date 2018-09 Scripps Option Agreement Research And Development Arrangement Contract To Perform For Others [Line Items] License agreement entered date 2018-09 Description of conditions to terminate license agreement The Company has the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt. Right to terminate agreement upon prior written notice 90 days Right to terminate agreement if breach remains uncured 60 days Right to terminate agreement incase of nonpayment 10 days Funding payments as consideration to support research activities $ 700,000 Agreement term 1 year License agreement extended date 2021-12 Scripps Option Agreement | Scenario Forecast Research And Development Arrangement Contract To Perform For Others [Line Items] Additional funding payments made as consideration to support research activities $ 600,000 MEE Research And Development Arrangement Contract To Perform For Others [Line Items] License fee payment $ 20,000 Description of conditions to terminate license agreement The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60) business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. Right to terminate agreement upon prior written notice 30 days Right to terminate agreement if breach remains uncured 60 days Right to terminate agreement incase of nonpayment 30 days Right to terminate agreement upon prior written notice if insolvent 45 days MEE | Maximum Research And Development Arrangement Contract To Perform For Others [Line Items] Milestone payments $ 350,000 MEE | Non-Exclusive Patent License Agreement Research And Development Arrangement Contract To Perform For Others [Line Items] License agreement entered date 2019-02 Cambridge Research And Development Arrangement Contract To Perform For Others [Line Items] License fee payment $ 50,000 $ 50,000 $ 50,000 Description of conditions to terminate license agreement We have the right to terminate for any reason upon 90 days’ prior to written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed. Right to terminate agreement upon prior written notice 90 days Right to terminate agreement if breach remains uncured 30 days Annual license fee $ 50,000 Cambridge | Maximum Research And Development Arrangement Contract To Perform For Others [Line Items] Milestone payments $ 10,500 Cambridge | Patent License Agreement Research And Development Arrangement Contract To Perform For Others [Line Items] License agreement entered date 2019-12 X - DefinitionAdditional funding payments made as consideration to support research activities. + ReferencesNo definition available. + Details Name: freq_AdditionalFundingPaymentsMadeAsConsiderationToSupportResearchActivities Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of funding received as grant. + ReferencesNo definition available. + Details Name: freq_AmountOfFundingReceivedAsGrant Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAnnual license fee + ReferencesNo definition available. + Details Name: freq_AnnualLicenseFee Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDescription of conditions to terminate license agreement. + ReferencesNo definition available. + Details Name: freq_DescriptionOfConditionsToTerminateLicenseAgreement Namespace Prefix: freq_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of future development obligations. + ReferencesNo definition available. + Details Name: freq_DescriptionOfFutureDevelopmentObligations Namespace Prefix: freq_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFunding payments made as consideration to support research activities. + ReferencesNo definition available. + Details Name: freq_FundingPaymentsMadeAsConsiderationToSupportResearchActivities Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGrant term period. + ReferencesNo definition available. + Details Name: freq_GrantTermPeriod Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionIncrease (decrease) in research and development expenses. + ReferencesNo definition available. + Details Name: freq_IncreaseDecreaseInResearchAndDevelopmentExpense Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLicense agreement entered date. + ReferencesNo definition available. + Details Name: freq_LicenseAgreementEnteredDate Namespace Prefix: freq_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionLicense agreement extended date. + ReferencesNo definition available. + Details Name: freq_LicenseAgreementExtendedDate Namespace Prefix: freq_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionLicense fee payment. + ReferencesNo definition available. + Details Name: freq_LicenseFeePayment Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMilestone payments. + ReferencesNo definition available. + Details Name: freq_MilestonePayments Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of shares of common stock issued. + ReferencesNo definition available. + Details Name: freq_PercentageOfSharesOfCommonStockIssued Namespace Prefix: freq_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionRight to terminate agreement if breach remains uncured. + ReferencesNo definition available. + Details Name: freq_RightToTerminateAgreementIfBreachRemainsUncured Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRight to terminate agreement incase of nonpayment. + ReferencesNo definition available. + Details Name: freq_RightToTerminateAgreementIncaseOfNonpayment Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRight to terminate agreement upon prior written notice. + ReferencesNo definition available. + Details Name: freq_RightToTerminateAgreementUponPriorWrittenNotice Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRight to terminate agreement upon prior written notice if insolvent. + ReferencesNo definition available. + Details Name: freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRight to terminate licensed patents upon prior written notice. + ReferencesNo definition available. + Details Name: freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of agreement. + ReferencesNo definition available. + Details Name: freq_TermOfAgreement Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 17 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details Name: us-gaap_PaymentForManagementFee Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_ResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_PatentLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=freq_ScrippsOptionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_NonExclusivePatentLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 96 R65.htm IDEA: XBRL DOCUMENT v3.21.1 Collaboration Agreement - Additional Information (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 12 Months Ended 18 Months Ended Jul. 31, 2019 Dec. 31, 2020 Sep. 30, 2020 Jun. 30, 2020 Mar. 31, 2020 Dec. 31, 2019 Sep. 30, 2019 Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2020 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Royalty $ 16,000 Revenue $ 9,950 $ 11,247 $ 8,523 $ 7,264 $ 4,709 $ 24,238 $ 36,984 28,947 Research and development 37,415 18,784 License and Collaboration Agreement | Astellas Pharma LLC Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Payments received under collaboration agreement $ 80,000 Agreement termination notice period 60 days Right to terminate agreement if breach remains uncured 90 days Right to terminate agreement incase of nonpayment 45 days Transaction price allocated to single combined performance obligation 80,000 Accrued upfront payment related to sub License revenue $ 16,000 16,000 $ 16,000 Royalty $ 16,000 Upfront fee recognized as revenue $ 80,000 Revenue 37,000 28,900 Revenue from contract with customer application input method 12,900 Revenue remaining performance obligation $ 64,000 64,000 Research and development $ 1,046 186 License and Collaboration Agreement | Astellas Pharma LLC | Royalty Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Revenue $ 16,000 License and Collaboration Agreement | Astellas Pharma LLC | Phase 2b Clinical Trial | Europe Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Revenue recognized potential development milestone payments to receive $ 65,000 License and Collaboration Agreement | Astellas Pharma LLC | Phase 2b Clinical Trial | Asia Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Revenue recognized potential development milestone payments to receive 25,000 License and Collaboration Agreement | Astellas Pharma LLC | Phase 3 Clinical Trial | Europe Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Revenue recognized potential development milestone payments to receive 100,000 License and Collaboration Agreement | Astellas Pharma LLC | Phase 3 Clinical Trial | Asia Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Revenue recognized potential development milestone payments to receive 40,000 License and Collaboration Agreement | Maximum | Astellas Pharma LLC Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Revenue recognized potential development milestone payments to receive 230,000 Revenue recognized commercialization milestone payments to receive 315,000 Potential commercial milestone payments eligible to receive upon successful commercialization $ 315,000 X - DefinitionAgreement termination notice period. + ReferencesNo definition available. + Details Name: freq_AgreementTerminationNoticePeriod Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionContract with customer liability revenue recognized from commercialization milestones. + ReferencesNo definition available. + Details Name: freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRevenue from contract with customer application input method. + ReferencesNo definition available. + Details Name: freq_RevenueFromContractWithCustomerApplicationInputMethod Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRevenue recognition potential commercial milestone payments eligible upon successful commercialization. + ReferencesNo definition available. + Details Name: freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRevenue recognition transaction price. + ReferencesNo definition available. + Details Name: freq_RevenueRecognitionTransactionPrice Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRight to terminate agreement if breach remains uncured. + ReferencesNo definition available. + Details Name: freq_RightToTerminateAgreementIfBreachRemainsUncured Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRight to terminate agreement incase of nonpayment. + ReferencesNo definition available. + Details Name: freq_RightToTerminateAgreementIncaseOfNonpayment Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionUpfront fee recognized as revenue. + ReferencesNo definition available. + Details Name: freq_UpfrontFeeRecognizedAsRevenue Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received from collaborators during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details Name: us-gaap_ProceedsFromCollaborators Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details Name: us-gaap_RoyaltyExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase2bClinicalTrialMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_AsiaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase3ClinicalTrailMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 97 R66.htm IDEA: XBRL DOCUMENT v3.21.1 Commitments and Contingencies - Additional Information (Details) 12 Months Ended Dec. 11, 2020 USD ($) Jan. 07, 2020 ft² Term Dec. 31, 2020 USD ($) Dec. 31, 2019 USD ($) Jan. 01, 2020 USD ($) Dec. 31, 2016 Lessee Lease Description [Line Items] Operating lease ROU assets $ 1,700,000 $ 30,551,000 $ 1,200,000 Current lease liabilities 397,000 Non-current lease liabilities 30,597,000 Operating lease cost 470,000 Variable lease cost 510,000 Short term lease cost 106,000 Lease expense 835,000 $ 269,000 Cash paid for amounts included in the measurement of lease liabilities 484,000 Commitment payments related to research 600,000 Losses related to indemnification obligations 0 $ 0 Hayden LLC | Lexington Lease Lessee Lease Description [Line Items] Operating lease term 10 years Lease expiration date May 31, 2031 Rentable area of office space | ft² 61,307 Lease commencement date Dec. 11, 2020 Number of additional lease extension terms | Term 2 Lease extension term 5 years Lease Termination Agreement Lessee Lease Description [Line Items] Payment of fee to landlord $ 200,000 Lease Termination Agreement | ARE-MA Region No. 20, LLC Lessee Lease Description [Line Items] Lease expiration date Mar. 31, 2021 Massachusetts Lessee Lease Description [Line Items] Operating lease term 5 years Lease, description of option to extend The lease was extended in November 2019 and expires in February 2025. Lease agreement amended date 2019-11 Lease commencement date 2020-02 Lease expiration date 2025-02 Connecticut Lessee Lease Description [Line Items] Lease, expiration year 2021 Woburn Massachusetts Facility Lessee Lease Description [Line Items] Operating lease term 5 years X - DefinitionLease expiration year. + ReferencesNo definition available. + Details Name: freq_LeaseExpirationYear Namespace Prefix: freq_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating lease agreement amended date. + ReferencesNo definition available. + Details Name: freq_OperatingLeaseAgreementAmendedDate Namespace Prefix: freq_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionOperating lease agreement commencement date. + ReferencesNo definition available. + Details Name: freq_OperatingLeaseAgreementCommencementDate Namespace Prefix: freq_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionOperating lease agreement expiration date. + ReferencesNo definition available. + Details Name: freq_OperatingLeaseAgreementExpirationDate Namespace Prefix: freq_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionOperating lease commencement date. + ReferencesNo definition available. + Details Name: freq_OperatingLeaseCommencementDate Namespace Prefix: freq_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionOperating lease number of additional extension terms. + ReferencesNo definition available. + Details Name: freq_OperatingLeaseNumberOfAdditionalExtensionTerms Namespace Prefix: freq_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionOperating lease termination fee. + ReferencesNo definition available. + Details Name: freq_OperatingLeaseTerminationFee Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOperating leases additional extension term. + ReferencesNo definition available. + Details Name: freq_OperatingLeasesAdditionalExtensionTerm Namespace Prefix: freq_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDate which lease or group of leases is set to expire, in CCYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe minimum amount the entity agreed to spend under the long-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details Name: us-gaap_LossContingencyLossInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNet rentable area for properties owned. + ReferencesNo definition available. + Details Name: us-gaap_NetRentableArea Namespace Prefix: us-gaap_ Data Type: num:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 5 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(1) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=freq_HaydenLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=freq_LexingtonLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=freq_LeasesTerminationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=freq_AREMARegionNo20LLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_MA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_CT Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 98 R67.htm IDEA: XBRL DOCUMENT v3.21.1 Commitments and Contingencies - Schedule of Leases (Details) Dec. 31, 2020 Commitments And Contingencies Disclosure [Abstract] Weighted-average remaining lease term 10 years 3 months 18 days Weighted-average discount rate 8.50% X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(4) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(3) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 99 R68.htm IDEA: XBRL DOCUMENT v3.21.1 Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details) - USD ($) $ in Thousands Dec. 31, 2020 Dec. 11, 2020 Jan. 01, 2020 Commitments And Contingencies Disclosure [Abstract] 2021 $ 2,928 2022 4,159 2023 4,284 2024 4,412 2025 4,545 Thereafter 27,070 Total minimum lease payments 47,398 Less: amount of lease payments representing interest (16,404) Present value of future lease payments 30,994 $ 1,700 $ 1,500 Less: current lease liabilities (397) Noncurrent lease liabilities $ 30,597 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 100 R69.htm IDEA: XBRL DOCUMENT v3.21.1 Commitments and Contingencies - Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases (Details) $ in Thousands Dec. 31, 2020 USD ($) Commitments And Contingencies Disclosure [Abstract] 2021 $ 2,986 2022 4,159 2023 4,284 2024 4,412 2025 4,545 2026 and beyond 27,070 Total minimum lease payments $ 47,456 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 101 R70.htm IDEA: XBRL DOCUMENT v3.21.1 Employee Benefit Plan - Additional Information (Details) - USD ($) $ in Millions 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Compensation And Retirement Disclosure [Abstract] Maximum percentage of employee contribution to retirement plan 90.00% Percentage of employer matching contribution 100.00% Percentage of employee annual compensation matched by the employer 5.00% Employers matching contribution vesting percentage 100.00% Employers matching contribution $ 0.4 $ 0.2 X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of discretionary contributions made by an employer to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage employer matches of the employee's percentage contribution matched. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of employer's matching contributions to a defined contribution plan that vests in a given year. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum percentage of employee gross pay the employee may contribute to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration XML 102 R71.htm IDEA: XBRL DOCUMENT v3.21.1 Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands 12 Months Ended Dec. 31, 2020 Dec. 31, 2019 Dr. Langer Related Party Transaction [Line Items] Payment to director $ 1,980 $ 10 X - DefinitionAmount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 17 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details Name: us-gaap_PaymentForManagementFee Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 103 R72.htm IDEA: XBRL DOCUMENT v3.21.1 Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 12 Months Ended Dec. 31, 2020 Sep. 30, 2020 Jun. 30, 2020 Mar. 31, 2020 Dec. 31, 2019 Sep. 30, 2019 Jun. 30, 2019 Mar. 31, 2019 Dec. 31, 2020 Dec. 31, 2019 Quarterly Financial Information Disclosure [Abstract] Total revenue $ 9,950 $ 11,247 $ 8,523 $ 7,264 $ 4,709 $ 24,238 $ 36,984 $ 28,947 Total expenses 20,182 16,588 14,548 12,177 10,202 24,813 $ 6,852 $ 5,826 63,495 47,693 Net loss (10,232) (5,341) (6,025) (4,913) (5,493) (575) (6,852) (5,826) (26,511) (18,746) Cumulative Series C convertible preferred stock dividends (40) (1,014) (1,054) Net loss attributable to common stockholders $ (10,232) $ (5,341) $ (6,025) $ (4,913) $ (5,533) $ (1,589) $ (6,852) $ (5,826) $ (26,511) $ (19,800) Net loss per share attributable to common stockholders-basic and diluted $ (0.30) $ (0.16) $ (0.19) $ (0.16) $ (0.19) $ (0.73) $ (3.42) $ (3.24) $ (0.82) $ (2.29) X - DefinitionOperating and non-operating expenses net. + ReferencesNo definition available. + Details Name: freq_OperatingAndNonOperatingExpensesNet Namespace Prefix: freq_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256 + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAccretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends). + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityDividendsAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration EXCEL 104 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 105 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 106 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 107 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 187 456 1 false 80 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.frequencytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 100050 - Statement - Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) Sheet http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Cash Flows Sheet http://www.frequencytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Organization and Basis of Presentation Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Prepaid Expenses Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpenses Prepaid Expenses Notes 11 false false R12.htm 100110 - Disclosure - Property and Equipment Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 100120 - Disclosure - Accrued Expenses Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 100130 - Disclosure - Debt Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebt Debt Notes 14 false false R15.htm 100140 - Disclosure - Convertible Preferred Stock Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock Convertible Preferred Stock Notes 15 false false R16.htm 100150 - Disclosure - Non-controlling Interest Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterest Non-controlling Interest Notes 16 false false R17.htm 100160 - Disclosure - Stockholders' Equity Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 100170 - Disclosure - Stock-based Compensation Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 18 false false R19.htm 100180 - Disclosure - Employee Stock Purchase Plan Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlan Employee Stock Purchase Plan Notes 19 false false R20.htm 100190 - Disclosure - Income Taxes Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 20 false false R21.htm 100200 - Disclosure - Research and License Agreements Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreements Research and License Agreements Notes 21 false false R22.htm 100210 - Disclosure - Collaboration Agreement Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement Collaboration Agreement Notes 22 false false R23.htm 100220 - Disclosure - Commitments and Contingencies Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 23 false false R24.htm 100230 - Disclosure - Employee Benefit Plan Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan Employee Benefit Plan Notes 24 false false R25.htm 100240 - Disclosure - Related Party Transactions Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 25 false false R26.htm 100250 - Disclosure - Subsequent Events Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 26 false false R27.htm 100260 - Disclosure - Selected Quarterly Data (Unaudited) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited Selected Quarterly Data (Unaudited) Notes 27 false false R28.htm 100270 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 28 false false R29.htm 100280 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 29 false false R30.htm 100290 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurements 30 false false R31.htm 100300 - Disclosure - Prepaid Expenses (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesTables Prepaid Expenses (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpenses 31 false false R32.htm 100310 - Disclosure - Property and Equipment (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment 32 false false R33.htm 100320 - Disclosure - Accrued Expenses (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpenses 33 false false R34.htm 100330 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquity 34 false false R35.htm 100340 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation 35 false false R36.htm 100350 - Disclosure - Income Taxes (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes 36 false false R37.htm 100360 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies 37 false false R38.htm 100370 - Disclosure - Selected Quarterly Data (Unaudited) (Tables) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables Selected Quarterly Data (Unaudited) (Tables) Tables http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited 38 false false R39.htm 100380 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails Organization and Basis of Presentation - Additional Information (Details) Details 39 false false R40.htm 100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) Details 41 false false R42.htm 100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 42 false false R43.htm 100420 - Disclosure - Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 43 false false R44.htm 100430 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) Details 44 false false R45.htm 100440 - Disclosure - Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details) Details 45 false false R46.htm 100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 46 false false R47.htm 100460 - Disclosure - Property and Equipment - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails Property and Equipment - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 48 false false R49.htm 100480 - Disclosure - Debt - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails Debt - Additional Information (Details) Details 49 false false R50.htm 100490 - Disclosure - Convertible Preferred Stock - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails Convertible Preferred Stock - Additional Information (Details) Details 50 false false R51.htm 100500 - Disclosure - Non-controlling Interest - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails Non-controlling Interest - Additional Information (Details) Details 51 false false R52.htm 100510 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 52 false false R53.htm 100520 - Disclosure - Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) Details 53 false false R54.htm 100530 - Disclosure - Stock-based Compensation - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-based Compensation - Additional Information (Details) Details 54 false false R55.htm 100540 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details) Details 55 false false R56.htm 100550 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details) Details 56 false false R57.htm 100560 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails Stock-based Compensation - Summary of Status of Restricted Common Stock (Details) Details 57 false false R58.htm 100570 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails Employee Stock Purchase Plan - Additional Information (Details) Details 58 false false R59.htm 100580 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 59 false false R60.htm 100590 - Disclosure - Income Taxes - Schedule of Reconciliation Pre-tax Income (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationPreTaxIncomeDetails Income Taxes - Schedule of Reconciliation Pre-tax Income (Details) Details 60 false false R61.htm 100600 - Disclosure - Income Taxes - Schedule of Provision (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionDetails Income Taxes - Schedule of Provision (Details) Details 61 false false R62.htm 100610 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details) Details 62 false false R63.htm 100620 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails Income Taxes - Schedule of Deferred Tax Assets (Details) Details 63 false false R64.htm 100630 - Disclosure - Research and License Agreements - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails Research and License Agreements - Additional Information (Details) Details 64 false false R65.htm 100640 - Disclosure - Collaboration Agreement - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails Collaboration Agreement - Additional Information (Details) Details 65 false false R66.htm 100650 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 66 false false R67.htm 100660 - Disclosure - Commitments and Contingencies - Schedule of Leases (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesDetails Commitments and Contingencies - Schedule of Leases (Details) Details 67 false false R68.htm 100670 - Disclosure - Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfReconcilesUndiscountedCashFlowsToOperatingLeaseLiabilityRecordedOnConsolidatedBalanceSheetDetails Commitments and Contingencies - Schedule of Reconciles the Undiscounted Cash Flows to the Operating Lease Liability Recorded on the Consolidated Balance Sheet (Details) Details 68 false false R69.htm 100690 - Disclosure - Commitments and Contingencies - Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureAggregateMinimumPaymentsUnderNoncancelableOperatingLeasesAndShortTermLeasesDetails Commitments and Contingencies - Schedule of Future Aggregate Minimum Payments Under Noncancelable Operating Leases and Short Term Leases (Details) Details 69 false false R70.htm 100700 - Disclosure - Employee Benefit Plan - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails Employee Benefit Plan - Additional Information (Details) Details 70 false false R71.htm 100710 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 71 false false R72.htm 100720 - Disclosure - Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details) Sheet http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details) Details http://www.frequencytx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables 72 false false All Reports Book All Reports freq-20201231.xml freq-20201231.xsd freq-20201231_cal.xml freq-20201231_def.xml freq-20201231_lab.xml freq-20201231_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 true true ZIP 109 0001564590-21-016117-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-016117-xbrl.zip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Ĝ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end

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2020	Mar. 19, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Entity Central Index Key	0001703647
Entity File Number	001-39062
Entity Registrant Name	Frequency Therapeutics, Inc.
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	47-2324450
Entity Address Address Line	19 Presidential Way
Entity Address, Address Line Two	2nd Floor
Entity Address City Or Town	Woburn
Entity Address State Or Province	MA
Entity Address Postal Zip Code	01801
City Area Code	866
Local Phone Number	389-1970
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	FREQ
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 625.8
Entity Common Stock, Shares Outstanding		34,177,771
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	Portions of the Proxy Statement for the registrant’s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 220,341	$ 200,158
Short-term marketable securities		17,197
Prepaid expenses and other current assets	4,723	4,000
Total current assets	225,064	221,355
Property and equipment, net	7,287	1,762
Right of use assets	30,551
Restricted cash	1,820	101
Total assets	264,722	223,218
Current liabilities:
Accounts payable	5,506	1,219
Accrued expenses	6,663	3,239
Deferred revenue	14,068	48,152
Lease liabilities	397
Other current liabilities		170
Total current liabilities	26,634	52,780
Deferred revenue, net of current portion		2,900
Lease liabilities, net of current portion	30,597
Term Loan	15,000
Long-term liabilities		180
Total liabilities	72,231	55,860
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2020 and December 31, 2019, respectively
Common stock, $0.001 par value; 200,000,000 shares authorized, 33,964,000 and 30,844,507 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	34	31
Additional paid-in capital	287,829	236,161
Accumulated other comprehensive income	27	54
Accumulated deficit	(95,399)	(68,888)
Total stockholders’ equity	192,491	167,358
Total liabilities and stockholders’ equity	$ 264,722	$ 223,218

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019	Sep. 20, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized shares	10,000,000	10,000,000	148,724,922
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000	100,000,000
Common stock, issued shares	33,964,000	30,844,507
Common stock, outstanding shares	33,964,000	30,844,507

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Revenue	$ 36,984,000	$ 28,947,000
Operating expenses:
Royalty		16,000,000
Research and development	37,415,000	18,784,000
General and administrative	27,119,000	14,838,000
Total operating expenses	64,534,000	49,622,000
Loss from operations	(27,550,000)	(20,675,000)
Interest income	994,000	1,784,000
Realized gain on investments	84,000	138,000
Foreign exchange (loss) gain	(4,000)	7,000
Loss before income taxes	(26,476,000)	(18,746,000)
Provision for income taxes	(35,000)	0
Net loss	(26,511,000)	(18,746,000)
Cumulative Series C convertible preferred stock dividends		(1,054,000)
Net loss attributable to common stockholders	$ (26,511,000)	$ (19,800,000)
Net loss per share attributable to common stockholders-basic and diluted	$ (0.82)	$ (2.29)
Weighted-average shares of common stock outstanding-basic and diluted	32,253,227	8,649,245

Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) - USD ($) $ in Thousands	Total	Non-controlling Interest	Common Stock	Additional-paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Series C Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B-1 Convertible Preferred Stock	Series A Convertible Preferred Stock	Series A-1 Convertible Preferred Stock
Beginning Balance at Dec. 31, 2018		$ 3,773						$ 38,224	$ 9	$ 46,694	$ 8
Beginning Balance (in shares) at Dec. 31, 2018								41,857,005	10,000	62,528,507	10,000
Beginning Balance at Dec. 31, 2018	$ (48,282)		$ 2	$ 804		$ (49,088)
Beginning Balance (in shares) at Dec. 31, 2018			2,084,710
Stock-based compensation expense	3,609			3,609
Issuance of common stock upon exercise of stock options	$ 366		$ 1	365
Issuance of common stock upon exercise of options (in shares)	357,170		357,170
Issuance of convertible preferred stock							$ 61,687	$ 266
Issuance of convertible preferred stock (in shares)							39,492,960	288,991
Accretion of Series C preferred dividend	$ (1,054)					(1,054)
Accretion of Series C preferred dividend							$ 1,054
Issuance of common stock in initial public offering or private placement	79,696		$ 6	79,690
Issuance of common stock in initial public offering or private placement (in shares)			6,325,000
Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO	151,715		$ 22	151,693
Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)							(39,492,960)	(42,145,996)	(10.000)	(62,528,507)	(10,000)
Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO		$ (3,773)					$ (62,741)	$ (38,490)	$ (9)	$ (46,694)	$ (8)
Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)			22,077,627
Other comprehensive income (loss)	54				$ 54
Net loss	(18,746)					(18,746)
Ending Balance at Dec. 31, 2019	$ 167,358		$ 31	236,161	54	(68,888)
Ending Balance (in shares) at Dec. 31, 2019	30,844,507		30,844,507
Stock-based compensation expense	$ 9,983			9,983
Issuance of common stock upon exercise of stock options	$ 1,545		$ 1	1,544
Issuance of common stock upon exercise of options (in shares)	769,385		769,385
Issuance of common stock in initial public offering or private placement	$ 40,143		$ 2	40,141
Issuance of common stock in initial public offering or private placement (in shares)			2,350,108
Other comprehensive income (loss)	(27)				(27)
Net loss	(26,511)					(26,511)
Ending Balance at Dec. 31, 2020	$ 192,491		$ 34	$ 287,829	$ 27	$ (95,399)
Ending Balance (in shares) at Dec. 31, 2020	33,964,000		33,964,000

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (26,511)	$ (18,746)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation	9,983	3,609
Depreciation expense	1,146	813
Issuance of common stock for license agreement		54
Non-cash lease expense	434
Deferred lease incentives		(160)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(626)	(3,252)
Accounts payable	4,287	(644)
Deferred revenue	(36,984)	51,052
Accrued expenses	3,083	1,490
Net cash (used in) provided by operating activities	(45,188)	34,216
Cash flows from investing activities:
Purchases of property and equipment	(6,671)	(1,064)
Purchase of available for sale securities	(26,345)	(282,618)
Redemption of available for sale securities	43,418	265,421
Net cash provided by (used in) investing activities	10,402	(18,261)
Cash flows from financing activities:
Proceeds from issuance of common stock	1,545	80,062
Proceeds from Private Placement, net of issuance costs	40,143
Proceeds from Term Loan	15,000
Net cash provided by financing activities	56,688	142,015
Net increase in cash, cash equivalents, short-term investments, and restricted cash	21,902	157,970
Cash, cash equivalents, short-term investments and restricted cash at beginning of period	200,259	42,289
Cash, cash equivalents, short-term investments, and restricted cash at end of period	222,161	200,259
Non-cash items:
Right-of-use assets in exchange for lease liabilities	31,335
Cumulative Series C convertible preferred stock dividends		1,054
Conversion of preferred stock and non-controlling interest into common stock		151,715
Purchases of property and equipment included in accounts payable and accrued expenses	$ 2,145
Series B Convertible Preferred Stock
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs		266
Series C Convertible Preferred Stock
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs		$ 61,687

Organization and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands			1 Months Ended	12 Months Ended
	Jul. 20, 2020 USD ($) $ / shares shares	Sep. 20, 2019 $ / shares shares	Oct. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares
Subsidiary Sale Of Stock [Line Items]
Date of incorporation				Nov. 30, 2014
Reverse stock split ratio		0.148467
Reverse stock split, description				1-for-6.7355
Common stock, authorized shares		100,000,000		200,000,000	200,000,000
Preferred stock, authorized shares		148,724,922		10,000,000	10,000,000
Preferred stock, par value \| $ / shares		$ 0.001		$ 0.001	$ 0.001
Common stock, par value \| $ / shares				$ 0.001	$ 0.001
Net proceeds from issuance of common stock \| $				$ 1,545	$ 80,062
Accumulated deficit \| $				$ 95,399	$ 68,888
Common Stock
Subsidiary Sale Of Stock [Line Items]
Common stock shares issued and sold				2,350,108	6,325,000
Common Stock \| IPO
Subsidiary Sale Of Stock [Line Items]
Common stock shares issued and sold			6,325,000
Share price per share \| $ / shares			$ 14.00
Net proceeds from issuance of common stock \| $			$ 79,700
Number of common stock issued upon conversion of preferred stock			22,077,627
Common Stock \| Private Placement
Subsidiary Sale Of Stock [Line Items]
Common stock shares issued and sold	2,350,108
Share price per share \| $ / shares	$ 18.00
Common stock, par value \| $ / shares	$ 0.001
Net proceeds from issuance of common stock \| $	$ 40,100

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 11, 2020	Jan. 01, 2020
Summary Of Significant Accounting Policies [Line Items]
Foreign currency exchange (losses) gains		$ (4,000)	$ 7,000
Restricted cash		1,820,000	101,000
Fair value of term loan		$ 0
Fair value of term loan issued term		1 month
Impairment losses		$ 0	0
Right of use assets		30,551,000		$ 1,700,000	$ 1,200,000
Lease liability		$ 30,994,000		$ 1,700,000	$ 1,500,000
Accounting Standards Update 2018-11
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted		true
Change in accounting principle, accounting standards update, adoption date		Jan. 01, 2020
Accounting Standards Update 2016-01
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted		true
Change in accounting principle, accounting standards update, adoption date		Jan. 01, 2020
Change in accounting principle, accounting standards update, immaterial effect		true
Lexington Massachusetts facility
Summary Of Significant Accounting Policies [Line Items]
Restricted cash		$ 1,700,000
Woburn Massachusetts Facility
Summary Of Significant Accounting Policies [Line Items]
Restricted cash		$ 100,000	$ 100,000
Increase in right-of-use asset	$ 1,000,000
Increase in lease liability	$ 1,000,000

Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss attributable to common stockholders	$ (10,232)	$ (5,341)	$ (6,025)	$ (4,913)	$ (5,533)	$ (1,589)	$ (6,852)	$ (5,826)	$ (26,511)	$ (19,800)
Denominator:
Weighted-average shares of common stock outstanding- basic and diluted									32,253,227	8,649,245
Net loss per share attributable to common stockholders-basic and diluted	$ (0.30)	$ (0.16)	$ (0.19)	$ (0.16)	$ (0.19)	$ (0.73)	$ (3.42)	$ (3.24)	$ (0.82)	$ (2.29)

Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	6,819,891	19,554,414
Unvested Restricted Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	3,093	70,366
Series C Preferred (as converted to common stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		1,172,676
Series B Preferred (as converted to common stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		4,759,079
Series A Preferred (as converted to common stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		7,070,574
Conversion of Frequency Japan Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		513,047
Outstanding Stock Options (as converted to common stock)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	6,816,798	5,968,672

Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) - Recurring Basis - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Amortization Cost	$ 214,522	$ 217,262
Unrealized Gain	27	54
Fair Market Value	214,549	217,316
Money Market Funds \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Amortization Cost	214,522	200,131
Unrealized Loss		(12)
Unrealized Gain	27
Fair Market Value	$ 214,549	200,119
U.S. Government Treasury Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Amortization Cost		17,131
Unrealized Gain		66
Fair Market Value		$ 17,197

Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expense And Other Assets Current [Abstract]
Rent and deposits		$ 63
Research and development expenses	$ 1,729	801
Grant receivable		805
Accounts receivable	340
Insurance	2,552	2,132
Other	102	199
Total	$ 4,723	$ 4,000

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Total	$ 10,499	$ 3,828
Accumulated depreciation	(3,212)	(2,066)
Property and equipment, net	7,287	1,762
Lab Equipment
Property Plant And Equipment [Line Items]
Total	4,166	1,846
Furniture and Office Equipment
Property Plant And Equipment [Line Items]
Total	283	257
Software
Property Plant And Equipment [Line Items]
Total	291
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total	1,419	1,419
Construction in Progress
Property Plant And Equipment [Line Items]
Total	$ 4,340	$ 306

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation expense	$ 1,146	$ 813

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Payroll and employee related expenses	$ 5,062	$ 2,686
Professional fees	647	435
Third-party research and development expenses	874	118
Taxes and other	80
Total	$ 6,663	$ 3,239

Debt - Additional Information (Details) - Loan Agreement - Term Loan - USD ($) $ in Thousands		12 Months Ended
	Dec. 11, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Principal balance	$ 15,000
Payment terms, description		The Company will make monthly interest only payments through November 30, 2022. The principal balance and interest will be repaid in equal monthly installments after the interest only period and continuing through May 1, 2024 (the “Loan Maturity Date”)
Frequency of interest-only payments		monthly
Monthly interest only payments due	Nov. 30, 2022
Loan maturity date	May 01, 2024
Debt instrument, Interest rate		4.75%
Interest rate floor percentage	0.00%
Debt instrument final payment	$ 150,000
Prepayment Occurs on or Prior to First Anniversary of Closing Date
Debt Instrument [Line Items]
Debt instrument prepayment premium percentage	2.00%
Prepayment Occurs After First Anniversary of Closing Date and On or Prior to Second Anniversary of Closing Date
Debt Instrument [Line Items]
Debt instrument prepayment premium percentage	1.00%
Prepayment Occurs After Second Anniversary of Closing Date
Debt Instrument [Line Items]
Debt instrument prepayment premium percentage	0.00%
Prime Rate
Debt Instrument [Line Items]
Debt instrument, Interest rate	1.50%

Convertible Preferred Stock - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jul. 17, 2019	Dec. 31, 2018
Series A Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, issued shares			62,528,507
Series B Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, issued shares	288,911		41,857,005
Series C Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, issued shares		39,492,960
Convertible preferred stock, authorized shares		39,492,960
Preferred stock, net proceeds from shares issued		$ 61,687
Series A-1 Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, issued shares			10,000
Series B-1 Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, issued shares			10,000

Non-controlling Interest - Additional Information (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018
Series A-1 Preferred Stock \| LLC(FT-FJ)
Class Of Stock [Line Items]
Preferred stock, shares purchased		10,000
Preferred stock, voting rights	Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock
Series B-1 Preferred Stock \| LLC(FT-FJ)
Class Of Stock [Line Items]
Preferred stock, shares purchased		10,000
Preferred stock, voting rights	Each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock
Frequency Japan
Class Of Stock [Line Items]
Convertible preferred Stock, shares issued upon conversion		673,605
Voting percentage of preferred stock holder		70.00%

Stockholders' Equity - Additional Information (Details) - $ / shares	Dec. 31, 2020	Dec. 31, 2019	Sep. 20, 2019
Equity [Abstract]
Preferred stock, shares authorized	10,000,000	10,000,000	148,724,922
Preferred Stock, value per share	$ 0.001	$ 0.001	$ 0.001
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, authorized shares	200,000,000	200,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, issued shares	33,964,000	30,844,507
Common stock, outstanding shares	33,964,000	30,844,507

Stockholders' Equity - Schedule of Common Stock Shares Reserved for Future Issuance (Details) - shares	Dec. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Shares of common stock reserved for future issuance	8,292,721	7,828,326
Stock Options Outstanding
Class Of Stock [Line Items]
Shares of common stock reserved for future issuance	6,816,798	5,968,672
Shares Available for Future Grant Under Stock Option Plan
Class Of Stock [Line Items]
Shares of common stock reserved for future issuance	1,475,923	1,859,654

Stock-based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Sep. 17, 2019	Nov. 13, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares reserved for issuance	8,292,721	7,828,326
Options vesting period	4 years
Expected dividend yield	0.00%	0.00%
Options exercised	769,385	357,170
Aggregate intrinsic value of stock options exercised	$ 16,667	$ 5,896
Weighted-average grant date fair value of stock options granted	16.41	4.05
Total grant date fair value of stock options vested	$ 7,907	$ 2,990
Total unrecognized stock-based compensation expense relating to unvested stock options	$ 31,006	$ 13,820
Unrecognized unvested stock options, weighted-average period	3 years 29 days	2 years 9 months 3 days
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 9,983
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 3,609
Restricted Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting period	4 years
Total value of restricted stock awards, vested based on estimated fair value of stock	$ 20	$ 73
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options expiration period	10 years
2014 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares reserved for issuance				8,550,415
Common stock, shares available for future grants	0
Options exercised	767,534	357,170
Aggregate intrinsic value of stock options exercised	$ 1.94	$ 1.02
2019 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of authorized shares reserved for issuance			3,100,000
Period for automatic increase in common stock available for future issuance	10 years
Percentage of shares issued from outstanding number of shares	4.00%
Common stock future issuance, description	In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company’s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company’s board of directors.
Options exercised	1,851
Aggregate intrinsic value of stock options exercised	$ 18.93

Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate	1.10%	2.00%
Expected term (in years)	6 years	5 years 10 months 24 days
Expected volatility	79.10%	79.40%
Expected dividend yield	0.00%	0.00%

Stock-based Compensation - Summary of Status of Restricted Common Stock (Details) - Restricted Common Stock	12 Months Ended
	Dec. 31, 2020 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Unvested, December 31, 2019 \| shares	70,366
Number of shares, Vested \| shares	(67,273)
Number of shares, Unvested, December 31, 2020 \| shares	3,093
Weighted average fair value, Unvested, December 31, 2019 \| $ / shares	$ 0.36
Weighted average fair value, Vested \| $ / shares	0.29
Weighted average fair value, Unvested, December 31, 2020 \| $ / shares	$ 1.75

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Oct. 31, 2019	Mar. 31, 2017	Feb. 28, 2017
Income Taxes Disclosure [Line Items]
Net tax benefit	$ 35,000	$ 0
Federal and state deferred tax benefits	0	0
Valuation allowance	26,995,000	16,204,000
Unrecognized tax benefits	0	0
Interest and penalties	$ 0	$ 0
Internal Revenue Service
Income Taxes Disclosure [Line Items]
Period of cumulative change in ownership	3 years
Operating loss carryforwards, utilization after ownership change				$ 10,800,000
Operating loss carryforwards, utilization after five years after ownership change				1,600,000
Operating loss carryforwards, utilization after 15 years thereafter after ownership change				180,000
Remaining pre ownership change in operating loss carryforwards written off due to expiration				$ 1,600,000
Internal Revenue Service \| Minimum
Income Taxes Disclosure [Line Items]
Cumulative change in ownership percentage	50.00%
Federal
Income Taxes Disclosure [Line Items]
Net operating loss carryforwards	$ 67,868,000
Net operating loss carryforwards expire through 2037	$ 22,400,000
Operating loss carryforwards expiration year	2037
Net operating loss carryforwards without expiration	$ 45,469,000
Tax credit carryforwards expiration year	2040
Federal \| Internal Revenue Service
Income Taxes Disclosure [Line Items]
Net operating loss carryforwards			$ 46,123,000		$ 12,400,000
Federal \| Research and Development
Income Taxes Disclosure [Line Items]
Tax credit carryforwards	$ 3,014,000
State
Income Taxes Disclosure [Line Items]
Operating loss carryforwards expiration year	2040
State \| Massachusetts
Income Taxes Disclosure [Line Items]
Net operating loss carryforwards	$ 43,386,000
Tax credit carryforwards expiration year	2035
State \| Massachusetts \| Research and Development
Income Taxes Disclosure [Line Items]
Tax credit carryforwards	$ 1,211,000

Income Taxes - Schedule of Reconciliation Pre-tax Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Domestic	$ (25,744)	$ (19,086)
Foreign	(732)	(714)
Total	$ (26,476)	$ (19,800)

Income Taxes - Schedule of Provision (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 35,000
Total current	35,000
Deferred:
Total provision (benefit)	$ 35,000	$ 0

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 17,885	$ 13,253
Research and development tax credits	3,992	1,138
Intangibles	360	358
Stock compensation	850	686
Accrued expenses		48
Deferred revenue	3,606	496
Other	142	189
Fixed assets	56	36
Lease liability	7,285
Right of use asset	(7,181)
Total deferred tax asset	26,995	16,204
Valuation allowance	$ (26,995)	$ (16,204)

Research and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended						3 Months Ended						12 Months Ended		16 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Feb. 28, 2019	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2016	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue							$ 9,950,000	$ 11,247,000	$ 8,523,000	$ 7,264,000	$ 4,709,000	$ 24,238,000	$ 36,984,000	$ 28,947,000
Dr. Langer
Research And Development Arrangement Contract To Perform For Others [Line Items]
Payment to director													1,980,000	10,000
Grant
Research And Development Arrangement Contract To Perform For Others [Line Items]
Decrease in research and development expenses													$ 323,000	845,000
Research and Development \| Grant
Research And Development Arrangement Contract To Perform For Others [Line Items]
Amount of funding received as grant					$ 1,596,000
Grant term period					2 years
MIT
Research And Development Arrangement Contract To Perform For Others [Line Items]
Description of future development obligations													The Company’s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product.
License fee payment						$ 50,000
Percentage of shares of common stock issued						5.00%
Description of conditions to terminate license agreement													The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.
Right to terminate agreement upon prior written notice						3 months
Right to terminate agreement if breach remains uncured						90 days
Right to terminate agreement incase of nonpayment						30 days
MIT \| Astellas Pharma LLC \| Royalty
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue														16,000,000
MIT \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments						$ 2,900,000
MIT \| Patent License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date						2016-12
CALIBR
Research And Development Arrangement Contract To Perform For Others [Line Items]
License fee payment				$ 1,000,000
Percentage of shares of common stock issued				50.00%
Description of conditions to terminate license agreement													The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.
Right to terminate agreement upon prior written notice				30 days
Right to terminate agreement if breach remains uncured				30 days
Right to terminate licensed patents upon prior written notice				90 days
CALIBR \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments				$ 26,000,000
CALIBR \| Patent License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date				2018-09
Scripps Option Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date				2018-09
Description of conditions to terminate license agreement													The Company has the right to terminate by giving 90 days’ advance notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days. Each party has the right to terminate in the event of the other party’s material breach that remains uncured for 60 days or if the other party becomes bankrupt.
Right to terminate agreement upon prior written notice				90 days
Right to terminate agreement if breach remains uncured				60 days
Right to terminate agreement incase of nonpayment				10 days
Funding payments as consideration to support research activities				$ 700,000
Agreement term				1 year
License agreement extended date	2021-12
Scripps Option Agreement \| Scenario Forecast
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional funding payments made as consideration to support research activities															$ 600,000
MEE
Research And Development Arrangement Contract To Perform For Others [Line Items]
License fee payment			$ 20,000
Description of conditions to terminate license agreement													The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days after MEE notifies the Company of such failure. MEE shall have the right to terminate if the Company fails to maintain the required insurance. MEE shall also have the right to terminate the MEE License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEE has the right to terminate for any other default not cured within sixty (60) business days written notice. MEE also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights.
Right to terminate agreement upon prior written notice			30 days
Right to terminate agreement if breach remains uncured			60 days
Right to terminate agreement incase of nonpayment			30 days
Right to terminate agreement upon prior written notice if insolvent			45 days
MEE \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments			$ 350,000
MEE \| Non-Exclusive Patent License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date			2019-02
Cambridge
Research And Development Arrangement Contract To Perform For Others [Line Items]
License fee payment		$ 50,000									$ 50,000			$ 50,000
Description of conditions to terminate license agreement													We have the right to terminate for any reason upon 90 days’ prior to written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.
Right to terminate agreement upon prior written notice		90 days
Right to terminate agreement if breach remains uncured		30 days
Annual license fee		$ 50,000
Cambridge \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments		$ 10,500
Cambridge \| Patent License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date		2019-12

Collaboration Agreement - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended						12 Months Ended		18 Months Ended
	Jul. 31, 2019	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty									$ 16,000
Revenue		$ 9,950	$ 11,247	$ 8,523	$ 7,264	$ 4,709	$ 24,238	$ 36,984	28,947
Research and development								37,415	18,784
License and Collaboration Agreement \| Astellas Pharma LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received under collaboration agreement	$ 80,000
Agreement termination notice period	60 days
Right to terminate agreement if breach remains uncured	90 days
Right to terminate agreement incase of nonpayment	45 days
Transaction price allocated to single combined performance obligation								80,000
Accrued upfront payment related to sub License revenue		$ 16,000						16,000		$ 16,000
Royalty							$ 16,000
Upfront fee recognized as revenue										$ 80,000
Revenue								37,000	28,900
Revenue from contract with customer application input method									12,900
Revenue remaining performance obligation						$ 64,000			64,000
Research and development								$ 1,046	186
License and Collaboration Agreement \| Astellas Pharma LLC \| Royalty
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue									$ 16,000
License and Collaboration Agreement \| Astellas Pharma LLC \| Phase 2b Clinical Trial \| Europe
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized potential development milestone payments to receive	$ 65,000
License and Collaboration Agreement \| Astellas Pharma LLC \| Phase 2b Clinical Trial \| Asia
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized potential development milestone payments to receive	25,000
License and Collaboration Agreement \| Astellas Pharma LLC \| Phase 3 Clinical Trial \| Europe
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized potential development milestone payments to receive	100,000
License and Collaboration Agreement \| Astellas Pharma LLC \| Phase 3 Clinical Trial \| Asia
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized potential development milestone payments to receive	40,000
License and Collaboration Agreement \| Maximum \| Astellas Pharma LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized potential development milestone payments to receive	230,000
Revenue recognized commercialization milestone payments to receive	315,000
Potential commercial milestone payments eligible to receive upon successful commercialization	$ 315,000

Commitments and Contingencies - Additional Information (Details)			12 Months Ended
	Dec. 11, 2020 USD ($)	Jan. 07, 2020 ft² Term	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jan. 01, 2020 USD ($)	Dec. 31, 2016
Lessee Lease Description [Line Items]
Operating lease ROU assets	$ 1,700,000		$ 30,551,000		$ 1,200,000
Current lease liabilities			397,000
Non-current lease liabilities			30,597,000
Operating lease cost			470,000
Variable lease cost			510,000
Short term lease cost			106,000
Lease expense			835,000	$ 269,000
Cash paid for amounts included in the measurement of lease liabilities			484,000
Commitment payments related to research			600,000
Losses related to indemnification obligations			0	$ 0
Hayden LLC \| Lexington Lease
Lessee Lease Description [Line Items]
Operating lease term		10 years
Lease expiration date		May 31, 2031
Rentable area of office space \| ft²		61,307
Lease commencement date		Dec. 11, 2020
Number of additional lease extension terms \| Term		2
Lease extension term		5 years
Lease Termination Agreement
Lessee Lease Description [Line Items]
Payment of fee to landlord			$ 200,000
Lease Termination Agreement \| ARE-MA Region No. 20, LLC
Lessee Lease Description [Line Items]
Lease expiration date	Mar. 31, 2021
Massachusetts
Lessee Lease Description [Line Items]
Operating lease term						5 years
Lease, description of option to extend			The lease was extended in November 2019 and expires in February 2025.
Lease agreement amended date			2019-11
Lease commencement date			2020-02
Lease expiration date			2025-02
Connecticut
Lessee Lease Description [Line Items]
Lease, expiration year			2021
Woburn Massachusetts Facility
Lessee Lease Description [Line Items]
Operating lease term			5 years